Wait O O
5 O O
weeks O O
after O O
stopping O O
escitalopram B-drug B-drug
before O O
starting O O
a O O
non-selective B-group B-group
MAO I-group I-group
inhibitor I-group I-group
. O O

However O O
, O O
coadministration O O
of O O
escitalopram B-drug B-drug
( O O
20 O O
mg O O
) O O
and O O
ritonavir B-drug B-drug
( O O
600 O O
mg O O
) O O
, O O
a O O
potent O O
inhibitor O O
of O O
CYP3A4 O O
, O O
did O O
not O O
significantly O O
affect O O
the O O
pharmacokinetics O O
of O O
escitalopram B-drug B-drug
. O O

This O O
loss O O
of O O
microtubules O O
on O O
cooling O O
the O O
nerves O O
and O O
their O O
reappearance O O
on O O
rewarming O O
was O O
a O O
rapid O O
process O O
; O O

The O O
potential O O
for O O
increased O O
sedation O O
when O O
guanfacine B-drug B-drug
is O O
given O O
with O O
other O O
CNS-depressant B-group O
drug I-group O
should O O
be O O
appreciated O O
. O O

The O O
potential O O
effects O O
of O O
increased O O
plasma O O
concentrations O O
of O O
midazolam B-drug B-drug
or O O
other O O
benzodiazepines B-group B-group
metabolized O O
via O O
CYP3A4 O O
( O O
alprazolam B-drug B-drug
, O O
triazolam B-drug B-drug
) O O
should O O
be O O
considered O O
when O O
coadministering O O
these O O
agents O O
with O O
Aprepitant B-drug B-drug
. O O

Oral O O
anticoagulant B-group B-group
agents I-group I-group
: O O
Pharmacokinetic O O
drug-drug O O
interactions O O
between O O
Argatroban B-drug B-drug
and O O
warfarin B-drug B-drug
( O O
7.5 O O
mg O O
single O O
oral O O
dose O O
) O O
have O O
not O O
been O O
demonstrated O O
. O O

Drug/Laboratory O O
Test-Interactions O O
None O O
observed O O
. O O

The O O
ratios O O
of O O
the O O
AUCs O O
of O O
unbound O O
valproate B-drug B-drug
to O O
the O O
AUCs O O
of O O
the O O
total O O
valproate B-drug B-drug
were O O
11.1 O O
% O O
, O O
13.0 O O
% O O
, O O
and O O
11.5 O O
% O O
, O O
with O O
coadministration O O
of O O
0 O O
, O O
1200 O O
, O O
and O O
2400 O O
mg/day O O
of O O
Felbatol B-brand B-brand
, O O
respectively O O
. O O

The O O
results O O
of O O
the O O
ERMBT O O
after O O
2 O O
weeks O O
of O O
rifabutin B-drug B-drug
and O O
rifampin B-drug B-drug
therapy O O
were O O
increased O O
187 O O
and O O
156 O O
% O O
, O O
respectively O O
. O O

Interations O O

CANCIDAS B-brand B-brand
reduced O O
the O O
blood O O
AUC0-12 O O
of O O
tacrolimus B-drug B-drug
by O O
approximately O O
20 O O
% O O
, O O
peak O O
blood O O
concentration O O
( O O
Cmax O O
) O O
by O O
16 O O
% O O
, O O
and O O
12-hour O O
blood O O
concentration O O
( O O
C12hr O O
) O O
by O O
26 O O
% O O
in O O
healthy O O
subjects O O
when O O
tacrolimus B-drug B-drug
( O O
2 O O
doses O O
of O O
0.1 O O
mg/kg O O
12 O O
hours O O
apart O O
) O O
was O O
administered O O
on O O
the O O
10th O O
day O O
of O O
CANCIDAS B-brand B-brand
70 O O
mg O O
daily O O
, O O
as O O
compared O O
to O O
results O O
from O O
a O O
control O O
period O O
in O O
which O O
tacrolimus B-drug B-drug
was O O
administered O O
alone O O
. O O

This O O
combinational O O
action O O
in O O
reversing O O
vancomycin O B-drug
resistance O O
of O O
enterococci O O
highlights O O
novel O O
drug O O
targets O O
and O O
has O O
importance O O
in O O
the O O
design O O
of O O
new O O
therapeutic O O
regimes O O
against O O
resistant O O
pathogens O O
. O O

Concurrent O O
use O O
of O O
macrolides B-group B-group
and O O
warfarin B-drug B-drug
in O O
clinical O O
practice O O
has O O
been O O
associated O O
with O O
increased O O
anticoagulant O O
effects O O
. O O

Serial O O
plasma O O
and O O
urine O O
samples O O
for O O
measurement O O
of O O
amprenavir B-drug B-drug
, O O
rifabutin B-drug B-drug
, O O
and O O
rifampin B-drug B-drug
and O O
their O O
25-O-desacetyl B-drug_n O
metabolites I-drug_n O
, O O
were O O
measured O O
by O O
high-performance O O
liquid O O
chromatography O O
. O O

Nevirapine I-drug B-drug
and O O
rifampin B-drug B-drug
should O O
not O O
beadministered O O
concomitantly O O
becausedecreases O O
in O O
nevirapine B-drug B-drug
plasmaconcentrations O O
may O O
reduce O O
the O O
efficacy O O
ofthe O O
drug O O
. O O

Antibiotics B-group B-group
: O O
In O O
vitro O O
and/or O O
in O O
vivo O O
data O O
show O O
that O O
clarithromycin B-drug B-drug
, O O
erythromycin B-drug B-drug
, O O
and O O
troleandomycin B-drug B-drug
markedly O O
inhibit O O
the O O
metabolism O O
of O O
cisapride B-drug B-drug
, O O
which O O
can O O
result O O
in O O
an O O
increase O O
in O O
plasma O O
cisapride B-drug B-drug
levels O O
and O O
prolongation O O
of O O
the O O
QT O O
interval O O
on O O
the O O
ECG O O
. O O

The O O
treatment O O
of O O
ewes O O
with O O
an O O
intravenous O O
( O O
IV O O
) O O
injection O O
of O O
trichlorfon B-drug_n B-drug
, O O
insufficient O O
to O O
produce O O
significant O O
inhibition O O
of O O
erythrocyte O O
acetylcholinesterase O O
( O O
AChE O O
) O O
activity O O
, O O
appeared O O
to O O
produce O O
additive O O
effects O O
with O O
those O O
produced O O
by O O
subsequent O O
treatment O O
with O O
4 O O
mg O O
of O O
coumaphos/kg/day B-drug_n O
. O O

Consequently O O
, O O
it O O
is O O
recommended O O
not O O
to O O
exceed O O
a O O
single O O
2.5 O O
mg O O
Vardenafil B-drug B-drug
dose O O
in O O
a O O
72-hour O O
period O O
when O O
used O O
in O O
combination O O
with O O
ritonavir B-drug B-drug
. O O

Castor B-drug O
oil I-drug O
( O O
4 O O
ml/kg O O
, O O
p.o O O
. O O
) O O

Probenecid B-drug B-drug
: O O
Probenecid B-drug B-drug
increases O O
both O O
free O O
and O O
bound O O
ketoprofen B-drug B-drug
by O O
reducing O O
the O O
plasma O O
clearance O O
of O O
ketoprofen B-drug B-drug
to O O
about O O
one-third O O
, O O
as O O
well O O
as O O
decreasing O O
its O O
protein O O
binding O O
. O O

Nevertheless O O
, O O
caution O O
is O O
indicated O O
in O O
the O O
coadministration O O
of O O
escitalopram B-drug B-drug
and O O
drugs O O
metabolized O O
by O O
CYP2D6 O O
. O O

Capsules O O
INDOCIN B-brand B-brand
50 O O
mg O O
t.i.d O O
. O O
produced O O
a O O
clinically O O
relevant O O
elevation O O
of O O
plasma O O
lithium B-drug B-drug
and O O
reduction O O
in O O
renal O O
lithium B-drug B-drug
clearance O O
in O O
psychiatric O O
patients O O
and O O
normal O O
subjects O O
with O O
steady O O
state O O
plasma O O
lithium B-drug B-drug
concentrations O O
. O O

Therefore O O
, O O
increased O O
monitoring O O
of O O
digoxin B-drug B-drug
is O O
recommended O O
when O O
initiating O O
, O O
adjusting O O
, O O
or O O
discontinuing O O
COREG B-brand B-brand
. O O

Cimetidine B-drug B-drug
, O O
caffeine B-drug B-drug
, O O
and O O
erythromycin B-drug B-drug
may O O
increase O O
plasma O O
levels O O
of O O
Clozapine B-drug B-drug
, O O
potentially O O
resulting O O
in O O
adverse O O
effects O O
. O O

Analysis O O
of O O
16,16-dimethylprostaglandin B-drug_n B-drug_n
E2-induced O I-drug_n
diarrhea O O
in O O
cecectomized O O
rats O O
. O O

Response O O
to O O
sympathomimetic B-group B-group
agents I-group I-group
may O O
be O O
enhanced O O
by O O
colchicine B-drug B-drug
. O O

Therefore O O
, O O
digoxin B-drug B-drug
serum O O
levels O O
should O O
be O O
monitored O O
. O O

The O O
clinical O O
significance O O
of O O
these O O
findings O O
is O O
unknown O O
. O O

Increases O O
in O O
prothrombin O O
time O O
have O O
been O O
noted O O
in O O
patients O O
receiving O O
long- O B-group
term O O
warfarin B-drug B-drug
therapy O O
after O O
flutamide B-drug B-drug
was O O
initiated O O
. O O

. O O

Methotrexate B-drug B-drug
: O O
Caution O O
should O O
be O O
used O O
if O O
diflunisal B-drug B-drug
is O O
administered O O
concomitantly O O
with O O
methotrexate B-drug B-drug
. O O

dosage O O
adjustments O O
may O O
be O O
necessary O O
. O O
) O O

While O O
all O O
the O O
selective O B-group
serotonin B-group I-group
reuptake I-group I-group
inhibitors I-group I-group
( O O
SSRIs B-group B-group
) O O
, O O
e.g. O O
, O O
fluoxetine B-drug B-drug
, O O
sertraline B-drug B-drug
, O O
and O O
paroxetine B-drug B-drug
, O O
inhibit O O
P450 O O
2D6 O O
, O O
they O O
may O O
vary O O
in O O
the O O
extent O O
of O O
inhibition O O
. O O

Fulvestrant B-drug B-drug
was O O
not O O
mutagenic O O
or O O
clastogenic O O
in O O
multiple O O
in O O
vitro O O
tests O O
with O O
and O O
without O O
the O O
addition O O
of O O
a O O
mammalian O O
liver O O
metabolic O O
activation O O
factor O O
( O O
bacterial O O
mutation O O
assay O O
in O O
strains O O
of O O
Salmonella O O
typhimurium O O
and O O
Escherichia O O
coli O O
, O O
in O O
vitro O O
cytogenetics O O
study O O
in O O
human O O
lymphocytes O O
, O O
mammalian O O
cell O O
mutation O O
assay O O
in O O
mouse O O
lymphoma O O
cells O O
and O O
in O O
vivo O O
micronucleus O O
test O O
in O O
rat O O
. O O

Concomitantly O O
given O O
thiazide B-group B-group
diuretics I-group I-group
did O O
not O O
interfere O O
with O O
the O O
absorption O O
of O O
a O O
tablet O O
of O O
digoxin B-drug B-drug
. O O

After O O
1 O O
h O O
, O O
atracurium B-drug B-drug
was O O
discontinued O O
and O O
hoof O O
twitch O O
allowed O O
to O O
recover O O
to O O
75 O O
% O O
. O O

Depression O O
is O O
reaching O O
epidemic O O
proportions O O
in O O
the O O
western O O
world O O
. O O

When O O
these O O
drugs O O
are O O
administered O O
to O O
or O O
withdrawn O O
from O O
patients O O
receiving O O
Starlix B-brand B-brand
, O O
the O O
patient O O
should O O
be O O
observed O O
closely O O
for O O
changes O O
in O O
glycemic O O
control O O
. O O

When O O
amiloride B-drug B-drug
HCl O I-drug
is O O
administered O O
concomitantly O O
with O O
an O O
angiotensin-converting B-group B-group
enzyme I-group I-group
inhibitor I-group I-group
, O O
the O O
risk O O
of O O
hyperkalemia O O
may O O
be O O
increased O O
. O O

No O O
interactions O O
have O O
been O O
observed O O
between O O
nizatidine B-drug B-drug
and O O
theophylline B-drug B-drug
, O O
chlordiazepoxide B-drug B-drug
, O O
lorazepam B-drug B-drug
, O O
lidocaine B-drug B-drug
, O O
phenytoin B-drug B-drug
, O O
and O O
warfarin B-drug B-drug
. O O

Coadministration O O
of O O
valdecoxib B-drug B-drug
with O O
doses O O
higher O O
than O O
40 O O
mg O O
QD O O
omeprazole B-drug B-drug
has O O
not O O
been O O
studied O O
. O O

In O O
the O O
second O O
experiment O O
, O O
non-diabetic O O
and O O
streptozotocin-induced O O
diabetic O O
rats O O
were O O
fasted O O
, O O
and O O
the O O
same O O
procedures O O
were O O
followed O O
for O O
estimation O O
of O O
glucose B-drug O
tolerance O O
30 O O
min O O
after O O
glucose B-drug O
overload O O
. O O

Digoxin B-drug B-drug
, O O
Methotrexate B-drug B-drug
, O O
Cyclosporine B-drug B-drug
: O O
Diclofenac B-drug B-drug
, O O
like O O
other O O
NSAIDs B-group B-group
, O O
may O O
affect O O
renal O O
prostaglandins O O
and O O
increase O O
the O O
toxicity O O
of O O
certain O O
drugs O O
. O O

Studies O O
have O O
shown O O
that O O
the O O
bioavailability O O
of O O
isoniazid B-drug B-drug
is O O
reduced O O
significantly O O
when O O
administered O O
with O O
food O O
. O O

Drug-Drug O O
Interactions O O
Albuterol B-drug B-drug
- O O
STRATTERA B-brand B-brand
should O O
be O O
administered O O
with O O
caution O O
to O O
patients O O
being O O
treated O O
with O O
systemically-administered O O
( O O
oral O O
or O O
intravenous O O
) O O
albuterol B-drug B-drug
( O O
or O O
other O O
beta2 B-group B-group
agonists I-group I-group
) O O
because O O
the O O
action O O
of O O
albuterol B-drug B-drug
on O O
the O O
cardiovascular O O
system O O
can O O
be O O
potentiated O O
resulting O O
in O O
increases O O
in O O
heart O O
rate O O
and O O
blood O O
pressure O O
. O O

Drugs O O
Which O O
Require O O
a O O
Dose O O
Reduction O O
When O O
Coadminstered O O
With O O
VIRACEPT B-brand B-brand
Antimycobacterial B-group B-group
agents I-group I-group
: O O
rifabutin B-drug B-drug

phosphokinase O O

Acetaminophen B-drug B-drug
: O O
In O O
normal O O
volunteers O O
, O O
concomitant O O
administration O O
of O O
diflunisal B-drug B-drug
and O O
acetaminophen B-drug B-drug
resulted O O
in O O
an O O
approximate O O
50 O O
% O O
increase O O
in O O
plasma O O
levels O O
of O O
acetaminophen B-drug B-drug
. O O

In O O
a O O
single-dose O O
crossover O O
study O O
examining O O
lansoprazole B-drug B-drug
30 O O
mg O O
and O O
omeprazole B-drug B-drug
20 O O
mg O O
each O O
administered O O
alone O O
and O O
concomitantly O O
with O O
sucralfate B-drug B-drug
1 O O
gram O O
, O O
absorption O O
of O O
the O O
proton B-group B-group
pump I-group I-group
inhibitors I-group I-group
was O O
delayed O O
and O O
their O O
bioavailability O O
was O O
reduced O O
by O O
17 O O
% O O
and O O
16 O O
% O O
, O O
respectively O O
, O O
when O O
administered O O
concomitantly O O
with O O
sucralfate B-drug B-drug
. O O

Pharmacokinetics O O
. O O

Saquinavir B-drug B-drug
: O O
Coadministration O O
of O O
saquinavir B-drug B-drug
( O O
using O O
an O O
experimental O O
soft-gelatin O B-drug
capsule O O
formulation O O
of O O
saquinavir B-drug B-drug
1200mg O O
) O O
with O O
VIRACEPT B-brand B-brand
resulted O O
in O O
an O O
18 O O
% O O
increase O O
in O O
nelfinavir B-drug B-drug
plasma O O
AUC O O
and O O
a O O
4-fold O O
increase O O
in O O
saquinavir B-drug B-drug
plasma O O
A.C O O
. O O

This O O
is O O
based O O
on O O
the O O
results O O
from O O
3 O O
clinical O O
studies O O
using O O
histamine B-drug O
induced O O
skin O O
wheals O O
and O O
flares O O
coupled O O
with O O
population O O
pharmacokinetic O O
analysis O O
. O O

CONCLUSIONS O O
. O O

Other O O
: O O
There O O
appears O O
to O O
be O O
no O O
pharmacokinetic O O
interaction O O
between O O
acitretin B-drug B-drug
and O O
cimetidine B-drug B-drug
, O O
digoxin B-drug B-drug
, O O
or O O
glyburide B-drug B-drug
. O O

While O O
all O O
the O O
selective B-group B-group
serotonin I-group I-group
reuptake I-group I-group
inhibitors I-group I-group
( O O
SSRIs B-group B-group
) O O
, O O
e. O O
g. O O
, O O
fluoxetine B-drug B-drug
, O O
sertraline B-drug B-drug
, O O
and O O
paroxetine B-drug B-drug
, O O
inhibit O O
P450 O O
2D6 O O
, O O
they O O
may O O
vary O O
in O O
the O O
extent O O
of O O
inhibition O O
. O O

Substrate O O
of O O
CYP2D6 O O
( O O
minor O O
) O O
, O O
3A4 O O
( O O
major O O
) O O
; O O

this O O
interaction O O
is O O
not O O
expected O O
to O O
be O O
of O O
clinical O O
importance O O
. O O

Other O O
TNFa-blocking B-group B-group
agents I-group I-group
( O O
including O O
REMICADE B-brand B-brand
) O O
used O O
in O O
combination O O
with O O
anakinra B-drug B-drug
may O O
also O O
result O O
in O O
similar O O
toxicities O O
. O O

There O O
have O O
been O O
reports O O
of O O
positive O O
test O O
results O O
using O O
the O O
Bio-Rad O O
Laboratories O O
Platelia O O
Aspergillus O O
EIA O O
test O O
in O O
patients O O
receiving O O
piperacillin/tazobactam B-drug B-drug
injection O O
who O O
were O O
subsequently O O
found O O
to O O
be O O
free O O
of O O
Aspergillus O O
infection O O
. O O

MAO B-group B-group
Inhibitors I-group I-group
: O O
DURAGESIC B-brand B-brand
is O O
not O O
recommended O O
for O O
use O O
in O O
patients O O
who O O
have O O
received O O
MAOI B-group B-group
within O O
14 O O
days O O
because O O
severe O O
and O O
unpredictable O O
potentiation O O
by O O
MAO B-group B-group
inhibitors I-group I-group
has O O
been O O
reported O O
with O O
opioid B-group B-group
analgesics I-group I-group

INDOCIN B-brand B-brand
reduces O O
basal O O
plasma O O
renin O O
activity O O
( O O
PRA O O
) O O
, O O
as O O
well O O
as O O
those O O
elevations O O
of O O
PRA O O
induced O O
by O O
furosemide B-drug B-drug
administration O O
, O O
or O O
salt O O
or O O
volume O O
depletion O O
. O O

In O O
a O O
study O O
in O O
which O O
patients O O
with O O
active O O
RA O O
were O O
treated O O
for O O
up O O
to O O
24 O O
weeks O O
with O O
concurrent O O
ENBREL B-brand B-brand
and O O
anakinra B-drug B-drug
therapy O O
, O O
a O O
7 O O
% O O
rate O O
of O O
serious O O
infections O O
was O O
observed O O
, O O
which O O
was O O
higher O O
than O O
that O O
observed O O
with O O
ENBREL B-brand B-brand
alone O O
( O O
0 O O
% O O
) O O
. O O

The O O
antimicrobial O O
effect O O
of O O
a O O
benzoxazinorifamycin B-drug_n B-drug
, O O
KRM-1648 B-drug_n B-drug_n
, O O
either O O
alone O O
or O O
in O O
combination O O
with O O
ofloxacin B-drug B-drug
, O O
was O O
evaluated O O
in O O
vitro O O
against O O
two O O
type O O
strains O O
and O O
six O O
clinical O O
isolates O O
of O O
Mycobacterium O O
ulcerans O O
. O O

The O O
combination O O
of O O
therapeutic O O
doses O O
of O O
intravenous O O
dantrolene B-drug B-drug
sodium I-drug I-drug
and O O
verapamil B-drug B-drug
in O O
halothane B-drug B-drug
a-chloralose O O
anesthetized O O
swine O O
has O O
resulted O O
in O O
ventricular O O
fibrillation O O
and O O
cardiovascular O O
collapse O O
in O O
association O O
with O O
marked O O
hyperkalemia O O
. O O

Phenylbutazone B-drug B-drug
: O O
Phenylbutazone B-drug B-drug
causes O O
increase O O
( O O
by O O
about O O
80 O O
% O O
) O O
in O O
the O O
free O O
fraction O O
of O O
etodolac B-drug B-drug
. O O

These O O
drugs O O
include O O
the O O
thiazides B-group B-group
and O O
other O O
diuretics B-group B-group
, O O
corticosteroids B-group B-group
, O O
phe-nothiazines O B-group
, O O
thyroid B-group B-group
products I-group I-group
, O O
estrogens B-group B-group
, O O
oral O O
contraceptives B-group B-group
, O O
phenytoin B-drug B-drug
, O O
nicotinic B-drug B-drug
acid I-drug I-drug
, O O
sympathomimet-ics O B-group
, O O
calcium B-group B-group
channel I-group I-group
blocking I-group I-group
drugs I-group I-group
, O O
and O O
isoniazid B-drug B-drug
. O O

Fulvestrant B-drug B-drug
caused O O
an O O
increased O O
incidence O O
of O O
fetal O O
abnormalities O O
in O O
rats O O
( O O
tarsal O O
flexure O O
of O O
the O O
hind O O
paw O O
at O O
2 O O
mg/kg/day O O
IM O O
; O O

CIMETlDINE B-drug B-drug
: O O
Cerivastatin B-drug B-drug
plasma O O
concentrations O O
were O O
not O O
affected O O
by O O
co-administration O O
of O O
cimetidine B-drug B-drug
. O O

DIAMOX B-brand B-brand
modifies O O
phenytoin B-drug B-drug
metabolism O O
with O O
increased O O
serum O O
levels O O
of O O
phenytoin B-drug B-drug
. O O

In O O
vitro O O
studies O O
indicate O O
that O O
, O O
at O O
therapeutic O O
concentrations O O
of O O
salicylate B-group B-drug
( O O
300 O O
m O O
g/mL O O
) O O
, O O
the O O
binding O O
of O O
ketorolac B-drug B-drug
was O O
reduced O O
from O O
approximately O O
99.2 O O
% O O
to O O
97.5 O O
% O O
, O O
representing O O
a O O
potential O O
twofold O O
increase O O
in O O
unbound O O
ketorolac B-drug B-drug
plasma O O
levels O O
. O O

increased O O
norepinephrine-induced O O
platelet O O
aggregability O O

Ergot-containing O O
drugs O O
have O O
been O O
reported O O
to O O
cause O O
prolonged O O
vasospastic O O
reactions O O
. O O

No O O
formal O O
clinical O O
studies O O
have O O
been O O
conducted O O
to O O
assess O O
if O O
there O O
is O O
an O O
interactive O O
effect O O
on O O
bone O O
loss O O
between O O
systemic B-group O
corticosteroids I-group B-group
and O O
Accutane B-brand B-brand
. O O

Erythromycin B-drug B-drug
: O O
In O O
healthy O O
individuals O O
, O O
plasma O O
concentrations O O
of O O
atorvastatin B-drug B-drug
increased O O
approximately O O
40 O O
% O O
with O O
coadministration O O
of O O
atorvastatin B-drug B-drug
and O O
erythromycin B-drug B-drug
, O O
a O O
known O O
inhibitor O O
of O O
cytochrome O O
P450 O O
3A4 O O
. O O

to O O
contend O O
with O O
. O O

Cysteine B-drug B-drug
was O O
covalently O O
linked O O
to O O
carbodiimide O B-drug
activated O O
NaCMC B-drug_n B-drug_n
. O O

Warfarin B-drug B-drug
: O O
Meclofenamate B-drug B-drug
sodium I-drug I-drug
enhances O O
the O O
effect O O
of O O
warfarin B-drug B-drug
. O O

The O O
mean O O
changes O O
were O O
observed O O
to O O
be O O
less O O
than O O
1 O O
second O O
in O O
both O O
instances O O
, O O
however O O
, O O
and O O
are O O
unlikely O O
to O O
be O O
clinically O O
important O O
. O O

SUBJECTS O O
: O O
Twelve O O
healthy O O
male O O
volunteers O O
. O O

When O O
these O O
products O O
are O O
administered O O
concomitantly O O
, O O
prothrombin O O
time O O
or O O
other O O
suitable O O
coagulation O O
test O O
should O O
be O O
closely O O
monitored O O
. O O

Angiomax B-brand B-brand
should O O
be O O
used O O
with O O
caution O O
in O O
patients O O
with O O
disease O O
states O O
associated O O
with O O
an O O
increased O O
risk O O
of O O
bleeding O O
. O O

The O O
syndrome O O
requires O O
immediate O O
medical O O
attention O O
and O O
may O O
include O O
one O O
or O O
more O O
of O O
the O O
following O O
symptoms O O
: O O
excitement O O
, O O
hypomania O O
, O O
restlessness O O
, O O
loss O O
of O O
consciousness O O
, O O
confusion O O
, O O
disorientation O O
, O O
anxiety O O
, O O
agitation O O
, O O
motor O O
weakness O O
, O O
myoclonus O O
, O O
tremor O O
, O O
hemiballismus O O
, O O
hyperreflexia O O
, O O
ataxia O O
, O O
dysarthria O O
, O O
incoordination O O
, O O
hyperthermia O O
, O O
shivering O O
, O O
pupillary O O
dilation O O
, O O
diaphoresis O O
, O O
emesis O O
, O O
and O O
tachycardia O O
. O O

Probenecid B-drug B-drug
: O O
As O O
with O O
other O O
b-lactam B-group B-group
antibiotics I-group I-group
, O O
probenecid B-drug B-drug
inhibits O O
the O O
renal O O
excretion O O
of O O
cefdinir B-drug B-drug
, O O
resulting O O
in O O
an O O
approximate O O
doubling O O
in O O
A.C. O O
a O O
54 O O
% O O
increase O O
in O O
peak O O
cefdinir B-drug B-drug
plasma O O
levels O O
, O O
and O O
a O O
50 O O
% O O
prolongation O O
in O O
the O O
apparent O O
elimination O O
half-life O O
. O O

Future O O
trends O O
are O O
also O O
predicted O O
. O O

Coadministration O O
of O O
Aprepitant B-drug B-drug
with O O
these O O
drugs O O
or O O
other O O
drugs O O
that O O
are O O
known O O
to O O
be O O
metabolized O O
by O O
CYP2C9 O O
, O O
such O O
as O O
phenytoin B-drug B-drug
, O O
may O O
result O O
in O O
lower O O
plasma O O
concentrations O O
of O O
these O O
drugs O O
. O O

efavirenz B-drug B-drug
concentration O O

Indinavir I-drug B-drug

Lack O O
of O O
an O O
effect O O
of O O
azithromycin B-drug B-drug
on O O
the O O
disposition O O
of O O
zidovudine B-drug B-drug
and O O
dideoxyinosine B-drug B-drug
in O O
HIV-infected O O
patients O O
. O O

Although O O
increased O O
plasma O O
concentrations O O
( O O
AUC O O
0-24 O O
hrs O O
) O O
of O O
loratadine B-drug B-drug
and/or O O
descarboethoxyloratadine B-drug B-drug
were O O
observed O O
following O O
coadministration O O
of O O
loratadine B-drug B-drug
with O O
each O O
of O O
these O O
drugs O O
in O O
normal O O
volunteers O O
( O O
n O O
= O O
24 O O
in O O
each O O
study O O
) O O
, O O
there O O
were O O
no O O
clinically O O
relevant O O
changes O O
in O O
the O O
safety O O
profile O O
of O O
loratadine B-drug B-drug
, O O
as O O
assessed O O
by O O
electrocardiographic O O
parameters O O
, O O
clinical O O
laboratory O O
tests O O
, O O
vital O O
signs O O
, O O
and O O
adverse O O
events O O
. O O

The O O
conjugates O O
so O O
formed O O
often O O
appear O O
in O O
the O O
urine O O
as O O
mercapturic O O
acids O O
or O O
other O O
thioether O O
products O O
. O O

Agents O O
that O O
have O O
been O O
found O O
, O O
or O O
are O O
expected O O
to O O
have O O
decreased O O
plasma O O
levels O O
in O O
the O O
presence O O
of O O
EQUETROTM B-brand B-brand
due O O
to O O
induction O O
of O O
CYP O O
enzymes O O
are O O
the O O
following O O
: O O
Acetaminophen B-drug B-drug
, O O
alprazolam B-drug B-drug
, O O
amitriptyline B-drug B-drug
, O O
bupropion B-drug B-drug
, O O
buspirone B-drug B-drug
, O O
citalopram B-drug B-drug
, O O
clobazam B-drug B-drug
, O O
clonazepam B-drug B-drug
, O O
clozapine B-drug B-drug
, O O
cyclosporin B-drug B-drug
, O O
delavirdine B-drug B-drug
, O O
desipramine B-drug B-drug
, O O
diazepam B-drug B-drug
, O O
dicumarol B-drug B-drug
, O O
doxycycline B-drug B-drug
, O O
ethosuximide B-drug B-drug
, O O
felbamate B-drug B-drug
, O O
felodipine B-drug B-drug
, O O
glucocorticoids B-group B-group
, O O
haloperidol B-drug B-drug
, O O
itraconazole B-drug B-drug
, O O
lamotrigine B-drug B-drug
, O O
levothyroxine B-drug B-drug
, O O
lorazepam B-drug B-drug
, O O
methadone B-drug B-drug
, O O
midazolam B-drug B-drug
, O O
mirtazapine B-drug B-drug
, O O
nortriptyline B-drug B-drug
, O O
olanzapine B-drug B-drug
, O O
oral O O
contraceptives B-group B-group
( O O
3 O O
) O O
, O O
oxcarbazepine B-drug B-drug
, O O
Phenytoin B-drug B-drug
( O O
4 O O
) O O
, O O
praziquantel B-drug B-drug
, O O
protease B-group B-group
inhibitors I-group I-group
, O O
quetiapine B-drug B-drug
, O O
risperidone B-drug B-drug
, O O
theophylline B-drug B-drug
, O O
topiramate B-drug B-drug
, O O
tiagabine B-drug B-drug
, O O
tramadol B-drug B-drug
, O O
triazolam B-drug B-drug
, O O
valproate B-drug B-drug
, O O
warfarin B-drug B-drug
( O O
5 O O
) O O
, O O
ziprasidone B-drug B-drug
, O O
and O O
zonisamide B-drug B-drug
. O O

The O O
pharmacokinetics O O
of O O
nelfinavir B-drug B-drug
are O O
not O O
altered O O
to O O
a O O
clinically O O
significant O O
degree O O
when O O
it O O
is O O
administered O O
with O O
a O O
light O O
meal O O
1 O O
hour O O
after O O
VIDEX B-brand B-brand
. O O

. O O

Caution O O
should O O
be O O
used O O
if O O
naproxen B-drug B-drug
is O O
administered O O
concomitantly O O
with O O
methotrexate B-drug B-drug
. O O

It O O
is O O
recommended O O
to O O
avoid O O
concurrent O O
administration O O
of O O
ethambutol B-drug B-drug
with O O
aluminum B-drug B-drug
hydroxide I-drug I-drug
containing O O
antacids B-group B-group
for O O
at O O
least O O
4 O O
hours O O
following O O
ethambutol B-drug B-drug
administration O O
. O O

*Increased O O
and O O
decreased O O
prothrombin O O
time O O
responses O O
have O O
been O O
reported O O
. O O

Epinephrine B-drug B-drug
should O O
be O O
used O O
cautiously O O
in O O
patients O O
with O O
hyperthyroidism O O
, O O
hypertension O O
and O O
cardiac O O
arrhythmias O O
. O O

Atracurium B-drug B-drug
infusion O O
was O O
continued O O
for O O
a O O
third O O
hour O O
, O O
and O O
then O O
hoof O O
twitch O O
was O O
again O O
allowed O O
to O O
recover O O
spontaneously O O
to O O
75 O O
% O O
. O O

Patients O O
should O O
report O O
to O O
their O O
practitioners O O
any O O
new O O
rashes O O
, O O
itching O O
, O O
mouth O O
sores O O
, O O
or O O
unusual O O
taste O O
while O O
taking O O
auranofin B-drug B-drug
. O O

and O O
the O O
remaining O O
25.9 O O
% O O
( O O
95 O O
% O O
CI O O
, O O
+/- O O
9.3 O O
) O O
by O O
monitoring O O
and O O
follow-up O O
of O O
patients O O
. O O

immunosuppressant B-group B-group
agents I-group I-group
concentration O O

MAO B-group B-group
inhibitors I-group I-group
should O O
be O O
used O O
with O O
caution O O
in O O
patients O O
receiving O O
hydralazine B-drug B-drug
. O O

In O O
vitro O O
studies O O
have O O
shown O O
CASODEX B-brand B-brand
can O O
displace O O
coumarin B-group B-group
anticoagulants O I-group
, O O
such O O
as O O
warfarin B-drug B-drug
, O O
from O O
their O O
protein-binding O O
sites O O
. O O

chlorpropamide B-drug B-drug
; O O

The O O
benzodiazepines B-group B-group
, O O
including O O
alprazolam B-drug B-drug
, O O
produce O O
additive O O
CNS O O
depressant O O
effects O O
when O O
co-administered O O
with O O
other O O
psychotropic B-group B-group
medications I-group I-group
, O O
anticonvulsants B-group B-group
, O O
antihistaminics B-group B-group
, O O
ethanol B-drug B-drug
, O O
and O O
other O O
drugs O O
which O O
themselves O O
produce O O
CNS O O
depression O O
. O O

Digitalis B-group B-group
glycosides I-group I-group
enhanced O O
possibility O O
of O O
arrhythmias O O
or O O
digitalis B-group B-group
toxicity O O
associated O O
with O O
hypokalemia O O
. O O

In O O
the O O
presence O O
of O O
ouabain B-drug B-drug
( O O
10 O O
( O O
-5 O O
) O O
M O O
) O O
, O O
PTX B-drug_n B-drug_n
( O O
10 O O
( O O
-8 O O
) O O
M O O
) O O
failed O O
to O O
cause O O
the O O
first O O
contraction O O
; O O

no O O
other O O
specific O O
drug O O
interaction O O
studies O O
were O O
performed O O
. O O

INFORMATION O O
TO O O
BE O O
PROVIDED O O
TO O O
THE O O
PATIENT O O
OR O O
GUARDIAN O O
See O O
illustrated O O
Information O O
For O O
The O O
Patient O O
or O O
Guardian O O
section O O
. O O

Therefore O O
, O O
to O O
maximize O O
the O O
effects O O
of O O
fexofenadine B-drug B-drug
, O O
it O O
is O O
recommended O O
that O O
ALLEGRA B-brand B-brand
should O O
be O O
taken O O
with O O
water O O

Patients O O
were O O
intravenously O O
injected O O
a O O
chylomicron-like O O
emulsion O O
doubly O O
labeled O O
with O O
14C-cholesteryl O O
oleate O O
and O O
3H-triolein O O
at O O
baseline O O
and O O
after O O
treatments O O
. O O

increased O O
levels O O
of O O
fibrinogen B-drug O
and O O
fibrinogen B-drug O
activity O O
; O O

Warfarin B-drug B-drug
: O O
The O O
effects O O
of O O
warfarin B-drug B-drug
and O O
NSAIDs B-group B-group
on O O
GI O O
bleeding O O
are O O
synergistic O O
, O O
such O O
that O O
users O O
of O O
both O O
drugs O O
together O O
have O O
a O O
risk O O
of O O
serious O O
GI O O
bleeding O O
higher O O
than O O
users O O
of O O
either O O
drug O O
alone O O
. O O

A O O
greater O O
understanding O O
of O O
pain O O
mechanisms O O
will O O
aid O O
in O O
elucidating O O
the O O
role O O
of O O
antihistaminics B-group B-group
in O O
analgesia O O
. O O

In O O
vitro O O
, O O
propranolol B-drug B-drug
appears O O
to O O
be O O
displaced O O
from O O
its O O
binding O O
sites O O
by O O
diltiazem B-drug B-drug
. O O

For O O
example O O
, O O
the O O
plasma O O
nitrosourea B-group B-group
AUC O O
was O O
reduced O O
by O O
factors O O
of O O
1.05 O O
and O O
9.6 O O
for O O
MEC O O
values O O
of O O
1 O O
and O O
2 O O
micrograms O O
ml-1 O O
respectively O O
. O O

Proquin B-brand B-brand
XR I-brand I-brand
should O O
be O O
administered O O
at O O
least O O
4 O O
hours O O
before O O
or O O
2 O O
hours O O
after O O
these O O
products O O
. O O

Rifampin B-drug B-drug
markedly O O
increases O O
the O O
metabolic O O
clearance O O
of O O
amprenavir B-drug B-drug
, O O
and O O
coadministration O O
is O O
contraindicated O O
. O O

CNS-Active O O
Drugs O O
Ethanol B-drug B-drug
: O O
Sonata B-brand B-brand
10 O O
mg O O
potentiated O O
the O O
CNS-impairing O O
effects O O
of O O
ethanol B-drug B-drug
0.75 O O
g/kg O O
on O O
balance O O
testing O O
and O O
reaction O O
time O O
for O O
1 O O
hour O O
after O O
ethanol B-drug B-drug
administration O O
and O O
on O O
the O O
digit O O
symbol O O
substitution O O
test O O
( O O
DSST O O
) O O
, O O
symbol O O
copying O O
test O O
, O O
and O O
the O O
variability O O
component O O
of O O
the O O
divided O O
attention O O
test O O
for O O
2.5 O O
hours O O
after O O
ethanol B-drug B-drug
administration O O
. O O

Additionally O O
, O O
BREVIBLOC B-brand B-brand
should O O
not O O
be O O
used O O
to O O
control O O
supraventricular O O
tachycardia O O
in O O
the O O
presence O O
of O O
agents O O
which O O
are O O
vasoconstrictive O O
and O O
inotropic O O
such O O
as O O
dopamine B-drug B-drug
, O O
epinephrine B-drug B-drug
, O O
and O O
norepinephrine B-drug B-drug
because O O
of O O
the O O
danger O O
of O O
blocking O O
cardiac O O
contractility O O
when O O
systemic O O
vascular O O
resistance O O
is O O
high O O
. O O

Digoxin B-drug B-drug
: O O
The O O
concomitant O O
administration O O
of O O
DynaCirc B-brand B-brand
( O O
isradipine B-drug B-drug
) O O
and O O
digoxin B-drug B-drug
in O O
a O O
single-dose O O
pharmacokinetic O O
study O O
did O O
not O O
affect O O
renal O O
, O O
nonrenal O O
and O O
total O O
body O O
clearance O O
of O O
digoxin B-drug B-drug
. O O

In O O
vitro O O
studies O O
indicate O O
that O O
valdecoxib B-drug B-drug
is O O
a O O
moderate O O
inhibitor O O
of O O
CYP O O
2C19 O O
( O O
IC50 O O
= O O
6 O O
g/mL O O
or O O
19 O O
M O O
) O O
and O O
2C9 O O
( O O
IC50 O O
= O O
13 O O
g/mL O O
or O O
41 O O
M O O
) O O
, O O
and O O
a O O
weak O O
inhibitor O O
of O O
CYP O O
2D6 O O
( O O
IC50 O O
= O O
31 O O
g/mL O O
or O O
100 O O
M O O
) O O
and O O
3A4 O O
( O O
IC50 O O
= O O
44 O O
g/mL O O
or O O
141 O O
M O O
) O O
.. O O

If O O
the O O
drugs O O
are O O
used O O
together O O
, O O
caution O O
should O O
be O O
exercised O O
because O O
unexpected O O
hypotension O O
could O O
result O O
from O O
beta-blocker O O
inhibition O O
of O O
the O O
sympathetic O O
reflex O O
response O O
to O O
fenoldopam B-drug B-drug
. O O

Because O O
cholestyramine B-drug B-drug
binds O O
bile O O
acids O O
, O O
cholestyramine B-drug B-drug
resin B-group B-group
may O O
interfere O O
with O O
normal O O
fat O O
digestion O O
and O O
absorption O O
and O O
thus O O
may O O
prevent O O
absorption O O
of O O
fat B-group B-group
soluble I-group I-group
vitamins I-group I-group
such O O
as O O
A O O
, O O
D O O
, O O
E O O
, O O
and O O
K O O
. O O

. O O

Chapter O O
5 O O
focuses O O
on O O
metabolic O O
effects O O
, O O
specifically O O
lipid O O
metabolism O O
, O O
carbohydrate O O
metabolism O O
and O O
diabetes O O
, O O
coagulation O O
factors O O
, O O
and O O
blood O O
pressure O O
. O O

Therapeutic O O
concentrations O O
of O O
digoxin B-drug B-drug
, O O
warfarin B-drug B-drug
, O O
ibuprofen B-drug B-drug
, O O
naproxen B-drug B-drug
, O O
piroxicam B-drug B-drug
, O O
acetaminophen B-drug B-drug
, O O
phenytoin B-drug B-drug
andtolbutamide O I-drug
did O O
not O O
alter O O
ketorolac B-drug B-drug
tromethamine I-drug I-drug
protein O O
binding O O
. O O

6 O O
. O O

[ O O
Importance O O
of O O
pharmacogenetics O O
] O O
; O O
Pharmacogenetics O O
deals O O
with O O
the O O
differences O O
in O O
effect O O
of O O
drugs O O
caused O O
by O O
genetic O O
variation O O
. O O

INSPRA B-brand B-brand
should O O
not O O
be O O
used O O
with O O
drugs O O
described O O
as O O
strong O O
inhibitors O O
of O O
CYP3A4 O O
in O O
their O O
labeling O O
. O O

* O O
No O O
longer O O
marketed O O
in O O
the O O
US O O
. O O

The O O
peripheral O O
vasoconstriction O O
caused O O
by O O
high O O
doses O O
of O O
dopamine B-drug B-drug
HCl I-drug I-drug
is O O
antagonized O O
by O O
alpha-adrenergic B-group B-group
blocking I-group I-group
agents I-group I-group
. O O

Dosage O O
reduction O O
of O O
Cerubidine B-brand B-drug
may O O
be O O
required O O
when O O
used O O
concurrently O O
with O O
other O O
myelosuppressive O O
agents O O
. O O

In O O
amiodarone-treated B-drug O
patients O O
who O O
require O O
additional O O
antiarrhythmic B-drug B-drug
therapy O O
, O O
the O O
initial O O
dose O O
of O O
such O O
agents O O
should O O
be O O
approximately O O
half O O
of O O
the O O
usual O O
recommended O O
dose O O
. O O

Increased O O
thyroid-binding O O
globulin O O
( O O
TBG O O
) O O
leading O O
to O O
increased O O
circulating O O
total O O
thyroid O O
hormone O O
levels O O
, O O
as O O
measured O O
by O O
protein-bound O O
iodine O O
( O O
PBI O O
) O O
, O O
T4 O O
levels O O
( O O
by O O
column O O
or O O
by O O
radioimmunoassay O O
) O O
or O O
T3 O O
levels O O
by O O
radioimmunoassay O O
. O O

Drug O O
Interactions O O
, O O
General O O
: O O
Although O O
there O O
have O O
been O O
no O O
formal O O
interaction O O
studies O O
, O O
intravenous O O
fenoldopam B-drug B-drug
has O O
been O O
administered O O
safely O O
with O O
drugs O O
such O O
as O O
digitalis B-group B-group
and O O
sublingual O O
nitroglycerin B-drug B-drug
. O O

The O O
AUC O O
of O O
ciprofloxacin B-drug B-drug
was O O
decreased O O
an O O
average O O
of O O
15-fold O O
in O O
12 O O
healthy O O
subjects O O
given O O
ciprofloxacin B-drug B-drug
and O O
didanosine-placebo B-drug B-drug
tablets O O
concurrently O O
. O O

Allopurinol B-drug B-drug
: O O
The O O
AUC O O
of O O
didanosine B-drug B-drug
was O O
increased O O
about O O
4-fold O O
when O O
allopurinol B-drug B-drug
at O O
300 O O
mg/day O O
was O O
coadministered O O
with O O
a O O
single O O
200-mg O O
dose O O
of O O
VIDEX B-brand B-brand
to O O
two O O
patients O O
with O O
renal O O
impairment O O
( O O
CLcr=15 O O
and O O
18 O O
mL/min O O
) O O
. O O

ulcerans O O
was O O
between O O
0.012 O O
and O O
0.025 O O
mg/l O O
, O O
while O O
corresponding O O
values O O
for O O
rifampicin B-drug B-drug
and O O
rifabutin B-drug B-drug
were O O
in O O
the O O
range O O
of O O
0.1-0.8 O O
mg/l O O
and O O
0.1-0.4 O O
mg/l O O
respectively O O
. O O

Antibiotics B-group B-group
( O O
e.g. O O
, O O
erythromycin B-drug B-drug
, O O
trimethoprim B-drug B-drug
and O O
sulfamethoxazole B-drug B-drug
, O O
amoxicillin B-drug B-drug
) O O
. O O

If O O
such O O
measurements O O
are O O
necessary O O
, O O
the O O
use O O
of O O
other O O
methods O O
is O O
recommended O O
. O O

The O O
following O O
information O O
was O O
obtained O O
from O O
studies O O
in O O
normal O O
volunteers O O
. O O

. O O

Few O O
systemic O O
data O O
have O O
been O O
collected O O
on O O
the O O
metabolism O O
of O O
WELLBUTRIN B-brand B-brand
following O O
concomitant O O
administration O O
with O O
other O O
drugs O O
or O O
, O O
alternatively O O
, O O
the O O
effect O O
of O O
concomitant O O
administration O O
of O O
WELLBUTRIN B-brand B-brand
on O O
the O O
metabolism O O
of O O
other O O
drugs O O
. O O

While O O
the O O
recognition O O
of O O
drug O O
toxicity O O
resulting O O
from O O
interactions O O
is O O
of O O
importance O O
to O O
all O O
physciains O B-group
, O O
it O O
is O O
especially O O
so O O
for O O
the O O
clinician O O
responsible O O
for O O
the O O
welfare O O
of O O
those O O
in O O
the O O
aerospace O O
environment O O
. O O

The O O
serum O O
estrogen O O
concentrations O O
of O O
estradiol B-drug B-drug
+ O O
endotoxin-treated B-drug_n O
rats O O
decreased O O
by O O
50 O O
% O O
, O O
while O O
those O O
of O O
the O O
endotoxin-treated B-drug_n O
rats O O
increased O O
( O O
2- O O
to O O
5-fold O O
) O O
. O O

however O O
, O O
in O O
a O O
study O O
of O O
12 O O
normal O O
subjects O O
, O O
concurrent O O
administration O O
of O O
aspirin B-brand B-brand
decreased O O
ketoprofen B-drug B-drug
protein O O
binding O O
and O O
increased O O
ketoprofen B-drug B-drug
plasma O O
clearance O O
from O O
0.07 O O
L/kg/h O O
without O O
aspirin B-brand B-brand
to O O
0.11 O O
L/kg/h O O
with O O
aspirin B-brand B-brand
. O O

Everolimus B-drug B-drug
dose-proportionality O O
and O O
stability O O
over O O
time O O
were O O
assessed O O
in O O
the O O
context O O
of O O
linear O O
regression O O
and O O
ANOVA O O
models O O
. O O

Based O O
on O O
in O O
vitro O O
studies O O
in O O
human O O
liver O O
microsomes O O
, O O
des-ciclesonide B-drug B-drug
appears O O
to O O
have O O
no O O
inhibitory O O
or O O
induction O O
potential O O
on O O
the O O
metabolism O O
of O O
other O O
drugs O O
metabolized O O
by O O
CYP O O
450 O O
enzymes O O
. O O

Thiazides B-group B-group
: O O
Thiazides B-group B-group
are O O
known O O
to O O
induce O O
hypercalcemia O O
by O O
the O O
reduction O O
of O O
calcium O B-drug
excretion O O
in O O
urine O O
. O O

Cssmax O O
of O O
the O O
metabolite O O
, O O
ucb O O
L057 O O
, O O
was O O
approximately O O
doubled O O
in O O
the O O
presence O O
of O O
probenecid B-drug B-drug
while O O
the O O
fraction O O
of O O
drug O O
excreted O O
unchanged O O
in O O
the O O
urine O O
remained O O
the O O
same O O
. O O

Severe O O
hypoglycemia O O
has O O
been O O
reported O O
in O O
patients O O
concomitantly O O
receiving O O
azole B-group B-group
antifungal I-group I-group
agents I-group I-group
and O O
oral O O
hypoglycemic B-group B-group
agents I-group I-group
. O O

Corticosteroids B-group B-group
may O O
increase O O
the O O
clearance O O
of O O
chronic O O
high O O
dose O O
aspirin B-brand B-brand
. O O

adjust O O
salicylate B-group B-group
dosage O O
accordingly O O
if O O
effect O O
is O O
altered O O
. O O

Nevertheless O O
, O O
caution O O
is O O
indicated O O
in O O
the O O
co-administration O O
of O O
TCAs B-group B-group
with O O
any O O
of O O
the O O
SSRIs B-group B-group
and O O
also O O
in O O
switching O O
from O O
one O O
class O O
to O O
the O O
other O O
. O O

Chapter O O
2 O O
considers O O
the O O
mode O O
of O O
action O O
, O O
including O O
ovulation O O
prevention O O
; O O

Diuretics B-group B-group
: O O
Patients O O
on O O
diuretics B-group B-group
, O O
especially O O
those O O
in O O
whom O O
diuretic O B-group
therapy O O
was O O
recently O O
instituted O O
, O O
may O O
occasionally O O
experience O O
an O O
excessive O O
reduction O O
of O O
blood O O
pressure O O
after O O
initiation O O
of O O
therapy O O
with O O
Lotensin B-brand B-brand
. O O

Because O O
of O O
the O O
increased O O
risk O O
of O O
adverse O O
reactions O O
in O O
patients O O
who O O
have O O
been O O
taking O O
benzodiazepines B-group B-group
on O O
a O O
regular O O
basis O O
, O O
it O O
is O O
particularly O O
important O O
that O O
physicians O O
query O O
patients O O
or O O
their O O
guardians O O
carefully O O
about O O
benzodiazepine B-group B-group
, O O
alcohol B-drug B-drug
and O O
sedative B-group B-group
use O O
as O O
part O O
of O O
the O O
history O O
prior O O
to O O
any O O
procedure O O
in O O
which O O
the O O
use O O
of O O
ROMAZICON B-brand B-brand
is O O
planned O O
. O O

+15 O O
% O O
+5 O O
% O O
+15 O O
% O O
+4 O O
% O O

the O O
doses O O
of O O
naloxone B-drug B-drug
required O O
to O O
antagonize O O
the O O
effects O O
of O O
( B-drug_n B-drug_n
- I-drug_n I-drug_n
) I-drug_n I-drug_n
-NANM I-drug_n I-drug_n
were O O
more O O
than O O
100 O O
times O O
higher O O
than O O
those O O
required O O
to O O
antagonize O O
the O O
effects O O
of O O
morphine B-drug B-drug
. O O

Among O O
aspirin B-brand B-brand
or O O
NSAID B-group B-group
users O O
, O O
the O O
incidence O O
of O O
upper O O
gastrointestinal O O
adverse O O
events O O
in O O
patients O O
treated O O
with O O
ibandronate B-drug B-drug
2.5 O O
mg O O
daily O O
( O O
28.9 O O
% O O
) O O
was O O
similar O O
to O O
that O O
in O O
placebo-treated O O
patients O O
( O O
30.7 O O
% O O
) O O
. O O

Warfarin B-drug B-drug
: O O
The O O
effect O O
of O O
celecoxib B-drug B-drug
on O O
the O O
anti-coagulant O O
effect O O
of O O
warfarin B-drug B-drug
was O O
studied O O
in O O
a O O
group O O
of O O
healthy O O
subjects O O
receiving O O
daily O O
doses O O
of O O
2-5 O O
mg O O
of O O
warfarin B-drug B-drug
. O O

4 O O
. O O

Increased O O
anticoagulation O O
effects O O
due O O
to O O
interactions O O
of O O
erythromycin B-drug B-drug
with O O
various O O
oral O O
anticoagulents O B-group
may O O
be O O
more O O
pronounced O O
in O O
the O O
elderly O O
. O O

Colchicine B-drug B-drug
may O O
increase O O
sensitivity O O
to O O
the O O
CNS B-group B-group
depressants I-group I-group
. O O

Phenytoin B-drug B-drug
increases O O
the O O
clearance O O
of O O
busulfan B-drug B-drug
by O O
15 O O
% O O
or O O
more O O
, O O
possibly O O
due O O
to O O
the O O
induction O O
of O O
glutathione-S-transferase O O
. O O

In O O
clinical O O
trials O O
, O O
doxazosin B-drug B-drug
mesylate I-drug I-drug
tablets O O
have O O
been O O
administered O O
to O O
patients O O
on O O
a O O
variety O O
of O O
concomitant O O
medications O O
; O O

The O O
evidence O O
for O O
a O O
role O O
for O O
norepinephrine O B-drug
and O O
dopamine O B-drug
and O O
the O O
effects O O
of O O
antihistaminics B-group B-group
on O O
them O O
are O O
less O O
well O O
established O O
. O O

H2 B-group B-group
Blockers/Proton I-group I-group
Pump I-group I-group
Inhibitors I-group I-group
: O O
Long-term O O
suppression O O
of O O
gastric O O
acid O O
secretion O O
by O O
H2 B-group B-group
blockers I-group I-group
or O O
proton B-group B-group
pump I-group I-group
inhibitors I-group I-group
( O O
eg O O
, O O
famotidine B-drug B-drug
and O O
omeprazole B-drug B-drug
) O O
is O O
likely O O
to O O
reduce O O
dasatinib B-drug B-drug
exposure O O
. O O

abnormal O O
vaginal O O
bleeding O O
; O O

Inhibitors O O
or O O
substrates O O
of O O
CYP2D6 O O
( O O
i.e. O O
, O O
quinidine B-drug B-drug
, O O
selective B-group B-group
serotonin I-group I-group
reuptake I-group I-group
inhibitors I-group I-group
[ O O
SSRIs B-group B-group
] O O
) O O
may O O
increase O O
the O O
plasma O O
concentration O O
of O O
doxepin B-drug B-drug
when O O
administered O O
concomitantly O O
. O O

No O O
volunteer O O
showed O O
hormonal O O
evidence O O
of O O
ovulation O O
, O O
but O O
one O O
volunteer O O
reported O O
intermenstrual O O
bleeding O O
during O O
felbamate B-drug B-drug
treatment O O
. O O

Paralytic O O
ileus O O
may O O
occur O O
in O O
patients O O
taking O O
tricyclic B-drug B-group
antidepressants I-drug I-group
in O O
combination O O
with O O
anticholinergic-type B-drug B-group
drugs O I-group
. O O

Repeat O O
Treatment O O
Studies O O
evaluating O O
the O O
use O O
of O O
repeated O O
courses O O
of O O
Zmax B-brand O
have O O
not O O
been O O
conducted O O
. O O

The O O
extent O O
to O O
which O O
SSRI-TCA B-group B-group
interactions O O
may O O
pose O O
clinical O O
problems O O
will O O
depend O O
on O O
the O O
degree O O
of O O
inhibition O O
and O O
the O O
pharmacokinetics O O
of O O
the O O
SSRI B-group B-group
involved O O
. O O

this O O
can O O
cause O O
headaches O O
and O O
other O O
signs O O
of O O
hypertensive O O
crisis O O
. O O

chloral B-drug B-drug
hydrate* O O
; O O

Chlorpropamide B-drug B-drug
: O O
Chlorpropamides B-drug B-group
plasma O O
half-life O O
may O O
be O O
prolonged O O
by O O
allopurinol B-drug B-drug
, O O
since O O
allopurinol B-drug B-drug
and O O
chlorpropamide B-drug B-drug
may O O
compete O O
for O O
excretion O O
in O O
the O O
renal O O
tubule O O
. O O

This O O
is O O
especially O O
true O O
in O O
patients O O
who O O
may O O
subject O O
themselves O O
to O O
an O O
overdosage O O
of O O
drugs O O
. O O

Colchicine B-drug B-drug
para-aminosalicylic I-drug I-drug
acid I-drug I-drug
and O O
heavy O O
alcohol B-drug B-drug
intake O O
for O O
longer O O
than O O
2 O O
weeks O O
may O O
produce O O
malabsorption O O
of O O
vitamin B-drug B-drug
B12 I-drug I-drug
. O O

When O O
administered O O
concurrently O O
, O O
the O O
following O O
drugs O O
may O O
interact O O
with O O
beta-adrenergic B-group B-group
receptor I-group I-group
blocking I-group I-group
agents I-group I-group
: O O
Anesthetics B-group B-group
, O O
general O O
: O O
exaggeration O O
of O O
the O O
hypotension O O
induced O O
by O O
general O O
anesthetics B-group B-group
. O O

It O O
has O O
been O O
reported O O
that O O
Itraconazole B-drug B-drug
enhances O O
the O O
anticoagulant O O
effect O O
of O O
coumarin-like B-group B-group
drugs O I-group
. O O

Cimetidine B-drug B-drug
at O O
400 O O
mg O O
BID O O
( O O
the O O
usual O O
prescription O O
dose O O
) O O
co-administered O O
with O O
TIKOSYN B-brand B-brand
( O O
500 O O
mcg O O
BID O O
) O O
for O O
7 O O
days O O
has O O
been O O
shown O O
to O O
increase O O
dofetilide B-drug B-drug
plasma O O
levels O O
by O O
58 O O
% O O
. O O

. O O

Integumentary O O

341 O O
PI O O
affecting O O
197 O O
patients O O
( O O
31.5 O O
% O O
, O O
95 O O
% O O
CI O O
, O O
+/- O O
3.6 O O
) O O
were O O
identified O O
. O O

Because O O
bupropion B-drug B-drug
is O O
extensively O O
metabolized O O
, O O
the O O
coadministration O O
of O O
other O O
drugs O O
may O O
affect O O
its O O
clinical O O
activity O O
. O O

Nonsteroidal B-group B-group
Anti-Inflammatory I-group I-group
Drugs I-group I-group
( O O
NSAIDs B-group B-group
) O O
-A O O
drug O O
interaction O O
study O O
of O O
eplerenone B-drug B-drug
with O O
an O O
NSAID B-group B-group
has O O
not O O
been O O
conducted O O
. O O

Steroids B-group B-group
enhance O O
the O O
renal O O
toxicity O O
of O O
edetate B-drug B-drug
calcium I-drug I-drug
disodium I-drug I-drug
in O O
animals O O
. O O
7 O O
Edetate B-drug B-drug
calcium I-drug I-drug
disodium I-drug I-drug
interferes O O
with O O
the O O
action O O
of O O
zinc B-drug B-drug
insulin I-drug I-drug
preparations O O
by O O
chelating O O
the O O
zinc B-drug B-drug
. O O
7 O O

These O O
effects O O
are O O
usually O O
reversible O O
. O O

Vitamin B-group B-group
D I-group I-group
: O O
The O O
coadministration O O
of O O
any O O
of O O
the O O
vitamin B-group B-group
D I-group I-group
analogues O I-group
should O O
be O O
avoided O O
as O O
this O O
could O O
create O O
possible O O
additive O O
effects O O
and O O
hypercalcemia O O
. O O

H1 O O
and O O
H2 B-group B-group
Blockers I-group I-group
- O O
Although O O
not O O
reported O O
, O O
L-histidine B-drug B-drug
, O O
via O O
its O O
metabolism O O
to O O
histamine O O
, O O
might O O
decrease B-group O
the I-group O
efficacy O O
of O O
H1 O O
and O O
H2 B-group B-group
blockers I-group I-group
. O O

Serious O O
toxicity O O
may O O
result O O
if O O
dextromethorphan B-drug B-drug
is O O
coadministered O O
with O O
monoamine B-group B-group
oxidase I-group I-group
inhibitors I-group I-group
( O O
MAOIs B-group B-group
) O O
. O O

Human O O
pharmacokinetic O O
data O O
indicate O O
that O O
oral O O
ketoconazole B-drug B-drug
markedly O O
inhibits O O
the O O
metabolism O O
of O O
cisapride B-drug B-drug
, O O
resulting O O
in O O
a O O
mean O O
eight-fold O O
increase O O
in O O
AUC O O
of O O
cisapride B-drug B-drug
. O O

Growth O O
of O O
M O O
. O O

Opiate B-group B-group
agonists I-group I-group

Maximum O O
calculated O O
theophylline B-drug B-drug
clearance O O
ranged O O
from O O
2 O O
1/2 O O
to O O
3 O O
1/2 O O
times O O
baseline O O
. O O

Interactions O O
may O O
also O O
occur O O
with O O
the O O
following O O
: O O
anti-depressants/anti-anxiety B-group B-group
drugs I-group I-group
, O O
drugs O O
used O O
to O O
treat O O
an O O
overactive O O
thyroid O O
, O O
beta-blockers B-group B-group
( O O
e.g. O O
, O O
propranolol B-drug B-drug
) O O
, O O
sparfloxacin B-drug B-drug
, O O
grepafloxacin B-drug B-drug
, O O
guanethidine B-drug B-drug
, O O
guanadrel B-drug B-drug
, O O
metrizamide B-drug B-drug
, O O
cabergoline B-drug B-drug
, O O
lithium B-drug B-drug
, O O
narcotic B-group B-group
pain O O
medication O O
( O O
e.g. O O
, O O
codeine B-drug B-drug
) O O
, O O
drugs O O
used O O
to O O
aid O O
sleep O O
, O O
drowsiness-causing O O
antihistamines B-group B-group
( O O
e.g. O O
, O O
diphenhydramine B-drug B-drug
) O O
, O O
any O O
other O O
drugs O O
that O O
may O O
make O O
you O O
drowsy O O
. O O

however O O
, O O
there O O
was O O
extensive O O
concomitant O O
use O O
of O O
NSAIDs B-group B-group
in O O
clinical O O
studies O O
and O O
no O O
differential O O
effect O O
was O O
observed O O
. O O

however O O
, O O
at O O
lower O O
concentrations O O
only O O
zinc B-drug B-drug
demonstrated O O
toxicity O O
. O O

When O O
such O O
drugs O O
are O O
administered O O
to O O
a O O
patient O O
receiving O O
DIABINESE B-brand B-brand
, O O
the O O
patient O O
should O O
be O O
observed O O
closely O O
for O O
hypoglycemia O O
. O O

Drugs O O
that O O
may O O
decrease O O
dasatinib B-drug B-drug
plasma O O
concentrations O O
CYP3A4 O O
Inducers O O
: O O
Drugs O O
that O O
induce O O
CYP3A4 O O
activity O O
may O O
decrease O O
dasatinib B-drug B-drug
plasma O O
concentrations O O
. O O

Valproate I-drug B-drug
** O O

In O O
vitro O O
studies O O
have O O
shown O O
that O O
precipitation O O
occurs O O
when O O
eye O O
drops O O
containing O O
thimerosal B-drug_n B-drug
are O O
mixed O O
with O O
latanoprost B-drug B-drug
. O O

plasma O O
levels O O
of O O
several O O
closely O O
related O O
tricyclic B-group B-group
antidepressants I-group I-group
have O O
been O O
reported O O
to O O
be O O
increased O O
by O O
the O O
concomitant O O
administration O O
of O O
methylphenidate B-drug B-drug
or O O
hepatic O O
enzyme O O
inhibitors O O
( O O
e.g. O O
, O O
cimetidine B-drug B-drug
, O O
fluoxetine B-drug B-drug
) O O
and O O
decreased O O
by O O
the O O
concomitant O O
administration O O
of O O
hepatic O O
enzyme O O
inducers O O
( O O
e.g. O O
, O O
barbiturates B-group B-group
, O O
phenytoin B-drug B-drug
) O O
, O O
and O O
such O O
an O O
effect O O
may O O
be O O
anticipated O O
with O O
CMI B-drug O
as O O
well O O
. O O

Therefore O O
, O O
interactions O O
could O O
occur O O
following O O
concomitant O O
administration O O
of O O
psychotropic B-group B-group
drugs I-group I-group
( O O
e.g. O O
, O O
narcotics B-group B-group
, O O
analgesics B-group B-group
, O O
antiemetics B-group B-group
, O O
sedatives B-group B-group
, O O
tranquilizers B-group B-group
) O O
. O O

Although O O
no O O
clinical O O
drug-drug O O
interaction O O
studies O O
have O O
been O O
conducted O O
to O O
date O O
, O O
on O O
the O O
basis O O
of O O
the O O
in O O
vitro O O
studies O O
, O O
cytochrome O O
p450 O O
inhibitors O O
and O O
inducers O O
are O O
unlikely O O
to O O
affect O O
the O O
metabolism O O
of O O
clofarabine B-drug B-drug
. O O

ACE B-group B-group
inhibitors I-group I-group
: O O
Reports O O
suggest O O
that O O
NSAIDs B-group B-group
may O O
diminish O O
the O O
antihypertensive O O
effect O O
of O O
ACE B-group B-group
inhibitors I-group I-group
. O O

Due O O
to O O
its O O

This O O
conference O O
reviews O O
recent O O
developments O O
in O O
these O O
areas O O
, O O
examines O O
the O O
effects O O
of O O
drug O O
use O O
in O O
the O O
elderly O O
and O O
implications O O
for O O
management O O
, O O
and O O
discusses O O
current O O
information O O
on O O
how O O
age O O
may O O
influence O O
the O O
response O O
of O O
cancer O O
to O O
therapy O O
. O O

We O O
incorporate O O
the O O
principles O O
of O O
recovery O O
and O O
define O O
positive O O
and O O
constructive O O
alternatives O O
in O O
dealing O O
with O O
cocaine O B-drug
hunger O O
. O O

Although O O
a O O
causal O O
mechanism O O
and O O
a O O
cause-and-effect O O
relationship O O
have O O
not O O
been O O
established O O
, O O
current O O
evidence O O
suggests O O
that O O
renal O O
function O O
should O O
be O O
monitored O O
in O O
patients O O
on O O
thiazide B-group B-group
diuretics I-group I-group
and O O
allopurinol B-drug B-drug
even O O
in O O
the O O
absence O O
of O O
renal O O
failure O O
, O O
and O O
dosage O O
levels O O
should O O
be O O
even O O
more O O
conservatively O O
adjusted O O
in O O
those O O
patients O O
on O O
such O O
combined O O
therapy O O
if O O
diminished O O
renal O O
function O O
is O O
detected.. O O

These O O
effects O O
were O O
not O O
considered O O
clinically O O
important O O
. O O

Drugs O O
that O O
have O O
been O O
associated O O
with O O
peripheral O O
neuropathy O O
include O O
antiretroviral B-drug B-group
nucleoside I-drug I-group
analogues I-drug I-group
, O O
chloramphenicol B-drug B-drug
, O O
cisplatin B-drug B-drug
, O O
dapsone B-drug B-drug
, O O
disulfiram B-drug B-drug
, O O
ethionamide B-drug B-drug
, O O
glutethimide B-drug B-drug
, O O
gold B-drug B-drug
, O O
hydralazine B-drug B-drug
, O O
iodoquinol B-drug B-drug
, O O
isoniazid B-drug B-drug
, O O
metronidazole B-drug B-drug
, O O
nitrofurantoin B-drug B-drug
, O O
phenytoin B-drug B-drug
, O O
ribavirin B-drug B-drug
, O O
and O O
vincristine B-drug B-drug
. O O

. O O

Concurrent O O
use O O
of O O
phenothiazines B-group B-group
may O O
antagonize O O
the O O
anorectic O O
effect O O
of O O
diethylpropion B-drug B-drug
. O O

It O O
is O O
extensively O O
metabolized O O
, O O
predominantly O O
by O O
cytochrome O O
P450 O O
3A4 O O
. O O

There O O
are O O
other O O
agents O O
that O O
may O O
result O O
in O O
serious O O
and/or O O
life-threatening O O
drug O O
interactions O O
. O O

In O O
another O O
report O O
, O O
nine O O
patients O O
with O O
breast O O
cancer O O
were O O
reported O O
to O O
have O O
decreased O O
symptoms O O
of O O
methotrexate-related B-drug B-drug
toxicity O O
when O O
given O O
supplemental O O
L-glutamine B-drug B-drug
at O O
a O O
dose O O
of O O
0.5 O O
gram/kilogram/day O O
. O O

Other O O
nonsteroidal B-group B-group
anti-inflammatory I-group I-group
drugs I-group I-group
that O O
inhibit O O
prostaglandin O O
synthesis O O
have O O
been O O
shown O O
to O O
interfere O O
with O O
thiazide B-group B-group
diuretics I-group I-group
in O O
some O O
studies O O
and O O
with O O
potassium-sparing B-group B-group
diuretics I-group I-group
. O O

Both O O
groups O O
of O O
agents O O
lower O O
blood O O
levels O O
and O O
efficacy O O
of O O
amphetamines B-group B-group
. O O

- O O
Carmustine B-drug B-drug
( O O
e.g. O O
, O O
BiCNU B-brand B-drug
) O O
or O O

The O O
mechanism O O
of O O
these O O
interactions O O
has O O
been O O
evaluated O O
in O O
in O O
vitro O O
, O O
in O O
situ O O
, O O
and O O
in O O
vivo O O
animal O O
models O O
. O O

Concomitant O O
use O O
of O O
L-phenylalanine B-drug B-drug
and O O
non-selective B-group B-group
MAO I-group I-group
inhibitors I-group I-group
may O O
cause O O
hypertension O O
. O O

The O O
safety O O
of O O
such O O
concomitant O O
use O O
with O O
Activase B-brand B-brand
for O O
the O O
management O O
of O O
acute O O
ischemic O O
stroke O O
is O O
unknown O O
. O O

Veratrum B-group B-group
alkaloids I-group I-group
: O O
Amphetamines B-group B-group
inhibit O O
the O O
hypotensive O O
effect O O
of O O
veratrum B-group B-group
alkaloids I-group I-group
. O O

Rarely O O
salicylate B-group B-group
toxicity O O
may O O
occur O O
in O O
patients O O
who O O
discontinue O O
steroids B-group O
after O O
concurrent O O
high-dose O O
aspirin B-brand B-brand
therapy O O
. O O

Since O O
amiodarone B-drug B-drug
is O O
a O O
substrate O O
for O O
CYP3A4 O O
and O O
CYP2C8 O O
, O O
drugs/substances O O
that O O
inhibit O O
these O O
isoenzymes O O
may O O
decrease O O
the O O
metabolism O O
and O O
increase O O
serum O O
concentration O O
of O O
amiodarone B-drug B-drug
. O O

. O O

the O O
dose O O
of O O
Prostigmin B-brand B-drug
may O O
have O O
to O O
be O O
increased O O
accordingly O O
. O O

Accelerated O O
prothrombin O O
time O O
, O O
partial O O
thromboplastin O O
time O O
, O O
and O O
platelet O O
aggregation O O
time O O
; O O

Concomitant O O
administration O O
of O O
probenecid B-drug B-drug
doubled O O
the O O
AUC O O
for O O
cefprozil B-drug B-drug
. O O

Therefore O O
, O O
the O O
potential O O
exists O O
for O O
interaction O O
between O O
carbamazepine B-drug B-drug
and O O
any O O
agent O O
that O O
induces O O
CYP3A4 O O
. O O

Digoxin B-drug B-drug
: O O
Concomitant O O
administration O O
of O O
erythromycin B-drug B-drug
and O O
digoxin B-drug B-drug
has O O
been O O
reported O O
to O O
result O O
in O O
elevated O O
digoxin B-drug B-drug
serum O O
levels O O
. O O

The O O
effect O O
of O O
TORADOL B-brand B-brand
on O O
plasma O O
lithium B-drug B-drug
has O O
not O O
been O O
studied O O
, O O
but O O
cases O O
of O O
increased O O
lithium B-drug B-drug
plasma O O
levels O O
during O O
TORADOL B-brand B-brand
therapy O O
have O O
been O O
reported O O
. O O

These O O
studies O O
indicate O O
that O O
ketoconazole B-drug B-drug
or O O
erythromycin B-drug B-drug
co-administration O O
enhances O O
fexofenadine B-drug B-drug
gastrointestinal O O
absorption O O
. O O

Because O O
prostaglandina O O
play O O
an O O
important O O
role O O
in O O
hemostasis O O
and O O
ketoprofen B-drug B-drug
has O O
an O O
effect O O
on O O
platelet O O
function O O
as O O
well O O
, O O
concurent O O
therapy O O
with O O
ketoprofen B-drug B-drug
and O O
warfarin B-drug B-drug
requires O O
close O O
monitoring O O
of O O
patients O O
on O O
both O O
drugs O O
. O O

Initial O O
doses O O
of O O
adrenergic B-group B-group
agents I-group I-group
, O O
such O O
as O O
dopamine B-drug B-drug
or O O
epinephrine B-drug B-drug
, O O
should O O
be O O
reduced O O
and O O
titrated O O
to O O
achieve O O
the O O
desired O O
response O O
. O O

But O O
it O O
is O O
now O O
difficult O O
to O O
situate O O
the O O
exact O O
place O O
of O O
the O O
pharmacological O O
indications O O
of O O
magnesium B-drug B-drug
. O O

In O O
the O O
experiments O O
reported O O
here O O
, O O
we O O
examined O O
the O O
interactions O O
between O O
1,25 B-drug B-drug_n
( I-drug I-drug_n
OH I-drug I-drug_n
) I-drug I-drug_n
2D3 I-drug I-drug_n
and O O
the O O
antiestrogen B-group B-drug_n
4-hydroxytamoxifen B-drug_n B-drug_n
( O O
TAM B-drug_n B-drug_n
) O O
, O O
which O O
also O O
induces O O
apoptosis O O
in O O
MCF-7 O O
cells O O
. O O

Anti-HIV B-group B-group
protease I-group I-group
inhibitors I-group I-group
: O O
Saquinavir/ritonavir B-drug B-drug
combination O O

Diethyl B-drug_n B-drug_n
pyrocarbonate I-drug_n I-drug_n
, O O
at O O
pH O O
7.0 O O
, O O
was O O
used O O
to O O
chemically O O
modify O O
exposed O O
histidine O O
residues O O
on O O
toxin B-drug_n B-drug_n
A I-drug_n I-drug_n
. O O

in O O
vitro O O
data O O
on O O
metabolic O O
interactions O O
indicate O O
that O O
Keppra B-brand B-brand
is O O
unlikely O O
to O O
produce O O
, O O
or O O
be O O
subject O O
to O O
, O O
pharmacokinetic O O
interactions O O
. O O

Estrogen B-group O
increased O O
levels O O
of O O
corticosteroid-binding O O
globulin O O
, O O
thereby O O
increasing O O
the O O
bound O O
( O O
inactive O O
) O O
fraction O O
; O O

AMEVIVE B-brand B-brand
underwent O O
trans-placental O B-drug
passage O O
and O O
produced O O
in O O
utero O O
exposure O O
in O O
the O O
developing O O
monkeys O O
. O O

No O O
special O O
precautions O O
appear O O
to O O
be O O
necessary O O
when O O
oral O O
anticoagulant O B-group
therapy O O
is O O
begun O O
in O O
a O O
patient O O
already O O
stabilized O O
on O O
maintenance O O
thyroid O O
replacement O O
therapy O O
. O O

Diagnostic O O
, O O
treatment O O
and O O
aftercare O O
approaches O O
to O O
cocaine B-drug B-drug
abuse O O
. O O

Antidiabetic B-group B-group
drugs I-group I-group
: O O
( O O
oral O O
agents O O
and O O
insulin B-drug B-drug
) O O
- O O
dosage O O
adjustment O O
of O O
the O O
antidiabetic B-group B-group
drug I-group I-group
may O O
be O O
required O O
. O O

Although O O
studies O O
designed O O
to O O
examine O O
drug O O
interactions O O
have O O
not O O
been O O
done O O
, O O
it O O
was O O
noted O O
that O O
corticosteroid B-group B-group
or O O
ACTH B-drug B-group
treatment O O
of O O
relapses O O
for O O
periods O O
of O O
up O O
to O O
28 O O
days O O
has O O
been O O
administered O O
to O O
patients O O
( O O
N=180 O O
) O O
receiving O O
Betaseron B-brand B-brand
. O O

Indinavir I-drug B-drug
and O O
didanosine B-drug B-drug
formulations O O
containing O O
buffer O O
should O O
be O O
administered O O
at O O
least O O
one O O
hour O O
apart O O
on O O
an O O
empty O O
stomach O O
. O O

OBJECTIVES O O
: O O
To O O
examine O O
the O O
effects O O
of O O
acute O O
hydrocortisone B-drug B-drug
pretreatment O O
on O O
the O O
subjective O O
and O O
behavioral O O
effects O O
of O O
d-amphetamine B-drug B-drug
. O O

Efavirenz B-drug B-drug
has O O
been O O
shown O O
in O O
vivo O O
to O O
induce O O
CYP3A4 O O
. O O

The O O
beta-blocker B-group B-group
should O O
be O O
withdrawn O O
first O O
. O O

Although O O
this O O
interaction O O
has O O
not O O
been O O
reported O O
with O O
cinoxacin B-drug B-drug
, O O
caution O O
should O O
be O O
exercised O O
when O O
cinoxacin B-drug B-drug
is O O
given O O
concomitantly O O
with O O
caffeine-containing B-drug B-drug
products O O
. O O

It O O
is O O
probable O O
that O O
dexamethasone B-drug B-drug
, O O
given O O
as O O
antiemetic O O
prophylaxis O O
, O O
contributed O O
to O O
hyperglycemia O O
in O O
some O O
patients O O
. O O

[ O O
Drug O O
treatment O O
of O O
erection O O
disorders O O
in O O
patients O O
with O O
cardiovascular O O
disease O O
] O O
Erectile O O
dysfunction O O
is O O
a O O
frequent O O
condition O O
in O O
cardiovascular O O
patients O O
. O O

Physostigmine B-drug B-drug
briefly O O
reduced O O
the O O
amplitude O O
of O O
most O O
components O O
, O O
including O O
P2 O O
. O O

No O O
specific O O
studies O O
in O O
humans O O
have O O
been O O
performed O O
and O O
caution O O
is O O
recommended O O
. O O

Coadministered O O
Concentration O O
Concentration O O

Co-administration O O
of O O
lovastatin B-drug B-drug
, O O
atenolol B-drug B-drug
, O O
warfarin B-drug B-drug
, O O
furosemide B-drug B-drug
, O O
digoxin B-drug B-drug
, O O
celecoxib B-drug B-drug
, O O
hydrochlorothiazide B-drug B-drug
, O O
ramipril B-drug B-drug
, O O
valsartan B-drug B-drug
, O O
metformin B-drug B-drug
and O O
amlodipine B-drug B-drug
did O O
not O O
result O O
in O O
clinically O O
significant O O
increases O O
in O O
aliskiren B-drug B-drug
exposure O O
. O O

During O O
administration O O
of O O
multiple O O
oral O O
doses O O
of O O
TAMBOCOR B-brand B-brand
to O O
healthy O O
subjects O O
stabilized O O
on O O
a O O
maintenance O O
dose O O
of O O
digoxin B-drug B-drug
, O O
a O O
13 O O
% O O
-19 O O
% O O
increase O O
in O O
plasma O O
digoxin B-drug B-drug
levels O O
occurred O O
at O O
six O O
hours O O
postdose O O
. O O

Some O O
reports O O
have O O
shown O O
that O O
the O O
concomitant O O
administration O O
of O O
thiazides B-group B-group
with O O
vitamin B-group B-group
D I-group I-group
causes O O
hypercalcemia O O
. O O

This O O
report O O
describes O O
a O O
recently O O
identified O O
case O O
of O O
interference O O
of O O
acetylcysteine B-drug B-drug
with O O
the O O
urine O O
test O O
for O O
ketones O O
and O O
demonstrates O O
the O O
importance O O
of O O
a O O
thorough O O
medication O O
review O O
in O O
evaluating O O
abnormal O O
laboratory O O
tests O O
. O O

Nondepolarizing B-group B-group
Muscle I-group I-group
Relaxants I-group I-group
: O O
In O O
postmarketing O O
experience O O
there O O
have O O
been O O
reports O O
of O O
a O O
possible O O
interaction O O
between O O
TORADOLIV/IM O O
and O O
nondepolarizing B-group B-group
muscle I-group I-group
relaxants I-group I-group
that O O
resulted O O
in O O
apnea O O
. O O

Phenytoin B-drug B-drug
: O O
Amphetamines B-group B-group
may O O
delay O O
intestinal O O
absorption O O
of O O
phenytoin B-drug B-drug
; O O

faecalis O O
ATCC O O
51299 O O
showed O O
the O O
flavonoids O O
alone O O
significantly O O
lowered O O
numbers O O
of O O
colony O O
forming O O
units O O
( O O
CFUs O O
) O O
. O O

Catecholamine-depleting O O
drugs O O
( O O
eg O O
, O O
reserpine B-drug B-drug
) O O
may O O
have O O
an O O
additive O O
effect O O
when O O
given O O
with O O
beta-blocking B-group B-group
agents O I-group
. O O

in O O
vitro O O
, O O
Gleevec B-brand O
inhibits O O
the O O
cytochrome O O
P450 O O
isoenzyme O O
CYP2D6 O O
activity O O
at O O
similar O O
concentrations O O
that O O
affect O O
CYP3A4 O O
activity O O
. O O

When O O
the O O
STADOL B-brand B-brand
NS I-brand I-brand
was O O
administered O O
30 O O
minutes O O
after O O
the O O
sumatriptan B-drug B-drug
nasal O O
spray O O
, O O
the O O
AUC O O
of O O
butorphanol B-drug B-drug
increased O O
11 O O
% O O
and O O
Cmax O O
decreased O O
18 O O
% O O
. O O

Dosage O O
adjustments O O
of O O
BROVANA B-brand B-brand
are O O
not O O
necessary O O
when O O
the O O
drug O O
is O O
given O O
concomitantly O O
with O O
potent O O
CYP2D6 O O
inhibitors O O
. O O

Other O O
drugs O O
Drug O O
interactions O O
have O O
been O O
reported O O
with O O
concomitant O O
administration O O
of O O
erythromycin B-drug B-drug
and O O
other O O
medications O O
, O O
including O O
cyclosporine B-drug B-drug
, O O
hexobarbital B-drug B-drug
, O O
carbamazepine B-drug B-drug
, O O
alfentanil B-drug B-drug
, O O
disopyramide B-drug B-drug
, O O
phenytoin B-drug B-drug
, O O
bromocriptine B-drug B-drug
, O O
valproate B-drug B-drug
, O O
astemizole B-drug B-drug
, O O
and O O
lovastatin B-drug B-drug
. O O

Drug/Laboratory O O
Test O O
Interferences O O
: O O
Dicumarol B-drug B-drug
and O O
indanedione B-group B-drug
anticoagulants I-group B-group
, O O
including O O
anisindione B-drug B-drug
, O O
or O O
their O O
metabolites O O
may O O
color O O
alkaline O O
urine O O
red-orange O O
, O O
which O O
may O O
interfere O O
with O O
spectrophotometrically O O
determined O O
urinary O O
laboratory O O
tests O O
. O O

. O O

An O O
individual O O
who O O
is O O
stable O O
on O O
a O O
given O O
dose O O
of O O
TCA B-group B-group
may O O
become O O
abruptly O O
toxic O O
when O O
given O O
one O O
of O O
these O O
inhibiting O O
drugs O O
as O O
concomitant O O
therapy O O
. O O

Antacids B-group B-group
: O O
In O O
a O O
single O O
dose O O
study O O
( O O
n=6 O O
) O O
, O O
ingestion O O
of O O
an O O
antacid B-group B-group
containing O O
1.7-gram O O
of O O
magnesium B-drug B-drug
hydroxide I-drug I-drug
with O O
500-mg O O
of O O
mefenamic B-drug B-drug
acid I-drug I-drug
increased O O
the O O
Cmax O O
and O O
AUC O O
of O O
mefenamic B-drug B-drug
acid I-drug I-drug
by O O
125 O O
% O O
and O O
36 O O
% O O
, O O
respectively O O
. O O
A O O
number O O
of O O
compounds O O
are O O
inhibitors O O
of O O
CYP2C9 O O
including O O
fluconazole B-drug B-drug
, O O
lovastatin B-drug B-drug
and O O
trimethoprim B-drug B-drug
. O O

When O O
ouabain B-drug B-drug
was O O
applied O O
to O O
the O O
muscle O O
in O O
the O O
presence O O
of O O
phentolamine B-drug B-drug
, O O
both O O
first O O
and O O
second O O
contractile O O
responses O O
to O O
PTX B-drug_n B-drug_n
were O O
abolished O O
. O O

Studies O O
in O O
rats O O
have O O
shown O O
that O O
neomycin B-drug B-drug
administration O O
attenuates O O
certain O O
types O O
of O O
adrenocortical B-group O
steroid I-group O
dependent O O
hypertension O O
, O O
including O O
ACTH B-drug B-group
hypertension O O
. O O

If O O
these O O
agents O O
are O O
to O O
be O O
administered O O
concurrently O O
, O O
cyclosporine B-drug B-drug
concentrations O O
should O O
be O O
monitored O O
, O O
especially O O
when O O
diltiazem B-drug B-drug
therapy O O
is O O
initiated O O
, O O
adjusted O O
, O O
or O O
discontinued O O
. O O

We O O
conclude O O
that O O
ADL B-drug B-drug
8-2698 I-drug I-drug
prevents O O
morphine-induced B-drug B-drug
increases O O
in O O
gastrointestinal O O
transit O O
time O O
by O O
means O O
of O O
selective O B-group
peripheral O I-group
opioid O I-group
anitagonism O I-group
without O O
affecting O O
central O O
opioid O B-group
analgesia O O
. O O

Dose O O
reduction O O
of O O
CRIXIVAN B-brand B-brand
to O O
600 O O
mg O O
every O O
8 O O
hours O O
should O O
be O O
considered O O
when O O
taking O O
delavirdine B-drug B-drug
400 O O
mg O O
three O O
times O O
a O O
day O O
. O O

As O O
with O O
other O O
drugs O O
that O O
block O O
angiotensin O B-group
II O I-group
or O O
its O O
effects O O
, O O
concomitant O O
use O O
of O O
potassium-sparing B-group B-group
diuretics I-group I-group
( O O
e.g. O O
, O O
spironolactone B-drug B-drug
, O O
triamterene B-drug B-drug
, O O
amiloride B-drug B-drug
) O O
, O O
potassium B-drug B-drug
supplements O O
, O O
or O O
salt O O
substitutes O O
containing O O
potassium O B-drug
may O O
lead O O
to O O
increases O O
in O O
serum O O
potassium O O
. O O

In O O
healthy O O
subjects O O
, O O
no O O
significant O O
drug-drug O O
interaction O O
was O O
observed O O
when O O
Norpace B-brand B-brand
was O O
coadministered O O
with O O
either O O
propranolol B-drug B-drug
or O O
diazepam B-drug B-drug
. O O

Concomitant O O
administration O O
of O O
alosetron B-drug B-drug
and O O
fluvoxamine B-drug B-drug
is O O
contraindicated O O
. O O

Interaction O O
of O O
GABITRIL B-brand B-brand
with O O
Highly O O
Protein O O
Bound O O
Drugs O O
: O O
In O O
vitro O O
data O O
showed O O
that O O
tiagabine B-drug B-drug
is O O
96 O O
% O O
bound O O
to O O
human O O
plasma O O
protein O O
and O O
therefore O O
has O O
the O O
potential O O
to O O
interact O O
with O O
other O O
highly O O
protein O O
bound O O
compounds O O
. O O

Alternate O O
treatments O O
lacking O O
CYP3A4 O O
inducing O O
activity O O
should O O
be O O
considered O O
. O O

In O O
many O O
of O O
these O O
cases O O
, O O
buprenorphine B-drug B-drug
was O O
misused O O
by O O
self-injection O O
of O O
crushed O O
SUBUTEX B-brand B-brand
tablets O O
. O O

Sildenafil B-drug B-drug
citrate I-drug I-drug
- O O
Theoretically O O
, O O
L-arginine B-drug B-drug
supplements O O
taken O O
concomitantly O O
with O O
sildenafil B-drug B-drug
citrate I-drug I-drug
, O O
may O O
potentiate O O
the O O
effects O O
of O O
the O O
drug O O
. O O

. O O

Agents O O
Having O O
Vasodilator O O
Activity O O
: O O
Data O O
on O O
the O O
effect O O
of O O
concomitant O O
use O O
of O O
other O O
vasodilators B-group B-group
in O O
patients O O
receiving O O
captopril B-drug B-drug
for O O
heart O O
failure O O
are O O
not O O
available O O
; O O

The O O
coadministration O O
of O O
a O O
potent O O
CYP3A4 O O
enzyme O O
inducer O O
, O O
although O O
not O O
posing O O
a O O
safety O O
concern O O
, O O
thus O O
could O O
lead O O
to O O
ineffectiveness O O
of O O
zaleplon B-drug B-drug
. O O

Lithium B-drug B-drug
serum O O
concentrations O O
should O O
be O O
monitored O O
closely O O
when O O
initiating O O
or O O
changing O O
therapy O O
with O O
BEXTRA B-brand B-brand
in O O
patients O O
receiving O O
lithium B-drug B-drug
. O O

Five O O
, O O
10 O O
, O O
20 O O
, O O
or O O
50 O O
mg/kg O O
of O O
ketamine B-drug B-drug
alone O O
or O O
20 O O
, O O
50 O O
, O O
or O O
100 O O
mg/kg O O
of O O
metabolite O O
I O O
alone O O
produced O O
less O O
than O O
10 O O
minutes O O
of O O
hypnosis O O
. O O

Fluoxetine B-drug B-drug

Theophylline B-drug B-drug
alone O O
caused O O
identical O O
insulin O B-drug
and O O
glucagon O O
release O O
in O O
diabetics O O
and O O
normals O O
. O O

It O O
is O O
recommended O O
that O O
glucose O O
tests O O
based O O
on O O
enzymatic O O
glucose O O
oxidase O O
be O O
used O O
. O O

However O O
, O O
neither O O
phenobarbital B-drug B-drug
nor O O
diazepam B-drug B-drug
appears O O
to O O
affect O O
Dantrium B-brand B-drug
metabolism O O
. O O

Bile B-group B-group
acid I-group I-group
binding I-group I-group
resins I-group I-group
may O O
also O O
interfere O O
with O O
the O O
absorption O O
of O O
oral O O
phosphate B-drug B-drug
supplements O O
and O O
hydrocortisone B-drug B-drug
. O O

Cyclosporine B-drug B-drug
: O O
Because O O
cyclosporine B-drug B-drug
can O O
produce O O
nephrotoxicity O O
with O O
decreases O O
in O O
creatinine O O
clearance O O
and O O
rises O O
in O O
serum O O
creatinine O O
, O O
and O O
because O O
renal O O
excretion O O
is O O
the O O
primary O O
elimination O O
route O O
of O O
fibrate B-group B-group
drugs I-group I-group
including O O
TRICOR B-brand B-brand
, O O
there O O
is O O
a O O
risk O O
that O O
an O O
interaction O O
will O O
lead O O
to O O
deterioration O O
. O O

- O O
Antithyroid B-group B-group
agents I-group I-group
( O O
medicine O O
for O O
overactive O O
thyroid O O
) O O
or O O

In O O
the O O
digitalized O O
patient O O
, O O
slow O O
alterations O O
in O O
serum O O
levels O O
after O O
oral O O
administration O O
appeared O O
well O O
correlated O O
with O O
, O O
at O O
least O O
, O O
the O O
negative O O
chronotropic O O
effects O O
of O O
the O O
drug O O
. O O

Potential O O
for O O
Other O O
Drugs O O
to O O
Affect O O
ABILIFY B-brand B-brand
Aripiprazole I-brand B-drug
is O O
not O O
a O O
substrate O O
of O O
CYP1A1 O O
, O O
CYP1A2 O O
, O O
CYP2A6 O O
, O O
CYP2B6 O O
, O O
CYP2C8 O O
, O O
CYP2C9 O O
, O O
CYP2C19 O O
, O O
or O O
CYP2E1 O O
enzymes O O
. O O

Coadministration O O
of O O
oral O O
contraceptives B-group B-group
, O O
diazepam B-drug B-drug
, O O
phenytoin B-drug B-drug
, O O
or O O
quinidine B-drug B-drug
did O O
not O O
seem O O
to O O
change O O
the O O
pharmacokinetic O O
profile O O
of O O
esomeprazole B-drug B-drug
. O O

DRUG/LABORATORY O O
TEST O O
INTERACTIONS O O
1 O O
. O O

In O O
several O O
well-controlled O O
studies O O
, O O
guanfacine B-drug B-drug
was O O
administered O O
together O O
with O O
diuretics B-group B-group
with O O
no O O
drug O O
interactions O O
reported O O
. O O

Spermine B-drug B-drug
( O O
0.5-2 O O
mM O O
) O O
promoted O O
the O O
translocation O O
of O O
phosphatidate O O
phosphohydrolase O O
from O O
the O O
soluble O O
to O O
the O O
microsomal O O
fraction O O
in O O
a O O
cell-free O O
system O O
derived O O
from O O
rat O O
liver O O
. O O

Ethinyl B-drug B-drug
estradiol I-drug I-drug
and O O
Norethindrone B-drug B-drug

Due O O
to O O
the O O
potential O O
for O O
additive O O
effects O O
, O O
caution O O
and O O
careful O O
titration O O
are O O
warranted O O
in O O
patients O O
receiving O O
diltiazem B-drug B-drug
hydrochloride I-drug I-drug
concomitantly O O
with O O
other O O
agents O O
known O O
to O O
affect O O
cardiac O O
contractility O O
and/or O O
conduction O O
. O O

laryngeal O O
edema O O

Since O O
Zarontin B-brand B-brand
( O O
ethosuximide B-drug B-drug
) O O
may O O
interact O O
with O O
concurrently O O
administered O O
antiepileptic B-group B-group
drugs I-group I-group
, O O
periodic O O
serum O O
level O O
determinations O O
of O O
these O O
drugs O O
may O O
be O O
necessary O O
( O O
eg O O
, O O
ethosuximide B-drug B-drug
may O O
elevate O O
phenytoin B-drug B-drug
serum O O
levels O O
and O O
valproic B-drug B-drug
acid I-drug I-drug
has O O
been O O
reported O O
to O O
both O O
increase O O
and O O
decrease O O
ethosuximide B-drug B-drug
levels O O
) O O
. O O

Interactions O O
with O O
Mixed B-group O
Agonist/Antagonist I-group B-group
Opioid I-group I-group
Analgesics I-group I-group
: O O
Agonist/antagonist B-group B-group
analgesics I-group I-group
( O O
eg O O
, O O
pentazocine B-drug B-drug
, O O
nalbuphine B-drug B-drug
, O O
butorphanol B-drug B-drug
, O O
dezocine B-drug B-drug
and O O
buprenorphine B-drug B-drug
) O O
should O O
NOT O O
be O O
administered O O
to O O
a O O
patient O O
who O O
has O O
received O O
or O O
is O O
receiving O O
a O O
course O O
of O O
therapy O O
with O O
a O O
pure B-group O
agonist I-group B-group
opioid I-group I-group
analgesic I-group I-group
such O O
as O O
Levo-Dromoran B-brand B-brand
. O O

Amphotericin B-drug B-drug
B I-drug I-drug
or O O
Corticosteroids B-group B-group
or O O
Corticotropin B-drug B-drug
( O O
ACTH B-drug B-drug
) O O

If O O
oral O O
anticoagulants B-group B-group
are O O
also O O
being O O
given O O
, O O
compensatory O O
increases O O
in O O
clotting O O
factor O O
synthesis O O
are O O
impaired O O
. O O

Because O O
efficient O O
labeling O O
can O O
be O O
achieved O O
with O O
0.1 O O
% O O
biocytin O O
with O O
whole-cell O O
recording O O
, O O
higher O O
concentrations O O
are O O
contraindicated O O
. O O

Nevertheless O O
, O O
the O O
possibility O O
of O O
additive O O
negative O O
inotropic O O
effects O O
of O O
beta B-group B-group
blockers I-group I-group
and O O
flecainide B-drug B-drug
should O O
be O O
recognized O O
. O O

Caution O O
should O O
be O O
taken O O
when O O
ENABLEX B-brand B-brand
is O O
used O O
concomitantly O O
with O O
medications O O
that O O
are O O
predominantly O O
metabolized O O
by O O
CYP2D6 O O
and O O
which O O
have O O
a O O
narrow O O
therapeutic O O
window O O
, O O
such O O
as O O
flecainide B-drug B-drug
, O O
thioridazine B-drug B-drug
and O O
tricyclic B-group B-group
antidepressants I-group I-group
( O O
see O O
CLINICAL O O
PHARMACOLOGY O O
) O O
. O O

These O O
results O O
show O O
that O O
lung B-group B-group
surfactant I-group I-group
has O O
the O O
potential O O
of O O
enhancing O O
the O O
rate O O
and O O
extent O O
of O O
dissolution O O
of O O
drugs O O
administered O O
to O O
the O O
lung O O
. O O

Inhibition O O
of O O
renal O O
lithium B-drug B-drug
clearance O O
leading O O
to O O
increases O O
in O O
plasma O O
lithium B-drug B-drug
concentrations O O
has O O
also O O
been O O
reported O O
. O O

Effects O O
of O O
low O O
temperatures O O
on O O
microtubules O O
in O O
the O O
non-myelinated O O
axons O O
of O O
post-ganglionic O O
sympathetic O O
nerves O O
. O O

However O O
, O O
LDL-C O O
reduction O O
was O O
greater O O
when O O
atorvastatin B-drug B-drug
and O O
colestipol B-drug B-drug
were O O
coadministered O O
than O O
when O O
either O O
drug O O
was O O
given O O
alone O O
. O O

therefore O O
, O O
VIRACEPT B-brand B-brand
should O O
not O O
be O O
administered O O
concurrently O O
with O O
terfenadine B-drug B-drug
because O O
of O O
the O O
potential O O
for O O
serious O O
and/or O O
life-threatening O O
cardiac O O
arrhythmias O O
. O O

Results O O
with O O
warfarin B-drug B-drug
wshow O O
no O O
evidence O O
of O O
interaction O O
with O O
either O O
single O O
or O O
repeated O O
doses O O
of O O
Trileptal B-brand B-brand
. O O

The O O
magnitude O O
of O O
interaction O O
with O O
multiple O O
doses O O
of O O
erythromycin B-drug B-drug
is O O
unknown O O
. O O

In O O
general O O
, O O
most O O
patients O O
treated O O
with O O
dirithromycin B-drug B-drug
who O O
are O O
receiving O O
concomitant O O
theophylline B-drug B-drug
therapy O O
may O O
not O O
require O O
empiric O O
adjustment O O
of O O
theophylline B-drug B-drug
dosage O O
or O O
monitoring O O
of O O
theophylline B-drug B-drug
plasma O O
concentrations O O
. O O

and O O
glutamate B-drug B-drug
( O O
15 O O
mg/kg O O
e.w O O
. O O
) O O

Other O O
drugs O O
which O O
may O O
enhance O O
the O O
neuromuscular O O
blocking O O
action O O
of O O
nondepolarizing B-group O
agents I-group O
such O O
as O O
NIMBEX B-brand B-brand
include O O
certain O O
antibiotics B-group B-group
( O O
e. O O
g. O O
, O O
aminoglycosides B-group B-group
, O O
tetracyclines B-group B-group
, O O
bacitracin B-drug B-drug
, O O
polymyxins B-group B-group
, O O
lincomycin B-drug B-drug
, O O
clindamycin B-drug B-drug
, O O
colistin B-drug B-drug
, O O
and O O
sodium B-drug B-drug
colistemethate I-drug I-drug
) O O
, O O
magnesium B-group B-drug
salts O O
, O O
lithium B-drug B-drug
, O O
local O O
anesthetics B-group B-group
, O O
procainamide B-drug B-drug
, O O
and O O
quinidine B-drug B-drug
. O O

diseases O O
of O O
the O O
liver O O
, O O
gallbladder O O
, O O
and O O
bowel O O
; O O

In O O
in O O
vivo O O
studies O O
, O O
10- O O
to O O
30-mg/day O O
doses O O
of O O
aripiprazole B-drug B-drug
had O O
no O O
significant O O
effect O O
on O O
metabolism O O
by O O
CYP2D6 O O
( O O
dextromethorphan B-drug B-drug
) O O
, O O
CYP2C9 O O
( O O
warfarin B-drug B-drug
) O O
, O O
CYP2C19 O O
( O O
omeprazole B-drug B-drug
, O O
warfarin B-drug B-drug
) O O
, O O
and O O
CYP3A4 O O
( O O
dextromethorphan B-drug B-drug
) O O
substrates O O
. O O

Lapatinib B-drug B-drug
did O O
not O O
significantly O O
inhibit O O
the O O
following O O
enzymes O O
in O O
human O O
liver O O
microsomes O O
: O O
CYP1A2 O O
, O O
CYP2C9 O O
, O O
CYP2C19 O O
, O O
and O O
CYP2D6 O O
or O O
UGT O O
enzymes O O
in O O
vitro O O
, O O
however O O
, O O
the O O
clinical O O
significance O O
is O O
unknown O O
. O O

On O O
the O O
other O O
hand O O
, O O
the O O
enhanced O O
secretion O O
of O O
colonic O O
fluid O O
by O O
dmPGE2 B-drug_n B-drug_n
, O O
given O O
intraluminally O O
, O O
was O O
only O O
half O O
of O O
that O O
in O O
control O O
rats O O
, O O
whereas O O
the O O
colonic O O
transit-enhancing O O
effect O O
of O O
dmPGE2 B-drug_n B-drug_n
in O O
cecectomized O O
rats O O
was O O
more O O
pronounced O O
than O O
in O O
control O O
rats O O
at O O
15 O O
but O O
not O O
at O O
30 O O
min O O
after O O
its O O
administration O O
. O O

Increases O O
in O O
INR O O
and O O
prothrombin O O
time O O
may O O
lead O O
to O O
abnormal O O
bleeding O O
and O O
even O O
death O O
. O O

A O O
5-mg O O
Vardenafil B-drug B-drug
dose O O
should O O
not O O
be O O
exceeded O O
when O O
used O O
in O O
combination O O
with O O
200 O O
mg O O
once O O
daily O O
ketoconazole B-drug B-drug
. O O

Fluvoxamine B-drug B-drug
increased O O
mean O O
alosetron B-drug B-drug
plasma O O
concentrations O O
( O O
AUC O O
) O O
approximately O O
6-fold O O
and O O
prolonged O O
the O O
half-life O O
by O O
approximately O O
3-fold O O
. O O

[ O O
Stimulation O O
by O O
cerulein B-drug_n O
-- O O
an O O
analog O O
of O O
the O O
octapeptide O O
cholecystokinin O O
-- O O
of O O
3H-spiroperidol B-drug_n O
binding O O
after O O
the O O
long-term O O
administration O O
of O O
neuroleptics B-group B-group
] O O
It O O
has O O
been O O
established O O
in O O
experiments O O
on O O
white O O
male O O
rats O O
that O O
prolonged O O
administration O O
( O O
twice O O
a O O
day O O
for O O
14 O O
days O O
) O O
of O O
haloperidol B-drug B-drug
( O O
0.25 O O
mg/kg O O
) O O
and O O
pyreneperone B-drug_n B-drug
( O O
0.25 O O
mg/kg O O
) O O
resulted O O
in O O
the O O
reduced O O
interaction O O
between O O
3H-spiroperidol B-drug_n B-drug_n
and O O
low O O
affinity O O
binding O O
sites O O
for O O
apomorphine B-drug B-drug
in O O
subcortical O O
structures O O
, O O
whereas O O
3H-spiroperidol B-drug_n O
binding O O
with O O
high O O
affinity O O
binding O O
sites O O
for O O
apomorphine B-drug B-drug
increased O O
both O O
in O O
the O O
frontal O O
cortex O O
and O O
subcortical O O
structures O O
of O O
the O O
forebrain O O
. O O

Pulmonary O O
granulomata O O
, O O
subacute O O
hepatitis O O
and O O
other O O
lesions O O
resulting O O
from O O
intravenous O O
drug O O
use O O
were O O
common O O
findings O O
at O O
autopsy O O
. O O

Blunting O O
of O O
the O O
antihypertensive O O
effect O O
of O O
beta-adrenoceptor B-group B-group
blocking I-group I-group
agents I-group I-group
by O O
nonsteroidal B-group B-group
anti-inflammatory I-group I-group
drugs I-group I-group
has O O
been O O
reported O O
. O O

Therefore O O
, O O
when O O
heparin B-drug B-drug
sodium I-drug I-drug
is O O
given O O
with O O
dicumarol B-drug B-drug
or O O
warfarin B-drug B-drug
sodium I-drug I-drug
, O O
a O O
period O O
of O O
at O O
least O O
5 O O
hours O O
after O O
the O O
last O O
intravenous O O
dose O O
or O O
24 O O
hours O O
after O O
the O O
last O O
subcutaneous O O
dose O O
should O O
elapse O O
before O O
blood O O
is O O
drawn O O
if O O
a O O
valid O O
prothrombin O O
time O O
is O O
to O O
be O O
obtained O O
. O O

The O O
concurrent O O
use O O
of O O
TORADOL B-brand B-brand
with O O
muscle B-group B-group
relaxants I-group I-group
has O O
not O O
been O O
formally O O
studied O O
. O O

When O O
increases O O
in O O
the O O
dose O O
of O O
INDOCIN B-brand B-brand
are O O
made O O
, O O
they O O
should O O
be O O
made O O
carefully O O
and O O
in O O
small O O
increments O O
. O O

In O O
some O O
patients O O
, O O
a O O
disulfiram-like B-drug O
reaction O O
may O O
be O O
produced O O
by O O
the O O
ingestion O O
of O O
alcohol B-drug B-drug
. O O

+12 O O
% O O
+19 O O
% O O
-11 O O
% O O
-3 O O
% O O

Because O O
both O O
of O O
these O O
drugs O O
have O O
negative O O
inotropic O O
properties O O
and O O
the O O
effects O O
of O O
coadministration O O
with O O
TAMBOCOR B-brand B-brand
are O O
unknown O O
, O O
neither O O
disopyramide B-drug B-drug
nor O O
verapamil B-drug B-drug
should O O
be O O
administered O O
concurrently O O
with O O
TAMBOCOR B-brand B-brand
unless O O
, O O
in O O
the O O
judgment O O
of O O
the O O
physician O O
, O O
the O O
benefits O O
of O O
this O O
combination O O
outweigh O O
the O O
risks O O
. O O

The O O
20 O O
% O O
v/v O O
solution O O
of O O
alcohol B-drug B-drug
was O O
prepared O O
in O O
water O O
from O O
a O O
stock O O
solution O O
of O O
95 O O
% O O
ethanol B-drug B-drug
. O O

The O O
clinical O O
significance O O
of O O
this O O
interaction O O
in O O
preterm O O
neonates O O
is O O
not O O
known O O
. O O

Retrospective O O
analysis O O
of O O
side O O
effects O O
in O O
clinical O O
trials O O
showed O O
that O O
poor O O
2D6 O O
metabolizers O O
had O O
a O O
higher O O
rate O O
of O O
dizziness O O
during O O
up-titration O O
, O O
presumably O O
resulting O O
from O O
vasodilating O O
effects O O
of O O
the O O
higher O O
concentrations O O
of O O
the O O
a-blocking O O
R O O
( O O
+ O O
) O O
enantiomer O O
. O O

asthma O O
drugs O O
and O O
antipsychotics B-group B-group
. O O

bone O O
marrow O O
hypoplasia O O

( O O
20 O O
mg O O
QD O O
) O O

Coadministration O O
of O O
entecavir B-drug B-drug
with O O
lamivudine B-drug B-drug
, O O
adefovir B-drug B-drug
dipivoxil I-drug I-drug
, O O
or O O
tenofovir B-drug B-drug
disoproxil I-drug I-drug
fumarate I-drug I-drug
did O O
not O O
result O O
in O O
significant O O
drug O O
interactions O O
. O O

Because O O
of O O
the O O
possible O O
additive O O
effects O O
of O O
drugs O O
that O O
may O O
depress O O
the O O
nervous O O
system O O
, O O
ethanol B-drug B-drug
or O O
triazolam B-drug B-drug
should O O
be O O
used O O
cautiously O O
in O O
combination O O
with O O
tiagabine B-drug B-drug
. O O

Aminoglutethimide B-drug B-drug
: O O
Aminoglutethimide B-drug B-drug
may O O
diminish O O
adrenal O O
suppression O O
by O O
corticosteroids B-group B-group
. O O

Atropine B-drug B-drug
, O O
either O O
alone O O
or O O
in O O
combination O O
with O O
alcohol B-drug B-drug
, O O
produced O O
approximately O O
the O O
same O O
degree O O
of O O
enhancement O O
of O O
component O O
P2 O O
. O O

Animals O O
studies O O
on O O
the O O
various O O
dual-memory O O
theories O O
have O O
been O O
carried O O
out O O
mainly O O
on O O
the O O
basis O O
of O O
hippocampal O O
system O O
function O O
. O O

Sertraline B-drug B-drug

Potential O O
Drug O O
Interactions O O
Dofetilide B-drug B-drug
is O O
eliminated O O
in O O
the O O
kidney O O
by O O
cationic O O
secretion O O
. O O

was O O
evaluated O O
as O O
a O O
possible O O
explanation O O
for O O
the O O
association O O
of O O
deep-seated O O
infection O O
with O O
this O O
organism O O
and O O
abuse O O
of O O
these O O
drugs O O
. O O

When O O
Vardenafil B-drug B-drug
dosing O O
was O O
separated O O
from O O
terazosin B-drug B-drug
10 O O
mg O O
by O O
6 O O
hours O O
, O O
7 O O
of O O
28 O O
subjects O O
who O O
received O O
20 O O
mg O O
of O O
Vardenafil B-drug B-drug
experienced O O
a O O
decrease O O
in O O
standing O O
systolic O O
blood O O
pressure O O
below O O
85 O O
mm O O
Hg O O
. O O

However O O
, O O
reports O O
suggest O O
that O O
NSAIDs B-group B-group
may O O
diminish O O
the O O
antihypertensive O O
effect O O
of O O
ACE B-group B-group
inhibitors I-group I-group
. O O

The O O
neurochemical O O
and O O
functional O O
consequences O O
following O O
MPTP B-drug_n B-drug_n
administration O O
to O O
the O O
rat O O
were O O
evaluated O O
and O O
compared O O
to O O
similar O O
effects O O
following O O
methamphetamine B-drug B-drug
administration O O
. O O

Caffeine B-drug B-drug
administered O O
concurrently O O
with O O
ketoprofen B-drug B-drug
reduced O O
the O O
urine O O
volume O O
in O O
4 O O
healthy O O
volunteers O O
. O O

There O O
have O O
been O O
reports O O
of O O
theophylline-related B-drug B-drug
side-effects O O
in O O
patients O O
on O O
concomitant O O
theophylline-quinolone B-drug O
therapy O O
. O O

Non-steroidal B-group B-group
anti-inflammatory I-group I-group
drugs I-group I-group
( O O
but O O
not O O
aspirin B-brand B-brand
) O O
: O O
These O O
drugs O O
in O O
combination O O
with O O
very O O
high O O
doses O O
of O O
quinolones B-group B-group
have O O
been O O
shown O O
to O O
provoke O O
convulsions O O
in O O
pre-clinical O O
studies O O
. O O

In O O
vitro O O
human O O
liver O O
microsome O O
studies O O
and O O
an O O
in O O
vivo O O
metabolic O O
probe O O
study O O
demonstrated O O
that O O
alosetron B-drug B-drug
did O O
not O O
inhibit O O
CYP O O
enzymes O O
2D6 O O
, O O
3A4 O O
, O O
2C9 O O
, O O
or O O
2C19 O O
. O O

In O O
contrast O O
to O O
its O O
enantiomer O O
, O O
( B-drug_n B-drug_n
- I-drug_n I-drug_n
) I-drug_n I-drug_n
-NANM I-drug_n I-drug_n
failed O O
to O O
increase O O
FI O O
responding O O
significantly O O
in O O
either O O
species O O
; O O

The O O
extent O O
to O O
which O O
SSRI-TCAinteractions B-group B-group
may O O
pose O O
clinical O O
problems O O
will O O
depend O O
on O O
the O O
degree O O
of O O
inhibition O O
and O O
the O O
pharmacokinetics O O
of O O
the O O
SSRI B-group B-group
involved O O
. O O

Thus O O
, O O
in O O
addition O O
to O O
its O O
proposed O O
specific O O
information O O
processing O O
functions O O
( O O
i.e. O O
, O O
relational O O
) O O
, O O
the O O
hippocampus O O
would O O
play O O
a O O
role O O
in O O
addressing O O
information O O
to O O
the O O
brain O O
memory O O
system O O
that O O
, O O
in O O
a O O
given O O
situation O O
, O O
has O O
the O O
best O O
adaptive O O
value O O
. O O
( O O
ABSTRACT O O
TRUNCATED O O
AT O O
250 O O
WORDS O O
) O O

When O O
INDOCIN B-brand B-brand
is O O
given O O
to O O
patients O O
receiving O O
probenecid B-drug B-drug
, O O
the O O
plasma O O
levels O O
of O O
indomethacin B-drug B-drug
are O O
likely O O
to O O
be O O
increased O O
. O O

Antihistamines B-group B-group
: O O
Amphetamines B-group B-group
may O O
counteract O O
the O O
sedative O O
effect O O
of O O
antihistamines B-group B-group
. O O

Mixing O O
of O O
Insulins B-group B-group

There O O
was O O
not O O
a O O
significant O O
difference O O
( O O
p O O
> O O
0.05 O O
) O O
in O O
AUC O O
( O O
48.59 O O
+/- O O
8.52 O O
vs. O O
49.9 O O
+/- O O
9.93 O O
) O O
, O O
Cmax O O
( O O
7.73 O O
+/- O O
2.6 O O
vs. O O
6.6 O O
+/- O O
2.0 O O
) O O
, O O
and O O
tmax O O
( O O
1.1 O O
+/- O O
0.6 O O
vs. O O
1.6 O O
+/- O O
1.1 O O
) O O
for O O
levofloxacin B-drug B-drug
versus O O
levofloxacin/oxycodone B-drug B-drug
regimens O O
. O O

The O O
thiazolidinediones B-group B-group
( O O
rosiglitazone B-drug B-drug
and O O
pioglitazone B-drug B-drug
) O O
, O O
a O O
new O O
class O O
of O O
oral O O
antidiabetic B-group B-group
agents I-group I-group
, O O
are O O
" O O
insulin O O
sensitizers O O
" O O

Although O O
specific O O
drug O O
interaction O O
studies O O
in O O
HIV-1 O O
seropositive O O
subjects O O
have O O
not O O
been O O
conducted O O
for O O
the O O
classes O O
of O O
drugs O O
listed O O
in O O
Table O O
4 O O
, O O
additional O O
clinical O O
monitoring O O
may O O
be O O
warranted O O
when O O
co-administering O O
these O O
drugs O O
. O O

In O O
this O O
situation O O
, O O
special O O
patient O O
care O O
and O O
observation O O
are O O
appropriate O O
. O O

Labetalol B-drug B-drug
HCl I-drug I-drug
has O O
also O O
been O O
reported O O
to O O
produce O O
a O O
false O O
positive O O
test O O
for O O
amphetamine B-drug B-drug
when O O
screening O O
urine O O
for O O
the O O
presence O O
of O O
drugs O O
using O O
the O O
commercially O O
available O O
assay O O
methods O O
Toxi-Lab O O
A O O
( O O
thin-layer O O
chromatographic O O
assay O O
) O O
and O O
Emit-d.a.u O O
. O O
( O O
radioenzymatic O O
assay O O
) O O
. O O

Therefore O O
, O O
close O O
monitoring O O
of O O
prothrombin O O
time O O
is O O
recommended O O
and O O
adjustment O O
of O O
the O O
anticoagulant B-group B-group
dose O O
may O O
be O O
necessary O O
when O O
EULEXIN B-brand B-brand
Capsules O O
are O O
administered O O
concomitantly O O
with O O
warfarin B-drug B-drug
. O O

The O O
data O O
inTables O O
1 O O
and O O
3 O O
are O O
based O O
on O O
the O O
results O O
of O O
drug O O
interaction O O
studies O O
conducted O O
in O O
HIV-1 O O
seropositive O O
subjects O O
unless O O
otherwise O O
indicated O O
. O O

Phenobarbital B-drug B-drug
toxicity O O
has O O
been O O
reported O O
to O O
have O O
occurred O O
in O O
a O O
patient O O
on O O
chronic O O
phenobarbital B-drug B-drug
treatment O O
following O O
the O O
initiation O O
of O O
diclofenac B-drug B-drug
therapy O O
. O O

Hydrochlorothiazide B-drug B-drug
: O O
A O O
study O O
in O O
normal O O
healthy O O
volunteers O O
has O O
shown O O
that O O
concomitant O O
administration O O
of O O
DynaCirc B-brand B-brand
( O O
isradipine B-drug B-drug
) O O
and O O
hydrochlorothiazide B-drug B-drug
does O O
not O O
result O O
in O O
altered O O
pharmacoktnetics O O
of O O
either O O
drug O O
. O O

CANCIDAS B-brand B-brand
has O O
no O O
effect O O
on O O
the O O
pharmacokinetics O O
of O O
itraconazole B-drug B-drug
, O O
amphotericin B-drug B-drug
B I-drug I-drug
, O O
or O O
the O O
active O O
metabolite O O
of O O
mycophenolate O B-drug
. O O

Antidepressants B-group B-group
( O O
tricyclic B-group B-group
) O O
, O O
atropine B-drug B-drug
or O O
other O O
anticholinergic B-group B-group
agents I-group I-group
, O O
or O O
digitalis B-group B-group
glycosides I-group I-group
: O O
concurrent O O
use O O
with O O
arbutamine B-drug B-drug
may O O
produce O O
additive O O
inotropic O O
and/or O O
chronotropic O O
effects O O
. O O

This O O
interaction O O
appears O O
to O O
be O O
clinically O O
significant O O
. O O

Since O O
bacteriostatic O O
drugs O O
may O O
interfere O O
with O O
the O O
bactericidal O O
action O O
of O O
penicillin B-drug B-drug
, O O
it O O
is O O
advisable O O
to O O
avoid O O
giving O O
tetracyclines B-group B-group
in O O
conjunction O O
with O O
penicillin B-group B-drug
. O O

The O O
mean O O
reduction O O
of O O
growth O O
caused O O
by O O
the O O
drugs O O
was O O
1,000-fold O O
greater O O
for O O
49 O O
Pseudomonas O O
strains O O
from O O
normal O O
subjects O O
than O O
for O O
32 O O
strains O O
from O O
drug O O
addicts O O
( O O
4.2 O O
vs. O O
1.3 O O
logs O O
of O O
reduction O O
at O O
2 O O
hr O O
, O O
P O O
less O O
than O O
.0005 O O
) O O
. O O

Diazepam B-drug B-drug
: O O
Diazepam B-drug B-drug
( O O
Valium B-brand B-brand
) O O
is O O
a O O
CYP O O
3A4 O O
and O O
CYP O O
2C19 O O
substrate O O
. O O

INCREASED O O
PHENYTOIN B-drug B-drug
LEVELS O O
SHOULD O O
BE O O
TREATED O O
WITH O O
APPROPRIATE O O
DOSAGE O O
ADJUSTMENT O O
. O O

Therefore O O
, O O
if O O
concomitant O O
use O O
of O O
these O O
agents O O
is O O
indicated O O
because O O
of O O
demonstrated O O
hypokalemia O O
, O O
they O O
should O O
be O O
used O O
with O O
caution O O
and O O
with O O
frequent O O
monitoring O O
of O O
serum O O
potassium O O
. O O

Drugs O O
Metabolized O O
by O O
Cytochrome O O
P4502D6 O O
- O O
In O O
vitro O O
studies O O
did O O
not O O
reveal O O
an O O
inhibitory O O
effect O O
of O O
escitalopram B-drug B-drug
on O O
CYP2D6 O O
. O O

The O O
concomitant O O
administration O O
of O O
macrolide B-group B-group
antibiotics I-group I-group
and O O
other O O
hydroxymethylglutaryl B-group B-group
coenzyme I-group I-group
A I-group I-group
( I-group I-group
HMG-CoA I-group I-group
) I-group I-group
reductase I-group I-group
inhibitors I-group I-group
have O O
resulted O O
in O O
previous O O
reports O O
of O O
rhabdomyolysis O O
. O O

The O O
pressor O O
effects O O
of O O
ERGOMAR B-brand B-brand
and O O
other O O
vasoconstrictor B-group B-group
drugs I-group I-group
can O O
combine O O
to O O
cause O O
dangerous O O
hypertension O O
. O O

A O O
causal O O
relationship O O
between O O
these O O
events O O
and O O
the O O
concomitant O O
administration O O
of O O
lithium B-drug B-drug
and O O
HALDOL B-brand B-brand
has O O
not O O
been O O
established O O
; O O

Aortic O O
rings O O
with O O
intact O O
endothelium O O
from O O
the O O
high-dose O O
( O O
4 O O
mg/kg/day O O
) O O
estradiol B-drug B-drug
group O O
were O O
supersensitive O O
to O O
noradrenaline B-drug B-drug
compared O O
to O O
the O O
vehicle O O
or O O
low-dose O O
( O O
10 O O
microg/kg/day O O
) O O
estradiol O B-drug
groups O O
( O O
pD2 O O
values O O
= O O
7.86+/-0.09 O O
, O O
7.30+/-0.11 O O
and O O
7.35+/-0.04 O O
, O O
respectively O O
) O O
. O O

The O O
concurrent O O
use O O
of O O
two O O
or O O
more O O
drugs O O
with O O
anticholinergic O O
activity O O
-- O O
such O O
as O O
an O O
antipsychotic B-group B-group
drug I-group I-group
( O O
eg O O
, O O
chlorpromazine B-drug B-drug
) O O
, O O
an O O
antiparkinsonian B-group O
drug I-group O
( O O
eg O O
, O O
trihexyphenidyl B-drug O
) O O
, O O
and/or O O
a O O
tricyclic B-group B-group
antidepressant I-group I-group
( O O
eg O O
, O O
amitriptyline B-drug B-drug
) O O
-- O O
commonly O O
results O O
in O O
excessive O O
anticholinergic O O
effects O O
, O O
including O O
dry O O
mouth O O
and O O
associated O O
dental O O
complications O O
, O O
blurred O O
vision O O
, O O
and O O
, O O
in O O
patients O O
exposed O O
to O O
high O O
temperature O O
and O O
humidity O O
, O O
hyperpyrexia O O
. O O

Although O O
the O O
pattern O O
of O O
use O O
for O O
oral O O
allopurinol B-drug B-drug
includes O O
longer O O
term O O
therapy O O
, O O
particularly O O
for O O
gout O O
and O O
renal O O
calculi O O
, O O
the O O
experience O O
gained O O
may O O
be O O
relevant O O
. O O

Similarly O O
, O O
in O O
the O O
1-year O O
monthly O O
comparison O O
study O O
, O O
aspirin B-brand B-brand
and O O
nonsteroidal B-group B-group
anti-inflammatory I-group I-group
drugs I-group I-group
were O O
taken O O
by O O
39 O O
% O O
of O O
the O O
1602 O O
patients O O
. O O

These O O
factors O O
, O O
in O O
concert O O
with O O
age-dependent O O
alterations O O
in O O
immune O O
function O O
and O O
host O O
defense O O
, O O
may O O
help O O
to O O
explain O O
the O O
increased O O
risk O O
of O O
malignant O O
disease O O
in O O
aged O O
persons O O
. O O

Although O O
there O O
was O O
a O O
slight O O
reduction O O
in O O
blood O O
sugar O O
concentrations O O
during O O
concomitant O O
administration O O
of O O
flurbiprofen B-drug B-drug
and O O
hypoglycemic B-group B-group
agents I-group I-group
, O O
there O O
were O O
no O O
signs O O
or O O
symptoms O O
of O O
hypoglycemia O O
. O O

Survival O O
of O O
miracidia O O
was O O
reduced O O
by O O
increasing O O
metal O O
concentration O O
except O O
at O O
concentrations O O
of O O
10 O O
microg/l O O
for O O
single O O
metal O O
toxicity O O
where O O
survival O O
was O O
increased O O
above O O
the O O
control O O
. O O

- O O
Antihypertensives B-group B-group
: O O
Bumetanide B-drug B-drug
may O O
potentiate O O
the O O
effect O O
of O O
various O O
antihypertensive B-group B-group
drugs I-group I-group
, O O
necessitating O O
a O O
reduction O O
in O O
the O O
dosage O O
of O O
these O O
drugs O O
. O O

acetaminophen/theophylline B-drug B-drug
, O O
lidocaine/quinidine B-drug B-drug
, O O
phenobarbital/acetaminophen B-drug B-drug
, O O
phenobarbital/valproic B-drug B-drug
acid I-drug I-drug
, O O
quinidine/lidocaine B-drug B-drug
, O O
theophylline/acetaminophen B-drug B-drug
, O O
and O O
valproic B-drug B-drug
acid/phenobarbital I-drug I-drug
. O O

- O O
Increased O O
prothrombin O O
and O O
factors O O
VII O O
, O O
VIII O O
, O O
IX O O
, O O
and O O
X O O
; O O

Enalapril B-drug B-drug
IV O O
has O O
been O O
used O O
concomitantly O O
with O O
digitalis B-group B-group
without O O
evidence O O
of O O
clinically O O
significant O O
adverse O O
reactions O O
. O O

Administration O O
of O O
CMI B-drug O
has O O
been O O
reported O O
to O O
increase O O
the O O
plasma O O
levels O O
of O O
phenobarbital B-drug B-drug
, O O
if O O
given O O
concomitantly O O
. O O

eosinophilia O O

Presumably O O
, O O
phenytoin B-drug B-drug
acts O O
as O O
a O O
stimulator O O
of O O
coumarin B-group B-group
metabolism O O
and O O
has O O
been O O
reported O O
to O O
cause O O
decreased O O
serum O O
levels O O
of O O
the O O
coumarin B-group B-group
anticoagulants I-group I-group
and O O
increased O O
prothrombin-proconvertin O B-drug
concentrations O O
. O O

Johns O O
Wort O O
) O O
may O O
significantly O O
reduce O O
exposure O O
to O O
Gleevec B-brand B-brand
. O O

( O O
Read O O
circulars O O
for O O
lithium B-drug B-drug
preparations O O
before O O
use O O
of O O
such O O
concomitant O O
therapy O O
. O O
) O O

The O O
results O O
indicate O O
that O O
As B-drug_n B-drug_n
( I-drug_n I-drug_n
V I-drug_n I-drug_n
) I-drug_n I-drug_n
readily O O
penetrates O O
both O O
the O O
mucosal O O
and O O
serosal O O
surfaces O O
of O O
the O O
epithelial O O
membrane O O
. O O

Clarithromycin B-drug B-drug

Aspirin/Nonsteroidal B-brand B-group
Antiinflammatory B-group I-group
Drugs O I-group
( O O
NSAIDs B-group B-group
) O O

thyroid B-drug B-group
medication O I-group
; O O

Pharmacokinetic O O
interaction O O
studies O O
with O O
cetirizine B-drug B-drug
in O O
adults O O
were O O
conducted O O
with O O
pseudoephedrine B-drug B-drug
, O O
antipyrine B-drug B-drug
, O O
ketoconazole B-drug B-drug
, O O
erythromycin B-drug B-drug
and O O
azithromycin B-drug B-drug
. O O

When O O
given O O
i.p. O O
, O O
dmPGE2 B-drug_n B-drug_n
( O O
0.3 O O
mg/kg O O
) O O
induced O O
a O O
watery O O
stool O O
in O O
cecectomized O O
and O O
control O O
rats O O
with O O
the O O
same O O
efficacy O O
, O O
although O O
these O O
effects O O
were O O
short-lasting O O
as O O
compared O O
to O O
oral O O
administration O O
. O O

Prior O O
administration O O
of O O
4-methylpyrazole B-drug B-drug
( O O
90 O O
mg O O
kg O O
( O O
-1 O O
) O O
body O O
weight O O
) O O
was O O
shown O O
to O O
prevent O O
the O O
conversion O O
of O O
1,3-difluoro-2-propanol B-drug_n B-drug_n
( O O
100 O O
mg O O
kg O O
( O O
-1 O O
) O O
body O O
weight O O
) O O
to O O
( B-drug_n B-drug_n
- I-drug_n I-drug_n
) I-drug_n I-drug_n
-erythro-fluorocitrate I-drug_n I-drug_n
in O O
vivo O O
and O O
to O O
eliminate O O
the O O
fluoride O B-drug
and O O
citrate O O
elevations O O
seen O O
in O O
1,3-difluoro-2-propanol-intoxicated B-drug_n O
animals O O
. O O

Therefore O O
, O O
use O O
of O O
lamivudine B-drug B-drug
in O O
combination O O
with O O
zalcitabine B-drug B-drug
is O O
not O O
recommended O O

Echistatin B-drug_n B-drug
alone O O
had O O
no O O
effect O O
on O O
tyrosine O O
phosphorylation O O
in O O
T24 O O
cells O O
, O O
but O O
dose-dependently O O
inhibits O O
the O O
effects O O
of O O
contortrostatin B-drug_n B-drug_n
when O O
both O O
are O O
added O O
simultaneously O O
. O O

Patients O O
taking O O
diuretics B-group B-group
are O O
at O O
a O O
greater O O
risk O O
of O O
developing O O
renal O O
failure O O
secondary O O
to O O
a O O
decrease O O
in O O
renal O O
blood O O
flow O O
caused O O
by O O
prostaglandin O O
inhibition O O
. O O

Heparin B-drug B-drug
, O O
other O O
anticoagulants B-group B-group
, O O
thrombolytics B-group B-group
, O O
and O O
anti B-group B-group
platelet I-group I-group
agents I-group I-group
are O O
associated O O
with O O
an O O
increase O O
in O O
bleeding O O
. O O

- O O
Ethotoin B-drug B-drug
( O O
e.g. O O
, O O
Peganone B-brand B-brand
) O O
or O O

Further O O
, O O
they O O
bring O O
into O O
question O O
the O O
utility O O
of O O
using O O
PCP B-drug_n B-drug_n
combination O O
procedures O O
in O O
animals O O
to O O
screen O O
for O O
antipsychotic O O
potential O O
. O O

chloral B-drug B-drug
hydrate* O O
; O O

clofibrate B-drug B-drug
; O O

Caution O O
should O O
be O O
taken O O
in O O
concurrent O O
or O O
serial O O
use O O
of O O
other O O
neurotoxic O O
and/ O O
or O O
nephrotoxic O O
drugs O O
because O O
of O O
possible O O
enhancement O O
of O O
the O O
nephrotoxicity O O
and/or O O
ototoxicity O O
of O O
neomycin B-drug B-drug
. O O

Lithium B-drug B-drug
: O O
Ibuprofen B-drug B-drug
produced O O
an O O
elevation O O
of O O
plasma O O
lithium B-drug B-drug
levels O O
and O O
a O O
reduction O O
in O O
renal O O
lithium B-drug B-drug
clearance O O
in O O
a O O
study O O
of O O
eleven O O
normal O O
volunteers O O
. O O

fenoprofen B-drug B-drug
; O O

The O O
genotypes O O
of O O
CYP2C9 B-drug O
and O O
2C19 O O
, O O
the O O
enzymes O O
responsible O O
for O O
phenytoin O B-drug
metabolism O O
, O O
were O O
homozygous O O
for O O
the O O
wild-type O O
alleles O O
( O O
CYP2C9*1/*1 B-drug O
and O O
2C19*1/ O O
*1 O O
) O O
. O O

Gabapentin B-drug B-drug
had O O
no O O
effect O O
on O O
naproxen B-drug B-drug
pharmacokinetic O O
parameters O O
. O O

Coadministration O O
with O O
valdecoxib B-drug B-drug
( O O
40 O O
mg O O
BID O O
for O O
7 O O
days O O
) O O
resulted O O
in O O
a O O
significant O O
increase O O
in O O
dextromethorphan B-drug B-drug
plasma O O
levels O O
suggesting O O
that O O
, O O
at O O
these O O
doses O O
, O O
valdecoxib B-drug B-drug
is O O
a O O
weak O O
inhibitor O O
of O O
2D6 O O
. O O

- O O
Lofexidine B-drug B-drug
may O O
enhance O O
the O O
effects O O
of O O
anti-hypertensive B-group B-group
drug I-group I-group
therapy O O

Drug O O
Interactions O O
: O O
The O O
central O O
anticholinergic B-group O
syndrome O O
can O O
occur O O
when O O
anticholinergic O B-group
agents O I-group
such O O
as O O
AKINETON B-brand B-brand
are O O
administered O O
concomitantly O O
with O O
drugs O O
that O O
have O O
secondary O O
anticholinergic O O
actions O O
, O O
e.g. O O
, O O
certain O O
narcotic B-group B-group
analgesics I-group I-group
such O O
as O O
meperidine B-drug B-drug
, O O
the O O
phenothiazines B-group B-group
and O O
other O O
antipsychotics B-group B-group
, O O
tricyclic B-group B-group
antidepressants I-group I-group
, O O
certain O O
antiarrhythmics B-group B-group
such O O
as O O
the O O
quinidine B-drug B-drug
salts O O
, O O
and O O
antihistamines B-group B-group
. O O

unlike O O
ibogaine B-drug_n B-drug_n
, O O
18-MC B-drug_n B-drug_n
does O O
not O O
affect O O
responding O O
for O O
a O O
nondrug O O
reinforcer O O
( O O
water O O
) O O
. O O

INOmax B-brand O
has O O
been O O
administered O O
with O O
tolazoline B-drug B-drug
, O O
dopamine B-drug B-drug
, O O
dobutamine B-drug B-drug
, O O
steroids B-group B-group
, O O
surfactant B-drug B-group
, O O
and O O
high-frequency O O
ventilation O O
. O O

The O O
clinical O O
significance O O
of O O
this O O
interaction O O
with O O
doxepin B-drug B-drug
has O O
not O O
been O O
systematically O O
evaluated O O
. O O

in O O
vitro O O
, O O
Gleevec B-brand B-brand
inhibits O O
acetaminophen O B-drug
O-glucuronidation O O
( O O
Ki O O
value O O
of O O
58.5 O O
M O O
) O O
at O O
therapeutic O O
levels O O
. O O

There O O
were O O
several O O
factors O O
that O O
could O O
have O O
increased O O
his O O
risk O O
for O O
developing O O
rhabdomyolysis O O
, O O
including O O
chronic O O
renal O O
failure O O
. O O

These O O
small O O
changes O O
are O O
not O O
clinically O O
significant O O
and O O
no O O
dose O O
adjustment O O
is O O
necessary O O
. O O

and O O
diuretics B-group B-group
, O O
such O O
as O O
furosemide B-drug B-drug
. O O

D O I-group
. O O

NovoSeven B-brand B-brand
should O O
not O O
be O O
mixed O O
with O O
infusion O O
solutions O O
until O O
clinical O O
data O O
are O O
available O O
to O O
direct O O
this O O
use O O
. O O

Therefore O O
, O O
the O O
combined O O
use O O
of O O
lovastatin B-drug B-drug
with O O
fibrates B-group B-group
should O O
generally O O
be O O
avoided O O
. O O

Gentamycin B-drug B-drug
reduced O O
twitch O O
strength O O
from O O
40 O O
+/- O O
1 O O
% O O
( O O
mean O O
+/- O O
sem O O
) O O
to O O
29 O O
+/- O O
4 O O
% O O
within O O
7.0 O O
+/- O O
1.5 O O
min O O
( O O
P O O
= O O
0.02 O O
) O O
. O O

Therefore O O
, O O
co-administration O O
of O O
bupropion B-drug B-drug
with O O
drugs O O
that O O
are O O
metabolized O O
by O O
CYP2D6 O O
isoenzyme O O
including O O
certain O O
antidepressants B-group B-group
( O O
e.g. O O
, O O
nortriptyline B-drug B-drug
, O O
imipramine B-drug B-drug
, O O
desipramine B-drug B-drug
, O O
paroxetine B-drug B-drug
, O O
fluoxetine B-drug B-drug
, O O
sertraline B-drug B-drug
) O O
, O O
antipsychotics B-group B-group
( O O
e.g. O O
, O O
haloperidol B-drug B-drug
, O O
risperidone B-drug B-drug
, O O
thioridazine B-drug B-drug
) O O
, O O
beta-blockers B-group B-group
( O O
e.g. O O
, O O
metoprolol B-drug B-drug
) O O
, O O
and O O
Type B-group B-group
1C I-group I-group
antiarrhythmics I-group I-group
( O O
e.g. O O
, O O
propafenone B-drug B-drug
, O O
flecainide B-drug B-drug
) O O
, O O
should O O
be O O
approached O O
with O O
caution O O
and O O
should O O
be O O
initiated O O
at O O
the O O
lower O O
end O O
of O O
the O O
dose O O
range O O
of O O
the O O
concomitant O O
medication O O
. O O

The O O
plasma O O
and O O
tumour O O
total O O
nitrosourea B-group B-drug
peak O O
concentrations O O
were O O
reduced O O
by O O
1.5 O O
and O O
1.7 O O
fold O O
respectively O O
. O O

The O O
clinical O O
significance O O
of O O
this O O
reduction O O
is O O
not O O
known O O
, O O
hence O O
zalcitabine B-drug B-drug
is O O
not O O
recommended O O
to O O
be O O
ingested O O
simultaneously O O
with O O
magnesium/aluminum-containing B-drug B-group
antacids B-group I-group
. O O

phophatase O O

Therefore O O
, O O
hormonal B-group B-group
contraceptives I-group I-group
, O O
including O O
oral O O
, O O
injectable O O
, O O
transdermal O O
, O O
and O O
implantable O O
forms O O
, O O
may O O
not O O
be O O
reliable O O
when O O
TRACLEER B-brand B-brand
is O O
co-administered O O
. O O

Calcium B-drug B-drug
Supplements O O
: O O
Uncontrolled O O
intake O O
of O O
additional O O
calcium-containing B-drug O
preparations O O
should O O
be O O
avoided O O
. O O

It O O
is O O
recommended O O
that O O
glucose O O
tests O O
based O O
on O O
enzymatic O O
glucose O O
oxidase O O
reactions O O
( O O
such O O
as O O
Clinistix O O
or O O
Tes-Tape O O
) O O
be O O
used O O
. O O

Corticosteroids B-group B-group
: O O
A O O
relationship O O
of O O
functional O O
antagonism O O
exists O O
between O O
vitamin B-group B-group
D I-group I-group
analogues I-group I-group
, O O
which O O
promote O O
calcium O O
absorption O O
, O O
and O O
corticosteroids B-group B-group
, O O
which O O
inhibit O O
calcium O O
absorption O O
. O O

Infusion O O
requirements O O
of O O
NIMBEX B-brand B-brand
in O O
patients O O
administered O O
succinylcholine B-drug B-drug
prior O O
to O O
infusions O O
of O O
NIMBEX B-brand B-brand
were O O
comparable O O
to O O
or O O
slightly O O
greater O O
than O O
when O O
succinylcholine B-drug B-drug
was O O
not O O
administered O O
. O O

The O O
potentiation O O
resulted O O
from O O
a O O
CNS O O
pharmacodynamic O O
interaction O O
; O O

Since O O
fondaparinux B-drug B-drug
sodium I-drug I-drug
does O O
not O O
bind O O
significantly O O
to O O
plasma O O
proteins O O
other O O
than O O
ATIII O B-brand
, O O
no O O
drug O O
interactions O O
by O O
protein-binding O O
displacement O O
are O O
expected O O
. O O

Adjustment O O
of O O
dosage O O
of O O
oral O O
anticoagulants B-group B-group
may O O
be O O
required O O
. O O

However O O
, O O
because O O
bleeding O O
has O O
been O O
reported O O
when O O
ibuprofen B-drug B-drug
and O O
other O O
nonsteroidal B-group B-group
anti-inflammatory I-group I-group
agents I-group I-group
have O O
been O O
administered O O
to O O
patients O O
on O O
coumarin-type B-group B-group
anticoagulants I-group I-group
, O O
the O O
physician O O
should O O
be O O
cautious O O
when O O
administering O O
ibuprofen B-drug B-drug
to O O
patients O O
on O O
anticoagulants B-group B-group
. O O

In O O
vitro O O
data O O
suggest O O
that O O
itraconazole B-drug B-drug
also O O
markedly O O
inhibits O O
the O O
biotransformation O O
system O O
mainly O O
responsible O O
for O O
the O O
metabolism O O
of O O
cisapride B-drug B-drug
; O O

fecal O O
excretion O O
, O O
too O O
, O O
was O O
increased O O
by O O
supplementary O O
iron B-drug B-drug
; O O

No O O
statistically O O
significant O O
differences O O
between O O
treatment O O
groups O O
were O O
observed O O
for O O
any O O
of O O
the O O
calculated O O
digoxin B-drug B-drug
pharmacokinetic O O
parameters O O
. O O

Medications O O
can O O
cause O O
in O O
vivo O O
effects O O
when O O
the O O
concentration O O
or O O
activity O O
of O O
the O O
analyte O O
is O O
altered O O
before O O
the O O
analysis O O
and O O
therefore O O
the O O
assay O O
result O O
is O O
true O O
and O O
accurate O O
. O O

tadalafil I-drug B-drug
concentration O O

Neomycin B-drug B-drug
has O O
no O O
effect O O
on O O
the O O
blood O O
pressure O O
or O O
metabolic O O
responses O O
to O O
ACTH B-group B-drug
in O O
sheep O O
. O O

The O O
concurrent O O
use O O
of O O
anticholinergics B-group B-group
with O O
hydrocodone B-drug B-drug
may O O
produce O O
paralytic O O
ileus O O
. O O

Modification O O
of O O
surface O O
histidine O O
residues O O
abolishes O O
the O O
cytotoxic O O
activity O O
of O O
Clostridium B-drug_n B-drug_n
difficile I-drug_n I-drug_n
toxin I-drug_n I-drug_n
A I-drug_n I-drug_n
. O O

Induction O O
of O O
apoptosis O O
in O O
breast O O
cancer O O
cells O O
in O O
response O O
to O O
vitamin B-group B-group
D I-group I-group
and O O
antiestrogens B-group B-group
. O O

These O O
six O O
volunteers O O
received O O
terfenadine B-drug B-drug
alone O O
( O O
60 O O
mg O O
twice O O
daily O O
) O O
for O O
8 O O
days O O
, O O
followed O O
by O O
terfenadine B-drug B-drug
in O O
combination O O
with O O
dirithromycin B-drug B-drug
( O O
500 O O
mg O O
once O O
daily O O
) O O
for O O
10 O O
days O O
. O O

However O O
, O O
there O O
are O O
limited O O
in O O
vivo O O
data O O
suggesting O O
a O O
modest O O
CYP2D6 O O
inhibitory O O
effect O O
for O O
escitalopram B-drug B-drug
, O O
i.e. O O
, O O
coadministration O O
of O O
escitalopram B-drug B-drug
( O O
20 O O
mg/day O O
for O O
21 O O
days O O
) O O
with O O
the O O
tricyclic B-group B-group
antidepressant I-group I-group
desipramine B-drug B-drug
( O O
single O O
dose O O
of O O
50 O O
mg O O
) O O
, O O
a O O
substrate O O
for O O
CYP2D6 O O
, O O
resulted O O
in O O
a O O
40 O O
% O O
increase O O
in O O
Cmax O O
and O O
a O O
100 O O
% O O
increase O O
in O O
AUC O O
of O O
desipramine B-drug B-drug
. O O

Ketoconazole/Itraconazole B-drug B-drug
, O O
Macrolides B-group B-group
, O O
Including O O
Erythromycin B-drug B-drug

Transient O O
and O O
minor O O
adverse O O
events O O
occurred O O
with O O
similar O O
frequency O O
on O O
placebo O O
and O O
rofecoxib B-drug B-drug
treatments O O
, O O
and O O
no O O
treatment-related O O
pattern O O
was O O
apparent O O
. O O

The O O
following O O
drug O O
interactions O O
were O O
observed O O
in O O
some O O
patients O O
undergoing O O
treatment O O
with O O
oral O O
allopurinol B-drug B-drug
. O O

. O O

INDOCIN B-brand B-brand
and O O
potassium-sparing B-group B-group
diuretics I-group I-group
each O O
may O O
be O O
associated O O
with O O
increased O O
serum O O
potassium O O
levels O O
. O O

Potassium-sparing B-group B-group
diuretics I-group I-group
( O O
spironolactone B-drug B-drug
, O O
amiloride B-drug B-drug
, O O
triamterene B-drug B-drug
, O O
and O O
others O O
) O O
or O O
potassium B-drug B-drug
supplements O O
can O O
increase O O
the O O
risk O O
of O O
hyperkalemia O O
. O O

Therefore O O
, O O
erlotinib B-drug B-drug
exposure O O
may O O
be O O
increased O O
in O O
patients O O
with O O
hepatic O O
dysfunction O O
. O O

alone O O
. O O

Pregnancy O O
Pregnancy O O
Category O O
D O O
: O O
. O O

Nevirapine B-drug B-drug
is O O
known O O
to O O
be O O
an O O
inducer O O
of O O
these O O
enzymes O O
. O O

Therefore O O
, O O
in O O
patients O O
taking O O
insulin B-drug B-drug
or O O
oral O O
hypoglycemics B-group B-group
, O O
regular O O
monitoring O O
of O O
blood O O
glucose O B-drug
is O O
recommended O O
. O O

It O O
is O O
recommended O O
that O O
in O O
patients O O
taking O O
anticoagulants B-group B-group
, O O
prothrombin O O
time O O
be O O
determined O O
before O O
starting O O
lovastatin B-drug B-drug
and O O
frequently O O
enough O O
during O O
early O O
therapy O O
to O O
insure O O
that O O
no O O
significant O O
alteration O O
of O O
prothrombin O O
time O O
occurs O O
. O O

Similarly O O
, O O
there O O
is O O
currently O O
little O O
adequate O O
evidence O O
on O O
either O O
the O O
presence O O
or O O
the O O
absence O O
of O O
serious O O
adverse O O
reactions O O
to O O
such O O
doses O O
of O O
ascorbic B-drug B-drug
acid I-drug I-drug
, O O
although O O
many O O
such O O
reactions O O
have O O
been O O
hypothesized O O
. O O

These O O
agents O O
include O O
medications O O
such O O
as O O
: O O
anticoagulants B-group B-group
, O O
platelet B-group B-group
inhibitors I-group I-group
including O O
acetylsalicylic B-drug B-drug
acid I-drug I-drug
, O O
sali-cylates O B-group
, O O
NSAIDs B-group B-group
( O O
including O O
ketorolac B-drug B-drug
tromethamine I-drug I-drug
) O O
, O O
dipyridamole B-drug B-drug
, O O
or O O
sulfinpyrazone B-drug B-drug
. O O

Diminished O O
urinary O O
excretion O O
of O O
norfloxacin B-drug B-drug
has O O
been O O
reported O O
during O O
the O O
concomitant O O
administration O O
of O O
probenecid B-drug B-drug
and O O
norfloxacin B-drug B-drug
. O O

Retention O O
was O O
calculated O O
by O O
the O O
balance O O
technique O O
and O O
by O O
the O O
comparative O O
slaughter O O
technique O O
. O O

St. O O
John O O
s O O
wort O O
( O O
Hypericum O O
perforatum O O
) O O

Either O O
single O O
( O O
170 O O
mg/kg O O
) O O
or O O
repeated O O
( O O
75 O O
mg/kg O O
per O O
day O O
for O O
5 O O
days O O
) O O
oral O O
administration O O
of O O
cypermethrin B-drug B-drug
was O O
found O O
to O O
produce O O
significant O O
oxidative O O
stress O O
in O O
cerebral O O
and O O
hepatic O O
tissues O O
of O O
rats O O
, O O
as O O
was O O
evident O O
by O O
the O O
elevation O O
of O O
the O O
level O O
of O O
thiobarbituric O O
acid O O
reactive O O
substances O O
( O O
TBARS O O
) O O
in O O
both O O
tissues O O
, O O
either O O
4 O O
or O O
24 O O
h O O
after O O
treatment O O
. O O

The O O
use O O
of O O
REGRANEX B-brand B-brand
Gel O O
with O O
other O O
topical O O
drugs O O
has O O
not O O
been O O
studied O O
. O O

Histidine O B-drug
modification O O
had O O
no O O
effect O O
on O O
the O O
glucosyl O O
transferase O O
enzyme O O
activity O O
of O O
toxin B-drug_n B-drug_n
A I-drug_n I-drug_n
. O O

Hypotension O O
, O O
AV O O
conduction O O
disturbances O O
, O O
and O O
left O O
ventricular O O
failure O O
have O O
been O O
reported O O
in O O
some O O
patients O O
receiving O O
beta-adrenergic B-group B-group
blocking I-group I-group
agents I-group I-group
when O O
an O O
oral O O
calcium B-group B-group
antagonist I-group I-group
was O O
added O O
to O O
the O O
treatment O O
regimen O O
. O O

When O O
a O O
diuretic B-group B-group
is O O
added O O
to O O
the O O
therapy O O
of O O
a O O
patient O O
receiving O O
PRINIVIL B-brand B-brand
, O O
an O O
additional O O
antihypertensive O O
effect O O
is O O
usually O O
observed O O
. O O

METHODS O O
. O O

These O O
recommendations O O
are O O
based O O
on O O
either O O
drug O O
interaction O O
studies O O
or O O
predicted O O
interactions O O
due O O
to O O
the O O
expected O O
magnitude O O
of O O
interaction O O
and O O
potential O O
for O O
serious O O
events O O
or O O
loss O O
of O O
efficacy O O
. O O

free O O
T4 O O
concentration O O
is O O
unaltered O O
: O O
impaired O O
glucose O O
tolerance O O
; O O

The O O
inhibition O O
of O O
CYP-2C19 O O
by O O
OXC B-drug B-drug
and O O
MHD B-drug_n B-drug_n
, O O
however O O
, O O
is O O
clinically O O
relevant O O
. O O

anticholinergics B-group B-group
or O O
other O O
medications O O
with O O
anticholinergic O O
activity O O
- O O
anticholinergic O O
effects O O
may O O
be O O
potentiated O O
when O O
these O O
medications O O
are O O
used O O
concurrently O O
with O O
diphenidol B-drug B-drug
; O O

Lopinavir/Ritonavir B-drug B-drug

Other O O
factors O O
may O O
increase O O
the O O
risk O O
of O O
this O O
drug O O
interaction O O
, O O
including O O
the O O
administration O O
of O O
other O O
medications O O
that O O
are O O
associated O O
with O O
myopathy O O
, O O
underlying O O
renal O O
insufficiency O O
, O O
and O O
administration O O
of O O
high O O
doses O O
of O O
HMG-CoA B-group B-group
reductase I-group I-group
inhibitors I-group I-group
. O O

When O O
such O O
drugs O O
are O O
withdrawn O O
from O O
a O O
patient O O
receiving O O
MICRONASE B-brand B-brand
, O O
the O O
patient O O
should O O
be O O
observed O O
closely O O
for O O
hypoglycemia O O
. O O

Other O O
Drug O O
Interactions O O
Oral O O
Contraceptives B-group B-group
Keppra B-brand B-brand
( O O
500 O O
mg O O
twice O O
daily O O
) O O
did O O
not O O
influence O O
the O O
pharmacokinetics O O
of O O
an O O
oral O O
contraceptive B-group B-group
containing O O
0.03 O O
mg O O
ethinyl B-drug B-drug
estradiol I-drug I-drug
and O O
0.15 O O
mg O O
levonorgestrel B-drug B-drug
, O O
or O O
of O O
the O O
luteinizing O B-drug
hormone O I-drug
and O O
progesterone O B-drug
levels O O
, O O
indicating O O
that O O
impairment O O
of O O
contraceptive O O
efficacy O O
is O O
unlikely O O
. O O

Amitriptyline B-drug B-drug
: O O
Concurrent O O
administration O O
of O O
25 O O
mg O O
or O O
100 O O
mg O O
cinacalcet B-drug B-drug
with O O
50 O O
mg O O
amitriptyline B-drug B-drug
increased O O
amitriptyline B-drug B-drug
exposure O O
and O O
nortriptyline B-drug_n B-drug
( O O
active O O
metabolite O O
) O O
exposure O O
by O O
approximately O O
20 O O
% O O
in O O
CYP2D6 O O
extensive O O
metabolizers O O
. O O

When O O
patients O O
being O O
treated O O
with O O
labetalol B-drug B-drug
have O O
a O O
positive O O
urine O O
test O O
for O O
amphetamine B-drug B-drug
using O O
these O O
techniques O O
confirmation O O
should O O
be O O
made O O
by O O
using O O
more O O
specific O O
methods O O
such O O
as O O
a O O
gas O O
chromatographic-mass O O
spectrometer O O
technique O O
. O O

Cyclosporine B-drug B-drug
: O O
Combination O O
hormonal B-group B-group
contraceptives I-group I-group
may O O
inhibit O O
the O O
metabolism O O
of O O
cyclosporine B-drug B-drug
, O O
leading O O
to O O
increased O O
plasma O O
concentrations O O
; O O

Since O O
indomethacin B-drug B-drug
and O O
potassium-sparing B-group B-group
diuretics I-group I-group
, O O
including O O
MIDAMOR B-brand B-brand
, O O
may O O
each O O
be O O
associated O O
with O O
increased O O
serum O O
potassium O O
levels O O
, O O
the O O
potential O O
effects O O
on O O
potassium O O
kinetics O O
and O O
renal O O
function O O
should O O
be O O
considered O O
when O O
these O O
agents O O
are O O
administered O O
concurrently O O
. O O

Some O O
preliminary O O
data O O
suggest O O
that O O
calcium B-group B-group
blockers I-group I-group
also O O
increase O O
generation O O
of O O
vasodilator O O
and O O
platelet O O
antiaggregant O O
prostacyclin O B-drug
, O O
which O O
could O O
contribute O O
to O O
decrease O O
in O O
platelet O O
function O O
. O O

Hypotension O O
Patients O O
on O O
Diuretic B-group O
Therapy O O
: O O
Patients O O
on O O
diuretics B-group B-group
and O O
especially O O
those O O
in O O
whom O O
diuretic B-group B-group
therapy O O
was O O
recently O O
instituted O O
, O O
as O O
well O O
as O O
those O O
on O O
severe O O
dietary O O
salt O O
restriction O O
or O O
dialysis O O
, O O
may O O
occasionally O O
experience O O
a O O
precipitous O O
reduction O O
of O O
blood O O
pressure O O
usually O O
within O O
the O O
first O O
hour O O
after O O
receiving O O
the O O
initial O O
dose O O
of O O
captopril B-drug B-drug
. O O

Theophylline B-drug B-drug
: O O
Ethinyl B-drug B-drug
estradiol I-drug I-drug
may O O
inhibit O O
the O O
metabolism O O
of O O
theophylline B-drug B-drug
, O O
leading O O
to O O
increased O O
plasma O O
concentrations O O
. O O

by O O
the O O
nonlinear O O
kinetic O O
characteristics O O
for O O
verapamil B-drug B-drug
and O O
diltiazem B-drug B-drug
( O O
and O O
probably O O
for O O
nifedipine B-drug B-drug
, O O
as O O
well O O
) O O
and O O
the O O
derivative O O
implications O O
for O O
decreased O O
dosing O O
frequency O O
requirements O O
; O O

In O O
eight O O
HIV-infected O O
patients O O
, O O
the O O
steady-state O O
AUC O O
of O O
ciprofloxacin B-drug B-drug
was O O
decreased O O
an O O
average O O
of O O
26 O O
% O O
( O O
95 O O
% O O
CI O O
= O O
14 O O
% O O
, O O
37 O O
% O O
) O O
when O O
ciprofloxacin B-drug B-drug
was O O
administered O O
2 O O
hours O O
prior O O
to O O
a O O
marketed O O
chewable/dispersible O O
tablet O O
formulation O O
of O O
VIDEX B-brand B-brand
. O O

Coadministration O O
of O O
gly-buride O B-drug
and O O
metformin B-drug B-drug
did O O
not O O
result O O
in O O
any O O
changes O O
in O O
either O O
metformin B-drug B-drug
pharmacokinetics O O
or O O
pharmaco-dynamics O O
. O O

Patients O O
who O O
begin O O
taking O O
diclofenac B-drug B-drug
or O O
who O O
increase O O
their O O
diclofenac B-drug B-drug
dose O O
or O O
any O O
other O O
NSAID B-group B-group
while O O
taking O O
digoxin B-drug B-drug
, O O
methotrexate B-drug B-drug
, O O
or O O
cyclosporine B-drug B-drug
may O O
develop O O
toxicity O O
characteristics O O
for O O
these O O
drugs O O
. O O

Mercaptopurine/Azathioprine B-drug B-drug
: O O
Allopurinol B-drug B-drug
inhibits O O
the O O
enzymatic O O
oxidation O O
of O O
mercaptopurine B-drug B-drug
and O O
azathioprine B-drug B-drug
to O O
6-thiouric B-drug B-drug_n
acid I-drug I-drug_n
. O O

There O O
was O O
a O O
small O O
increase O O
in O O
plasma O O
concentrations O O
of O O
capecitabine B-drug B-drug
and O O
one O O
metabolite O O
( O O
5-DFCR B-drug_n O
) O O
; O O

Concomitant O O
oral O O
administration O O
of O O
ketoconazole B-drug B-drug
( O O
a O O
known O O
inhibitor O O
of O O
CYP3A4 O O
activity O O
in O O
the O O
liver O O
and O O
in O O
the O O
intestinal O O
mucosa O O
) O O
caused O O
an O O
eight-fold O O
increase O O
of O O
the O O
systemic O O
exposure O O
to O O
oral O O
budesonide B-drug B-drug
. O O

Probenecid B-drug B-drug
or O O
Cimetidine B-drug B-drug
: O O
Concomitant O O
administration O O
of O O
probenecid B-drug B-drug
or O O
cimetidine B-drug B-drug
decreases O O
the O O
elimination O O
of O O
zalcitabine B-drug B-drug
, O O
most O O
likely O O
by O O
inhibition O O
of O O
renal O O
tubular O O
secretion O O
of O O
zalcitabine B-drug B-drug
. O O

There O O
is O O
no O O
information O O
on O O
the O O
effect O O
of O O
other O O
highly O O
plasma O O
protein O O
bound O O
drugs O O
on O O
doxazosin B-drug B-drug
binding O O
. O O

sickle O O
cell O O
disease O O
; O O

Buprenorphine B-drug B-drug
is O O
metabolized O O
to O O
norbuprenorphine B-drug_n B-drug
by O O
cytochrome O O
CYP O O
3A4 O O
. O O

Patients O O
receiving O O
other O O
narcotic B-group B-group
analgesics I-group I-group
, O O
antipsychotics B-group B-group
, O O
antianxiety B-group B-group
agents I-group I-group
, O O
or O O
other O O
CNS B-group B-group
depressants I-group I-group
( O O
including O O
alcohol B-drug B-drug
) O O
concomitantly O O
with O O
hydrocodone B-drug B-drug
and O O
acetaminophen B-drug B-drug
tablets O O
may O O
exhibit O O
an O O
additive O O
CNS O O
depression O O
. O O

Depending O O
on O O
the O O
traction O O
of O O
drug O O
metabolized O O
by O O
P450 O O
2D6 O O
, O O
the O O
increase O O
in O O
plasma O O
concentration O O
may O O
be O O
small O O
, O O
or O O
quite O O
large O O
( O O
8 O O
fold O O
increase O O
in O O
plasma O O
AUC O O
of O O
the O O
TCA B-group B-group
) O O
. O O

Isoproterenol B-drug B-drug
alone O O
at O O
a O O
dose O O
of O O
2.7 O O
mg/kg/day O O
( O O
approximately O O
7 O O
times O O
the O O
maximum O O
recommended O O
daily O O
inhalation O O
dose O O
in O O
adults O O
on O O
a O O
mg/m2 O O
basis O O
) O O
increased O O
both O O
resorptions O O
and O O
malformations O O
. O O

This O O
could O O
facilitate O O
the O O
action O O
of O O
fatty O O
acids O O
and O O
enable O O
cells O O
to O O
increase O O
their O O
capacity O O
for O O
triacylglycerol O O
synthesis O O
to O O
match O O
an O O
increased O O
availability O O
of O O
fatty O O
acids O O
. O O

Formal O O
drug O O
interaction O O
studies O O
have O O
not O O
been O O
conducted O O
with O O
ORENCIA B-brand B-brand
. O O

Benzylpenicillin B-drug B-drug
, O O
ampicillin B-drug B-drug
, O O
oxacillin B-drug B-drug
, O O
chlortetracycline B-drug B-drug
, O O
doxycycline B-drug B-drug
, O O
cephalothin B-drug B-drug
, O O
erythromycin B-drug B-drug
, O O
and O O
sulfamethoxazole B-drug B-drug
have O O
no O O
influence O O
in O O
vitro O O
on O O
the O O
protein O O
binding O O
of O O
diclofenac B-drug B-drug
in O O
human O O
serum O O
. O O

Cyclosporine B-drug B-drug
, O O
hexobarbital B-drug B-drug
and O O
phenytoin B-drug B-drug
concentrations O O
. O O

Anticholinergic B-group B-group
agents I-group I-group
: O O
Although O O
ipratropium B-drug B-drug
bromide I-drug I-drug
is O O
minimally O O
absorbed O O
into O O
the O O
systemic O O
circulation O O
, O O
there O O
is O O
some O O
potential O O
for O O
an O O
additive O O
interaction O O
with O O
concomitantly O O
used O O
anticholinergic B-group B-group
medications I-group I-group
. O O

Preliminary O O
animal O O
and O O
human O O
studies O O
have O O
shown O O
that O O
small O O
quantities O O
of O O
systemically O O
administered O O
leucovorin B-drug B-drug
enter O O
the O O
CSF O O
primarily O O
as O O
5-methyltetrahydro-folate O O
and O O
, O O
in O O
humans O O
, O O
remain O O
1 O O
to O O
3 O O
orders O O
of O O
magnitude O O
lower O O
than O O
the O O
usual O O
methotrexate B-drug B-drug
concentrations O O
following O O
intrathecal O O
administration O O
. O O

THE O O
POTENTIATING O O
ACTION O O
OF O O
HYDROXYZINE B-drug B-drug
MUST O O
BE O O
CONSIDERED O O
WHEN O O
THE O O
DRUG O O
IS O O
USED O O
IN O O
CONJUNCTION O O
WITH O O
CENTRAL B-group B-group
NERVOUS I-group I-group
SYSTEM I-group I-group
DEPRESSANTS I-group I-group
SUCH O O
AS O O
NARCOTICS B-group O
, O O
NON-NARCOTIC B-group B-group
ANALGESICS I-group I-group
AND O O
BARBITURATES B-group B-group
. O O

Cholestyramine B-drug B-drug
increases O O
enterohepatic O O
elimination O O
of O O
amiodarone B-drug B-drug
and O O
may O O
reduce O O
its O O
serum O O
levels O O
and O O
t1/2 B-drug O
. O O

Patients O O
receiving O O
these O O
drugs O O
in O O
combination O O
with O O
zalcitabine B-drug B-drug
should O O
be O O
monitored O O
for O O
signs O O
of O O
toxicity O O
and O O
the O O
dose O O
of O O
zalcitabine B-drug B-drug
reduced O O
if O O
warranted O O
. O O

. O O

Thiazides B-group B-group
: O O
Thiazides B-group B-group
are O O
known O O
to O O
induce O O
hypercalcemia O O
by O O
the O O
reduction O O
of O O
calcium B-drug B-drug
excretion O O
in O O
urine O O
. O O

The O O
drugs O O
may O O
, O O
however O O
, O O
be O O
administered O O
alternately O O
provided O O
a O O
proper O O
interval O O
has O O
elapsed O O
between O O
doses O O
. O O

Data O O
suggest O O
that O O
coadministration O O
of O O
oral O O
ketoconazole B-drug B-drug
and O O
cisapride B-drug B-drug
can O O
result O O
in O O
prolongation O O
of O O
the O O
QT O O
interval O O
on O O
the O O
ECG O O
. O O

. O O

The O O
plasma O O
concentration O O
of O O
CMI B-drug O
has O O
been O O
reported O O
to O O
be O O
increased O O
by O O
the O O
concomitant O O
administration O O
of O O
haloperidol B-drug B-drug
; O O

In O O
vitro O O
studies O O
have O O
shown O O
that O O
naproxen B-drug B-drug
anion O O
, O O
because O O
of O O
its O O
affinity O O
for O O
protein O O
, O O
may O O
displace O O
from O O
their O O
binding O O
sites O O
other O O
drugs O O
which O O
are O O
also O O
albumin-bound O O
. O O

Caution O O
should O O
be O O
exercised O O
when O O
these O O
2 O O
agents O O
are O O
coadministered O O
. O O

In O O
the O O
case O O
of O O
digoxin B-drug B-drug
, O O
serum O O
levels O O
should O O
be O O
monitored O O
. O O

Ranitidine B-drug B-drug
150 O O
mg O O
twice O O
daily O O
did O O
not O O
interact O O
significantly O O
with O O
nisoldipine B-drug B-drug
( O O
AUC O O
was O O
decreased O O
by O O
15-20 O O
% O O
) O O
. O O

Therefore O O
, O O
in O O
patients O O
taking O O
VIOXX B-brand B-brand
, O O
antiplatelet O O
therapies O O
should O O
not O O
be O O
discontinued O O
and O O
should O O
be O O
considered O O
in O O
patients O O
with O O
an O O
indication O O
for O O
cardiovascular O O
prophylaxis O O
. O O

Co-administration O O
of O O
bosentan B-drug B-drug
decreased O O
the O O
plasma O O
concentrations O O
of O O
cyclosporine B-drug B-drug
A I-drug O
( O O
a O O
CYP3A4 O O
substrate O O
) O O
by O O
approximately O O
50 O O
% O O
. O O

Diuretics B-group B-group
: O O
Diclofenac B-drug B-drug
and O O
other O O
NSAIDs B-group B-group
can O O
inhibit O O
the O O
activity O O
of O O
diuretics B-group B-group
. O O

Clinical O O
experience O O
with O O
concomitant O O
administration O O
of O O
bosentan B-drug B-drug
and O O
warfarin B-drug B-drug
in O O
patients O O
with O O
pulmonary O O
arterial O O
hypertension O O
did O O
not O O
show O O
clinically O O
relevant O O
changes O O
in O O
INR O O
or O O
warfarin B-drug B-drug
dose O O
( O O
baseline O O
vs. O O
end O O
of O O
the O O
clinical O O
studies O O
) O O
, O O
and O O
the O O
need O O
to O O
change O O
the O O
warfarin B-drug B-drug
dose O O
during O O
the O O
trials O O
due O O
to O O
changes O O
in O O
INR O O
or O O
due O O
to O O
adverse O O
events O O
was O O
similar O O
among O O
bosentan- B-drug O
and O O
placebo-treated O O
patients O O
. O O

This O O
included O O
post O O
myocardial O O
infarction O O
patients O O
who O O
were O O
receiving O O
intravenous O O
or O O
transdermal O O
nitroglycerin B-drug B-drug
. O O

Potentiation O O
of O O
the O O
hypotensive O O
effects O O
of O O
nitrates B-group B-group
for O O
patients O O
with O O
ischemic O O
heart O O
disease O O
has O O
not O O
been O O
evaluated O O
, O O
and O O
concomitant O O
use O O
of O O
Vardenafil B-drug B-drug
and O O
nitrates B-group B-group
is O O
contraindicated O O
. O O

sulindac B-drug B-drug
; O O

. O O

No O O
differences O O
in O O
safety O O
or O O
efficacy O O
were O O
observed O O
between O O
older O O
and O O
younger O O
patients O O
, O O
but O O
there O O
were O O
not O O
sufficient O O
data O O
to O O
exclude O O
important O O
differences O O
. O O

Increased O O
thyroid-binding O O
globulin O O
( O O
TBG O O
) O O
levels O O
leading O O
to O O
increased O O
circulating O O
total O O
thyroid O O
hormone O O
levels O O
as O O
measured O O
by O O
protein-bound O O
iodine B-drug O
( O O
PBI O O
) O O
, O O
T4 O O
levels O O
( O O
by O O
column O O
or O O
by O O
radioimmunoassay O O
) O O
or O O
T3 O O
levels O O
by O O
radioimmunoassay O O
. O O

Bosentan B-drug B-drug
is O O
also O O
expected O O
to O O
reduce O O
plasma O O
concentrations O O
of O O
other O O
oral O O
hypoglycemic B-group B-group
agents I-group I-group
that O O
are O O
predominantly O O
metabolized O O
by O O
CYP2C9 O O
or O O
CYP3A4 O O
. O O

2 O O
. O O

In O O
vitro O O
data O O
suggest O O
that O O
itraconazole B-drug B-drug
, O O
when O O
compared O O
to O O
ketoconazole B-drug B-drug
, O O
has O O
a O O
less O O
pronounced O O
effect O O
on O O
the O O
biotransformation O O
system O O
responsible O O
for O O
the O O
metabolism O O
of O O
astemizole B-drug B-drug
. O O

These O O
data O O
suggest O O
the O O
modified O O
histidine O O
residues O O
on O O
toxin B-drug_n B-drug_n
A I-drug_n I-drug_n
are O O
critical O O
to O O
its O O
cytotoxic O O
activity O O
. O O

Misonidazole B-drug_n B-drug
has O O
a O O
complex O O
effect O O
on O O
oral O O
CCNU B-drug B-drug
pharmacokinetics O O
. O O

Free O O
T4 O O
and O O
free O O
T3 O O
concentrations O O
are O O
unaltered O O
. O O

Alcohol B-drug B-drug
: O O
It O O
should O O
be O O
borne O O
in O O
mind O O
that O O
alcohol B-drug B-drug
ingestion O O
may O O
increase O O
the O O
danger O O
inherent O O
in O O
any O O
intentional O O
or O O
unintentional O O
SINEQUAN B-brand B-brand
overdosage O O
. O O

A O O
similar O O
effect O O
would O O
be O O
expected O O
with O O
eszopiclone B-drug B-drug
. O O

Plasma O O
concentrations O O
decreased O O
by O O
SUSTIVA B-brand B-brand
; O O

The O O
effect O O
may O O
be O O
mediated O O
by O O
the O O
known O O
inhibition O O
of O O
cimetidine B-drug B-drug
on O O
hepatic O O
cytochrome O O
P-450 O O
, O O
the O O
enzyme O O
system O O
probably O O
responsible O O
for O O
the O O
first-pass O O
metabolism O O
of O O
nifedipine B-drug B-drug
. O O

No O O
formal O O
drug-interaction O O
studies O O
have O O
been O O
performed O O
, O O
and O O
a O O
clinically O O
significant O O
interaction O O
with O O
other O O
medications O O
used O O
in O O
the O O
treatment O O
of O O
hypoxic O O
respiratory O O
failure O O
can O O
not O O
be O O
excluded O O
based O O
on O O
the O O
available O O
data O O
. O O

unreliable O O
prothrombin O O
time O O
determinations O O
; O O

Since O O
etodolac B-drug B-drug
has O O
a O O
well-defined O O
pharmacokinetic-pharmacodynamic O O
relationship O O
, O O
measurement O O
of O O
pharmacokinetic O O
parameters O O
is O O
clinically O O
relevant O O
. O O

Core O O
temperature O O
was O O
decreased O O
in O O
rats O O
in O O
a O O
dose-dependent O O
manner O O
when O O
ethanol B-drug B-drug
was O O
administered O O
to O O
rats O O
treated O O
with O O
disulfiram B-drug B-drug
8 O O
hours O O
before O O
the O O
ethanol B-drug B-drug
challenge O O
. O O

Other O O
drug O O
interactions O O

These O O
drugs O O
include O O
the O O
thiazides B-group B-group
and O O
other O O
diuretics B-group B-group
, O O
corticosteroids B-group B-group
, O O
phenothiazines B-group B-group
, O O
thyroid O B-group
products O I-group
, O O
estrogens B-group B-group
, O O
oral O O
contraceptives B-group B-group
, O O
phenytoin B-drug B-drug
, O O
nicotinic B-drug B-drug
acid I-drug I-drug
, O O
sympathomimetics B-group B-group
, O O
calcium B-group B-group
channel I-group I-group
blocking I-group I-group
drugs I-group I-group
, O O
and O O
isoniazid B-drug B-drug
. O O

When O O
you O O
are O O
using O O
idoxuridine B-drug B-drug
, O O
it O O
is O O
especially O O
important O O
that O O
your O O
health O O
care O O
professional O O
know O O
if O O
you O O
are O O
using O O
the O O
following O O
: O O
Eye O O
product O O
containing O O
boric B-drug B-drug
acid I-drug I-drug
. O O

Rifabutin B-drug B-drug
did O O
not O O
significantly O O
affect O O
amprenavir B-drug B-drug
's O O
pharmacokinetics O O
. O O

an O O
oral O O
200 O O
mg O O
dose O O
achieves O O
a O O
highest O O
level O O
of O O
approximately O O
5 O O
uM O O
in O O
people O O
) O O
; O O

These O O
drugs O O
should O O
not O O
be O O
given O O
concomitantly O O
. O O

The O O
mechanisms O O
of O O
metal O O
toxicity O O
to O O
miracidia O O
are O O
briefly O O
discussed O O
. O O

Dolasetron B-drug B-drug
does O O
not O O
influence O O
anesthesia O O
recovery O O
time O O
in O O
patients O O
. O O

Co-administration O O
of O O
TIKOSYN B-brand B-brand
with O O
verapamil B-drug B-drug
resulted O O
in O O
increases O O
in O O
dofetilide B-drug B-drug
peak O O
plasma O O
levels O O
of O O
42 O O
% O O
, O O
although O O
overall O O
exposure O O
to O O
dofetilide B-drug B-drug
was O O
not O O
significantly O O
increased O O
. O O

Theophylline B-drug B-drug
decreased O O
the O O
binding O O
of O O
acetaminophen B-drug B-drug
by O O
a O O
net O O
change O O
of O O
6.8 O O
% O O
( O O
percentage O O
increase O O
in O O
FDF O O
, O O
8.8 O O
% O O
) O O
at O O
277.5 O O
micromol/L O O
; O O

This O O
small O O
decrease O O
in O O
excretion O O
of O O
gabapentin B-drug B-drug
by O O
cimetidine B-drug B-drug
is O O
not O O
expected O O
to O O
be O O
of O O
clinical O O
importance O O
. O O

The O O
average O O
infusion O O
rate O O
requirement O O
may O O
be O O
decreased O O
by O O
as O O
much O O
as O O
30 O O
% O O
to O O
40 O O
% O O
. O O

This O O
report O O
describes O O
two O O
cases O O
in O O
which O O
theophylline B-drug B-drug
clearance O O
accelerated O O
markedly O O
with O O
concomitant O O
phenytoin B-drug B-drug
administration O O
. O O

Minimum O O
inhibitory O O
concentrations O O
( O O
MICs O O
) O O
and O O
viable O O
counts O O
were O O
determined O O
in O O
Iso-sensitest O O
broth O O
using O O
a O O
microtitre O O
method O O
. O O

Consequently O O
, O O
caution O O
is O O
advised O O
if O O
the O O
concomitant O O
administration O O
of O O
REVIA B-brand B-brand
and O O
other O O
drugs O O
is O O
required O O
. O O

Sinus O O
bradycardia O O
has O O
been O O
reported O O
with O O
oral O O
amiodarone B-drug B-drug
in O O
combination O O
with O O
lidocaine B-drug B-drug
( O O
CYP3A4 B-drug O
substrate O O
) O O
given O O
for O O
local O O
anesthesia B-drug O
. O O

Need O O
for O O
more O O
inhalations O O
than O O
usual O O
of O O
short-acting B-group O
, I-group O
inhaled I-group O
beta2-agonists I-group B-group
. O O

The O O
clinical O O
significance O O
of O O
these O O
changes O O
is O O
unknown O O
. O O

Cimetidine B-drug B-drug
at O O
doses O O
of O O
100 O O
mg O O
BID O O
( O O
OTC O O
dose O O
) O O
resulted O O
in O O
a O O
13 O O
% O O
increase O O
in O O
dofetilide B-drug B-drug
plasma O O
levels O O
( O O
500 O O
mcg O O
single O O
dose O O
) O O
. O O

Blood O O
levels O O
of O O
hydrodolasetron B-drug_n B-drug
increased O O
24 O O
% O O
when O O
dolasetron B-drug B-drug
was O O
coadministered O O
with O O
cimetidine B-drug B-drug
( O O
nonselective O O
inhibitor O O
of O O
cytochrome O O
P-450 O O
) O O
for O O
7 O O
days O O
, O O
and O O
decreased O O
28 O O
% O O
with O O
coadministration O O
of O O
rifampin B-drug B-drug
( O O
potent O O
inducer O O
of O O
cytochrome O O
P-450 O O
) O O
for O O
7 O O
days O O
. O O

Rifabutin B-drug B-drug
, O O
another O O
rifamycin B-drug B-drug
, O O
is O O
structurally O O
similar O O
to O O
rifampin B-drug B-drug
and O O
may O O
possibly O O
have O O
some O O
of O O
the O O
same O O
drug O O
interactions O O
as O O
rifampin B-drug B-drug
. O O

Binding O O
to O O
plasma O O
proteins O O
is O O
reduced O O
by O O
warfarin B-drug B-drug
and O O
clotibrate O B-drug
and O O
increased O O
by O O
tolbutamide B-drug B-drug
. O O

( O O
600 O O
mg O O
Q12h O O
) O O

Cisapride B-drug B-drug
is O O
metabolized O O
mainly O O
via O O
the O O
cytochrome O O
P450 O O
3A4 O O
enzyme O O
. O O

The O O
clinical O O
significance O O
of O O
this O O
increased O O
bioavailability O O
and O O
whether O O
similar O O
increases O O
will O O
occur O O
in O O
patients O O
given O O
oral O O
H2-antagonists B-group B-group
is O O
unknown O O
; O O

The O O
clinical O O
significance O O
of O O
this O O
interaction O O
is O O
not O O
known O O
; O O

Literature O O
reports O O
indicate O O
that O O
coadministration O O
of O O
indomethacin B-drug B-drug
may O O
reduce O O
the O O
natriuretic O O
and O O
antihypertensive O O
effects O O
of O O
furosemide B-drug B-drug
in O O
some O O
patients O O
by O O
inhibiting O O
prostaglandin O O
synthesis O O
. O O

Drug O O
regimens O O
in O O
patients O O
with O O
cardiovascular O O
disease O O
are O O
frequently O O
complex O O
and O O
can O O
be O O
significantly O O
affected O O
by O O
alterations O O
in O O
renal O O
function O O
. O O

SUBUTEX B-brand B-brand
and O O
SUBOXONE B-brand B-brand
should O O
be O O
prescribed O O
with O O
caution O O
to O O
patients O O
on O O
benzodiazepines B-group B-group
or O O
other O O
drugs O O
that O O
act O O
on O O
the O O
central O O
nervous O O
system O O
, O O
regardless O O
of O O
whether O O
these O O
drugs O O
are O O
taken O O
on O O
the O O
advice O O
of O O
a O O
physician O O
or O O
are O O
taken O O
as O O
drugs O O
of O O
abuse O O
. O O

The O O
effect O O
of O O
digoxin B-drug B-drug
on O O
Exjade B-brand B-brand
pharmacokinetics O O
has O O
not O O
been O O
studied O O
. O O

The O O
antimicrobial O O
combinations O O
of O O
GL B-drug_n B-drug_n
with O O
four O O
antibiotics B-group B-group
resulted O O
in O O
additive O O
effect O O
in O O
most O O
instances O O
, O O
synergism O O
in O O
two O O
instances O O
, O O
and O O
antagonism O O
in O O
two O O
instances O O
. O O

The O O
pharmacokinetics O O
of O O
a O O
1-mg O O
dose O O
of O O
butorphanol B-drug B-drug
administered O O
as O O
STADOL B-brand B-brand
NS I-brand I-brand
were O O
not O O
affected O O
by O O
the O O
coadministration O O
of O O
cimetidine B-drug B-drug
( O O
300 O O
mg O O
QID O O
) O O
. O O

In O O
post-marketing O O
experience O O
, O O
bleeding O O
events O O
have O O
been O O
reported O O
, O O
predominantly O O
in O O
the O O
elderly O O
, O O
in O O
association O O
with O O
increases O O
in O O
prothrombin O O
time O O
in O O
patients O O
receiving O O
VIOXX B-brand B-brand
concurrently O O
with O O
warfarin B-drug B-drug
. O O

Interactions O O
between O O
treatments O O
with O O
coumaphos B-drug_n O
, O O
bishydroxycoumarin B-drug B-drug
( O O
an O O
anticoagulant B-group B-group
) O O
, O O
trichlorfon B-drug_n B-drug
( O O
an O O
organophosphorous B-group O
compound I-group O
) O O
, O O
and O O
phenobarbital B-drug B-drug
sodium I-drug I-drug
( O O
an O O
inducer O O
of O O
microsomal O O
enzymes O O
) O O
were O O
investigated O O
in O O
sheep O O
. O O

Clinical O O
comments O O
about O O
possible O O
dosage O O
modifications O O
based O O
on O O
these O O
pharmacokinetic O O
changes O O
are O O
listed O O
in O O
Table O O
3 O O
. O O

In O O
contrast O O
, O O
in O O
isolated O O
single O O
pancreatic O O
acinar O O
cells O O
, O O
RR B-drug_n B-drug_n
had O O
no O O
effect O O
on O O
InsP B-drug_n B-drug_n
( I-drug_n O
3 I-drug_n O
) I-drug_n O
-induced O O
responses O O
. O O

Other O O
No O O
clinically O O
important O O
pharmacokinetic O O
interactions O O
occurred O O
when O O
Lotensin B-brand B-brand
was O O
administered O O
concomitantly O O
with O O
hydrochlorothiazide B-drug B-drug
, O O
chlorthalidone B-drug B-drug
, O O
furosemide B-drug B-drug
, O O
digoxin B-drug B-drug
, O O
propranolol B-drug B-drug
, O O
atenolol B-drug B-drug
, O O
naproxen B-drug B-drug
, O O
or O O
cimetidine B-drug B-drug
. O O

These O O
differences O O
were O O
reflected O O
in O O
the O O
roughly O O
twofold O O
greater O O
antitumour O O
activity O O
for O O
the O O
oral O O
route O O
. O O

ISUPREL B-brand B-brand
should O O
be O O
used O O
with O O
caution O O
, O O
if O O
at O O
all O O
, O O
when O O
potent O O
inhalational O O
anesthetics B-group B-group
such O O
as O O
halothane B-drug B-drug
are O O
employed O O
because O O
of O O
potential O O
to O O
sensitize O O
the O O
myocardium O O
to O O
effects O O
of O O
sympathomimetic B-group B-group
amines I-group I-group
. O O

Drugs O O
Metabolized O O
by O O
P450 O O
2D6 O O
The O O
biochemical O O
activity O O
of O O
the O O
drug O O
metabolizing O O
isozyme O O
cytochrome O O
P450 O O
2D6 O O
( O O
debrisoquin O O
hydroxylase O O
) O O
is O O
reduced O O
in O O
a O O
subset O O
of O O
the O O
caucasian O O
population O O
( O O
about O O
7 O O
to O O
10 O O
% O O
of O O
caucasians O O
are O O
so O O
called O O
poor O O
metabolizers O O
) O O
; O O

Conversely O O
, O O
the O O
coumarin B-group B-group
anticoagulants I-group I-group
have O O
been O O
reported O O
to O O
increase O O
the O O
serum O O
levels O O
and O O
prolong O O
the O O
serum O O
half-life O O
of O O
phenytoin B-drug B-drug
by O O
inhibiting O O
its O O
metabolism O O
. O O

Antinociception O O
was O O
measured O O
by O O
the O O
hot-plate O O
method O O
. O O

The O O
possibility O O
of O O
worsened O O
glucose O O
control O O
in O O
patients O O
using O O
these O O
agents O O
should O O
be O O
considered O O
. O O

Catecholamine-depleting B-group O
drugs I-group O
, O O
such O O
as O O
reserpine B-drug B-drug
, O O
may O O
have O O
an O O
additive O O
effect O O
when O O
given O O
with O O
beta-blocking B-group B-group
agents I-group I-group
. O O

Antacids B-group B-group
or O O
H B-group B-group
2 I-group I-group
-receptor I-group I-group
antagonists I-group I-group
: O O
The O O
effect O O
of O O
increased O O
gastric O O
pH O O
on O O
the O O
bioavailability O O
of O O
ceftibuten B-drug B-drug
was O O
evaluated O O
in O O
18 O O
healthy O O
adult O O
volunteers O O
. O O

In O O
vitro O O
and O O
in O O
vivo O O
studies O O
have O O
shown O O
that O O
esomeprazole B-drug B-drug
is O O
not O O
likely O O
to O O
inhibit O O
CYPs O O
1A2 O O
, O O
2A6 O O
, O O
2C9 O O
, O O
2D6 O O
, O O
2E1 O O
and O O
3A4 O O
. O O

The O O
use O O
of O O
antacids B-group B-group
should O O
be O O
considered O O
in O O
place O O
of O O
H2 B-group B-group
blockers I-group I-group
or O O
proton B-group B-group
pump I-group I-group
inhibitors I-group I-group
in O O
patients O O
receiving O O
SPRYCEL B-brand B-brand
therapy O O
. O O

No O O
significant O O
drug O O
interactions O O
have O O
been O O
reported O O
in O O
studies O O
of O O
candesartan B-drug B-drug
cilexetil I-drug I-drug
given O O
with O O
other O O
drugs O O
such O O
as O O
glyburide B-drug B-drug
, O O
nifedipine B-drug B-drug
, O O
digoxin B-drug B-drug
, O O
warfarin B-drug B-drug
, O O
hydrochlorothiazide B-drug B-drug
, O O
and O O
oral O O
contraceptives B-group B-group
in O O
healthy O O
volunteers O O
, O O
or O O
given O O
with O O
enalapril B-drug B-drug
to O O
patients O O
with O O
heart O O
failure O O
( O O
NYHA O O
class O O
II O O
and O O
III O O
) O O
. O O

Potential O O
pharmacokinetic O O
interactions O O
were O O
assessed O O
in O O
clinical O O
pharmacokinetic O O
studies O O
( O O
phenytoin B-drug B-drug
, O O
valproate B-drug B-drug
, O O
oral O O
contraceptive B-group B-group
, O O
digoxin B-drug B-drug
, O O
warfarin B-drug B-drug
, O O
probenecid B-drug B-drug
) O O
and O O
through O O
pharmacokinetic O O
screening O O
in O O
the O O
placebo-controlled O O
clinical O O
studies O O
in O O
epilepsy O O
patients O O
. O O

N=13 O O
) O O
. O O

Concomitant O O
use O O
of O O
bupropion B-drug B-drug
with O O
other O O
drugs O O
metabolized O O
by O O
CYP2D6 O O
has O O
not O O
been O O
formally O O
studied O O
. O O

Warfarin B-drug B-drug
: O O
The O O
effects O O
of O O
warfarin B-drug B-drug
and O O
NSAIDs B-group B-group
on O O
GI O O
bleeding O O
are O O
synergistic O O
, O O
such O O
that O O
users O O
of O O
both O O
drugs O O
together O O
have O O
a O O
risk O O
of O O
serious O O
GI O O
bleeding O O
higher O O
than O O
that O O
of O O
users O O
of O O
either O O
drug O O
alone O O
. O O

Systemic O O
exposure O O
to O O
acetaminophen B-drug B-drug
is O O
expected O O
to O O
be O O
increased O O
when O O
coadministered O O
with O O
Gleevec B-brand B-brand
. O O

If O O
such O O
drugs O O
are O O
used O O
they O O
should O O
be O O
administered O O
with O O
an O O
interval O O
of O O
at O O
least O O
5 O O
minutes O O
between O O
applications O O
. O O

Others O O
reported O O
: O O
Neuropsychiatric O O
: O O
Confusion O O
( O O
1-11 O O
% O O
) O O
, O O
headache O O
( O O
4-8 O O
% O O
) O O
, O O
insomnia O O
( O O
2-7 O O
% O O
) O O
; O O

Effects O O
of O O
sympathomimetics B-group B-group
are O O
increased O O
with O O
MAO B-group B-group
inhibitors I-group I-group
and O O
beta B-group B-group
adrenergic I-group I-group
blockers I-group I-group
. O O

Other O O
Cardiovascular O O
Agents O O
: O O
Enalapril B-drug B-drug
and O O
enalapril B-drug B-drug
IV O O
have O O
been O O
used O O
concomitantly O O
with O O
beta B-group B-group
adrenergic-blocking I-group I-group
agents I-group I-group
, O O
methyldopa B-drug B-drug
, O O
nitrates B-group B-group
, O O
calcium-blocking B-group B-group
agents I-group I-group
, O O
hydralazine B-drug B-drug
, O O
prazosin B-drug B-drug
and O O
digoxin B-drug B-drug
without O O
evidence O O
of O O
clinically O O
significant O O
adverse O O
interactions O O
. O O

The O O
co-administration O O
of O O
Natrecor B-brand B-brand
with O O
IV O O
vasodilators B-group B-group
such O O
as O O
nitroglycerin B-drug B-drug
, O O
nitroprusside B-drug B-drug
, O O
milrinone B-drug B-drug
, O O
or O O
IV O O
ACE B-group B-group
inhibitors I-group I-group
has O O
not O O
been O O
evaluated O O
( O O
these O O
drugs O O
were O O
not O O
co-administered O O
with O O
Natrecor B-brand B-brand
in O O
clinical O O
trials O O
) O O
. O O

Ketoconazole B-drug B-drug

The O O
contribution O O
of O O
each O O
of O O
the O O
treatments O O
to O O
this O O
adverse O O
reaction O O
is O O
unknown O O
but O O
the O O
possibility O O
of O O
a O O
drug O O
interaction O O
can O O
not O O
be O O
excluded O O
. O O

v. O O
Patients O O
should O O
be O O
cautioned O O
regarding O O
potential O O
adverse O O
cardiovascular O O
effects O O
, O O
such O O
as O O
palpitations O O
or O O
chest O O
pain O O
. O O

Research O O
has O O
shown O O
that O O
herbal O O
remedy O O
use O O
may O O
be O O
associated O O
with O O
acute O O
renal O O
failure O O
. O O

Because O O
oral O O
anticoagulants B-group B-group
may O O
interfere O O
with O O
the O O
hepatic O O
metabolism O O
of O O
phenytoin B-drug B-drug
, O O
toxic O O
levels O O
of O O
the O O
anticonvulsant B-group B-group
may O O
occur O O
when O O
an O O
oral O O
anticoagulant B-group B-group
and O O
phenytoin B-drug B-drug
are O O
administered O O
concurrently O O
. O O

Irinotecan B-drug B-drug
concentrations O O
were O O
similar O O
in O O
patients O O
receiving O O
bolus-IFL O O
alone O O
and O O
in O O
combination O O
with O O
AVASTIN B-brand B-brand
. O O

Possible O O
drug O O
interactions O O
of O O
HUMORSOL B-brand B-brand
with O O
succinylcholine B-drug B-drug
or O O
with O O
other O O
anticholinesterase B-group B-group
agents I-group I-group
. O O

The O O
interaction O O
of O O
Activase B-brand B-brand
with O O
other O O
cardioactive O O
or O O
cerebroactive O O
drugs O O
has O O
not O O
been O O
studied O O
. O O

Concurrent O O
use O O
of O O
tetracyclines B-group B-group
with O O
oral O O
contraceptives B-group B-group
may O O
render O O
oral O O
contraceptives B-group B-group
less O O
effective O O
. O O

600-1800 O O

Insulin B-drug B-drug
: O O
A O O
clinical O O
study O O
in O O
6 O O
insulin-dependent O O
diabetic O O
patients O O
demonstrated O O
no O O
effect O O
of O O
EXTRANEAL B-brand B-brand
on O O
insulin B-drug B-drug
absorption O O
from O O
the O O
peritoneal O O
cavity O O
or O O
on O O
insulins B-drug B-group
ability O O
to O O
control O O
blood O O
glucose O O
when O O
insulin B-drug B-drug
was O O
administered O O
intraperitoneally O O
with O O
EXTRANEAL B-brand B-brand
. O O

indinavir I-drug B-drug
concentration O O

Imipramine B-drug B-drug
( O O
5 O O
mg/kg O O
) O O
, O O
moclobemide B-drug B-drug
( O O
30 O O
mg/kg O O
) O O
, O O
clonazepam B-drug B-drug
( O O
0.25 O O
mg/kg O O
) O O
, O O
fluoxetine B-drug B-drug
( O O
20 O O
mg/kg O O
) O O
sertraline B-drug B-drug
( O O
30 O O
mg/kg O O
) O O
or O O
vehicle O O
was O O
administered O O
. O O

The O O
LST O O
mice O O
did O O
not O O
show O O
any O O
changes O O
in O O
the O O
Kd O O
and O O
Bmax O O
in O O
either O O
the O O
STR O O
or O O
the O O
NAC O O
. O O

When O O
such O O
drugs O O
are O O
withdrawn O O
from O O
a O O
patient O O
receiving O O
MICRONASE B-brand B-brand
, O O
the O O
patient O O
should O O
be O O
observed O O
closely O O
for O O
loss O O
of O O
control O O
. O O

There O O
is O O
evidence O O
that O O
the O O
use O O
of O O
halofantrine B-drug B-drug
after O O
Mefloquineuine O O
causes O O
a O O
significant O O
lengthening O O
of O O
the O O
QTc O O
interval O O
. O O

Systemic O O
clonidine B-drug B-drug
may O O
inhibit O O
the O O
production O O
of O O
catecholamines O O
in O O
response O O
to O O
insulin-induced O B-drug
hypoglycemia O O
and O O
mask O O
the O O
signs O O
and O O
symptoms O O
of O O
hypoglycemia O O
. O O

therefore O O
, O O
plasma O O
concentrations O O
of O O
phenytoin B-drug B-drug
should O O
also O O
be O O
monitored O O
when O O
it O O
is O O
given O O
concurrently O O
with O O
Itraconazole B-drug B-drug
. O O

While O O
18-MC B-drug_n B-drug_n
and O O
ibogaine B-drug_n B-drug_n
have O O
similar O O
affinities O O
for O O
kappa O O
opioid O B-group
and O O
possibly O O
nicotinic O O
receptors O O
, O O
18-MC B-drug_n B-drug_n
has O O
much O O
lower O O
affinities O O
than O O
ibogaine B-drug_n B-drug_n
for O O
NMDA O O
and O O
sigma-2 O O
receptors O O
, O O
sodium O O
channels O O
, O O
and O O
the O O
5-HT O O
transporter O O
. O O

The O O
specific O O
objectives O O
of O O
this O O
study O O
were O O
to O O
elucidate O O
metal O O
toxicity O O
to O O
hatching O O
, O O
survival O O
and O O
avoidance O O
behaviour O O
of O O
Schistosoma O O
mansoni O O
miracidia O O
. O O

Although O O
the O O
relevance O O
of O O
these O O
reports O O
and O O
any O O
mechanism O O
of O O
coagulation O O
alterations O O
is O O
unclear O O
, O O
patients O O
on O O
warfarin B-drug B-drug
should O O
have O O
their O O
prothrombin O O
time O O
monitored O O
. O O

( O O
Thiazide B-group B-group
diuretics I-group I-group
may O O
raise O O
the O O
level O O
of O O
blood O O
uric O O
acid O O
; O O

A O O
conservative O O
approach O O
to O O
dosing O O
felodipine B-drug B-drug
should O O
be O O
taken O O
. O O

the O O
disulfiram B-drug B-drug
should O O
be O O
discontinued O O
if O O
such O O
signs O O
appear O O
. O O

This O O
may O O
increase O O
or O O
enhance O O
the O O
occurrence O O
of O O
osteomalacia O O
in O O
some O O
patients O O
receiving O O
chronic O O
phenytoin B-drug B-drug
therapy O O
. O O

Glucose B-drug B-drug
and O O
insulin B-drug B-drug
exert O O
additive O O
ocular O O
and O O
renal O O
vasodilator O O
effects O O
on O O
healthy O O
humans O O
. O O

The O O
rate O O
of O O
metabolism O O
and O O
the O O
leukopenic O O
activity O O
of O O
cyclophosphamide B-drug B-drug
reportedly O O
are O O
increased O O
by O O
chronic O O
administration O O
of O O
high O O
doses O O
of O O
phenobarbital B-drug B-drug
. O O

Exjade B-brand B-brand
should O O
not O O
be O O
combined O O
with O O
other O O
iron O B-drug
chelator O O
therapies O O
, O O
as O O
safety O O
of O O
such O O
combinations O O
has O O
not O O
been O O
established O O
. O O

the O O
remainder O O
were O O
of O O
uncertain O O
cause O O
. O O

In O O
occasional O O
susceptible O O
patients O O
or O O
in O O
those O O
receiving O O
anticholinergic B-group B-group
drugs I-group I-group
( O O
including O O
antiparkinsonism O B-group
agents O I-group
) O O
in O O
addition O O
, O O
the O O
atropine-like O O
effects O O
may O O
become O O
more O O
pronounced O O
( O O
e.g. O O
, O O
paralytic O O
ileus O O
) O O
. O O

Thioridazine B-drug B-drug
: O O
Coadministration O O
of O O
single O O
doses O O
of O O
Sonata B-brand B-brand
20 O O
mg O O
and O O
thioridazine B-drug B-drug
50 O O
mg O O
produced O O
additive O O
effects O O
on O O
decreased O O
alertness O O
and O O
impaired O O
psychomotor O O
performance O O
for O O
2 O O
to O O
4 O O
hours O O
after O O
administration O O
. O O

Pharmacology O O
and O O
pharmacotherapy O O
of O O
cardiovascular O O
drugs O O
in O O
patients O O
with O O
chronic O O
renal O O
disease O O
. O O

No O O
drug O O
interactions O O
have O O
been O O
identified O O
. O O

Motility O O
agents O O

No O O
Important O O
Interactions O O
To O O
Date O O
Levosimendan B-drug B-drug
does O O
not O O
have O O
clinically O O
important O O
pharmacokinetic O O
interactions O O
with O O
captopril B-drug B-drug
, O O
beta-blockers B-group B-group
, O O
felodipine B-drug B-drug
, O O
digoxin B-drug B-drug
, O O
warfarin B-drug B-drug
, O O
isosorbide B-drug B-drug
mononitrate I-drug I-drug
, O O
carvedilol B-drug B-drug
, O O
ethanol B-drug B-drug
or O O
itraconazole B-drug B-drug
. O O

Selective B-group B-group
serotonin I-group I-group
reuptake I-group I-group
inhibitors I-group I-group
( O O
SSRIs B-group B-group
) O O
( O O
e.g. O O
, O O
fluoxetine B-drug B-drug
, O O
fluvoxamine B-drug B-drug
, O O
paroxetine B-drug B-drug
, O O
sertraline B-drug B-drug
) O O
have O O
been O O
reported O O
, O O
rarely O O
, O O
to O O
cause O O
weakness O O
, O O
hyperreflexia O O
, O O
and O O
incoordination O O
when O O
coadministered O O
with O O
5-HTv O B-group
agonists O I-group
. O O

1 O O
hour O O
after O O
starting O O
the O O
oxycodone B-drug B-drug
or O O
levofloxacin B-drug B-drug
500 O O
mg O O
p.o O O
. O O

Vitamin B-group B-drug
A I-group I-drug
and O O
oral O O
retinoids B-group B-group
: O O
Concomitant O O
administration O O
of O O
vitamin B-group B-drug
A I-group O
and/or O O
other O O
oral O O
retinoids B-group B-group
with O O
acitretin B-drug B-drug
must O O
be O O
avoided O O
because O O
of O O
the O O
risk O O
of O O
hypervitaminosis O O
A O O
. O O

Drug/Laboratory O O
Test O O
Interactions O O
: O O
Amphetamines B-group B-group
can O O
cause O O
a O O
significant O O
elevation O O
in O O
plasma O O
corticosteroid O O
levels O O
. O O

In O O
addition O O
, O O
higher-than O B-drug
expected O O
steady-state O O
serum O O
concentrations O O
of O O
tricyclic B-group B-group
antidepressants I-group I-group
have O O
been O O
observed O O
when O O
therapy O O
is O O
initiated O O
in O O
patients O O
already O O
taking O O
cimetidine B-drug B-drug
. O O

However O O
, O O
higher O O
plasma O O
concentrations O O
of O O
AMICAR B-brand B-brand
may O O
occur O O
in O O
patients O O
with O O
severe O O
renal O O
failure O O
. O O

During O O
concomitant O O
therapy O O
with O O
ibuprofen B-drug B-drug
, O O
the O O
patient O O
should O O
be O O
observed O O
closely O O
for O O
signs O O
of O O
renal O O
failure O O
, O O
as O O
well O O
as O O
to O O
assure O O
diuretic B-group O
efficacy O O
. O O

Antifungal B-group B-group
Agents I-group I-group

Cisapride B-drug B-drug
should O O
not O O
be O O
used O O
concomitantly O O
with O O
other O O
drugs O O
known O O
to O O
prolong O O
the O O
QT O O
interval O O
: O O
certain O O
antiarrhythmics B-group B-group
, O O
including O O
those O O
of O O
Class O O
IA O O
( O O
such O O
as O O
quinidine B-drug B-drug
and O O
procainamide B-drug B-drug
) O O
and O O
Class O B-drug
III O I-drug
( O O
such O O
as O O
sotalol B-drug B-drug
) O O
; O O

therefore O O
, O O
coadministration O O
of O O
Aprepitant B-drug B-drug
with O O
drugs O O
that O O
strongly O O
induce O O
CYP3A4 O O
activity O O
( O O
e.g. O O
, O O
rifampin B-drug B-drug
, O O
carbamazepine B-drug B-drug
, O O
phenytoin B-drug B-drug
) O O
may O O
result O O
in O O
reduced O O
plasma O O
concentrations O O
of O O
aprepitant B-drug B-drug
that O O
may O O
result O O
in O O
decreased O O
efficacy O O
of O O
Aprepitant B-drug B-drug
. O O

Warfarin B-drug B-drug
: O O
Anticoagulant O B-group
activity O O
should O O
be O O
monitored O O
, O O
particularly O O
in O O
the O O
first O O
few O O
days O O
after O O
initiating O O
or O O
changing O O
VIOXX B-brand B-brand
therapy O O
in O O
patients O O
receiving O O
warfarin B-drug B-drug
or O O
similar O O
agents O O
, O O
since O O
these O O
patients O O
are O O
at O O
an O O
increased O O
risk O O
of O O
bleeding O O
complications O O
. O O

Although O O
beta-adrenergic B-group B-group
blockers I-group I-group
or O O
calcium B-group B-group
channel I-group I-group
blockers I-group I-group
and O O
digoxin B-drug B-drug
may O O
be O O
useful O O
in O O
combination O O
to O O
control O O
atrial O O
fibrillation O O
, O O
their O O
additive O O
effects O O
on O O
AV O O
node O O
conduction O O
can O O
result O O
in O O
advanced O O
or O O
complete O O
heart O O
block O O
. O O

subjects O O
. O O

No O O
specific O O
information O O
available O O

It O O
is O O
proposed O O
that O O
the O O
phosphohydrolase O O
becomes O O
metabolically O O
active O O
when O O
it O O
combines O O
with O O
membranes O O
and O O
that O O
polyamines O B-group
might O O
help O O
to O O
regulate O O
this O O
interaction O O
. O O

These O O
results O O
suggest O O
that O O
both O O
dexamethasone B-drug B-drug
and O O
retinyl B-drug B-drug
acetate I-drug I-drug
, O O
and O O
possibly O O
other O O
glucocorticoids B-group B-group
and O O
retinoids B-group B-group
, O O
may O O
regulate O O
the O O
proliferation O O
of O O
prostate O O
epithelium O O
by O O
a O O
dose-dependent O O
modification O O
of O O
the O O
activity O O
of O O
insulin B-drug B-drug
and O O
EGF B-drug_n B-drug_n
. O O

Neurochemical O O
and O O
functional O O
consequences O O
following O O
1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine B-drug_n B-drug_n
( O O
MPTP B-drug_n B-drug_n
) O O
and O O
methamphetamine B-drug B-drug
. O O

There O O
are O O
few O O
data O O
regarding O O
the O O
coadministration O O
of O O
radiation O O
therapy O O
and O O
epirubicin B-drug B-drug
. O O

Cimetidine B-drug B-drug
increased O O
the O O
AUC O O
of O O
epirubicin B-drug B-drug
by O O
50 O O
% O O
. O O

TRACRIUM B-brand B-brand
should O O
not O O
be O O
administered O O
until O O
a O O
patient O O
has O O
recovered O O
from O O
succinylcholine-induced B-drug B-drug
neuromuscular O O
block O O
. O O

We O O
conclude O O
that O O
the O O
prophylactic O O
and O O
antidotal O O
properties O O
of O O
4-methylpyrazole B-drug B-drug_n
seen O O
in O O
animals O O
treated O O
with O O
1,3-difluoro-2-propanol B-drug_n B-drug_n
derive O O
from O O
its O O
capacity O O
to O O
inhibit O O
the O O
NAD+-dependent O O
oxidation O O
responsible O O
for O O
converting O O
1,3-difluoro-2-propanol B-drug_n B-drug_n
to O O
1,3-difluoroacetone B-drug_n B-drug_n
in O O
the O O
committed O O
step O O
of O O
the O O
toxic O O
pathway O O
. O O

No O O
drugs O O
are O O
known O O
to O O
interfere O O
with O O
the O O
conversion O O
of O O
fosphenytoin B-drug B-drug
to O O
phenytoin B-drug B-drug
. O O

Patients O O
receiving O O
concomitant O O
lovastatin B-drug B-drug
and O O
erythromycin B-drug B-drug
should O O
be O O
carefully O O
monitored O O
; O O

Combination O O
Therapy O O
: O O
Any O O
form O O
of O O
therapy O O
which O O
adds O O
to O O
the O O
stress O O
of O O
the O O
patient O O
, O O
interferes O O
with O O
nutrition O O
or O O
depresses O O
bone O O
marrow O O
function O O
will O O
increase O O
the O O
toxicity O O
of O O
Floxuridine B-drug B-drug
. O O

The O O
1-year O O
risk O O
of O O
relapse O O
( O O
rehospitalisation O O
) O O
was O O
significantly O O
lower O O
with O O
olanzapine B-drug B-drug
than O O
with O O
haloperidol B-drug B-drug
treatment O O
. O O

Vitamin B-group B-drug
A I-group I-drug
: O O
Because O O
of O O
the O O
relationship O O
of O O
Accutane B-brand B-brand
to O O
vitamin B-group B-drug
A I-group O
, O O
patients O O
should O O
be O O
advised O O
against O O
taking O O
vitamin B-group B-drug
supplements I-group O
containing O O
vitamin B-group B-drug
A I-group O
to O O
avoid O O
additive O O
toxic O O
effects O O

similar O O
events O O
have O O
been O O
reported O O
in O O
patients O O
taking O O
other O O
psychotropic B-group B-group
drugs I-group I-group
or O O
even O O
Clozapine B-drug B-drug
by O O
itself O O
. O O

In O O
EM O O
individuals O O
treated O O
with O O
paroxetine B-drug B-drug
or O O
fluoxetine B-drug B-drug
, O O
the O O
AUC O O
of O O
atomoxetine B-drug B-drug
is O O
approximately O O
6- O O
to O O
8-fold O O
and O O
Css O O
, O O
max O O
is O O
about O O
3- O O
to O O
4-fold O O
greater O O
than O O
atomoxetine B-drug B-drug
alone O O
. O O

The O O
risk O O
of O O
using O O
bromocriptine B-drug B-drug
mesylate I-drug I-drug
in O O
combination O O
with O O
other O O
drugs O O
has O O
not O O
been O O
systematically O O
evaluated O O
, O O
but O O
alcohol B-drug B-drug
may O O
potentiate O O
the O O
side O O
effects O O
of O O
bromocriptine B-drug B-drug
mesylate I-drug I-drug
. O O

Fatalities O O
have O O
been O O
reported O O
. O O

However O O
, O O
retinyl B-drug B-drug
acetate I-drug I-drug
stimulated O O
, O O
but O O
did O O
not O O
significantly O O
inhibit O O
, O O
proliferation O O
in O O
the O O
presence O O
of O O
insulin B-drug B-drug
. O O

In O O
a O O
study O O
in O O
which O O
the O O
2 O O
mg O O
clonazepam B-drug B-drug
orally O O
disintegrating O O
tablet O O
was O O
administered O O
with O O
and O O
without O O
propantheline B-drug B-drug
( O O
an O O
anticholinergic B-group B-group
agent I-group I-group
with O O
multiple O O
effects O O
on O O
the O O
GI O O
tract O O
) O O
to O O
healthy O O
volunteers O O
, O O
the O O
AUC O O
of O O
clonazepam B-drug B-drug
was O O
10 O O
% O O
lower O O
and O O
the O O
Cmax O O
of O O
clonazepam B-drug B-drug
was O O
20 O O
% O O
lower O O
when O O
the O O
orally O O
disintegrating O O
tablet O O
was O O
given O O
with O O
propantheline B-drug B-drug
compared O O
to O O
when O O
it O O
was O O
given O O
alone O O
. O O

Agents O O
Increasing O O
Serum O O
Potassium O O
: O O
Enalapril B-drug B-drug
and O O
enalapril B-drug B-drug
IV O O
attenuate O O
potassium O O
loss O O
caused O O
by O O
thiazide-type B-group B-group
diuretics I-group I-group
. O O

4 O O
. O O

Protease B-group B-group
inhibitors I-group I-group
: O O
Amprenavir B-drug B-drug
, O O
lopinavir B-drug B-drug
, O O
nelfinavir B-drug B-drug
, O O
and O O
ritonavir B-drug B-drug
have O O
been O O
shown O O
to O O
decrease O O
plasma O O
levels O O
of O O
combination B-group B-group
hormonal I-group I-group
contraceptives I-group I-group
; O O

The O O
effect O O
of O O
a O O
higher O O
ketoconazole B-drug B-drug
dose O O
( O O
400 O O
mg/day O O
) O O
has O O
not O O
been O O
studied O O
. O O

Although O O
clinical O O
studies O O
have O O
not O O
been O O
performed O O
, O O
based O O
on O O
the O O
involvement O O
of O O
the O O
cytochrome O O
P-450 O O
3A O O
family O O
in O O
clonazepam B-drug B-drug
metabolism O O
, O O
inhibitors O O
of O O
this O O
enzyme O O
system O O
, O O
notably O O
oral O O
antifungal B-group B-group
agents I-group I-group
, O O
should O O
be O O
used O O
cautiously O O
in O O
patients O O
receiving O O
clonazepam B-drug B-drug
. O O

Carbamazepine B-drug B-drug
, O O
clonazepam B-drug B-drug
, O O
ethosuximide B-drug B-drug

As O O
a O O
result O O
, O O
when O O
giving O O
these O O
drugs O O
concomitantly O O
, O O
plasma O O
warfarin B-drug B-drug
levels O O
may O O
change O O
with O O
the O O
potential O O
for O O
increases O O
in O O
coagulation O O
time O O
. O O

Ritonavir B-drug B-drug
: O O
Coadministration O O
of O O
ritonavir B-drug B-drug
with O O
VIRACEPT B-brand B-brand
resulted O O
in O O
a O O
152 O O
% O O
increase O O
in O O
nelfinavir B-drug B-drug
plasma O O
AUC O O
and O O
very O O
little O O
change O O
in O O
ritonavir B-drug B-drug
plasma O O
A.C O O
. O O

These O O
usually O O
clear O O
within O O
a O O
week O O
, O O
leaving O O
only O O
the O O
" O O
drug O O
hunger O O
" O O

- O O
Although O O
not O O
a O O
true O O
drug O O
interaction O O
, O O
tricyclic B-group B-group
antidepressants I-group I-group
may O O
precipitate O O
seizures O O
in O O
susceptible O O
patients O O
and O O
Cerebyx B-brand B-brand
dosage O O
may O O
need O O
to O O
be O O
adjusted O O

Selective B-group B-group
Serotonin I-group I-group
Reuptake I-group I-group
Inhibitors I-group I-group
( O O
SSRIs B-group B-group
) O O
: O O
SSRIs B-group B-group
( O O
e.g. O O
, O O
fluoxetine B-drug B-drug
, O O
fluvoxamine B-drug B-drug
, O O
paroxetine B-drug B-drug
, O O
sertraline B-drug B-drug
) O O
have O O
been O O
rarely O O
reported O O
to O O
cause O O
weakness O O
, O O
hyperreflexia O O
, O O
and O O
incoordination O O
when O O
coadministered O O
with O O
5-HT1 B-group B-group
agonists I-group I-group
. O O

Lamivudine B-drug B-drug
is O O
predominantly O O
eliminated O O
in O O
the O O
urine O O
by O O
active O O
organic O O
cationic O O
secretion O O
. O O

Because O O
prostaglandins O B-group
play O O
an O O
important O O
role O O
in O O
hemostasis O O
, O O
and O O
NSAIDs B-group B-group
affect O O
platelet O O
function O O
as O O
well O O
, O O
concurrent O O
therapy O O
with O O
all O O
NSAIDs B-group B-group
, O O
including O O
diclofenac B-drug B-drug
, O O
and O O
warfarin B-drug B-drug
requires O O
close O O
monitoring O O
of O O
patients O O
to O O
be O O
certain O O
that O O
no O O
change O O
in O O
their O O
anticoagulant B-group B-group
dosage O O
is O O
required O O
. O O

Cytosine B-drug B-drug
arabinoside I-drug O
, O O
a O O
cytostatic B-group O
agent I-group O
, O O
has O O
been O O
reported O O
to O O
inactivate O O
the O O
antifungal O O
activity O O
of O O
flucytosine B-drug B-drug
by O O
competitive O O
inhibition O O
. O O

Administration O O
of O O
eszopiclone B-drug B-drug
3 O O
mg O O
to O O
a O O
patient O O
taking O O
another O O
drug O O
that O O
is O O
highly O O
protein-bound O O
would O O
not O O
be O O
expected O O
to O O
cause O O
an O O
alteration O O
in O O
the O O
free O O
concentration O O
of O O
either O O
drug O O
. O O

Pyrazolone B-group B-drug
Derivatives I-group I-drug
( O O
phenylbutazone B-drug B-drug
, O O
oxyphenbutazone B-drug B-drug
, O O
and O O
possibly O O
dipyrone B-drug B-drug
) O O
: O O
Concomitant O O
administration O O
with O O
aspirin B-drug B-brand
may O O
increase O O
the O O
risk O O
of O O
gastrointestinal O O
ulceration O O
. O O

18-MC B-drug_n B-drug_n
, O O
a O O
novel O O
iboga O O
alkaloid O O
congener O O
, O O
is O O
being O O
developed O O
as O O
a O O
potential O O
treatment O O
for O O
multiple O O
forms O O
of O O
drug O O
abuse O O
. O O

Drugs O O
With O O
A O O
Narrow O O
Therapeutic O O
Index O O
Digoxin B-drug B-drug
A O O
single O O
dose O O
of O O
eszopiclone B-drug B-drug
3 O O
mg O O
did O O
not O O
affect O O
the O O
pharmacokinetics O O
of O O
digoxin B-drug B-drug
measured O O
at O O
steady O O
state O O
following O O
dosing O O
of O O
0.5 O O
mg O O
twice O O
daily O O
for O O
one O O
day O O
and O O
0.25 O O
mg O O
daily O O
for O O
the O O
next O O
6 O O
days O O
. O O

Mineral B-drug_n B-drug
Oil-Concomitant O O
intake O O
of O O
mineral B-drug_n O
oil I-drug_n O
and O O
vitamin B-group B-group
K I-group I-group
may O O
reduce O O
the O O
absorption O O
of O O
vitamin B-group B-group
K I-group I-group
. O O

Lithium B-drug B-drug
carbonate I-drug I-drug
: O O
The O O
anorectic O O
and O O
stimulatory O O
effects O O
of O O
amphetamines B-group B-group
may O O
be O O
inhibited O O
by O O
lithium B-drug B-drug
carbonate I-drug I-drug
. O O

400-2800 O O

Studies O O
with O O
famotidine B-drug B-drug
in O O
man O O
, O O
in O O
animal O O
models O O
, O O
and O O
in O O
vitro O O
have O O
shown O O
no O O
significant O O
interference O O
with O O
the O O
disposition O O
of O O
compounds O O
metabolized O O
by O O
the O O
hepatic O O
microsomal O O
enzymes O O
, O O
e.g. O O
, O O
cytochrome O O
P450 O O
system O O
. O O

Agents O O
with O O
Increased O O
Levels O O
in O O
the O O
Presence O O
of O O
Carbamazepine B-drug B-drug
: O O
EQUETROTM B-brand B-brand
increases O O
the O O
plasma O O
levels O O
of O O
the O O
following O O
agents O O
: O O
Clomipramine B-drug B-drug
HCl I-drug I-drug
, O O
Phenytoin B-drug B-drug
( O O
6 O O
) O O
, O O
and O O
primidone B-drug B-drug
Thus O O
, O O
if O O
a O O
patient O O
has O O
been O O
titrated O O
to O O
a O O
stable O O
dosage O O
on O O
one O O
of O O
the O O
agents O O
in O O
this O O
category O O
, O O
and O O
then O O
begins O O
a O O
course O O
of O O
the O O
treatment O O
with O O
EQUETROTM B-brand B-brand
, O O
it O O
is O O
reasonable O O
to O O
expect O O
that O O
a O O
dose O O
decrease O O
for O O
the O O
concomitant O O
agent O O
may O O
be O O
necessary O O
. O O

These O O
doses O O
were O O
6 O O
to O O
11 O O
times O O
( O O
mouse O O
) O O
and O O
8 O O
to O O
16 O O
times O O
( O O
rat O O
) O O
the O O
human O O
AUC O O
( O O
0-24 O O
) O O
based O O
on O O
the O O
maximum O O
recommended O O
human O O
dose O O
of O O
80 O O
mg/day O O
. O O

In O O
some O O
patients O O
the O O
combined O O
use O O
of O O
indomethacin B-drug B-drug
and O O
diflunisal B-drug B-drug
has O O
been O O
associated O O
with O O
fatal O O
gastrointestinal O O
hemorrhage O O
. O O

FLUOTHANE B-brand B-brand
may O O
augment O O
the O O
hypotension O O
caused O O
by O O
the O O
ganglionic-blocking O O
effect O O
of O O
tubocurarine B-drug B-drug
. O O

Specific O O
studies O O
with O O
ibandronate B-drug B-drug
have O O
not O O
been O O
performed O O
. O O

Acetazolamide B-drug B-drug
may O O
elevate O O
cyclosporine B-drug B-drug
levels O O
. O O

Similarly O O
, O O
of O O
over O O
1600 O O
patients O O
enrolled O O
in O O
a O O
study O O
comparing O O
once-monthly O B-drug
with O O
daily O O
dosing O O
regimens O O
of O O
ibandronate B-drug B-drug
, O O
14 O O
% O O
of O O
patients O O
used O O
anti-peptic O O
agents O O
. O O

In O O
vitro O O
interaction O O
of O O
prostaglandin B-drug B-drug
F2alpha I-drug I-drug
and O O
oxytocin B-drug B-drug
in O O
placental O O
vessels O O
. O O

These O O
effects O O
may O O
be O O
due O O
to O O
a O O
relatively O O
specific O O
blockade O O
of O O
diverse O O
potassium O O
channel O O
types O O
. O O

250-500 O O

Patients O O
taking O O
both O O
flurbiprofen B-drug B-drug
and O O
a O O
beta-blocker B-group B-group
should O O
be O O
monitored O O
to O O
ensure O O
that O O
a O O
satisfactory O O
hypotensive O O
effect O O
is O O
achieved O O
. O O

When O O
such O O
drugs O O
are O O
withdrawn O O
from O O
a O O
patient O O
receiving O O
DIABINESE B-brand B-brand
, O O
the O O
patient O O
should O O
be O O
observed O O
closely O O
for O O
loss O O
of O O
control O O
. O O

In O O
patients O O
receiving O O
mercaptopurine B-drug B-drug
( O O
Purinethol B-brand B-drug
) O O
or O O
azathioprine B-drug B-drug
( O O
Imuran B-brand B-brand
) O O
, O O
the O O
concomitant O O
administration O O
of O O
300-600 O O
mg O O
of O O
allopurinol B-drug B-drug
per O O
day O O
will O O
require O O
a O O
reduction O O
in O O
dose O O
to O O
approximately O O
one-third O O
to O O
one-fourth O O
of O O
the O O
usual O O
dose O O
of O O
mercaptopurine B-drug B-drug
or O O
azathioprine B-drug B-drug
. O O

In O O
a O O
study O O
of O O
schizophrenic O O
patients O O
who O O
received O O
clozapine B-drug B-drug
under O O
steady O O
state O O
conditions O O
, O O
fluvoxamine B-drug B-drug
or O O
paroxetine B-drug B-drug
was O O
added O O
in O O
16 O O
and O O
14 O O
patients O O
, O O
respectively O O
. O O

Longitudinal O O
assessment O O
of O O
everolimus B-drug B-drug
in O O
de O O
novo O O
renal O O
transplant O O
recipients O O
over O O
the O O
first O O
post-transplant O O
year O O
: O O
pharmacokinetics O O
, O O
exposure-response O O
relationships O O
, O O
and O O
influence O O
on O O
cyclosporine B-drug B-drug
. O O

Nevertheless O O
, O O
plasma O O
lithium B-drug B-drug
levels O O
should O O
be O O
monitored O O
with O O
appropriate O O
adjustment O O
to O O
the O O
lithium B-drug B-drug
dose O O
in O O
accordance O O
with O O
standard O O
clinical O O
practice O O
. O O

Because O O
the O O
small O O
magnitude O O
and O O
the O O
direction O O
of O O
the O O
effect O O
on O O
theophylline B-drug B-drug
clearance O O
, O O
this O O
interaction O O
is O O
unlikely O O
to O O
be O O
clinical O O
concern O O
. O O

When O O
such O O
drugs O O
are O O
administered O O
to O O
a O O
patient O O
receiving O O
MICRONASE B-brand B-brand
, O O
the O O
patient O O
should O O
be O O
closely O O
observed O O
for O O
loss O O
of O O
control O O
. O O

No O O
drug-drug O O
interaction O O
studies O O
in O O
human O O
subjects O O
have O O
been O O
conducted O O
. O O

Depending O O
on O O
the O O
fraction O O
of O O
drug O O
metabolized O O
by O O
P450 O O
2D6 O O
, O O
the O O
increase O O
in O O
plasma O O
concentration O O
may O O
be O O
small O O
, O O
or O O
quite O O
large O O
( O O
8-fold O O
increase O O
in O O
plasma O O
AUC O O
of O O
the O O
TCA B-group B-group
) O O
. O O

With O O
combined O O
use O O
, O O
clinicians O O
should O O
be O O
aware O O
, O O
when O O
phenytoin B-drug B-drug
is O O
added O O
, O O
of O O
the O O
potential O O
for O O
reexacerbation O O
of O O
pulmonary O O
symptomatology O O
due O O
to O O
lowered O O
serum O O
theophylline B-drug B-drug
concentrations O O
. O O

There O O
is O O
one O O
reported O O
case O O
of O O
a O O
patient O O
with O O
acute O O
delirium O O
associated O O
with O O
the O O
simultaneous O O
use O O
of O O
fluphenazine B-drug B-drug
and O O
oral O O
clonidine B-drug B-drug
. O O

Sublingual O O
nitroglycerin B-drug B-drug
may O O
be O O
taken O O
if O O
necessary O O
for O O
the O O
control O O
of O O
acute O O
angina O O
attacks O O
during O O
Bepridil B-drug B-drug
therapy O O
. O O

Ketoconazole B-drug B-drug
( O O
200 O O
mg O O
q12h O O
) O O
+307 O O
% O O
+73 O O
% O O

Studies O O
with O O
other O O
oral O O
or O O
implant O O
contraceptives B-group B-group
have O O
not O O
been O O
conducted O O
. O O

Effect O O
of O O
coadministered O O
drugs O O
and O O
ethanol B-drug B-drug
on O O
the O O
binding O O
of O O
therapeutic O O
drugs O O
to O O
human O O
serum O O
in O O
vitro O O
. O O

A O O
possible O O
drug O O
interaction O O
of O O
FOSCAVIR B-brand B-brand
and O O
intravenous O O
pentamidine B-drug B-drug
has O O
been O O
described O O
. O O

Caution O O
should O O
also O O
be O O
taken O O
in O O
concurrent O O
or O O
serial O O
use O O
of O O
other O O
aminoglycosides B-group B-group
and O O
polymyxins B-group B-group
because O O
they O O
may O O
enhance O O
neomycin O B-drug
s O O
nephrotoxicity O O
and/or O O
ototoxicity O O
and O O
potentiate O O
neomycin B-drug B-drug
sulfate I-drug I-drug
neuromuscular O O
blocking O O
effects O O
. O O

In O O
nine O O
otherwise O O
healthy O O
subjects O O
with O O
epilepsy O O
ingesting O O
carbamazepine B-drug B-drug
, O O
the O O
steady-state O O
trough O O
( O O
Cmin O O
) O O
carbamazepine B-drug B-drug
concentration O O
was O O
8 O O
2 O O
micrograms/mL O O
. O O

The O O
mean O O
AUC O O
values O O
of O O
EE O O
were O O
decreased O O
by O O
48 O O
% O O
[ O O
90 O O
% O O
CI O O
: O O
22-65 O O
] O O
in O O
one O O
study O O
and O O
52 O O
% O O
[ O O
90 O O
% O O
CI O O
: O O
38-52 O O
] O O
in O O
another O O
study O O
[ O O
1,2 O O
] O O
. O O

Barbiturates B-group B-group
, O O
phenytoin B-drug B-drug
, O O
or O O
rifampin B-drug B-drug
increased O O
metabolic O O
clearance O O
of O O
fludrocortisone B-drug B-drug
acetate I-drug I-drug
because O O
of O O
the O O
induction O O
of O O
hepatic O O
enzymes O O
. O O

There O O
have O O
been O O
rare O O
reports O O
of O O
reddish O O
stools O O
in O O
patients O O
who O O
have O O
received O O
cefdinir B-drug B-drug
in O O
Japan O O
. O O

Beta-blockers B-group B-group
, O O
clonidine B-drug B-drug
, O O
lithium B-drug B-drug
salts O O
, O O
and O O
alcohol B-drug B-drug
may O O
either O O
potentiate O O
or O O
weaken O O
the O O
blood-glucose-lowering O O
effect O O
of O O
insulin B-drug B-drug
. O O

Aspirin B-brand B-brand
: O O
When O O
Lodine B-brand B-brand
is O O
administered O O
with O O
aspirin B-brand B-brand
, O O
its O O
protein O O
binding O O
is O O
reduced O O
, O O
although O O
the O O
clearance O O
of O O
free O O
etodolac B-drug B-drug
is O O
not O O
altered O O
. O O

The O O
behavioral O O
effects O O
of O O
these O O
two O O
drugs O O
differ O O
, O O
and O O
they O O
do O O
not O O
act O O
on O O
the O O
same O O
target O O
sites O O
in O O
the O O
brain O O
, O O
although O O
they O O
may O O
share O O
, O O
or O O
partly O O
share O O
, O O
certain O O
properties O O
. O O

The O O
extent O O
of O O
plasma O O
protein O O
binding O O
of O O
atovaquone B-drug B-drug
in O O
human O O
plasma O O
is O O
not O O
affected O O
by O O
the O O
presence O O
of O O
therapeutic O O
concentrations O O
of O O
phenytoin B-drug B-drug
( O O
15 O O
mcg/ O O
mL O O
) O O
, O O
nor O O
is O O
the O O
binding O O
of O O
phenytoin B-drug B-drug
affected O O
by O O
the O O
presence O O
of O O
atovaquone B-drug B-drug
. O O

Inhibitors O O
of O O
renal O O
cationic O O
secretion O O
are O O
contraindicated O O
with O O
TIKOSYN B-brand B-brand
. O O

Nonsteroidal B-group B-group
anti-inflammatory I-group I-group
agents I-group I-group
( O O
NSAIDS B-group B-group
) O O
: O O
Concomitant O O
use O O
of O O
aspirin B-brand B-brand
( O O
or O O
other O O
nonsteroidal B-group B-group
antiinflammatory I-group I-group
agents I-group I-group
) O O
and O O
corticosteroids B-group B-group
increases O O
the O O
risk O O
of O O
gastrointestinal O O
side O O
effects O O
. O O

Consider O O
doubling O O
the O O
rifabutin B-drug B-drug
dose O O
in O O
regimens O O
where O O
rifabutin B-drug B-drug
is O O
given O O
2 O O
or O O
3 O O
times O O
a O O
week O O
. O O

Diflunisal B-drug B-drug
decreased O O
the O O
hyperuricemic O O
effect O O
of O O
hydrochlorothiazide B-drug B-drug
. O O

Patients O O
who O O
are O O
concomitantly O O
receiving O O
VELCADE B-brand B-brand
and O O
drugs O O
that O O
are O O
inhibitors O O
or O O
inducers O O
of O O
cytochrome O O
P450 O O
3A4 O O
should O O
be O O
closely O O
monitored O O
for O O
either O O
toxicities O O
or O O
reduced O O
efficacy O O
. O O

Bosentan B-drug B-drug
is O O
an O O
inducer O O
of O O
CYP3A4 O O
and O O
CYP2C9 O O
. O O

therefore O O
, O O
the O O
efficacy O O
of O O
oral O O
contraceptives B-group B-group
during O O
administration O O
of O O
Aprepitant B-drug B-drug
may O O
be O O
reduced O O
. O O

The O O
effects O O
of O O
concomitant O O
phenytoin B-drug B-drug
administration O O
on O O
the O O
steady-state O O
pharmacokinetics O O
of O O
quetiapine B-drug B-drug
. O O

It O O
is O O
unknown O O
whether O O
the O O
concomitant O O
administration O O
of O O
proton B-group B-group
pump I-group I-group
inhibitors I-group I-group
affects O O
duloxetine B-drug B-drug
absorption O O
. O O

Routine O O
administration O O
of O O
vaccines B-group B-group
or O O
toxoids O B-group
should O O
be O O
deferred O O
until O O
corticosteroid B-group B-group
therapy O O
is O O
discontinued O O
if O O
possible O O
. O O

While O O
it O O
is O O
not O O
known O O
whether O O
this O O
interaction O O
occurs O O
with O O
fibrates B-group B-group
other O O
than O O
gemfibrozil B-drug B-drug
, O O
myopathy O O
and O O
rhabdomyolysis O O
have O O
occasionally O O
been O O
associated O O
with O O
the O O
use O O
of O O
fibrates B-group B-group
alone O O
, O O
including O O
clofibrate B-drug B-drug
. O O

Clarithromycin B-drug B-drug

The O O
minimal O O
inhibitory O O
concentration O O
as O O
well O O
as O O
minimal O O
bactericidal O O
concentration O O
of O O
KRM-1648 B-drug_n B-drug_n
against O O
M O O
. O O

In O O
vitro O O
studies O O
indicate O O
that O O
the O O
binding O O
is O O
not O O
easily O O
removed O O
. O O

There O O
are O O
rare O O
reports O O
, O O
however O O
, O O
from O O
marketing O O
experiences O O
, O O
of O O
changes O O
in O O
effects O O
of O O
insulin B-drug B-drug
or O O
oral O O
hypoglycemic B-group B-group
agents I-group I-group
in O O
the O O
presence O O
of O O
diclofenac B-drug B-drug
that O O
necessitated O O
changes O O
in O O
the O O
doses O O
of O O
such O O
agents O O
. O O

Consequently O O
, O O
interactions O O
with O O
other O O
drugs O O
which O O
are O O
highly O O
protein O O
bound O O
( O O
e.g. O O
, O O
anticoagulants B-group B-group
) O O
would O O
not O O
be O O
expected O O
. O O

No O O
significant O O
drug-drug O O
pharmacokinetic O O
interactions O O
have O O
been O O
found O O
in O O
interaction O O
studies O O
with O O
hydrochlorothiazide B-drug B-drug
, O O
digoxin B-drug B-drug
, O O
warfarin B-drug B-drug
, O O
cimetidine B-drug B-drug
and O O
phenobarbital B-drug B-drug
. O O

Calcium B-drug B-drug
Supplements O O
: O O
Uncontrolled O O
intake O O
of O O
additional O O
calcium-containing B-drug O
preparations O O
should O O
be O O
avoided O O
. O O

DOSTINEX B-brand B-brand
should O O
not O O
be O O
administered O O
concurrently O O
with O O
D2-antagonists O B-group
, O O
such O O
as O O
phenothiazines B-group B-group
, O O
butyrophenones B-group B-group
, O O
thioxanthines B-group B-group
, O O
or O O
metoclopramide B-drug B-drug
. O O

Interference O O
with O O
the O O
absorption O O
of O O
oral O O
phosphate B-drug_n B-drug
supplements O O
has O O
been O O
observed O O
with O O
another O O
positively-charged O B-group
bile O I-group
acid O I-group
sequestrant O I-group
. O O

Warfarin B-drug B-drug
: O O
In O O
a O O
short-term O O
controlled O O
study O O
in O O
14 O O
normal O O
volunteers O O
, O O
ketoprofen B-drug B-drug
did O O
not O O
significantly O O
interfere O O
with O O
the O O
effect O O
of O O
warfarin B-drug B-drug
on O O
prothrombin O O
time O O
. O O

Co-administration O O
: O O
Concomitant O O
use O O
of O O
Argatroban B-drug B-drug
with O O
antiplatelet B-group B-group
agents I-group I-group
, O O
thrombolytics B-group B-group
, O O
and O O
other O O
anticoagulants B-group B-group
may O O
increase O O
the O O
risk O O
of O O
bleeding O O
. O O

Corresponding O O
values O O
for O O
free O O
valproate B-drug B-drug
Cmin O O
concentrations O O
were O O
7 O O
3 O O
, O O
9 O O
4 O O
, O O
and O O
11 O O
6 O O
micrograms/mL O O
for O O
0 O O
, O O
1200 O O
, O O
and O O
2400 O O
mg/day O O
Felbatol B-brand B-brand
, O O
respectively O O
. O O

Indinavir B-drug B-drug
is O O
an O O
inhibitor O O
of O O
the O O
cytochrome O O
P450 O O
isoform O O
CYP3A4 O O
. O O

Currently O O
, O O
there O O
are O O
no O O
safety O O
and O O
efficacy O O
data O O
available O O
from O O
the O O
use O O
of O O
this O O
combination O O
. O O

structural O O
heart O O
disease O O
is O O
a O O
known O O
risk O O
factor O O
for O O
arrhythmia O O
. O O

Ergot B-group B-group
alkaloids I-group I-group

Magnesium/Aluminum-containing B-drug B-drug
Antacid B-group B-group
Products I-group O
: O O
Absorption O O
of O O
zalcitabine B-drug B-drug
is O O
moderately O O
reduced O O
( O O
approximately O O
25 O O
% O O
) O O
when O O
coadministered O O
with O O
magnesium/aluminum-containing B-drug B-drug
antacid B-group B-group
products I-group O
. O O

This O O
increase O O
is O O
greatest O O
in O O
the O O
evening O O
. O O

Pressor O O
amines O O
( O O
e.g. O O
, O O
norepinephrine B-drug B-drug
) O O
: O O
possible O O
decreased O O
response O O
to O O
pressor O O
amines O O
but O O
not O O
sufficient O O
to O O
preclude O O
their O O
use O O
. O O

Antihistamines B-group B-group
( O O
e.g. O O
, O O
chlorpheniramine B-group B-drug
) O O
. O O

Ranitidine B-drug B-drug
produced O O
smaller O O
, O O
non-significant O O
increases O O
. O O

Increased O O
plasma O O
concentrations O O
of O O
terfenadine B-drug B-drug
, O O
astemizole B-drug B-drug
, O O
and O O
cisapride B-drug B-drug
cause O O
QT O O
prolongation O O
and O O
have O O
been O O
associated O O
with O O
torsades O O
de O O
pointes-type O O
ventricular O O
tachycardia O O
, O O
sometimes O O
fatal O O
. O O

Aspirin B-brand B-brand
: O O
Animal O O
studies O O
wshow O O
that O O
aspirin B-brand B-brand
given O O
with O O
nonsteroidal B-group B-group
anti-inflammatory I-group I-group
agents I-group I-group
, O O
including O O
ibuprofen B-drug B-drug
, O O
yields O O
a O O
net O O
decrease O O
in O O
anti-inflammatory O O
activity O O
with O O
lowered O O
blood O O
levels O O
of O O
the O O
non-aspirin O B-group
drug O I-group
. O O

Furthermore O O
, O O
rifampin B-drug B-drug
, O O
phenytoin B-drug B-drug
, O O
phenobarbital B-drug B-drug
, O O
and O O
other O O
inducers O O
of O O
cytochrome O O
P450 O O
3A4 O O
may O O
cause O O
a O O
reduction O O
in O O
plasma O O
bexarotene B-drug B-drug
concentrations O O
. O O

Reduced O O
levels O O
( O O
up O O
to O O
20 O O
% O O
) O O
of O O
total O O
glutathione O B-drug
( O O
total O O
GSH O O
) O O
, O O
and O O
elevation O O
of O O
conjugated O O
dienes O O
( O O
approximately O O
60 O O
% O O
in O O
liver O O
by O O
single O O
dose O O
at O O
4 O O
h O O
) O O
also O O
indicated O O
the O O
presence O O
of O O
an O O
oxidative O O
insult O O
. O O

General O O
In O O
vitro O O
studies O O
in O O
human O O
liver O O
microsomes O O
demonstrated O O
no O O
evidence O O
of O O
cytochrome O O
P450-mediated O O
drug O O
interactions O O
that O O
are O O
likely O O
to O O
be O O
of O O
clinical O O
relevance O O
. O O

Correlative O O
clinical O O
studies O O
have O O
not O O
been O O
performed O O
. O O

This O O
interaction O O
, O O
which O O
has O O
not O O
been O O
investigated O O
using O O
higher O O
doses O O
of O O
fluvoxamine B-drug B-drug
, O O
may O O
be O O
more O O
pronounced O O
if O O
a O O
300 O O
mg O O
daily O O
dose O O
is O O
co-administered O O
, O O
particularly O O
since O O
fluvoxamine B-drug B-drug
exhibits O O
non-linear O O
pharmacokinetics O O
over O O
the O O
dosage O O
range O O
100-300 O O
mg O O
. O O
If O O
alprazolam B-drug B-drug
is O O
co-administered O O
with O O
Fluvoxamine B-drug B-drug
Tablets O O
, O O
the O O
initial O O
alprazolam B-drug B-drug
dosage O O
should O O
be O O
at O O
least O O
halved O O
and O O
titration O O
to O O
the O O
lowest O O
effective O O
dose O O
is O O
recommended O O
. O O

Both O O
of O O
these O O
strategies O O
will O O
become O O
more O O
feasible O O
as O O
specific O O
molecular O O
differences O O
between O O
tumor O O
and O O
normal O O
cells O O
are O O
being O O
rapidly O O
identified O O
and O O
new O O
combination O O
therapies O O
that O O
take O O
advantage O O
of O O
these O O
differences O O
are O O
being O O
designed O O
and O O
tested O O
. O O

Hypothermia O O
as O O
an O O
index O O
of O O
the O O
disulfiram-ethanol B-drug B-drug
reaction O O
in O O
the O O
rat O O
. O O

Furosemide B-drug B-drug
: O O
Clinical O O
studies O O
, O O
as O O
well O O
as O O
post-marketing O O
observations O O
, O O
have O O
shown O O
that O O
NSAIDs B-group B-group
can O O
reduce O O
the O O
natriuretic O O
effect O O
of O O
furosemide B-drug B-drug
and O O
thiazides B-group B-group
in O O
some O O
patients O O
. O O

In O O
dogs O O
, O O
cimetidine B-drug B-drug
unchanged O O
the O O
secretion O O
of O O
cardiotrast B-drug O
, O O
a O O
test O O
agent O O
for O O
anionic O O
transport O O
. O O

This O O
effect O O
of O O
aspirin B-brand B-brand
( O O
which O O
also O O
lowers O O
serum O O
concentrations O O
of O O
other O O
nonsteroidal B-group B-group
anti-inflammatory I-group I-group
drugs I-group I-group
given O O
with O O
it O O
) O O
has O O
been O O
demonstrated O O
in O O
patients O O
with O O
rheumatoid O O
arthritis O O
( O O
n= O O
15 O O
) O O
as O O
well O O
as O O
normal O O
volunteers O O
( O O
n= O O
16 O O
) O O
. O O

In O O
extremely O O
acidic O O
conditions O O
, O O
Duloxetine B-drug B-drug
, O O
unprotected O O
by O O
the O O
enteric O O
coating O O
, O O
may O O
undergo O O
hydrolysis O O
to O O
form O O
naphthol O B-drug
. O O

Amprenavir B-drug B-drug
inhibits O O
CYP3A4 O O
. O O

Anticoagulants B-group B-group
: O O
There O O
have O O
been O O
reports O O
of O O
increased O O
anticoagulant O O
effects O O
when O O
erythromycin B-drug B-drug
and O O
oral O O
anticoagulants B-group B-group
were O O
used O O
concomitantly O O
. O O

Oral O O
neomycin B-drug B-drug
sulfate I-drug I-drug
may O O
enhance O O
the O O
effect O O
of O O
coumarin B-group B-group
in O O
anticoagulants B-group B-group
by O O
decreasing O O
vitamin O B-group
K O I-group
availability O O
. O O

The O O
physician O O
should O O
be O O
alert O O
for O O
possible O O
combined O O
drug O O
actions O O
, O O
desirable O O
or O O
undesirable O O
, O O
involving O O
cyclophosphamide B-drug B-drug
even O O
though O O
cyclophosphamide B-drug B-drug
has O O
been O O
used O O
successfully O O
concurrently O O
with O O
other O O
drugs O O
, O O
including O O
other O O
cytotoxic O B-group
drugs O I-group
. O O

Among O O
fifteen O O
species O O
of O O
bacteria O O
tested O O
, O O
the O O
antimicrobial O O
activity O O
of O O
GL B-drug_n B-drug_n
was O O
the O O
most O O
potent O O
against O O
Micrococcus O O
luteus O O
( O O
MIC O O
, O O
0.75 O O
mg/ml O O
) O O
. O O

Aprepitant I-drug B-drug
is O O
a O O
substrate O O
for O O
CYP3A4 O O
; O O

This O O
may O O
lead O O
to O O
reduced O O
clearance O O
of O O
caffeine B-drug B-drug
and O O
a O O
prolongation O O
of O O
its O O
plasma O O
half-life O O
. O O

Aripiprazole B-drug B-drug
also O O
does O O
not O O
undergo O O
direct O O
glucuronidation O O
. O O

Alcohol B-drug B-drug
, O O
in O O
particular O O
, O O
has O O
been O O
found O O
to O O
exhibit O O
additive O O
effects O O
of O O
this O O
variety O O
. O O

Vitamin B-drug B-drug
D3 I-drug I-drug
administration O O
to O O
rachitic O O
chicks O O
was O O
effective O O
in O O
significantly O O
elevating O O
duodenal O O
arsenate B-drug_n O
absorption O O
, O O
acting O O
primarily O O
to O O
enhance O O
serosal O O
transport O O
. O O

TBg O O
may O O
also O O
be O O
increased O O
during O O
infectious O O
hepatitis O O
. O O

. O O

The O O
plasma O O
concentrations O O
of O O
bosentan B-drug B-drug
were O O
also O O
decreased O O
by O O
approximately O O
30 O O
% O O
. O O

Drugs O O
that O O
induce O O
hepatic O O
enzymes O O
such O O
as O O
phenobarbital B-drug B-drug
, O O
phenytoin B-drug B-drug
and O O
rifampin B-drug B-drug
may O O
increase O O
the O O
clearance O O
of O O
corticosteroids B-group B-group
and O O
may O O
require O O
increases O O
in O O
corticosteroid B-group B-group
dose O O
to O O
achieve O O
the O O
desired O O
response O O
. O O

Amiodarone B-drug B-drug
: O O
Amiodarone B-drug B-drug
therapy O O
alone O O
can O O
cause O O
hypothyroidism O O
or O O
hyperthyroidism O O
. O O

Higher O O
concentrations O O
of O O
dexamethasone B-drug B-drug
( O O
10 O O
( O O
-8 O O
) O O
- O O
10 O O
( O O
-6 O O
) O O
M O O
) O O
or O O
retinyl B-drug B-drug
acetate I-drug I-drug
( O O
3 O O
X O O
10 O O
( O O
-8 O O
) O O
- O O
10 O O
( O O
-7 O O
) O O
M O O
) O O
enhance O O
the O O
mitogenic O O
activity O O
of O O
EGF B-drug_n B-drug_n
. O O

Certain O O
drugs O O
tend O O
to O O
produce O O
hyperglycemia O O
and O O
may O O
lead O O
to O O
loss O O
of O O
control O O
. O O

Recent O O
studies O O
and O O
consensus O O
reports O O
have O O
expanded O O
our O O
understanding O O
of O O
its O O
efficacy O O
, O O
safety O O
, O O
contraindications O O
, O O
and O O
drug O O
interactions O O
. O O

Drugs O O
That O O
Inhibit O O
CYP3A4 O O
( O O
Ketoconazole B-drug B-drug
) O O
CYP3A4 O O
is O O
a O O
major O O
metabolic O O
pathway O O
for O O
elimination O O
of O O
eszopiclone B-drug B-drug
. O O

A O O
pharmacokinetic O O
study O O
evaluating O O
the O O
administration O O
of O O
a O O
single O O
dose O O
of O O
INSPRA B-brand B-brand
100 O O
mg O O
with O O
ketoconazole B-drug B-drug
200 O O
mg O O
BID O O
, O O
a O O
potent O O
inhibitor O O
of O O
the O O
CYP3A4 O O
pathway O O
, O O
showed O O
a O O
1.7-fold O O
increase O O
in O O
Cmax O O
of O O
eplerenone B-drug B-drug
and O O
a O O
5.4-fold O O
increase O O
in O O
AUC O O
of O O
eplerenone B-drug B-drug
. O O

Caution O O
should O O
be O O
exercised O O
and O O
dose O O
reduction O O
of O O
the O O
concomitant O O
substrate O O
drug O O
should O O
be O O
considered O O
when O O
dosing O O
lapatinib B-drug B-drug
concurrently O O
with O O
medications O O
with O O
narrow O O
therapeutic O O
windows O O
that O O
are O O
substrates O O
of O O
CYP3A4 O O
or O O
CYP2C8 O O
. O O

As O O
with O O
other O O
agents B-group O
with I-group O
b-blocking I-group B-group
properties I-group O
, O O
if O O
COREG B-brand B-brand
is O O
to O O
be O O
administered O O
orally O O
with O O
calcium B-group B-group
channel I-group I-group
blockers I-group I-group
of O O
the O O
verapamil B-drug B-drug
or O O
diltiazem B-drug B-drug
type O O
, O O
it O O
is O O
recommended O O
that O O
ECG O O
and O O
blood O O
pressure O O
be O O
monitored O O
. O O

No O O
formal O O
assessments O O
of O O
drug-drug O O
interactions O O
between O O
Vidaza B-brand B-brand
and O O
other O O
agents O O
have O O
been O O
conducted O O

Pregnancies O O
have O O
been O O
reported O O
by O O
users O O
of O O
combined B-group B-group
hormonal I-group I-group
contraceptives I-group I-group
who O O
also O O
used O O
some O O
form O O
of O O
St. O O
Johns O O
Wort O O
. O O

Phenobarbital B-drug B-drug

Specific O O
drug O O
interaction O O
studies O O
have O O
not O O
been O O
performed O O
with O O
SUSTIVA B-brand B-brand
and O O
NRTIs B-group B-group
other O O
than O O
lamivudine B-drug B-drug
and O O
zidovudine B-drug B-drug
. O O

Concomitant O O
administration O O
of O O
Norpace B-brand B-brand
and O O
quinidine B-drug B-drug
resulted O O
in O O
slight O O
increases O O
in O O
plasma O O
disopyramide B-drug B-drug
levels O O
and O O
slight O O
decreases O O
in O O
plasma O O
quinidine B-drug B-drug
levels O O
. O O

OBJECTIVE O O
: O O
To O O
report O O
a O O
case O O
of O O
rhabdomyolysis O O
resulting O O
from O O
concomitant O O
use O O
of O O
clarithromycin B-drug B-drug
and O O
simvastatin B-drug B-drug
. O O

Drugs O O
with O O
a O O
Narrow O O
Therapeutic O O
Index O O
Digoxin B-drug B-drug
: O O
Sonata B-brand B-brand
( O O
10 O O
mg O O
) O O
did O O
not O O
affect O O
the O O
pharmacokinetic O O
or O O
pharmacodynamic O O
profile O O
of O O
digoxin B-drug B-drug
( O O
0.375 O O
mg O O
q24h O O
for O O
8 O O
days O O
) O O
. O O

Coadministration O O
with O O
compounds O O
that O O
are O O
potent O O
inducers O O
of O O
CYP3A4 O O
( O O
eg O O
, O O
phenobarbital B-drug B-drug
, O O
phenytoin B-drug B-drug
, O O
dexamethasone B-drug B-drug
, O O
carbamazepine B-drug B-drug
) O O
may O O
result O O
in O O
decreased O O
plasma O O
levels O O
of O O
saquinavir B-drug B-drug
. O O

Warfarin B-drug B-drug
: O O
Quinolones B-group B-group
, O O
including O O
enoxacin B-drug B-drug
, O O
decrease O O
the O O
clearance O O
of O O
R-warfarin B-drug B-drug
, O O
the O O
less O O
active O O
isomer O O
of O O
racemic O O
warfarin B-drug B-drug
. O O

Drug/Laboratory O O
Test O O
Interactions O O
Phenytoin B-drug B-drug
may O O
decrease O O
serum O O
concentrations O O
of O O
14 O O
. O O

Combination O O
hormonal B-group B-group
contraceptives I-group I-group
may O O
also O O
decrease O O
the O O
plasma O O
concentration O O
of O O
acetaminophen B-drug B-drug
. O O

Digoxin B-drug B-drug
: O O
When O O
multiple O O
doses O O
of O O
atorvastatin B-drug B-drug
and O O
digoxin B-drug B-drug
were O O
coadministered O O
, O O
steady-state O O
plasma O O
digoxin B-drug B-drug
concentrations O O
increased O O
by O O
approximately O O
20 O O
% O O
. O O

Oxcarbazepine B-drug B-drug
was O O
evaluated O O
in O O
human O O
liver O O
microsomes O O
to O O
determine O O
its O O
capacity O O
to O O
inhibit O O
the O O
major O O
cytochrome O O
P450 O O
enzymes O O
responsible O O
for O O
the O O
metabolism O O
of O O
other O O
drugs O O
. O O

In O O
studies O O
with O O
finasteride B-drug B-drug
, O O
no O O
clinically O O
meaningful O O
changes O O
in O O
luteinizing O B-drug
hormone O I-drug
( O O
LH O O
) O O
, O O
follicle-stimulating O B-drug
hormone O I-drug
( O O
FSH O B-drug
) O O
or O O
prolactin O B-drug
were O O
detected O O
. O O

Phenytoin B-drug B-drug

Amiodarone B-drug B-drug
caused O O
a O O
three- O O
to O O
fivefold O O
increase O O
in O O
serum O O
reverse O O
triiodothyronine O O
levels O O
, O O
but O O
changes O O
in O O
thyroid O O
function O O
were O O
not O O
quantitatively O O
related O O
to O O
the O O
changes O O
in O O
digoxin B-drug B-drug
pharmacokinetics O O
. O O

The O O
clinical O O
significance O O
of O O
this O O
finding O O
is O O
unknown O O
; O O

Additive O O
CNS O O
depression O O
may O O
occur O O
when O O
antihistamines B-group B-group
are O O
administered O O
concomitantly O O
with O O
other O O
CNS B-group B-group
depressants I-group I-group
including O O
barbiturates B-group B-group
, O O
tranquilizers B-group B-group
, O O
and O O
alcohol B-drug B-drug
. O O

This O O
article O O
looks O O
at O O
five O O
commonly O O
used O O
immunosuppressive B-group B-group
drugs I-group I-group
in O O
turn O O
( O O
corticosteroids B-group B-group
, O O
cyclosporin B-drug B-drug
, O O
azathioprine B-drug B-drug
, O O
methotrexate B-drug B-drug
, O O
cyclophosphamide B-drug B-drug
) O O
, O O
discussing O O
the O O
main O O
, O O
non-infection O O
, O O
unwanted O O
effects O O
, O O
ways O O
to O O
avoid O O
them O O
and O O
what O O
to O O
do O O
if O O
problems O O
arise O O
. O O

Nevertheless O O
, O O
caution O O
is O O
indicated O O
in O O
the O O
co-administration O O
of O O
TCAs B-group B-group
with O O
any O O
of O O
the O O
SSRIs B-group B-group
and O O
also O O
in O O
switching O O
from O O
one O O
class O O
to O O
the O O
other O O
. O O

No O O
pharmacokinetic-based O O
drug-drug O O
interaction O O
studies O O
have O O
been O O
conducted O O
with O O
SYNAREL B-brand B-brand
. O O

Prescribers O O
are O O
advised O O
to O O
consult O O
the O O
package O O
insert O O
of O O
medication O O
administered O O
concomitantly O O
with O O
hormonal B-group B-group
contraceptives I-group I-group
, O O
since O O
some O O
medications O O
may O O
decrease O O
the O O
effectiveness O O
of O O
these O O
birth O O
control O O
products O O
. O O

Co-administration O O
of O O
anastrozole B-drug B-drug
and O O
tamoxifen B-drug B-drug
resulted O O
in O O
a O O
reduction O O
of O O
anastrozole B-drug B-drug
plasma O O
levels O O
by O O
27 O O
% O O
compared O O
with O O
those O O
achieved O O
with O O
anastrozole B-drug B-drug
alone O O
. O O

The O O
mechanism O O
of O O
this O O
pharmacodynamic O O
interaction O O
is O O
not O O
known O O
. O O

Patients O O
receiving O O
high O O
doses O O
of O O
salicylates B-group B-group
concomitantly O O
with O O
furosemide B-drug B-drug
, O O
as O O
in O O
rheumatic O O
disease O O
, O O
may O O
experience O O
salicylate B-group B-group
toxicity O O
at O O
lower O O
doses O O
because O O
of O O
competitive O O
renal O O
excretory O O
sites O O
. O O

When O O
lansoprazole B-drug B-drug
was O O
administered O O
concomitantly O O
with O O
theophylline B-drug B-drug
( O O
CYP1A2 O O
, O O
CYP3A O O
) O O
, O O
a O O
minor O O
increase O O
( O O
10 O O
% O O
) O O
in O O
the O O
clearance O O
of O O
theophylline B-drug B-drug
was O O
seen O O
. O O

Caution O O
is O O
advised O O
in O O
using O O
Duloxetine B-drug B-drug
in O O
patients O O
with O O
conditions O O
that O O
may O O
slow O O
gastric O O
emptying O O
( O O
e.g. O O
, O O
some O O
diabetics O O
) O O
. O O

Diuretic B-group B-group
agents I-group I-group
reduce O O
the O O
renal O O
clearance O O
of O O
lithium B-drug B-drug
and O O
add O O
a O O
high O O
risk O O
of O O
lithium B-drug B-drug
toxicity O O
. O O

MAO B-group B-group
inhibitors I-group I-group
prolong O O
and O O
intensify O O
the O O
anticholinergic O O
effects O O
of O O
antihistamines B-group B-group
. O O

These O O
cells O O
express O O
the O O
vitamin O B-group
D O I-group
receptor O O
and O O
exhibit O O
doubling O O
times O O
comparable O O
to O O
the O O
parental O O
MCF-7 O O
cells O O
, O O
even O O
when O O
grown O O
in O O
100 O O
mM O O
1,25 B-drug B-drug
( I-drug I-drug
OH I-drug I-drug
) I-drug I-drug
2D3 I-drug I-drug
. O O

Some O O
reports O O
have O O
shown O O
that O O
the O O
concomitant O O
administration O O
of O O
thiazides B-group B-group
with O O
vitamin B-group B-group
D I-group I-group
causes O O
hypercalcemia O O
. O O

The O O
concomitant O O
administration O O
of O O
uricosuric B-group B-group
agents I-group I-group
and O O
allopurinol B-drug B-drug
has O O
been O O
associated O O
with O O
a O O
decrease O O
in O O
the O O
excretion O O
of O O
oxypurines O B-drug
( O O
hypoxanthine O B-drug
and O O
xanthine O B-drug
) O O
and O O
an O O
increase O O
in O O
urinary O O
uric O O
acid O O
excretion O O
compared O O
with O O
that O O
observed O O
with O O
allopurinol B-drug B-drug
alone O O
. O O

TAMBOCOR B-brand B-brand
has O O
been O O
used O O
in O O
a O O
large O O
number O O
of O O
patients O O
receiving O O
diuretics B-group B-group
without O O
apparent O O
interaction O O
. O O

Drugs O O
That O O
Inhibit O O
Aldehyde O O
Oxidase O O
The O O
aldehyde O O
oxidase O O
enzyme O O
system O O
is O O
less O O
well O O
studied O O
than O O
the O O
cytochrome O O
P450 O O
enzyme O O
system O O
. O O

A O O
study O O
in O O
eight O O
healthy O O
volunteers O O
has O O
shown O O
a O O
50 O O
% O O
increase O O
in O O
mean O O
peak O O
nimodipine B-drug B-drug
plasma O O
concentrations O O
and O O
a O O
90 O O
% O O
increase O O
in O O
mean O O
area O O
under O O
the O O
curve O O
, O O
after O O
a O O
one O O
week O O
course O O
of O O
cimetidine B-drug B-drug
at O O
1,000 O O
mg/day O O
and O O
nimodipine B-drug B-drug
at O O
90 O O
mg/day O O
. O O

We O O
have O O
selected O O
a O O
subclone O O
of O O
MCF-7 O O
cells O O
resistant O O
to O O
1,25 B-drug B-drug
( I-drug I-drug
OH I-drug I-drug
) I-drug I-drug
2D3 I-drug I-drug
( O O
MCF-7D3Res O O
) O O
. O O

Antagonism O O
between O O
lincomycin B-drug B-drug
and O O
erythromycin B-drug B-drug
in O O
vitro O O
has O O
been O O
demonstrated O O
. O O

The O O
data O O
suggest O O
that O O
the O O
histidine O O
residues O O
may O O
be O O
crucial O O
to O O
the O O
receptor-binding O O
activity O O
of O O
toxin B-drug_n B-drug_n
A I-drug_n I-drug_n
. O O

The O O
following O O
precautions O O
should O O
be O O
kept O O
in O O
mind O O
in O O
the O O
treatment O O
of O O
anticholinesterase O O
poisoning O O
although O O
they O O
do O O
not O O
bear O O
directly O O
on O O
the O O
use O O
of O O
atropine B-drug B-drug
and O O
pralidoxime B-drug B-drug
. O O

Drug/Laboratory O O
Test O O
Interactions O O
None O O
known O O
. O O

Other O O
Chemotherapy O O
Agents O O
In O O
a O O
separate O O
study O O
, O O
concomitant O O
administration O O
of O O
lapatinib B-drug B-drug
with O O
capecitabine B-drug B-drug
did O O
not O O
meaningfully O O
alter O O
the O O
pharmacokinetics O O
of O O
either O O
agent O O
( O O
or O O
the O O
metabolites O O
of O O
capecitabine B-drug B-drug
) O O
. O O

Labetalol B-drug B-drug
HCl I-drug I-drug
blunts O O
the O O
reflex O O
tachycardia O O
produced O O
by O O
nitroglycerin B-drug B-drug
without O O
preventing O O
its O O
hypotensive O O
effect O O
. O O

It O O
is O O
advisable O O
to O O
check O O
coagulation O O
time O O
within O O
the O O
first O O
few O O
days O O
after O O
the O O
start O O
and O O
discontinuation O O
of O O
cisapride B-drug B-drug
therapy O O
, O O
with O O
an O O
appropriate O O
adjustment O O
of O O
the O O
anticoagulant B-group B-group
dose O O
, O O
if O O
necessary O O
. O O

This O O
is O O
especially O O
important O O
in O O
patients O O
who O O
may O O
use O O
alcohol B-drug B-drug
excessively O O
. O O

It O O
is O O
likely O O
that O O
use O O
of O O
epirubicin B-drug B-drug
with O O
radiotherapy O O
may O O
sensitize O O
tissues O O
to O O
the O O
cytotoxic O O
actions O O
of O O
irradiation O O
. O O

Carbamazepine B-drug B-drug
overdose O O
recognized O O
by O O
a O O
tricyclic B-group B-group
antidepressant I-group I-group
assay O O
. O O

The O O
concomitant O O
use O O
of O O
vasopressors B-group B-group
, O O
vasoconstricting O B-group
agents O I-group
( O O
such O O
as O O
ergonovine B-drug B-drug
) O O
and O O
some O O
oxytocic B-group B-group
drugs I-group I-group
may O O
result O O
in O O
severe O O
hypertension O O
. O O

Concurrent O O
use O O
with O O
general O O
anesthetics B-group B-group
may O O
result O O
in O O
arrhythmias O O
. O O

Thrombolytic B-group B-group
agents I-group I-group
: O O
The O O
safety O O
and O O
effectiveness O O
of O O
Argatroban B-drug B-drug
with O O
thrombolytic B-group B-group
agents I-group I-group
have O O
not O O
been O O
established O O
. O O

Non-steroidal B-group B-group
Anti-inflammatory I-group I-group
Agents I-group I-group
: O O
In O O
some O O
patients O O
with O O
compromised O O
renal O O
function O O
who O O
are O O
being O O
treated O O
with O O
nonsteroidal B-group B-group
anti-inflammatory I-group I-group
drugs I-group I-group
, O O
the O O
co-administration O O
of O O
enalapril B-drug B-drug
may O O
result O O
in O O
a O O
further O O
deterioration O O
of O O
renal O O
function O O
. O O

This O O
indicates O O
that O O
tiagabine B-drug B-drug
does O O
not O O
cause O O
induction O O
or O O
inhibition O O
of O O
the O O
hepatic O O
microsomal O O
enzyme O O
systems O O
responsible O O
for O O
the O O
metabolism O O
of O O
antipyrine B-drug B-drug
. O O

indinavir I-drug B-drug
concentration O O

Cimetidine B-drug B-drug
: O O
Co-administration O O
with O O
high O O
doses O O
of O O
cimetidine B-drug B-drug
[ O O
800 O O
mg O O
twice O O
daily O O
] O O
increased O O
the O O
Cmax O O
of O O
rofecoxib B-drug B-drug
by O O
21 O O
% O O
, O O
the O O
AUC0-120hr O O
by O O
23 O O
% O O
and O O
the O O
t1/2 O O
by O O
15 O O
% O O
. O O

Other O O
drug O O
interactions O O
Cimetidine B-drug B-drug
, O O
erythromycin B-drug B-drug
and O O
dextropropoxyphene B-drug B-drug
had O O
no O O
effect O O
on O O
the O O
pharmacokinetics O O
of O O
MHD B-drug_n B-drug_n
. O O

Standard O O
monitoring O O
of O O
methotrexate-related B-drug B-drug
toxicity O O
should O O
be O O
continued O O
if O O
VIOXX B-brand B-brand
and O O
methotrexate B-drug B-drug
are O O
administered O O
concomitantly O O
. O O

Risk O O
of O O
Anaphylactic O O
Reaction O O
While O O
taking O O
beta-blockers B-group B-group
, O O
patients O O
with O O
a O O
history O O
of O O
severe O O
anaphylactic O O
reaction O O
to O O
a O O
variety O O
of O O
allergens O O
may O O
be O O
more O O
reactive O O
to O O
repeated O O
challenge O O
, O O
either O O
accidental O O
, O O
diagnostic O O
, O O
or O O
therapeutic O O
. O O

In O O
healthy O O
volunteers O O
, O O
treatment O O
with O O
finasteride B-drug B-drug
did O O
not O O
alter O O
the O O
response O O
of O O
LH O B-drug
and O O
FSH O O
to O O
gonadotropin-releasing O O
hormone O O
indicating O O
that O O
the O O
hypothalamic-pituitary-testicular O O
axis O O
was O O
not O O
affected O O
. O O

Rifabutin I-drug B-drug

The O O
prior O O
administration O O
of O O
succinylcholine B-drug B-drug
does O O
not O O
enhance O O
the O O
duration O O
, O O
but O O
quickens O O
the O O
onset O O
and O O
may O O
increase O O
the O O
depth O O
, O O
of O O
neuromuscular O O
block O O
induced O O
by O O
TRACRIUM B-brand B-brand
. O O

ranitidine* B-drug B-drug
; O O

The O O
appropriate O O
interval O O
between O O
administration O O
of O O
these O O
agents O O
and O O
dexfenfluramine B-drug B-drug
has O O
not O O
been O O
established O O
. O O

The O O
half-life O O
increased O O
from O O
4.0 O O
to O O
4.8 O O
hours O O
. O O

There O O
is O O
no O O
pharmacokinetic O O
interaction O O
between O O
zaleplon B-drug B-drug
and O O
diphenhydramine B-drug B-drug
following O O
the O O
administration O O
of O O
a O O
single O O
dose O O
( O O
10 O O
mg O O
and O O
50 O O
mg O O
, O O
respectively O O
) O O
of O O
each O O
drug O O
. O O

saquinavir I-drug B-drug
concentration O O

The O O
adverse O O
experience O O
profile O O
seen O O
with O O
KEMSTROTM B-brand B-brand
was O O
similar O O
to O O
that O O
seen O O
with O O
baclofen B-drug B-drug
tablets O O
. O O

Agents O O
that O O
are O O
CYP3A4 O O
inhibitors O O
that O O
have O O
been O O
found O O
, O O
or O O
are O O
expected O O
, O O
to O O
increase O O
plasma O O
levels O O
of O O
EQUETROTM B-brand B-brand
are O O
the O O
following O O
: O O
Acetazolamide B-drug B-drug
, O O
azole B-group B-group
antifungals I-group I-group
, O O
cimetidine B-drug B-drug
, O O
clarithromycin B-drug B-drug
( O O
1 O O
) O O
, O O
dalfopristin B-drug B-drug
, O O
danazol B-drug B-drug
, O O
delavirdine B-drug B-drug
, O O
diltiazem B-drug B-drug
, O O
erythromycin B-drug B-drug
( O O
1 O O
) O O
, O O
fluoxetine B-drug B-drug
, O O
fluvoxamine B-drug B-drug
, O O
grapefruit O O
juice O O
, O O
isoniazid B-drug B-drug
, O O
itraconazole B-drug B-drug
, O O
ketoconazole B-drug B-drug
, O O
loratadine B-drug B-drug
, O O
nefazodone B-drug B-drug
, O O
niacinamide B-drug B-drug
, O O
nicotinamide B-drug B-drug
, O O
protease B-group B-group
inhibitors I-group I-group
, O O
propoxyphene B-drug B-drug
, O O
quinine B-drug B-drug
, O O
quinupristin B-drug B-drug
, O O
troleandomycin B-drug B-drug
, O O
valproate B-drug B-drug
( O O
1 O O
) O O
, O O
verapamil B-drug B-drug
, O O
zileuton B-drug B-drug
. O O

In O O
three O O
separate O O
controlled O O
, O O
parallel O O
group O O
clinical O O
pharmacology O O
studies O O
, O O
desloratadine B-drug B-drug
at O O
the O O
clinical O O
dose O O
of O O
5 O O
mg O O
has O O
been O O
coadministered O O
with O O
azithromycin B-drug B-drug
500 O O
mg O O
followed O O
by O O
250 O O
mg O O
once O O
daily O O
for O O
4 O O
days O O
( O O
n=18 O O
) O O
or O O
with O O
fluoxetine B-drug B-drug
20 O O
mg O O
once O O
daily O O
for O O
7 O O
days O O
after O O
a O O
23 O O
day O O
pretreatment O O
period O O
with O O
fluoxetine B-drug B-drug
( O O
n=18 O O
) O O
or O O
with O O
cimetidine B-drug B-drug
600 O O
mg O O
every O O
12 O O
hours O O
for O O
14 O O
days O O
( O O
n=18 O O
) O O
under O O
steady O O
state O O
conditions O O
to O O
normal O O
healthy O O
male O O
and O O
female O O
volunteers O O
. O O

Concomitant O O
use O O
of O O
digoxin B-drug B-drug
and O O
sympathomimetics B-group B-group
increases O O
the O O
risk O O
of O O
cardiac O O
arrhythmias O O
. O O

Olanzapine B-drug B-drug
is O O
associated O O
with O O
significantly O O
fewer O O
extrapyramidal O O
symptoms O O
than O O
haloperidol B-drug B-drug
and O O
risperidone B-drug B-drug
. O O

lithium B-drug B-drug
; O O

Drugs O O
which O O
impair O O
glomerular O O
filtration O O
may O O
prolong O O
the O O
biological O O
half-life O O
of O O
flucytosine B-drug B-drug
. O O

Meperidine B-drug B-drug
: O O
Amphetamines B-group B-group
potentiate O O
the O O
analgesic O O
effect O O
of O O
meperidine B-drug B-drug
. O O

- O O
Dantrolene B-drug B-drug
( O O
e.g. O O
, O O
Dantrium B-brand B-brand
) O O
or O O

Drug-Laboratory O O
Test O O
Interactions O O
There O O
are O O
no O O
reported O O
drug-laboratory O O
test O O
interactions O O
. O O

Lodine B-brand B-brand
treatment O O
is O O
associated O O
with O O
a O O
small O O
decrease O O
in O O
serum O O
uric O O
acid O O
levels O O
. O O

Immediate O O
and O O
Extended O O
Release O O
Tablets O O
The O O
hypoglycemic O O
action O O
of O O
sulfonylureas B-group B-group
may O O
be O O
potentiated O O
by O O
certain O O
drugs O O
including O O
nonsteroidal B-group B-group
anti-inflammatory I-group I-group
agents I-group I-group
, O O
some O O
azoles B-group O
and O O
other O O
drugs O O
that O O
are O O
highly O O
protein O O
bound O O
, O O
salicylates B-group B-group
, O O
sulfonamides B-group B-group
, O O
chloramphenicol B-drug B-drug
, O O
probenecid B-drug B-drug
, O O
coumarins B-group B-group
, O O
monoamine B-group B-group
oxidase I-group I-group
inhibitors I-group I-group
, O O
and O O
beta B-group B-group
adrenergic I-group I-group
blocking I-group I-group
agents I-group I-group
. O O

CYP3A4 O O
inducers O O
: O O
CYP3A4 O O
inducers O O
may O O
decrease O O
the O O
levels/effects O O
of O O
ethinyl B-drug B-drug
estradiol I-drug I-drug
. O O

Aprepitant I-drug B-drug
, O O
when O O
given O O
as O O
a O O
regimen O O
of O O
125 O O
mg O O
on O O
Day O O
1 O O
and O O
80 O O
mg/day O O
on O O
Days O O
2 O O
and O O
3 O O
, O O
increased O O
the O O
AUC O O
of O O
methylprednisolone B-drug B-drug
, O O
a O O
CYP3A4 O O
substrate O O
, O O
by O O
1.34-fold O O
on O O
Day O O
1 O O
and O O
by O O
2.5-fold O O
on O O
Day O O
3 O O
, O O
when O O
methylprednisolone B-drug B-drug
was O O
coadministered O O
intravenously O O
as O O
125 O O
mg O O
on O O
Day O O
1 O O
and O O
orally O O
as O O
40 O O
mg O O
on O O
Days O O
2 O O
and O O
3 O O
. O O

Catecholamine-depleting O O
drugs O O
( O O
e.g. O O
, O O
reserpine B-drug B-drug
) O O
: O O
additive O O
effect O O
; O O

Doxazosin B-drug B-drug
mesylate I-drug I-drug
tablets O O
have O O
been O O
used O O
with O O
the O O
following O O
drugs O O
or O O
drug O O
classes O O
: O O
1 O O
. O O

Because O O
there O O
is O O
a O O
theoretical O O
basis O O
that O O
these O O
effects O O
may O O
be O O
additive O O
, O O
use O O
of O O
ergotamine-containing B-drug B-drug
or O O
ergot-type B-group B-group
medications I-group I-group
( O O
like O O
dihydroergotamine B-drug B-drug
or O O
methysergide B-drug B-drug
) O O
and O O
AXERT B-brand B-brand
within O O
24 O O
hours O O
of O O
each O O
other O O
should O O
be O O
avoided O O
. O O

Miracidia O O
demonstrated O O
a O O
rapid O O
avoidance O O
behaviour O O
when O O
briefly O O
exposed O O
to O O
heavy O O
metals O O
. O O

Carbamazepine B-drug B-drug
: O O
In O O
healthy O O
subjects O O
receiving O O
the O O
CYP3A4 O O
inducer O O
, O O
carbamazepine B-drug B-drug
, O O
at O O
100 O O
mg O O
twice O O
daily O O
for O O
3 O O
days O O
and O O
200 O O
mg O O
twice O O
daily O O
for O O
17 O O
days O O
, O O
systemic O O
exposure O O
( O O
AUC O O
) O O
to O O
lapatinib B-drug B-drug
was O O
decreased O O
approximately O O
72 O O
% O O
. O O

The O O
aim O O
of O O
this O O
paper O O
was O O
to O O
study O O
the O O
interaction O O
between O O
neurotensin B-drug_n B-drug
and O O
both O O
enkephalins B-drug_n B-group
or O O
its O O
synthetic O O
analogue O O
D-Ala2-metenkephalinamide B-drug_n B-drug
, O O
or O O
tuftsin B-drug_n B-drug_n
, O O
on O O
the O O
antinonciceptive O O
effect O O
of O O
these O O
peptides O O
in O O
mice O O
after O O
intracisternal O O
injection O O
. O O

Coadministration O O
of O O
this O O
oral O O
contraceptive B-group B-group
did O O
not O O
influence O O
the O O
pharmacokinetics O O
of O O
levetiracetam B-drug B-drug
. O O

The O O
magnitude O O
of O O
interaction O O
within O O
the O O
recommended O O
dose O O
ranges O O
of O O
either O O
drug O O
is O O
not O O
known O O
. O O

Treatment O O
of O O
toxin B-drug_n B-drug_n
A I-drug_n I-drug_n
with O O
[ O O
( O O
14 O O
) O O
C O O
] O O
-diethyl B-drug_n O
pyrocarbonate I-drug_n O
revealed O O
concentration O O
dependent O O
labelling O O
of O O
histidine O O
residues O O
on O O
the O O
toxin O O
molecules O O
. O O

Cross-reactions O O
with O O
non-Aspergillus O O
polysaccharides O B-group
and O O
polyfuranoses O B-group
with O O
the O O
Bio-Rad O O
Laboratories O O
Platelia O O
Aspergillus O O
EIA O O
test O O
have O O
been O O
reported O O
. O O

Drug/Laboratory O O
Test O O
Interactions O O
: O O
A O O
false-positive O O
reaction O O
for O O
glucose O O
in O O
the O O
urine O O
may O O
occur O O
with O O
copper O O
reduction O O
tests O O
( O O
Benedict O O
s O O
or O O
Fehling O O
s O O
solution O O
or O O
with O O
Clinitest O O
tablets O O
) O O
but O O
not O O
with O O
enzyme-based O O
tests O O
for O O
glycosuria O O
. O O

Grapefruit O O
juice O O
should O O
not O O
be O O
taken O O
during O O
treatment O O
with O O
oral O O
amiodarone O B-drug
. O O

monitor O O
cyclosporine B-drug B-drug
levels O O
. O O

Table O O
3 O O
Established O O
Drug O O
Interactions O O
: O O
Alteration O O
in O O
Dose O O
or O O
Regimen O O
May O O
Be O O
Recommended O O
Based O O
on O O
Drug O O
Interaction O O
Studies O O

Anagrelide B-drug B-drug
is O O
an O O
inhibitor O O
of O O
cyclic O O
AMP O O
PDE O O
III O O
. O O

Cyclosporine B-drug B-drug
: O O
Concomitant O O
administration O O
of O O
nicardipine B-drug B-drug
and O O
cyclosporine B-drug B-drug
levels O O
. O O

This O O
interaction O O
may O O
result O O
in O O
myopathy O O
and O O
rhabdomyolysis O O
, O O
particularly O O
in O O
patients O O
with O O
renal O O
insufficiency O O
or O O
those O O
who O O
are O O
concurrently O O
taking O O
medications O O
associated O O
with O O
myopathy O O
. O O

FLUOTHANE B-brand B-brand
augments O O
the O O
action O O
of O O
non-depolarising B-group B-group
muscle I-group I-group
relaxants O I-group
and O O
the O O
muscle O O
relaxant O O
effects O O
of O O
aminoglycosides B-group B-group
. O O

Twelve O O
strains O O
of O O
Staphylococcus O O
aureus O O
( O O
a O O
frequent O O
cause O O
of O O
infection O O
in O O
heroin B-drug_n B-drug_n
, O O
but O O
not O O
in O O
pentazocine B-drug B-drug
and O O
tripelennamine B-drug B-drug
, O O
addicts O O
) O O
were O O
completely O O
inhibited O O
by O O
the O O
drug O O
combination O O
. O O

Recovery O O
programs O O
should O O
be O O
flexible O O
and O O
involve O O
individual O O
and O O
family O O
education O O
on O O
recovery O O
and O O
the O O
nature O O
of O O
addictive O O
disease O O
. O O

- O O
Skeletal B-group B-group
muscle I-group I-group
relaxants I-group I-group
, O O
nondepolarizing O O
( O O
e.g. O O
, O O
tubocurarine B-drug B-drug
) O O
: O O
Possible O O
increased O O
responsiveness O O
to O O
the O O
muscle B-group B-group
relaxant I-group I-group

Continued O O
admistration O O
of O O
the O O
drug O O
is O O
required O O
to O O
maintain O O
barpress O O
response O O
in O O
this O O
strain O O
of O O
dogs O O
. O O

A O O
dose O O
increase O O
of O O
lopinavir/ritonavir B-drug B-drug
to O O
533/133 O O
mg O O
twice O O
daily O O
with O O
food O O
isrecommended O O
in O O
combination O O
with O O
nevirapine B-drug B-drug
. O O

Nevertheless O O
, O O
caution O O
should O O
be O O
used O O
in O O
patients O O
receiving O O
concomitant O O
treatment O O
with O O
other O O
drugs O O
that O O
are O O
either O O
inhibitors O O
or O O
inducers O O
of O O
these O O
enzymes O O
. O O

Permanent O O
nerve O O
damage O O
could O O
theoretically O O
occur O O
if O O
vitamin O O
B12 O O
deficiency O O
is O O
not O O
treated O O
. O O

- O O
Carbamazepine B-drug B-drug
( O O
e.g. O O
, O O
Tegretol B-brand B-brand
) O O
or O O

Anagrelide B-drug B-drug
is O O
metabolized O O
at O O
least O O
in O O
part O O
by O O
CYP1A2 O O
. O O

If O O
the O O
usual O O
amounts O O
of O O
nondepolarizing O B-group
relaxants O I-group
are O O
given O O
, O O
the O O
time O O
for O O
recovery O O
from O O
neuromuscular O O
blockade O O
will O O
be O O
longer O O
in O O
the O O
presence O O
of O O
Enflurane B-drug B-drug
than O O
when O O
halothane B-drug B-drug
or O O
nitrous B-drug B-drug
oxide I-drug I-drug
with O O
a O O
balanced O O
technique O O
are O O
used O O
. O O

Although O O
not O O
studied O O
systematically O O
in O O
clinical O O
trials O O
, O O
no O O
drug O O
interactions O O
were O O
observed O O
when O O
vecuronium B-drug B-drug
, O O
pancuronium B-drug B-drug
, O O
or O O
atracurium B-drug B-drug
were O O
administered O O
following O O
varying O O
degrees O O
of O O
recovery O O
from O O
single O O
doses O O
or O O
infusions O O
of O O
NIMBEX B-brand B-brand
. O O

Free O O
T3 O O
resin O O
uptake O O
is O O
decreased O O
, O O
reflecting O O
the O O
elevated O O
TBG O O
; O O

In O O
both O O
periods O O
, O O
blood O O
and O O
urine O O
were O O
sampled O O
at O O
regular O O
intervals O O
. O O

Interest O O
in O O
administering O O
compounds O O
in O O
combination O O
lies O O
both O O
in O O
enhancing O O
efficacious O O
effects O O
and O O
in O O
limiting O O
adverse O O
effects O O
. O O

May O O
interact O O
with O O
addictive O O
medications O O
, O O
especially O O
central B-group B-group
nervous I-group I-group
system I-group I-group
( I-group I-group
CNS I-group I-group
) I-group I-group
depressants I-group I-group
with O O
habituating O O
potential O O
( O O
prolonged O O
concurrent O O
use O O
may O O
increase O O
the O O
risk O O
of O O
habituation O O
) O O
, O O
alcohol B-drug B-drug
or O O
CNS O O
depression O O
producing O O
medications O O
( O O
concurrent O O
use O O
may O O
increase O O
the O O
CNS O O
depressant O O
effects O O
of O O
either O O
these O O
medications O O
or O O
ethinamate B-drug B-drug
) O O
. O O

There O O
were O O
no O O
significant O O
differences O O
among O O
the O O
pD2 O O
values O O
for O O
noradrenaline B-drug B-drug
in O O
aortic O O
rings O O
without O O
endothelium O O
. O O

Consequently O O
, O O
concomitant O O
administration O O
of O O
Aprepitant B-drug B-drug
with O O
strong O O
CYP3A4 O O
inhibitors O O
( O O
e.g. O O
, O O
ketoconazole B-drug B-drug
, O O
itraconazole B-drug B-drug
, O O
nefazodone B-drug B-drug
, O O
troleandomycin B-drug B-drug
, O O
clarithromycin B-drug B-drug
, O O
ritonavir B-drug B-drug
, O O
nelfinavir B-drug B-drug
) O O
should O O
be O O
approached O O
with O O
caution O O
. O O

Additional O O
animals O O
in O O
both O O
dose O O
groups O O
developed O O
B-cell O O
hyperplasia O O
of O O
the O O
spleen O O
and O O
lymph O O
nodes O O
. O O

When O O
the O O
CYP2D6 O O
inhibitor O O
is O O
withdrawn O O
from O O
the O O
combination O O
therapy O O
, O O
aripiprazole B-drug B-drug
dose O O
should O O
then O O
be O O
increased O O
. O O

( O O
Indomethacin B-drug B-drug
) O O
diuretics B-group B-group
are O O
used O O
concomitantly O O
, O O
the O O
patient O O
should O O
be O O
observed O O
closely O O
to O O
determine O O
if O O
the O O
desired O O
effect O O
of O O
the O O
diuretic B-group B-group
is O O
obtained O O
. O O

Preliminary O O
studies O O
indicate O O
that O O
the O O
concomitant O O
use O O
of O O
dobutamine B-drug B-drug
and O O
nitroprusside B-drug B-drug
results O O
in O O
a O O
higher O O
cardiac O O
output O O
and O O
, O O
usually O O
, O O
a O O
lower O O
pulmonary O O
wedge O O
pressure O O
than O O
when O O
either O O
drug O O
is O O
used O O
alone O O
. O O

In O O
order O O
to O O
use O O
the O O
pharmacological O O
properties O O
of O O
induced O O
therapeutic O O
hypermagnesaemia O O
, O O
high O O
oral O O
doses O O
of O O
magnesium B-drug B-drug
( O O
> O O
10 O O
mg/kg/day O O
) O O
are O O
advisable O O
for O O
chronic O O
indications O O
and O O
the O O
parenteral O O
route O O
is O O
suitable O O
for O O
acute O O
indications O O
. O O

insulin B-drug B-drug
requirements O O
may O O
be O O
increased O O
, O O
decreased O O
, O O
or O O
unchanged O O
. O O
) O O

The O O
CYP3A4 O O
isoenzyme O O
is O O
present O O
in O O
both O O
the O O
liver O O
and O O
intestines O O
. O O

No O O
information O O
available O O

DIDREX B-brand B-brand
should O O
not O O
be O O
used O O
concomitantly O O
with O O
other O O
CNS B-group B-group
stimulants I-group I-group
. O O

however O O
, O O
as O O
with O O
other O O
NSAIDs B-group B-group
, O O
concomitant O O
administration O O
of O O
Lodine B-brand B-brand
and O O
aspirin B-brand B-brand
is O O
not O O
generally O O
recommended O O
because O O
of O O
the O O
potential O O
of O O
increased O O
adverse O O
effects O O
. O O

Therefore O O
, O O
when O O
hydroflumethiazide B-drug B-drug
and O O
nonsteroidal B-group B-group
anti-inflammatory I-group I-group
agents I-group I-group
are O O
used O O
concomitantly O O
, O O
the O O
patient O O
should O O
be O O
observed O O
closely O O
to O O
determine O O
if O O
the O O
desired O O
effect O O
of O O
the O O
diuretic B-group B-group
is O O
obtained O O
. O O
) O O

In O O
such O O
cases O O
, O O
therefore O O
, O O
more O O
frequent O O
dosing O O
may O O
be O O
required O O
to O O
achieve O O
or O O
maintain O O
the O O
desired O O
hypotensive O O
response O O
. O O

Gabapentin B-drug B-drug
is O O
not O O
appreciably O O
metabolized O O
nor O O
does O O
it O O
interfere O O
with O O
the O O
metabolism O O
of O O
commonly O O
coadministered O O
antiepileptic B-group B-group
drugs I-group I-group
. O O

Drugs O O
that O O
Inhibit O O
or O O
Induce O O
Cytochrome O O
P450 O O
3A4 O O
Enzymes O O
Lapatinib B-drug B-drug
undergoes O O
extensive O O
metabolism O O
by O O
CYP3A4 O O
, O O
and O O
concomitant O O
administration O O
of O O
strong O O
inhibitors O O
or O O
inducers O O
of O O
CYP3A4 O O
alter O O
lapatinib B-drug B-drug
concentrations O O
significantly O O
. O O

When O O
initiating O O
a O O
multi-day O O
course O O
of O O
grepafloxacin B-drug B-drug
in O O
a O O
patient O O
maintained O O
on O O
theophylline B-drug B-drug
, O O
the O O
theophylline B-drug B-drug
maintenance O O
dose O O
should O O
be O O
halved O O
for O O
the O O
period O O
of O O
concurrent O O
use O O
of O O
grepafloxacin B-drug B-drug
and O O
monitoring O O
of O O
serum O O
theophylline B-drug B-drug
concentrations O O
should O O
be O O
initiated O O
as O O
a O O
guide O O
to O O
further O O
dosage O O
adjustments O O
. O O

ZEBETA B-brand B-brand
should O O
be O O
used O O
with O O
care O O
when O O
myocardial B-group B-group
depressants I-group I-group
or O O
inhibitors O O
of O O
AV O O
conduction O O
, O O
such O O
as O O
certain O O
calcium B-group B-group
antagonists I-group I-group
( O O
particularly O O
of O O
the O O
phenylalkylamine B-group B-drug
[ O O
verapamil B-drug B-drug
] O O
and O O
benzothiazepine B-group B-drug
[ O O
diltiazem B-drug B-drug
] O O
classes O O
) O O
, O O
or O O
antiarrhythmic B-group B-drug
agents I-group I-drug
, O O
such O O
as O O
disopyramide B-drug B-drug
, O O
are O O
used O O
concurrently O O
. O O

Elevated O O
cyclosporine B-drug B-drug
serum O O
levels O O
have O O
been O O
reported O O
with O O
the O O
concomitant O O
use O O
of O O
quinolones B-group B-group
and O O
cyclosporine B-drug B-drug
. O O

Cytotoxic B-group B-group
Agents I-group I-group
: O O
Enhanced O O
bone O O
marrow O O
suppression O O
by O O
cyclophosphamide B-drug B-drug
and O O
other O O
cytotoxic B-group B-group
agents I-group I-group
has O O
been O O
reported O O
among O O
patients O O
with O O
neoplastic O O
disease O O
, O O
except O O
leukemia O O
, O O
in O O
the O O
presence O O
of O O
allopurinol B-drug B-drug
. O O

100-150 O O

Once O O
a O O
stable O O
prothrombin O O
time O O
has O O
been O O
documented O O
, O O
prothrombin O O
times O O
can O O
be O O
monitored O O
at O O
the O O
intervals O O
usually O O
recommended O O
for O O
patients O O
on O O
coumarin B-group B-group
anticoagulants I-group I-group
. O O

It O O
is O O
recommended O O
that O O
serum O O
lithium B-drug B-drug
levels O O
be O O
monitored O O
frequently O O
if O O
enalapril B-drug B-drug
is O O
administered O O
concomitantly O O
with O O
lithium B-drug B-drug
. O O

- O O
Non-steroidal B-group B-group
Anti-inflammatory I-group I-group
Drugs I-group I-group
: O O
In O O
some O O
patients O O
, O O
the O O
administration O O
of O O
a O O
non-steroidal B-group B-group
anti-inflammatory I-group I-group
agent I-group I-group
can O O
reduce O O
the O O
diuretic O B-group
, O O
natriuretic O O
, O O
and O O
antihypertensive O O
effects O O
of O O
loop O O
, O O
potassium-sparing O O
and O O
thiazide B-drug B-group
diuretics I-drug I-group
. O O

The O O
reluctance O O
to O O
treat O O
aggressively O O
is O O
understandable O O
because O O
the O O
geriatric O O
population O O
is O O
susceptible O O
to O O
adverse O O
drug O O
reactions O O
. O O

Leukocyte B-drug_n O
transfusions I-drug_n O
: O O
acute O O
pulmonary O O
toxicity O O
has O O
been O O
reported O O
in O O
patients O O
receiving O O
intravenous O O
amphotericin B-drug B-drug
B I-drug I-drug
and O O
leukocyte B-drug_n O
transfusions I-drug_n O
. O O

The O O
effect O O
of O O
corticosteroids B-group B-group
on O O
oral O O
anticoagulants B-group B-group
is O O
variable O O
. O O

The O O
levorotatory O O
isomer O O
had O O
opioid-antagonist O B-group
and O O
non-opioid O O
agonist O O
effects O O
in O O
pigeons O O
and O O
mixed O O
opioid O O
agonist-antagonist O O
effects O O
in O O
monkeys O O
. O O

The O O
interaction O O
is O O
a O O
consequence O O
of O O
blocking O O
hepatic O O
metabolism O O
of O O
vardenafil B-drug B-drug
by O O
ritonavir B-drug B-drug
, O O
a O O
highly O O
potent O O
CYP3A4 O O
inhibitor O O
, O O
which O O
also O O
inhibits O O
CYP2C9 O O
. O O

Samples O O
for O O
plasma O O
and O O
urine O O
immunoreactive O O
digoxin B-drug B-drug
concentrations O O
were O O
collected O O
through O O
120 O O
hours O O
following O O
the O O
digoxin B-drug B-drug
dose O O
. O O

. O O

The O O
pharmacokinetics O O
of O O
irbesartan B-drug B-drug
were O O
not O O
affected O O
by O O
coadministration O O
of O O
nifedipine B-drug B-drug
or O O
hydrochlorothiazide B-drug B-drug

griseofulvin B-drug B-drug
; O O

Praziquantel B-drug B-drug
: O O
In O O
the O O
fed O O
state O O
, O O
praziquantel B-drug B-drug
( O O
40 O O
mg/kg O O
) O O
increased O O
mean O O
maximum O O
plasma O O
concentration O O
and O O
area O O
under O O
the O O
curve O O
of O O
albendazole B-drug B-drug
sulfoxide I-drug I-drug
by O O
about O O
50 O O
% O O
in O O
healthy O O
subjects O O
( O O
n=10 O O
) O O
compared O O
with O O
a O O
separate O O
group O O
of O O
subjects O O
( O O
n=6 O O
) O O
given O O
albendazole B-drug B-drug
alone O O
. O O

Such O O
individuals O O
are O O
referred O O
to O O
as O O
poor O O
metabolizers O O
of O O
drugs O O
such O O
as O O
debrisoquin B-drug B-drug
, O O
dextromethorphan B-drug B-drug
, O O
and O O
the O O
tricyclic B-group B-group
antidepressants I-group I-group
. O O

When O O
these O O
products O O
are O O
administered O O
concomitantly O O
, O O
prothrombin O O
time O O
or O O
other O O
suitable O O
coagulation O O
tests O O
should O O
be O O
monitored O O
. O O

- O O
Anticoagulants B-group B-group
: O O
Interaction O O
studies O O
in O O
humans O O
have O O
shown O O
bumetanide B-drug B-drug
to O O
have O O
no O O
effect O O
on O O
warfarin B-drug B-drug
metabolism O O
or O O
on O O
plasma O O
prothrombin O O
activity O O
. O O

Both O O
studies O O
used O O
12 O O
subjects O O
. O O

Lithium B-drug B-drug
: O O
Nonsteroidal B-group B-group
anti-inflammatory I-group I-group
agents I-group I-group
have O O
been O O
reported O O
to O O
increase O O
steadystate O O
plasma O O
lithium B-drug B-drug
levels O O
. O O

After O O
etofibrate B-drug B-drug
treatment O O
, O O
there O O
was O O
decrease O O
of O O
total O O
cholesterol O B-drug
and O O
triglyceride O B-drug
plasma O O
levels O O
and O O
a O O
trend O O
to O O
increase O O
high-density O O
lipoprotein O O
cholesterol O O
plasma O O
levels O O
. O O

nc1,2 O O
30 O O
% O O
decrease O O
[ O O
CI O O
: O O
3 O O
% O O
decrease O O
, O O
48 O O
% O O
decrease O O
] O O

Patients O O
receiving O O
hydantoins B-group B-group
, O O
sulfonamides B-group B-group
, O O
or O O
sulfonylureas B-group B-group
should O O
be O O
observed O O
for O O
increased O O
activity O O
of O O
these O O
drugs O O
and O O
, O O
therefore O O
, O O
signs O O
of O O
toxicity O O
from O O
these O O
drugs O O
. O O

In O O
vitro O O
drug O O
metabolism O O
studies O O
indicate O O
that O O
Starlix B-brand B-brand
is O O
predominantly O O
metabolized O O
by O O
the O O
cytochrome O O
P450 O O
isozyme O O
CYP2C9 O O
( O O
70 O O
% O O
) O O
and O O
to O O
a O O
lesser O O
extent O O
CYP3A4 O O
( O O
30 O O
% O O
) O O
. O O

zaleplon B-drug B-drug
did O O
not O O
affect O O
the O O
pharmacokinetics O O
of O O
ethanol B-drug B-drug
. O O

Dofetilide B-drug B-drug
is O O
not O O
an O O
inhibitor O O
of O O
CYP3A4 O O
nor O O
of O O
other O O
cytochrome O O
P450 O O
isoenzymes O O
( O O
e.g. O O
, O O
CYP2C9 O O
, O O
CYP2D6 O O
) O O
and O O
is O O
not O O
expected O O
to O O
increase O O
levels O O
of O O
drugs O O
metabolized O O
by O O
CYP3A4 O O
. O O

Reductions O O
in O O
serum O O
endogenous O O
vitamin O O
D O O
concentrations O O
have O O
been O O
observed O O
following O O
the O O
administration O O
of O O
300 O O
mg/day O O
to O O
1200 O O
mg/day O O
ketoconazole B-drug B-drug
for O O
a O O
week O O
to O O
healthy O O
men O O
. O O

n-Octyl O B-drug_n
and O O
n-cetyl O O
gallate O B-drug
also O O
showed O O
good O O
inhibition O O
, O O
while O O
gallic O B-drug
acid O I-drug
itself O O
was O O
not O O
so O O
active O O
, O O
suggesting O O
that O O
the O O
presence O O
of O O
hydrophobic O O
side O O
chain O O
is O O
important O O
for O O
the O O
suppressive O O
effect O O
. O O

These O O
agents O O
should O O
not O O
be O O
used O O
in O O
patients O O
treated O O
with O O
Itraconazole B-drug B-drug
. O O

18-Methoxycoronaridine B-drug_n B-drug_n
( O O
18-MC B-drug_n B-drug_n
) O O
and O O
ibogaine B-drug_n B-drug_n
: O O
comparison O O
of O O
antiaddictive O O
efficacy O O
, O O
toxicity O O
, O O
and O O
mechanisms O O
of O O
action O O
. O O

Conjugation O O
at O O
NaCMC B-drug_n B-drug_n
with O O
cysteine B-drug B-drug
moieties O O
significantly O O
improves O O
the O O
intestinal O O
permeation O O
of O O
the O O
hydrophilic O O
molecule O O
NaFlu B-drug B-drug
and O O
the O O
model O O
peptide O O
drugs O O
bacitracin B-drug B-drug
and O O
insulin B-drug B-drug
in O O
vitro O O
, O O
therefore O O
this O O
conjugated O O
system O O
maybe O O
useful O O
for O O
peroral O O
administration O O
of O O
peptide O B-group
drugs O I-group
in O O
the O O
future O O
. O O

Reproductive O O
toxicology O O
studies O O
have O O
been O O
performed O O
in O O
cynomolgus O O
monkeys O O
at O O
doses O O
up O O
to O O
5 O O
mg/kg/week O O
( O O
about O O
62 O O
times O O
the O O
human O O
dose O O
based O O
on O O
body O O
weight O O
) O O
and O O
have O O
revealed O O
no O O
evidence O O
of O O
impaired O O
fertility O O
or O O
harm O O
to O O
the O O
fetus O O
due O O
to O O
AMEVIVE B-brand B-brand
. O O

Since O O
both O O
alcohol B-drug B-drug
and O O
organoleads O O
are O O
present O O
in O O
the O O
environment O O
and O O
seem O O
to O O
influence O O
limbic O O
integration O O
, O O
the O O
interaction O O
of O O
these O O
two O O
compounds O O
was O O
assessed O O
in O O
the O O
present O O
experiment O O
. O O

Interactions O O
between O O
theraputic O O
agents O O
have O O
been O O
recognized O O
as O O
increasingly O O
important O O
causes O O
of O O
drug O O
at O O
their O O
usual O O
recommended O O
dose O O
may O O
, O O
under O O
certain O O
conditions O O
, O O
produce O O
toxicity O O
of O O
life-endangering O O
proportions O O
. O O

We O O
examined O O
the O O
effect O O
of O O
exogenous O O
estradiol B-drug B-drug
on O O
the O O
changes O O
in O O
serum O O
steroid O O
hormone O O
levels O O
induced O O
by O O
a O O
nonlethal O O
dose O O
of O O
Escherichia O O
coli O O
endotoxin B-drug_n O
in O O
male O O
rats O O
and O O
the O O
deaths O O
due O O
to O O
nonlethal O O
and O O
lethal O O
doses O O
of O O
endotoxin B-drug_n B-drug
. O O

Therefore O O
, O O
it O O
should O O
be O O
used O O
with O O
caution O O
in O O
patients O O
receiving O O
such O O
agents O O
. O O

Meperidine B-drug B-drug
: O O
Amphetamines B-group B-group
potentiate O O
the O O
analgesic O O
effect O O
of O O
meperidine B-drug B-drug
. O O

A O O
direct O O
causal O O
relationship O O
has O O
not O O
been O O
established O O
, O O
but O O
physicians O O
should O O
consider O O
the O O
possibility O O
that O O
diclofenac B-drug B-drug
may O O
alter O O
a O O
diabetic O O
patient O O
s O O
response O O
to O O
insulin B-drug B-drug
or O O
oral O O
hypoglycemic B-group B-group
agents I-group I-group
. O O

Both O O
ibogaine B-drug_n B-drug_n
and O O
18-MC B-drug_n B-drug_n
decrease O O
extracellular O O
levels O O
of O O
dopamine O B-drug
in O O
the O O
nucleus O O
accumbens O O
, O O
but O O
only O O
ibogaine B-drug_n B-drug_n
increases O O
extracellular O O
levels O O
of O O
serotonin O O
in O O
the O O
nucleus O O
accumbens O O
. O O

Before O O
prescribing O O
a O O
symptomatic O O
( O O
pharmaceutical O O
) O O
treatment O O
for O O
patients O O
with O O
an O O
erection O O
disorder O O
, O O
attention O O
should O O
be O O
given O O
tot O O
the O O
sexological O O
, O O
psychological O O
and O O
medical O O
backgrounds O O
of O O
the O O
disorder O O
. O O

In O O
a O O
study O O
in O O
36 O O
patients O O
with O O
mild O O
to O O
moderate O O
hypertension O O
where O O
the O O
antihypertensive O O
effects O O
of O O
PRINIVIL B-brand B-brand
alone O O
were O O
compared O O
to O O
PRINIVIL B-brand B-brand
given O O
concomitantly O O
with O O
indomethacin B-drug B-drug
, O O
the O O
use O O
of O O
indomethacin B-drug B-drug
was O O
associated O O
with O O
a O O
reduced O O
antihypertensive O O
effect O O
, O O
although O O
the O O
difference O O
between O O
the O O
two O O
regimens O O
was O O
not O O
significant O O
. O O

In O O
this O O
study O O
we O O
investigated O O
the O O
effect O O
of O O
ginsenosides B-drug_n B-drug_n
on O O
high O O
threshold O O
voltage-dependent O O
Ca O O
( O O
2+ O O
) O O
channel O O
subtypes O O
using O O
their O O
selective B-group O
Ca I-group O
( I-group O
2+ I-group O
) I-group O
channel I-group O
blockers I-group O
nimodipine B-drug B-drug
( O O
L-type O O
) O O
, O O
omega-conotoxin B-drug_n B-drug_n
GVIA I-drug_n I-drug_n
( O O
N-type O O
) O O
, O O
or O O
omega-agatoxin B-drug_n B-drug
IVA I-drug_n O
( O O
P-type O O
) O O
in O O
bovine O O
chromaffin O O
cells O O
. O O

Dose O O
reduction O O
or O O
interruption O O
of O O
TARCEVA B-brand B-brand
should O O
be O O
considered O O
if O O
changes O O
in O O
liver O O
function O O
are O O
severe O O
. O O

Trimethoprim B-drug B-drug
Alone O O
or O O
in O O
Combination O O
with O O
Sulfamethoxazole B-drug B-drug
: O O
Concomitant O O
use O O
of O O
trimethoprim B-drug B-drug
alone O O
or O O
in O O
combination O O
with O O
sulfamethoxazole B-drug B-drug
is O O
contraindicated O O
. O O

This O O
paper O O
critically O O
reviews O O
the O O
suitability O O
of O O
the O O
urinary O O
thioether O O
assay O O
as O O
a O O
method O O
for O O
the O O
detection O O
of O O
exposure O O
to O O
electrophilic O O
agents O O
or O O
their O O
precursors O O
. O O

clinical O O
implications O O
are O O
unclear O O
. O O

Nabilone B-drug B-drug
has O O
been O O
shown O O
to O O
have O O
an O O
additive O O
CNS O O
depressant O O
effect O O
when O O
given O O
with O O
either O O
diazepam B-drug B-drug
, O O
secobarbitone B-brand B-drug
sodium I-brand I-drug
, O O
alcohol B-drug B-drug
or O O
codeine B-drug B-drug
. O O

The O O
interaction O O
may O O
be O O
a O O
result O O
of O O
inhibition O O
of O O
both O O
CYP2C9 B-drug O
and O O
2C19 O O
by O O
fluvoxamine B-drug B-drug
. O O

Other O O
nephrotoxic O O
medications O O
: O O
agents O O
such O O
as O O
aminoglycosides B-group B-group
, O O
cyclosporine B-drug B-drug
, O O
and O O
pentamidine B-drug B-drug
may O O
enhance O O
the O O
potential O O
for O O
drug-induced O O
renal O O
toxicity O O
, O O
and O O
should O O
be O O
used O O
concomitantly O O
only O O
with O O
great O O
caution O O
. O O

Methotrexate B-drug B-drug
: O O
An O O
increased O O
risk O O
of O O
hepatitis O O
has O O
been O O
reported O O
to O O
result O O
from O O
combined O O
use O O
of O O
methotrexate B-drug B-drug
and O O
etretinate B-drug B-drug
. O O

certain O O
antipsychotic B-group B-group
medications I-group I-group
( O O
such O O
as O O
sertindole B-drug O
) O O
; O O

Phenytoin B-drug B-drug
, O O
phenobarbital B-drug B-drug
and O O
carbamazepine B-drug B-drug
are O O
ge O O
nerally O O
classified O O
as O O
enzyme O O
inducers O O
; O O

Sertraline B-drug B-drug
neutralized O O
the O O
increase O O
of O O
glycemia O O
induced O O
by O O
oral O O
glucose B-drug B-drug
overload O O
. O O

Drug/ O O
Laboratory O O
Test O O
Interactions O O
Certain O O
endocrine O O
and O O
liver O O
function O O
tests O O
may O O
be O O
affected O O
by O O
estrogen-containing B-group B-group
oral O O
contraceptives B-group B-group
. O O

- O O
Divalproex B-drug B-drug
( O O
e.g. O O
, O O
Depakote B-brand B-brand
) O O
or O O

This O O
is O O
especially O O
important O O
for O O
drugs O O
associated O O
with O O
serious O O
toxicity O O
, O O
such O O
as O O
other O O
antiarrhythmics B-group B-group
. O O

In O O
a O O
study O O
in O O
hypertensive O O
patients O O
, O O
addition O O
of O O
isradipine B-drug B-drug
to O O
existing O O
hydrochlorothiazide B-drug B-drug
therapy O O
did O O
not O O
result O O
in O O
any O O
unexpected O O
adverse O O
effects O O
, O O
and O O
isradipine B-drug B-drug
had O O
an O O
additional O O
antihypertensive O O
effect O O
. O O

Acarbose B-drug B-drug
did O O
not O O
interfere O O
with O O
the O O
absorption O O
or O O
disposition O O
of O O
the O O
sulfonylurea B-drug B-group
glyburide I-drug B-drug
in O O
diabetic O O
patients O O
. O O

These O O
effects O O
are O O
usually O O
reversible O O
. O O

Inhibitors O O
Of O O
Endogenous O O
Prostaglandin O O
Synthesis O O
It O O
has O O
been O O
reported O O
that O O
indomethacin B-drug B-drug
may O O
reduce O O
the O O
antihypertensive O O
effect O O
of O O
captopril B-drug B-drug
, O O
especially O O
in O O
cases O O
of O O
low O O
renin O O
hypertension O O
. O O

Pregnancy O O
( O O
Category O O
B O B-drug
) O O

Therefore O O
, O O
diflunisal B-drug B-drug
and O O
INDOCIN B-brand B-brand
should O O
not O O
be O O
used O O
concomitantly O O
. O O

Therefore O O
, O O
unless O O
otherwise O O
specified O O
, O O
appropriate O O
dosage O O
adjustments O O
may O O
be O O
necessary O O
. O O

Drug-Drug O O
Interactions O O
Between O O
Keppra B-brand B-brand
And O O
Other O O
Antiepileptic B-group B-group
Drugs I-group I-group
( O O
AEDs B-group B-group
) O O
Phenytoin B-drug B-drug
Keppra B-brand B-brand
( O O
3000 O O
mg O O
daily O O
) O O
had O O
no O O
effect O O
on O O
the O O
pharmacokinetic O O
disposition O O
of O O
phenytoin B-drug B-drug
in O O
patients O O
with O O
refractory O O
epilepsy O O
. O O

The O O
benefits O O
of O O
Mefloquine B-drug B-drug
therapy O O
should O O
be O O
weighed O O
against O O
the O O
possibility O O
of O O
adverse O O
effects O O
in O O
patients O O
with O O
cardiac O O
disease O O
. O O

Each O O
treatment O O
period O O
was O O
separated O O
by O O
14 O O
to O O
21 O O
days O O
. O O

Zimelidine B-drug_n B-drug
etomidate B-drug I-drug
antagonism O O

In O O
these O O
cases O O
, O O
your O O
doctor O O
may O O
want O O
to O O
change O O
the O O
dose O O
, O O
or O O
other O O
precautions O O
may O O
be O O
necessary O O
. O O

Other O O
significant O O
inhibitors O O
of O O
CYP2D6 O O
, O O
such O O
as O O
fluoxetine B-drug B-drug
or O O
paroxetine B-drug B-drug
, O O
would O O
be O O
expected O O
to O O
have O O
similar O O
effects O O
and O O
, O O
therefore O O
, O O
should O O
be O O
accompanied O O
by O O
similar O O
dose O O
reductions O O
. O O

Patients O O
with O O
major O O
psychotic O O
disorders O O
, O O
treated O O
with O O
neuroleptics B-group B-group
, O O
should O O
be O O
treated O O
with O O
dopamine B-group B-group
agonists I-group I-group
only O O
if O O
the O O
potential O O
benefits O O
outweigh O O
the O O
risks O O
. O O

Nine O O
additional O O
patients O O
who O O
had O O
initial O O
positive O O
tests O O
were O O
negative O O
on O O
repeat O O
testing O O
. O O

Antiepileptic B-group B-group
Drugs I-group I-group
: O O
Sporadic O O
cases O O
of O O
seizures O O
have O O
been O O
reported O O
during O O
concomitant O O
use O O
of O O
TORADOL B-brand B-brand
and O O
antiepileptic B-group B-group
drugs I-group I-group
( O O
phenytoin B-drug B-drug
, O O
carbamazepine B-drug B-drug
) O O
. O O

Concomitant O O
Drug O O

- O O
Plicamycin B-drug B-drug
( O O
e.g. O O
, O O
Mithracin B-brand B-drug
) O O
or O O

Digoxin B-drug B-drug
: O O
When O O
Starlix B-brand B-brand
120 O O
mg O O
before O O
meals O O
was O O
administered O O
in O O
combination O O
with O O
a O O
single O O
1-mg O O
dose O O
of O O
digoxin B-drug B-drug
to O O
healthy O O
volunteers O O
, O O
there O O
were O O
no O O
clinically O O
relevant O O
changes O O
in O O
the O O
pharmacokinetics O O
of O O
either O O
agent O O
. O O

Additional O O
interactions O O

Therefore O O
, O O
inhibitors O O
of O O
these O O
enzymes O O
are O O
expected O O
to O O
reduce O O
vardenafil B-drug B-drug
clearance O O
. O O

Ketoconazole B-drug B-drug
: O O
In O O
healthy O O
subjects O O
receiving O O
ketoconazole B-drug B-drug
, O O
a O O
CYP3A4 O O
inhibitor O O
, O O
at O O
200 O O
mg O O
twice O O
daily O O
for O O
7 O O
days O O
, O O
systemic O O
exposure O O
( O O
AUC O O
) O O
to O O
lapatinib B-drug B-drug
was O O
increased O O
to O O
approximately O O
3.6-fold O O
of O O
control O O
and O O
half-life O O
increased O O
to O O
1.7-fold O O
of O O
control O O
. O O

Guidelines O O
are O O
provided O O
to O O
assist O O
the O O
clinician O O
in O O
his O O
logical O O
approach O O
to O O
the O O
identification O O
of O O
drug O O
interactions O O
when O O
serious O O
drug O O
toxicity O O
is O O
encountered O O
in O O
a O O
pateint O O
. O O

Because O O
of O O
foscarnets B-drug O
tendency O O
to O O
cause O O
renal O O
impairment O O
, O O
the O O
use O O
of O O
FOSCAVIR B-brand B-brand
should O O
be O O
avoided O O
in O O
combination O O
with O O
potentially O O
nephrotoxic O O
drugs O O
such O O
as O O
aminoglycosides B-group B-group
, O O
amphotericin B-drug B-drug
B I-drug I-drug
and O O
intravenous O O
pentamidine B-drug B-drug
unless O O
the O O
potential O O
benefits O O
outweigh O O
the O O
risks O O
to O O
the O O
patient O O
. O O

Epinephrine B-drug B-drug
may O O
antagonize O O
the O O
neuron O O
blockade O O
produced O O
by O O
guanethidine B-drug B-drug
resulting O O
in O O
decreased O O
antihypertensive O O
effect O O
and O O
requiring O O
increased O O
dosage O O
of O O
the O O
latter O O
. O O

Because O O
CYP O O
3A4 O O
inhibitors O O
may O O
increase O O
plasma O O
concentrations O O
of O O
buprenorphine B-drug B-drug
, O O
patients O O
already O O
on O O
CYP O O
3A4 O O
inhibitors O O
such O O
as O O
azole B-group B-group
antifungals I-group I-group
( O O
e.g O O
. O O

With O O
each O O
successive O O
generation O O
more O O
people O O
are O O
becoming O O
more O O
severely O O
depressed O O
at O O
a O O
younger O O
age O O
. O O

saquinavir I-drug B-drug
concentration O O

Marked O O
symptomatic O O
orthostatic O O
hypotension O O
has O O
been O O
reported O O
when O O
calcium B-group B-group
channel I-group I-group
blockers I-group I-group
and O O
organic B-group O
nitrates I-group B-group
were O O
used O O
in O O
combination O O
. O O

Thus O O
no O O
dosing O O
adjustments O O
are O O
necessary O O
during O O
concomitant O O
use O O
with O O
these O O
agents O O
. O O

Concomitant O O
administration O O
of O O
Sonata B-brand B-brand
( O O
10 O O
mg O O
) O O
and O O
cimetidine B-drug B-drug
( O O
800 O O
mg O O
) O O
produced O O
an O O
85 O O
% O O
increase O O
in O O
the O O
mean O O
Cmax O O
and O O
AUC O O
of O O
zaleplon B-drug B-drug
. O O

This O O
antagonistic O O
effect O O
of O O
probenecid B-drug B-drug
on O O
bumetanide B-drug B-drug
natriuresis O O
is O O
not O O
due O O
to O O
a O O
direct O O
action O O
on O O
sodium O O
excretion O O
but O O
is O O
probably O O
secondary O O
to O O
its O O
inhibitory O O
effect O O
on O O
renal O O
tubular O O
secretion O O
of O O
bumetanide B-drug B-drug
. O O

For O O
information O O
on O O
the O O
pharmacokinetics O O
of O O
Gemzar B-brand B-brand
and O O
cisplatin B-drug B-drug
in O O
combination O O
, O O
see O O
Drug O O
Interactions O O
under O O
CLINICAL O O
PHARMACOLOGY O O
section O O
. O O

Caffeine-related B-drug O
adverse O O
effects O O
have O O
occurred O O
in O O
patients O O
consuming O O
caffeine B-drug B-drug
while O O
on O O
therapy O O
with O O
enoxacin B-drug B-drug
. O O

Cholestyramine B-drug B-drug
: O O
Cholestyramine B-drug B-drug
may O O
increase O O
the O O
clearance O O
of O O
corticosteroids B-group B-group
. O O

Among O O
these O O
patients O O
, O O
the O O
incidence O O
of O O
upper O O
gastrointestinal O O
adverse O O
experiences O O
in O O
the O O
patients O O
treated O O
with O O
Ibandronate B-drug B-drug
150 O O
mg O O
once O O
monthly O O
was O O
similar O O
to O O
that O O
in O O
patients O O
treated O O
with O O
Ibandronate B-drug B-drug
2.5 O O
mg O O
once O O
daily O O
. O O

Ampicillin B-drug B-drug
: O O
In O O
a O O
study O O
of O O
healthy O O
volunteers O O
, O O
chloroquine B-drug B-drug
significantly O O
reduced O O
the O O
bioavailability O O
of O O
ampicillin B-drug B-drug
. O O

Metal O O
mixtures O O
had O O
no O O
effect O O
on O O
egg B-drug O
hatching O O
. O O

Because O O
of O O
its O O
primary O O
CNS O O
effect O O
, O O
caution O O
should O O
be O O
used O O
when O O
EQUETROTM B-brand B-brand
is O O
taken O O
with O O
other O O
centrally B-group O
acting I-group O
drugs I-group O
and O O
alcohol B-drug B-drug
. O O

Reports O O
suggest O O
that O O
NSAIDs B-group B-group
may O O
diminish O O
the O O
antihypertensive O O
effect O O
of O O
ACE B-group B-group
inhibitors I-group I-group
, O O
including O O
lisinopril B-drug B-drug
. O O

Thus O O
agents O O
likely O O
to O O
be O O
concomitantly O O
administered O O
with O O
Chirocaine B-brand B-drug
that O O
are O O
metabolized O O
by O O
this O O
isoenzyme O O
family O O
may O O
potentially O O
interact O O
with O O
Chirocaine B-brand B-drug
. O O

These O O
individuals O O
may O O
have O O
higher O O
than O O
expected O O
plasma O O
concentrations O O
of O O
tricyclic B-group B-group
antidepressants I-group I-group
when O O
given O O
usual O O
doses O O
. O O

In O O
order O O
to O O
approximate O O
the O O
steady O O
state O O
level O O
, O O
serum O O
digoxin B-drug B-drug
levels O O
should O O
be O O
drawn O O
either O O
before O O
or O O
at O O
least O O
six O O
hours O O
following O O
the O O
administration O O
of O O
an O O
oral O O
tablet O O
. O O

The O O
use O O
of O O
herbal O O
remedies O O
is O O
becoming O O
increasingly O O
popular O O
in O O
the O O
United O O
States O O
. O O

Drugs O O
that O O
may O O
decrease O O
imatinib B-drug B-drug
plasma O O
concentrations O O
: O O
Substances O O
that O O
are O O
inducers O O
of O O
CYP3A4 O O
activity O O
may O O
increase O O
metabolism O O
and O O
decrease O O
imatinib B-drug B-drug
plasma O O
concentrations O O
. O O

This O O
inhibition O O
can O O
result O O
in O O
unexpectedly O O
high O O
plasma O O
levels O O
of O O
other O O
drugs B-drug O
which O O
are O O
metabolized O O
by O O
those O O
CYP450 O O
enzymes O O
. O O

In O O
a O O
study O O
in O O
diabetics O O
with O O
microalbuminuria O O
INSPRA B-brand B-brand
200 O O
mg O O
combined O O
with O O
the O O
ACE B-group B-group
inhibitor I-group I-group
enalapril B-drug B-drug
10 O O
mg O O
increased O O
the O O
frequency O O
of O O
hyperkalemia O O
( O O
serum O O
potassium O O
5.5 O O
mEq/L O O
) O O
from O O
17 O O
% O O
on O O
enalapril B-drug B-drug
alone O O
to O O
38 O O
% O O
. O O

Tumor O O
phenotype O O
and O O
susceptibility O O
to O O
progression O O
as O O
an O O
expression O O
of O O
subpopulations O O
of O O
initiated O O
murine O O
cells O O
. O O

Rifampin B-drug B-drug
and O O
warfarin B-drug B-drug
: O O
a O O
drug O O
interaction O O
. O O

When O O
catecholamines B-group B-group
are O O
administered O O
, O O
dilute O O
solutions O O
should O O
be O O
used O O
and O O
blood O O
pressure O O
should O O
be O O
monitored O O
closely O O
. O O

Iodine B-drug B-drug
or O O
iodine B-drug B-drug
excess O O
may O O
decrease O O
the O O
effect O O
of O O
Carbimazole B-drug B-drug
, O O
and O O
an O O
iodine B-drug O
deficiency O O
can O O
increase O O
the O O
effect O O
of O O
Carbimazole B-drug B-drug
. O O

Elevated O O
serum O O
levels O O
of O O
cyclosporine B-drug B-drug
have O O
been O O
reported O O
with O O
the O O
concomitant O O
use O O
of O O
some O O
quinolones B-group B-group
and O O
cyclosporine B-drug B-drug
. O O

See O O
WARNINGS O O
, O O
Myopathy/Rhabdomyolysis O O
. O O

Acetazolamide B-drug B-drug
increases O O
lithium B-drug B-drug
excretion O O
and O O
the O O
lithium B-drug B-drug
may O O
be O O
decreased O O
. O O

Drugs O O
that O O
may O O
increase O O
dasatinib B-drug B-drug
plasma O O
concentrations O O
CYP3A4 O O
Inhibitors O O
: O O
Dasatinib B-drug B-drug
is O O
a O O
CYP3A4 O O
substrate O O
. O O

No O O
significant O O
interaction O O
has O O
been O O
found O O
with O O
broad-spectrum O B-group
antibiotics B-group I-group
. O O

Magnesium B-drug B-drug
: O O
Magnesium-containing B-drug B-drug
preparations O O
( O O
eg O O
, O O
antacids B-group B-group
) O O
may O O
cause O O
hypermagnesemia O O
and O O
should O O
therefore O O
not O O
be O O
taken O O
during O O
therapy O O
with O O
vitamin B-group B-group
D I-group I-group
by O O
patients O O
on O O
chronic O O
renal O O
dialysis O O
. O O

Currently O O
, O O
there O O
are O O
no O O
safety O O
and O O
efficacy O O
data O O
available O O
from O O
the O O
use O O
of O O
this O O
combination O O
. O O

Differential O O
regulation O O
of O O
tyrosine O O
phosphorylation O O
in O O
tumor O O
cells O O
by O O
contortrostatin B-drug_n B-drug_n
, O O
a O O
homodimeric O O
disintegrin O O
, O O
and O O
monomeric O O
disintegrins O O
echistatin B-drug_n O
and O O
flavoridin B-drug_n O
. O O

Usually O O
, O O
this O O
has O O
been O O
observed O O
in O O
patients O O
with O O
a O O
history O O
of O O
diabetes O O
mellitus O O
or O O
evidence O O
of O O
glucose O O
intolerance O O
prior O O
to O O
administration O O
of O O
CAMPTOSAR B-brand B-brand
. O O

. O O

Salt O O
substitutes O O
containing O O
potassium B-drug B-drug
should O O
also O O
be O O
used O O
with O O
caution O O
. O O

In O O
TAMBOCOR B-brand B-brand
clinical O O
trials O O
, O O
patients O O
who O O
were O O
receiving O O
beta B-group B-group
blockers I-group I-group
concurrently O O
did O O
not O O
experience O O
an O O
increased O O
incidence O O
of O O
side O O
effects O O
. O O

Benzodiazepines B-group B-group
: O O
Combination O O
hormonal B-group B-group
contraceptives I-group I-group
may O O
decrease O O
the O O
clearance O O
of O O
some O O
benzodiazepines B-group B-group
( O O
alprazolam B-drug B-drug
, O O
chlordiazepoxide B-drug B-drug
, O O
diazepam B-drug B-drug
) O O
and O O
increase O O
the O O
clearance O O
of O O
others O O
( O O
lorazepam B-drug B-drug
, O O
oxazepam B-drug B-drug
, O O
temazepam B-drug B-drug
) O O
. O O

All O O
animals O O
in O O
the O O
study O O
were O O
positive O O
for O O
an O O
endemic O O
primate O O
gammaherpes O O
virus O O
also O O
known O O
as O O
lymphocryptovirus O O
( O O
LCV O O
) O O
. O O

Cyclosporine B-drug B-drug
- O O
L-arginine B-drug B-drug
may O O
counteract O O
the O O
antinaturetic O O
effect O O
of O O
cyclosporin B-drug B-drug
. O O

Although O O
, O O
it O O
is O O
unknown O O
whether O O
this O O
could O O
result O O
in O O
clinically O O
significant O O
effects O O
, O O
caution O O
is O O
advised O O
when O O
administering O O
Cerebyx B-brand B-brand
with O O
other O O
drugs O O
that O O
significantly O O
bind O O
to O O
serum O O
albumin O O
. O O

Coingestion O O
of O O
acetaminophen B-drug B-drug
with O O
theophylline B-drug B-drug
, O O
phenobarbital B-drug B-drug
with O O
acetaminophen B-drug B-drug
, O O
and O O
valproic B-drug B-drug
acid I-drug I-drug
with O O
phenobarbital B-drug B-drug
at O O
high O O
to O O
toxic O O
concentrations O O
decreases O O
the O O
binding O O
of O O
the O O
target O O
drug O O
. O O

Alosetron B-drug B-drug
does O O
not O O
appear O O
to O O
induce O O
the O O
major O O
cytochrome O O
P450 O O
( O O
CYP O O
) O O
drug O O
metabolizing O O
enzyme O O
3A O O
. O O

3 O O
. O O

antacids B-group B-group
; O O

N=12 O O
) O O
are O O
identical O O
whether O O
the O O
drugs O O
are O O
administered O O
alone O O
or O O
together O O
. O O

Erythromycin B-drug B-drug
( O O
500 O O
mg O O
t.i.d O O
) O O
produced O O
a O O
4-fold O O
increase O O
in O O
vardenafil B-drug B-drug
AUC O O
and O O
a O O
3-fold O O
increase O O
in O O
Cmax O O
when O O
co-administered O O
with O O
Vardenafil B-drug B-drug
5 O O
mg O O
in O O
healthy O O
volunteers O O
. O O

HMG-CoA B-group B-group
Reductase I-group I-group
Inhibitor I-group I-group
: O O
atorvastatin B-drug B-drug

These O O
results O O
would O O
seem O O
to O O
dictate O O
against O O
the O O
clinical O O
use O O
of O O
methotrexate B-drug B-drug
with O O
ELSPAR B-brand B-brand
, O O
or O O
during O O
the O O
period O O
following O O
ELSPAR B-brand B-brand
therapy O O
when O O
plasma O O
asparagine O B-drug
levels O O
are O O
below O O
normal O O
. O O

Gastrointestinal O O
transit O O
time O O
( O O
lactulose O O
hydrogen O O
breath O O
test O O
) O O
was O O
measured O O
in O O
14 O O
volunteers O O
with O O
oral O O
and O O
intravenous O O
placebo O O
, O O
oral O O
placebo O O
and O O
intravenous O O
morphine B-drug B-drug
( O O
0.05 O O
mg O O
x O O
kg O O
( O O
-1 O O
) O O
) O O
, O O
and O O
oral O O
ADL B-drug B-drug
8-2698 I-drug I-drug
( O O
4 O O
mg O O
) O O
and O O
intravenous O O
morphine B-drug B-drug
( O O
0.05 O O
mg O O
x O O
kg O O
( O O
-1 O O
) O O
) O O
in O O
a O O
double O O
blind O O
, O O
cross-over O O
study O O
. O O

Also O O
, O O
bleeding O O
and/or O O
increased O O
prothrombin O O
time O O
have O O
been O O
reported O O
in O O
a O O
few O O
patients O O
taking O O
coumarin B-group B-group
anticoagulants O I-group
concomitantly O O
with O O
lovastatin B-drug B-drug
. O O

The O O
acceleration O O
of O O
gastric O O
emptying O O
by O O
cisapride B-drug B-drug
could O O
affect O O
the O O
rate O O
of O O
absorption O O
of O O
other O O
drugs O O
. O O

In O O
a O O
study O O
of O O
15 O O
male O O
subjects O O
( O O
ages O O
19 O O
to O O
35 O O
years O O
) O O
who O O
were O O
extensive O O
metabolizers O O
of O O
the O O
CYP2D6 O O
isoenzyme O O
, O O
daily O O
doses O O
of O O
bupropion B-drug B-drug
given O O
as O O
150 O O
mg O O
twice O O
daily O O
followed O O
by O O
a O O
single O O
dose O O
of O O
50 O O
mg O O
desipramine B-drug B-drug
increased O O
the O O
Cmax O O
, O O
AUC O O
, O O
and O O
t1/2 O O
of O O
desipramine B-drug B-drug
by O O
an O O
average O O
of O O
approximately O O
2- O O
, O O
5- O O
and O O
2-fold O O
, O O
respectively O O
. O O

Quinolones B-group B-group
, O O
including O O
cinoxacin B-drug B-drug
, O O
may O O
enhance O O
the O O
effects O O
of O O
oral O O
anticoagulants B-group B-group
, O O
such O O
as O O
warfarin B-drug B-drug
or O O
its O O
derivatives O O
. O O

The O O
selection O O
of O O
drugs O O
and O O
their O O
dosages O O
may O O
be O O
improved O O
, O O
and O O
the O O
number O O
of O O
adverse O O
effects O O
reduced O O
by O O
pharmacogenetic O O
investigations O O
. O O

Chlorthalidone B-drug B-drug
and O O
related O O
drugs O O
may O O
increase O O
the O O
responsiveness O O
to O O
tubocurarine B-drug B-drug
. O O

Although O O
a O O
3-day O O
regimen O O
of O O
Aprepitant B-drug B-drug
given O O
concomitantly O O
with O O
oral O O
contraceptives B-group B-group
has O O
not O O
been O O
studied O O
, O O
alternative O O
or O O
back-up O O
methods O O
of O O
contraception O O
should O O
be O O
used O O
. O O

Caffeine B-drug B-drug
: O O
Two O O
hundred O O
mg O O
of O O
caffeine B-drug B-drug
( O O
equivalent O O
to O O
1 O O
to O O
3 O O
cups O O
of O O
American O O
coffee O O
) O O
was O O
administered O O
to O O
16 O O
normal O O
, O O
healthy O O
volunteers O O
who O O
had O O
achieved O O
steady-state O O
blood O O
concentrations O O
of O O
lomefloxacin B-drug B-drug
after O O
being O O
dosed O O
at O O
400 O O
mg O O
qd O O
. O O

Their O O
concurrent O O
use O O
should O O
be O O
avoided O O
. O O

Metoclopramide B-drug B-drug
: O O
When O O
coadministered O O
with O O
MONUROL B-brand B-brand
, O O
metoclopramide B-drug B-drug
, O O
a O O
drug O O
which O O
increases O O
gastrointestinal O O
motility O O
, O O
lowers O O
the O O
serum O O
concentration O O
and O O
urinary O O
excretion O O
of O O
fosfomycin B-drug B-drug
. O O

Dosage O O
of O O
the O O
anticoagulant B-group B-group
may O O
require O O
reduction O O
in O O
order O O
to O O
maintain O O
satisfactory O O
therapeutic O O
hypoprothrombinemia O O
. O O

Among O O
the O O
proteins O O
that O O
undergo O O
tyrosine O O
phosphorylation O O
in O O
response O O
to O O
contortrostatin B-drug_n O
treatment O O
is O O
CAS O O
, O O
a O O
130 O O
kDa O O
adapter O O
protein O O
involved O O
in O O
integrin O O
signaling O O
. O O

Careful O O
observation O O
is O O
required O O
. O O

The O O
presence O O
of O O
food O O
in O O
the O O
stomach O O
does O O
not O O
alter O O
the O O
bioavailability O O
of O O
PRINIVIL B-brand B-brand
. O O

Epidural O B-group
clonidine B-drug B-drug
may O O
prolong O O
the O O
duration O O
of O O
pharmacologic O O
effects O O
of O O
epidural O B-drug
local O O
anesthetics B-group B-group
, O O
including O O
both O O
sensory O O
and O O
motor O O
blockade O O
. O O

Esomeprazole B-drug B-drug
is O O
extensively O O
metabolized O O
in O O
the O O
liver O O
by O O
CYP2C19 O O
and O O
CYP3A4 O O
. O O

also O O
induced O O
diarrhea O O
, O O
but O O
did O O
not O O
produce O O
a O O
watery O O
stool O O
in O O
cecectomized O O
rats O O
. O O

( O O
Concurrent O O
use O O
with O O
thiazide B-group B-group
diuretics I-group I-group
is O O
not O O
recommended O O
, O O
as O O
they O O
may O O
provoke O O
lithium B-drug B-drug
toxicity O O
because O O
of O O
reduced O O
renal O O
clearance O O
. O O
) O O

Coadministration O O
of O O
astemizole B-drug B-drug
with O O
ketoconazole B-drug B-drug
tablets O O
is O O
therefore O O
contraindicated O O
. O O

Based O O
on O O
the O O
literature O O
reports O O
, O O
the O O
same O O
effects O O
may O O
be O O
extrapolated O O
to O O
other O O
fruit O O
juices O O
such O O
as O O
apple O O
juice O O
. O O

Drugs O O
possessing O O
beta-blocking O O
properties O O
can O O
blunt O O
the O O
bronchodilator O O
effect O O
of O O
beta-receptor B-group B-group
agonist I-group I-group
drugs I-group I-group
in O O
patients O O
with O O
bronchospasm O O
; O O

Ritonavir B-drug B-drug

- O O
Dapsone B-drug B-drug
or O O

A O O
study O O
in O O
six O O
healthy O O
volunteers O O
has O O
shown O O
a O O
significant O O
increase O O
in O O
peak O O
diltiazem B-drug B-drug
plasma O O
levels O O
( O O
58 O O
% O O
) O O
and O O
AUC O O
( O O
53 O O
% O O
) O O
after O O
a O O
1-week O O
course O O
of O O
cimetidine B-drug B-drug
1200 O O
mg/day O O
and O O
a O O
single O O
dose O O
of O O
diltiazem B-drug B-drug
60mg O O
. O O

The O O
pathophysiologic O O
consequences O O
could O O
be O O
an O O
increased O O
synaptic O O
concentration O O
of O O
norepinephrine B-drug O
predisposing O O
to O O
adenylyl O O
cyclase O O
desensitization O O
. O O

However O O
, O O
a O O
significantly O O
higher O O
proportion O O
of O O
neurons O O
fired O O
spontaneous O O
action O O
potentials O O
with O O
either O O
0.05-0.2 O O
or O O
1 O O
% O O
biocytin O O
compared O O
to O O
no O O
biocytin O O
. O O

The O O
Factrel B-brand B-brand
test O O
should O O
be O O
conducted O O
in O O
the O O
absence O O
of O O
other O O
drugs O O
which O O
directly O O
affect O O
the O O
pituitary O O
secretion O O
of O O
the O O
gonadotropins O O
. O O

Cimetidine O B-drug
Co-administration O O
of O O
felodipine B-drug B-drug
with O O
cimetidine B-drug B-drug
( O O
a O O
non-specific O O
CYP-450 O O
inhibitor O O
) O O
resulted O O
in O O
an O O
increase O O
of O O
approximately O O
50 O O
% O O
in O O
the O O
AUC O O
and O O
the O O
Cmax O O
, O O
of O O
felodipine B-drug B-drug
. O O

triclofos B-drug B-drug
sodium I-drug I-drug
; O O

Metal O O
mixture O O
toxicity O O
investigation O O
was O O
undertaken O O
with O O
equal O O
concentrations O O
of O O
the O O
metals O O
. O O

A O O
pharmacokinetic O O
interaction O O
between O O
diltiazem B-drug B-drug
and O O
cyclosporine B-drug B-drug
has O O
been O O
observed O O
during O O
studies O O
involving O O
renal O O
and O O
cardiac O O
transplant O O
patients O O
. O O

Reversal O O
of O O
the O O
block O O
with O O
edrophonium B-drug B-drug
and O O
subsequent O O
recovery O O
of O O
the O O
horses O O
from O O
anaesthesia O O
were O O
uneventful O O
. O O

Mean O O
number O O
of O O
drugs O O
per O O
MAC O O
was O O
4 O O
( O O
95 O O
% O O
CI O O
, O O
+/- O O
0.2 O O
) O O
. O O

The O O
mean O O
minimum O O
lithium B-drug B-drug
concentration O O
increased O O
15 O O
% O O
and O O
the O O
renal O O
clearance O O
was O O
decreased O O
by O O
approximately O O
20 O O
% O O
. O O

Patients O O
undergoing O O
systemic O O
anticholinesterase O O
treatment O O
should O O
be O O
warned O O
of O O
the O O
possible O O
additive O O
effects O O
of O O
Phospholine B-drug B-drug
Iodide I-drug I-drug
. O O

The O O
presence O O
of O O
the O O
radiopharmaceutical B-group O
in O O
the O O
kidneys O O
, O O
along O O
with O O
an O O
increase O O
in O O
renal O O
retention O O
, O O
tend O O
to O O
produce O O
scintigraphic O O
results O O
that O O
falsely O O
identify O O
characteristics O O
related O O
to O O
diseases O O
such O O
as O O
renal O O
vascular O O
, O O
or O O
urinary O O
tract O O
obstruction O O
, O O
and O O
even O O
renal O O
cancer O O
. O O

When O O
given O O
concurrently O O
the O O
following O O
drugs O O
may O O
interact O O
with O O
thiazide B-group B-group
diuretics I-group I-group
. O O

Concomitant O O
use O O
with O O
other O O
oxytocic B-group B-group
agents I-group I-group
is O O
not O O
recommended O O
. O O

Anticonvulsants B-group B-group
: O O
Phenytoin B-drug B-drug
Phenobarbital I-drug I-drug
Carbamazepine I-drug I-drug

decreased O O
pharmacologic O O
effect O O
of O O
aspirin B-brand B-brand
. O O

The O O
inhibiting O O
effects O O
of O O
anticholinergic B-group B-group
drugs I-group I-group
on O O
gastric O O
hydrochloric O O
acid O O
secretion O O
are O O
antagonized O O
by O O
agents O O
used O O
to O O
treat O O
achlorhydria O O
and O O
those O O
used O O
to O O
test O O
gastric O O
secretion O O
. O O

The O O
possibility O O
of O O
interactions O O
with O O
other O O
drugs O O
administered O O
concurrently O O
should O O
be O O
considered O O
, O O
particularly O O
when O O
their O O
main O O
route O O
of O O
elimination O O
is O O
active O O
renal O O
secretion O O
via O O
the O O
organic O O
cationic O O
transport O O
system O O
( O O
e.g. O O
, O O
trimethoprim B-drug B-drug
) O O
. O O

The O O
following O O
information O O
was O O
obtained O O
from O O
the O O
literature O O
. O O

Co-administration O O
of O O
warfarin B-drug B-drug
and O O
cerivastatin B-drug B-drug
did O O
not O O
alter O O
the O O
pharmacokinetics O O
of O O
cerivastatin B-drug B-drug
sodium I-drug I-drug
. O O

However O O
, O O
the O O
antagonism O O
of O O
the O O
theophylline-induced B-drug B-drug
anxiogenic O O
effects O O
by O O
CGS21680 B-drug_n B-drug_n
was O O
only O O
observed O O
in O O
the O O
time O O
spent O O
in O O
the O O
light O O
zone O O
, O O
and O O
DPCPX-induced B-drug_n B-drug_n
anxiogenic O O
effects O O
were O O
neither O O
reversed O O
by O O
CGS B-drug B-drug_n
21680 I-drug I-drug_n
nor O O
by O O
CPA B-drug_n B-drug_n
. O O

No O O
clinical O O
or O O
drug O O
interaction O O
study O O
was O O
conducted O O
with O O
dolasetron B-drug B-drug
. O O

Although O O
other O O
hormonal B-group B-group
contraceptives I-group I-group
are O O
highly O O
effective O O
, O O
there O O
have O O
been O O
reports O O
of O O
pregnancy O O
from O O
women O O
who O O
have O O
used O O
combined B-group O
oral I-group O
contraceptives I-group B-group
, O O
as O O
well O O
as O O
topical/injectable/implantable/insertable O O
hormonal O O
birth O O
control O O
products O O
. O O

Anticoagulants B-group B-group
: O O
Warfarin B-drug B-drug

METHODS O O
: O O
The O O
study O O
was O O
carried O O
out O O
as O O
an O O
open O O
, O O
randomized O O
, O O
crossover O O
design O O
with O O
14 O O
healthy O O
participants O O
. O O

7 O O
. O O

However O O
, O O
in O O
a O O
single O O
in O O
vivo O O
rodent O O
study O O
denileukin B-drug O
diftitox I-drug O
had O O
no O O
effect O O
on O O
P450 O O
levels O O
. O O

If O O
hypotension O O
occurs O O
, O O
the O O
patient O O
should O O
be O O
placed O O
in O O
a O O
supine O O
position O O
and O O
, O O
if O O
necessary O O
, O O
receive O O
an O O
intravenous O O
infusion O O
of O O
normal O O
saline O O
. O O

There O O
have O O
been O O
no O O
formal O O
studies O O
of O O
the O O
interaction O O
of O O
LEVULAN B-brand B-brand
KERASTICK I-brand B-brand
for O O
Topical O O
Solution O O
with O O
any O O
other O O
drugs O O
, O O
and O O
no O O
drug-specific O O
interactions O O
were O O
noted O O
during O O
any O O
of O O
the O O
controlled O O
clinical O O
trials O O
. O O

In O O
addition O O
, O O
the O O
use O O
of O O
herbal O O
remedies O O
may O O
be O O
detrimental O O
for O O
the O O
patient O O
with O O
compromised O O
renal O O
function O O
. O O

This O O
may O O
result O O
in O O
increased O O
risk O O
of O O
theophylline-related B-drug B-drug
adverse O O
reactions O O
. O O

The O O
pharmacokinetics O O
of O O
estazolam B-drug B-drug
( O O
Cmax O O
and O O
AUC O O
) O O
were O O
not O O
affected O O
during O O
multiple-dose O O
fluoxetine B-drug B-drug
, O O
suggesting O O
no O O
clinically O O
significant O O
pharmacokinetic O O
interaction O O
. O O

Even O O
so O O
dextromethorphan B-drug B-drug
plasma O O
concentrations O O
in O O
the O O
presence O O
of O O
high O O
doses O O
of O O
valdecoxib B-drug B-drug
were O O
almost O O
5-fold O O
lower O O
than O O
those O O
seen O O
in O O
CYP O O
2D6 O O
poor O O
metabolizers O O
suggesting O O
that O O
dose O O
adjustment O O
is O O
not O O
necessary O O
. O O

CNS O O
Acting O O
Drugs O O
: O O
Given O O
the O O
primary O O
CNS O O
effects O O
of O O
Duloxetine B-drug B-drug
, O O
it O O
should O O
be O O
used O O
with O O
caution O O
when O O
it O O
is O O
taken O O
in O O
combination O O
with O O
or O O
substituted O O
for O O
other O O
centrally O O
acting O O
drugs O O
, O O
including O O
those O O
with O O
a O O
similar O O
mechanism O O
of O O
action O O
. O O

Slow O O
chylomicron O O
intravascular O O
catabolism O O
has O O
been O O
associated O O
with O O
coronary O O
artery O O
disease O O
and O O
screening O O
for O O
drugs O O
that O O
can O O
speed-up O O
this O O
process O O
can O O
be O O
important O O
. O O

Pretreatment O O
of O O
healthy O O
volunteers O O
with O O
multiple O O
doses O O
of O O
rifampin B-drug B-drug
followed O O
by O O
a O O
single O O
dose O O
of O O
Gleevec B-brand B-brand
, O O
increased O O
Gleevec B-brand B-brand
oral-dose O O
clearance O O
by O O
3.8-fold O O
, O O
which O O
significantly O O
( O O
p O O
0.05 O O
) O O
decreased O O
mean O O
cmax O O
and O O
AUC O O
( O O
0-8 O O
) O O
. O O

sertraline I-drug B-drug
concentration O O

Coadministration O O
of O O
almotriptan B-drug B-drug
and O O
the O O
potent O O
CYP3A4 O O
inhibitor O O
ketoconazole B-drug B-drug
( O O
400 O O
mg O O
q.d O O
. O O
for O O
3 O O
days O O
) O O
resulted O O
in O O
an O O
approximately O O
60 O O
% O O
increase O O
in O O
the O O
area O O
under O O
the O O
plasma O O
concentration-time O O
curve O O
and O O
maximal O O
plasma O O
concentrations O O
of O O
almotriptan B-drug B-drug
. O O

Delavirdine B-drug B-drug

Because O O
pregnancy O O
could O O
not O O
be O O
maintained O O
in O O
the O O
rabbit O O
following O O
doses O O
of O O
fulvestrant B-drug B-drug
of O O
1 O O
mg/kg/day O O
and O O
above O O
, O O
this O O
study O O
was O O
inadequate O O
to O O
fully O O
define O O
the O O
possible O O
adverse O O
effects O O
on O O
fetal O O
development O O
at O O
clinically O O
relevant O O
exposures O O
. O O

HMG-CoA B-group B-group
reductase I-group I-group
inhibitors I-group I-group
: O O
The O O
combined O O
use O O
of O O
TRICOR B-brand B-brand
and O O
HMG-CoA B-group B-group
reductase I-group I-group
inhibitors I-group I-group
should O O
be O O
avoided O O
unless O O
the O O
benefit O O
of O O
further O O
alterations O O
in O O
lipid O O
levels O O
is O O
likely O O
to O O
outweigh O O
the O O
increased O O
risk O O
of O O
this O O
drug O O
combination O O
. O O

Coadministration O O
of O O
diltiazem B-drug B-drug
with O O
rifampin B-drug B-drug
or O O
any O O
known O O
CYP3A4 O O
inducer O O
should O O
be O O
avoided O O
when O O
possible O O
, O O
and O O
alternative O O
therapy O O
considered O O
. O O

Acellular O B-drug
, O O
live O O
and O O
live-attenuated B-group B-group
vaccines I-group I-group
should O O
not O O
be O O
administered O O
during O O
RAPTIVA B-brand B-brand
treatment O O
. O O

Drugs O O
Highly O O
Bound O O
to O O
Plasma O O
Protein O O
Zaleplon B-drug B-drug
is O O
not O O
highly O O
bound O O
to O O
plasma O O
proteins O O
( O O
fraction O O
bound O O
60 O O
% O O
15 O O
% O O
) O O
; O O

The O O
administration O O
of O O
local O O
anesthetic B-group B-group
solutions I-group I-group
containing O O
epinephrine B-drug B-drug
or O O
norepinephrine B-drug B-drug
to O O
patients O O
receiving O O
monoamine B-group B-group
oxidase I-group I-group
inhibitors I-group I-group
or O O
tricyclic B-group B-group
antidepressants I-group I-group
may O O
produce O O
severe O O
, O O
prolonged O O
hypertension O O
. O O

Skeletal B-group B-group
muscle I-group I-group
relaxants I-group I-group
: O O
amphotericin B-drug B-drug
B-induced O O
hypokalemia O O
may O O
enhance O O
the O O
curariform O O
effect O O
of O O
skeletal B-group B-group
muscle I-group I-group
relaxants I-group I-group
( O O
e.g. O O
, O O
tubocurarine B-drug B-drug
) O O
. O O

[ O O
2 O O
epidemics O O
of O O
arsenical O O
encephalopathy O O
in O O
the O O
treatment O O
of O O
trypanosomiasis O O
, O O
Uganda O O
, O O
1992-1993 O O
] O O
Since O O
1988 O O
, O O
the O O
french O O
non-governmental O O
organisation O O
M O O
decins O O
Sans O O
Fronti O O
res O O
is O O
running O O
a O O
control O O
program O O
of O O
human O O
african O O
trypanosomiasis O O
in O O
the O O
district O O
of O O
Moyo O O
, O O
North-Uganda O B-drug_n
. O O

There O O
have O O
been O O
reports O O
of O O
increased O O
anticoagulant O O
effects O O
when O O
erythromycin B-drug B-drug
and O O
oral O O
anticoagulants B-group B-group
were O O
used O O
concomitantly O O
. O O

Verapamil B-drug B-drug
also O O
significantly O O
decreased O O
the O O
incidence O O
of O O
lymphatic O O
invasion O O
of O O
adenocarcinomas O O
, O O
which O O
was O O
enhanced O O
by O O
bombesin B-drug_n B-drug_n
. O O

However O O
, O O
high O O
doses O O
of O O
leucovorin B-drug B-drug
may O O
reduce O O
the O O
efficacy O O
of O O
intrathecally O O
administered O O
methotrexate B-drug B-drug
. O O

Other O O
factors O O
, O O
such O O
as O O
tolerance O O
and O O
sensitization O O
to O O
the O O
drugs O O
' O O
actions O O
and O O
the O O
development O O
of O O
withdrawal O O
symptoms O O
, O O
may O O
also O O
contribute O O
to O O
dependence O O
. O O

epilepsy O O
; O O

Cisplatin B-drug B-drug
was O O
administered O O
over O O
the O O
last O O
two O O
hours O O
of O O
the O O
thiosulfate B-drug B-drug
infusion O O
. O O

Determinants O O
of O O
cellular O O
sensitivity O O
to O O
topoisomerase-targeting B-group O
antitumor I-group O
drugs I-group O
. O O

Care O O
should O O
be O O
given O O
when O O
administering O O
this O O
drug O O
to O O
patients O O
with O O
symptoms O O
of O O
myasthenic O O
weakness O O
who O O
are O O
also O O
on O O
anticholinesterase B-group B-group
drugs I-group I-group
. O O

The O O
concomitant O O
administration O O
of O O
Exjade B-brand B-brand
and O O
vitamin B-drug B-drug
C I-drug I-drug
has O O
not O O
been O O
formally O O
studied O O
. O O

it O O
was O O
independent O O
of O O
the O O
influence O O
of O O
the O O
nueronal O O
cell O O
body O O
and O O
of O O
protein O O
synthesis O O
within O O
the O O
axon O O
. O O

An O O
altered O O
biodistribution O O
may O O
provide O O
misleading O O
information O O
that O O
can O O
either O O
mask O O
or O O
mimic O O
certain O O
disease O O
symptoms O O
. O O

Such O O
data O O
are O O
discussed O O
herein O O
, O O
with O O
emphasis O O
on O O
those O O
aspects O O
that O O
impact O O
on O O
the O O
clinical O O
use O O
of O O
the O O
calcium-entry B-group B-group
antagonists I-group I-group
. O O

Anticoagulants B-group B-group
: O O
Ten O O
patients O O
who O O
were O O
stabilized O O
on O O
oral O O
anticoagulants B-group B-group
were O O
given O O
guanfacine B-drug B-drug
, O O
1-2 O O
mg/day O O
, O O
for O O
4 O O
weeks O O
. O O

Concurrent O O
use O O
with O O
probenecid B-drug B-drug
or O O
other O O
drugs O O
significantly O O
eliminated O O
by O O
active O O
renal O O
tubular O O
secretion O O
may O O
result O O
in O O
increased O O
plasma O O
concentrations O O
of O O
penciclovir B-drug B-drug
. O O

Fenbufen B-drug B-drug
is O O
not O O
approved O O
in O O
the O O
United O O
States O O
at O O
this O O
time O O
. O O

TAXOL B-brand B-brand
contains O O
dehydrated O O
alcohol O B-drug
USP O O
, O O
396 O O
mg/mL O O
; O O

Another O O
oral O O
azole B-group B-group
antifungal I-group I-group
, O O
ketoconazole B-drug B-drug
, O O
inhibits O O
the O O
metabolism O O
of O O
astemizole B-drug B-drug
, O O
resulting O O
in O O
elevated O O
plasma O O
concentrations O O
of O O
astemizole B-drug B-drug
and O O
its O O
active O O
metabolite O O
desmethylastermizole B-drug_n B-drug
which O O
may O O
prolong O O
QT O O
intervals O O
. O O

Lansoprazole B-drug B-drug
has O O
also O O
been O O
shown O O
to O O
have O O
no O O
clinically O O
significant O O
interaction O O
with O O
amoxicillin B-drug B-drug
. O O

Potential O O
drug O O
interactions O O
between O O
Keppra B-brand B-brand
and O O
other O O
AEDs B-group B-group
( O O
carbamazepine B-drug B-drug
, O O
gabapentin B-drug B-drug
, O O
lamotrigine B-drug B-drug
, O O
phenobarbital B-drug B-drug
, O O
phenytoin B-drug B-drug
, O O
primidone B-drug B-drug
and O O
valproate B-drug B-drug
) O O
were O O
also O O
assessed O O
by O O
evaluating O O
the O O
serum O O
concentrations O O
of O O
levetiracetam B-drug B-drug
and O O
these O O
AEDs B-group B-group
during O O
placebo-controlled O O
clinical O O
studies O O
. O O

These O O
data O O
suggest O O
that O O
ginsenosides B-drug_n B-drug_n
are O O
negatively O O
coupled O O
to O O
three O O
types O O
of O O
calcium O O
channels O O
in O O
bovine O O
chromaffin O O
cell O O
, O O
including O O
an O O
omega-conotoxin B-drug_n B-drug_n
GVIA-sensitive O I-drug_n
( O O
N-type O O
) O O
channel O O
, O O
an O O
omega-agatoxin B-drug_n O
IVA-sensitive O O
( O O
P-type O O
) O O
channel O O
and O O
nimodipine/omega-conotoxin B-drug O
GVIA/omega-agatoxin B-drug_n O
VIA-resistant O O
( O O
presumptive O O
Q-type O O
) O O
channel O O
. O O

Drug O O
Interactions O O
with O O
Beta-Blockers B-group B-group
: O O
Concomitant O O
use O O
of O O
fenoldopam B-drug B-drug
with O O
beta-blockers B-group B-group
should O O
be O O
avoided O O
. O O

Morphine B-drug B-drug
prolonged O O
gastrointestinal O O
transit O O
time O O
from O O
69 O O
to O O
103 O O
minutes O O
( O O
P O O
= O O
.005 O O
) O O
; O O
this O O
was O O
prevented O O
by O O
ADL B-drug B-drug
8-2698 I-drug I-drug
( O O
P O O
= O O
.004 O O
) O O
. O O

Oral O O
Contraceptives B-group B-group
: O O
Coadministration O O
of O O
atorvastatin B-drug B-drug
and O O
an O O
oral O O
contraceptive B-group B-group
increased O O
AUC O O
values O O
for O O
norethindrone B-drug B-drug
and O O
ethinyl B-drug B-drug
estradiol I-drug I-drug
by O O
approximately O O
30 O O
% O O
and O O
20 O O
% O O
. O O

Caution O O
should O O
be O O
used O O
if O O
INDOCIN B-brand B-brand
is O O
administered O O
simultaneously O O
with O O
methotrexate B-drug B-drug
. O O

exfoliative O O
dermatitis O O

Therefore O O
, O O
it O O
would O O
be O O
expected O O
that O O
a O O
dosing O O
schedule O O
of O O
cerivastatin B-drug B-drug
sodium I-drug I-drug
given O O
at O O
bedtime O O
and O O
cholestyramine B-drug B-drug
given O O
before O O
the O O
evening O O
meal O O
would O O
not O O
result O O
in O O
a O O
significant O O
decrease O O
in O O
the O O
clinical O O
effect O O
of O O
cerivastatin B-drug B-drug
sodium I-drug I-drug
. O O

However O O
, O O
there O O
were O O
16 O O
% O O
and O O
32 O O
% O O
increases O O
in O O
the O O
AUC O O
and O O
Cmax O O
, O O
respectively O O
, O O
of O O
the O O
combined O O
moieties O O
of O O
threohydrobupropion B-drug_n O
and O O
erythrohydrobupropion B-drug_n O
. O O

The O O
permeability O O
of O O
the O O
cell O O
membrane O O
was O O
changed O O
as O O
evidenced O O
by O O
the O O
leakage O O
of O O
260-nm O O
absorbing O O
materials O O
, O O
amino O O
acids O O
, O O
proteins O O
, O O
and O O
inorganic O O
cations O O
. O O

Therefore O O
, O O
caution O O
should O O
be O O
used O O
when O O
administering O O
nitazoxanide B-drug B-drug
concurrently O O
with O O
other O O
highly O O
plasma O O
protein-bound O O
drugs O O
with O O
narrow O O
therapeutic O O
indices O O
, O O
as O O
competition O O
for O O
binding O O
sites O O
may O O
occur O O
( O O
e.g. O O
, O O
warfarin B-drug B-drug
) O O
. O O

The O O
plasma O O
maximum O O
concentration O O
and O O
area O O
under O O
the O O
plasma O O
concentration-time O O
curve O O
of O O
diltiazem B-drug B-drug
, O O
desacetyldiltiazem B-drug_n B-drug
, O O
and O O
desmethyldiltiazem B-drug_n B-drug
were O O
unchanged O O
after O O
coadministration O O
of O O
sirolimus B-drug B-drug
, O O
and O O
no O O
potentiation O O
of O O
the O O
effects O O
of O O
diltiazem B-drug B-drug
on O O
diastolic O O
or O O
systolic O O
blood O O
pressure O O
or O O
on O O
the O O
electrocardiographic O O
parameters O O
was O O
seen O O
. O O

Prothrombin O O
time O O
was O O
not O O
affected O O
by O O
levetiracetam B-drug B-drug
. O O

Noncardioselective B-group B-group
beta-blockers I-group I-group
( O O
nadolol B-drug B-drug
, O O
porpranolol O B-drug
, O O
timolol B-drug B-drug
) O O
may O O
exacerbate O O
rebound O O
hypertension O O
when O O
guanfacine B-drug B-drug
is O O
withdrawn O O
. O O

**No O O
significant O O
effect O O
. O O

Data O O
from O O
in O O
vitro O O
studies O O
of O O
benzodiazepines B-group B-group
other O O
than O O
alprazolam B-drug B-drug
suggest O O
a O O
possible O O
drug O O
interaction O O
for O O
the O O
following O O
: O O
ergotamine B-drug B-drug
, O O
cyclosporine B-drug B-drug
, O O
amiodarone B-drug B-drug
, O O
nicardipine B-drug B-drug
, O O
and O O
nifedipine B-drug B-drug
. O O

An O O
interacting O O
drug O O
which O O
leads O O
to O O
a O O
decrease O O
in O O
prothrombin O O
time O O
necessitating O O
an O O
increased O O
dose O O
of O O
oral O O
anticoagulant B-group B-group
to O O
maintain O O
an O O
adequate O O
degree O O
of O O
anticoagulation O O
may O O
, O O
if O O
abruptly O O
discontinued O O
, O O
increase O O
the O O
risk O O
of O O
subsequent O O
bleeding O O
. O O

Among O O
these O O
patients O O
, O O
the O O
incidence O O
of O O
upper O O
gastrointestinal O O
adverse O O
experiences O O
in O O
the O O
patients O O
treated O O
with O O
Ibandronate B-drug B-drug
was O O
similar O O
to O O
that O O
in O O
placebo-treated O O
patients O O
. O O

Corticosteroids B-group B-group
, O O
Methylxanthines B-group B-group
and O O
Diuretics B-group B-group
: O O
Concomitant O O
treatment O O
with O O
xanthine B-group B-group
derivatives I-group I-group
, O O
steroids B-group B-group
, O O
or O O
diuretics B-group B-group
may O O
potentiate O O
a O O
possible O O
hypokalemic O O
effect O O
of O O
beta2-agonists B-group B-group
. I-group O

Drug/Laboratory O O
Test O O
Interactions O O
The O O
presence O O
of O O
labetalol O B-drug
metabolites O O
in O O
the O O
urine O O
may O O
result O O
in O O
falsely O O
elevated O O
levels O O
of O O
urinary O O
catecholamines O O
, O O
metanephrine O B-drug
, O O
normetanephrine O B-drug
and O O
vanillylmandelic O B-drug
acid O I-drug
when O O
measured O O
by O O
fluorimetric O O
or O O
photometric O O
methods O O
. O O

Eight O O
healthy O O
volunteers O O
were O O
randomized O O
in O O
an O O
open-label O O
, O O
two-way O O
crossover O O
study O O
to O O
receive O O
oxycodone B-drug B-drug
, O O
5 O O
mg O O
p.o O O
. O O

Patients O O
taking O O
coumarin-derivative B-group B-group
anticoagulants I-group I-group
concomitantly O O
with O O
capecitabine B-drug B-drug
should O O
be O O
monitored O O
regularly O O
for O O
alterations O O
in O O
their O O
coagulation O O
parameters O O
( O O
PT O O
or O O
INR O O
) O O
. O O

Cytokines B-group O
( O O
interferon B-group B-drug
, O O
interleukin B-group O
) O O
: O O
Cytokines B-group B-group
have O O
been O O
reported O O
to O O
induce O O
both O O
hyperthyroidism O O
and O O
hypothyroidism O O
. O O

Corticotropin B-drug B-drug
may O O
accentuate O O
the O O
electrolyte O O
loss O O
associated O O
with O O
diuretic B-drug B-group
therapy O O
. O O

Because O O
of O O
the O O
low O O
dietary O O
cobalt B-drug B-drug
concentration O O
as O O
compared O O
to O O
the O O
iron B-drug B-drug
contents O O
of O O
the O O
diets O O
, O O
no O O
effect O O
of O O
cobalt B-drug B-drug
on O O
iron B-drug B-drug
absorption O O
and O O
excretion O O
occurred O O
. O O

Tricyclic B-group B-group
Antidepressants I-group I-group
: O O
Concurrent O O
use O O
may O O
increase O O
the O O
therapeutic O O
and O O
toxic O O
effects O O
of O O
both O O
drugs O O
, O O
possibly O O
due O O
to O O
increased O O
catecholamine O O
sensitivity O O
. O O

Drug-Drug O O
Interactions O O
: O O
The O O
pharmacokinetic O O
and O O
pharmacodynamic O O
interactions O O
between O O
UROXATRAL B-brand B-brand
and O O
other O O
alpha-blockers B-group B-group
have O O
not O O
been O O
determined O O
. O O

The O O
administration O O
of O O
SUPRAX B-brand B-brand
may O O
result O O
in O O
a O O
false-positive O O
reaction O O
for O O
glucose O O
in O O
the O O
urine O O
using O O
Clinitest O O
** O O
, O O
Benedict O O
s O O
solution O O
, O O
or O O
Fehling O O
s O O
solution O O
. O O

thyroid B-group B-group
drugs I-group I-group
; O O

No O O
formal O O
drug-drug O O
interaction O O
studies O O
, O O
however O O
, O O
have O O
been O O
conducted O O
. O O

The O O
reduction O O
in O O
MAC O O
was O O
correlated O O
with O O
brain O O
levels O O
of O O
ketamine B-drug B-drug
or O O
metabolite O O
I O O
, O O
suggesting O O
a O O
ketamine B-drug B-drug
: O O
metabolite O O
I O O
potency O O
ration O O
of O O
3:1 O O
. O O

In O O
vitro O O
studies O O
demonstrated O O
no O O
evidence O O
of O O
incompatibility O O
of O O
heparin B-drug B-drug
with O O
EXTRANEAL B-brand B-brand
. O O

The O O
action O O
of O O
colchicine B-drug B-drug
is O O
potentiated O O
by O O
alkalinizing B-group O
agents I-group O
. O O

In O O
male O O
Sprague-Dawley O O
rats O O
fasted O O
for O O
18 O O
h O O
, O O
concomitant O O
administration O O
of O O
caffeine B-drug B-drug
( O O
0.1 O O
g/kg O O
, O O
i.p O O
. O O
) O O

If O O
combination O O
therapy O O
is O O
needed O O
, O O
careful O O
consideration O O
should O O
be O O
given O O
to O O
the O O
pharmacology O O
of O O
all O O
agents O O
to O O
be O O
used O O
. O O

Zalcitabine B-drug B-drug
inhibited O O
lamivudine B-drug B-drug
phosphorylation O O
at O O
high O O
concentration O O
ratios O O
( O O
10 O O
and O O
100 O O
) O O
; O O

Lithium B-drug B-drug
generally O O
should O O
not O O
be O O
given O O
with O O
diuretics B-group B-group
because O O
they O O
reduce O O
its O O
renal O O
clearance O O
and O O
add O O
a O O
high O O
risk O O
of O O
lithium B-drug B-drug
toxicity O O
. O O

Valdecoxib B-drug B-drug
caused O O
a O O
statistically O O
significant O O
increase O O
in O O
plasma O O
exposures O O
of O O
R-warfarin B-drug B-drug
and O O
S-warfarin B-drug B-drug
( O O
12 O O
% O O
and O O
15 O O
% O O
, O O
respectively O O
) O O
, O O
and O O
in O O
the O O
pharmacodynamic O O
effects O O
( O O
prothrombin O O
time O O
, O O
measured O O
as O O
INR O O
) O O
of O O
warfarin B-drug B-drug
. O O

Lithium B-drug B-drug
: O O
NSAIDs B-group B-group
have O O
produced O O
an O O
elevation O O
of O O
plasma O O
lithium B-drug B-drug
levels O O
and O O
a O O
reduction O O
in O O
renal O O
lithium B-drug B-drug
clearance O O
. O O

Mutagenicity O O
studies O O
were O O
conducted O O
in O O
vitro O O
and O O
in O O
vivo O O
; O O

The O O
relative O O
risk O O
of O O
myocardial O O
infarction O O
during O O
sexual O O
activity O O
is O O
not O O
significantly O O
higher O O
than O O
for O O
healthy O O
persons O O
. O O

Those O O
for O O
which O O
effectiveness O O
is O O
reported O O
includes O O
diphenhydramine B-drug B-drug
, O O
hydroxyzine B-drug B-drug
, O O
orphenadrine B-drug B-drug
, O O
pyrilamine B-drug B-drug
, O O
phenyltoloxamine B-drug_n B-drug
, O O
promethazine B-drug B-drug
, O O
methdilazine B-drug B-drug
, O O
and O O
tripelennamine B-drug B-drug
. O O

Heart O O
rate O O
increased O O
initially O O
and O O
returned O O
to O O
normal O O
40 O O
minutes O O
after O O
ethanol B-drug B-drug
challenge O O
. O O

The O O
concentration O O
of O O
AMICAR B-brand B-brand
necessary O O
to O O
maintain O O
inhibition O O
of O O
fibrinolysis O O
is O O
0.99 O O
mMol/L O O
or O O
0.13 O O
mg/mL O O
. O O

Therefore O O
, O O
unless O O
otherwise O O
specified O O
, O O
appropriate O O
dosage O O
adjustments O O
may O O
be O O
necessary O O
. O O

Pharmacokinetic O O
data O O
suggest O O
that O O
absorption O O
, O O
metabolism O O
, O O
and O O
elimination O O
of O O
each O O
of O O
these O O
drugs O O
are O O
unchanged O O
when O O
they O O
are O O
used O O
together O O
. O O

Short-Acting B-group B-group
beta2-agonists I-group I-group
: O O
Aerosol O O
bronchodilators B-group B-group
of O O
the O O
short-acting O B-group
adrenergic O I-group
stimulant O I-group
type O I-group
may O O
be O O
used O O
for O O
relief O O
of O O
breakthrough O O
symptoms O O
while O O
using O O
formoterol B-drug B-drug
. O O

It O O
is O O
recommended O O
that O O
gabapentin B-drug B-drug
be O O
taken O O
at O O
least O O
2 O O
hours O O
following O O
Maalox B-brand B-brand
administration O O
. O O

ethacrynic B-drug B-drug
acid I-drug I-drug
; O O

Warfarin B-drug B-drug
: O O
When O O
healthy O O
subjects O O
were O O
administered O O
Starlix B-brand B-brand
120 O O
mg O O
three O O
times O O
daily O O
before O O
meals O O
for O O
four O O
days O O
in O O
combination O O
with O O
a O O
single O O
dose O O
of O O
warfarin B-drug B-drug
30 O O
mg O O
on O O
day O O
2 O O
, O O
there O O
were O O
no O O
alterations O O
in O O
the O O
pharmacokinetics O O
of O O
either O O
agent O O
. O O

Cerubidine B-brand B-drug
should O O
not O O
be O O
used O O
in O O
patients O O
who O O
have O O
previously O O
received O O
the O O
recommended O O
maximum O O
cumulative O O
doses O O
of O O
doxorubicin B-drug B-drug
or O O
Cerubidine B-brand B-drug
. O O

However O O
, O O
L-NAME B-drug_n B-brand
( O O
100 O O
and O O
300 O O
micromol/l O O
) O O
did O O
not O O
alter O O
the O O
effects O O
of O O
reseveratrol B-drug_n B-brand
on O O
arteries O O
from O O
dietary-obese O O
rats O O
, O O
giving O O
superimposed O O
concentration-responses O O
curves O O
. O O

- O O
a O O
sulfa-based O O
drug O O
such O O
as O O
sulfamethoxazole-trimethoprim B-drug B-drug
( O O
Bactrim B-brand B-brand
, O O
Septra B-brand B-brand
) O O
, O O
sulfisoxazole B-drug B-drug
( O O
Gantrisin B-brand B-brand
) O O
, O O
or O O
sulfasalazine B-drug B-drug
( O O
Azulfidine B-brand B-drug
) O O
; O O

Concomitant O O
use O O
of O O
SPRYCEL B-brand B-brand
and O O
drugs O O
that O O
inhibit O O
CYP3A4 O O
( O O
eg O O
, O O
ketoconazole B-drug B-drug
, O O
itraconazole B-drug B-drug
, O O
erythromycin B-drug B-drug
, O O
clarithromycin B-drug B-drug
, O O
ritonavir B-drug B-drug
, O O
atazanavir B-drug B-drug
, O O
indinavir B-drug B-drug
, O O
nefazodone B-drug B-drug
, O O
nelfinavir B-drug B-drug
, O O
saquinavir B-drug B-drug
, O O
telithromycin B-drug B-drug
) O O
may O O
increase O O
exposure O O
to O O
dasatinib B-drug B-drug
and O O
should O O
be O O
avoided O O
. O O

Patients O O
should O O
be O O
cautioned O O
against O O
engaging O O
in O O
hazardous O O
activities O O
requiring O O
complete O O
mental O O
alertness O O
such O O
as O O
operating O O
machinery O O
or O O
driving O O
a O O
motor O O
vehicle O O
. O O

If O O
a O O
diuretic B-group B-group
is O O
also O O
used O O
, O O
the O O
risk O O
of O O
lithium B-drug B-drug
toxicity O O
may O O
be O O
increased O O
. O O

Insulin B-drug B-drug
or O O
Oral O O
Hypoglycemics B-group B-group
: O O
Agents B-group O
with I-group O
b-blocking I-group B-group
properties I-group O
may O O
enhance O O
the O O
blood-sugar-reducing O O
effect O O
of O O
insulin B-drug B-drug
and O O
oral O O
hypoglycemics B-group B-group
. O O

The O O
following O O
drug O O
interactions O O
were O O
studied O O
with O O
ketoprofen B-drug B-drug
doses O O
of O O
200 O O
mg/day O O
. O O

The O O
gonadotropin O O
levels O O
may O O
be O O
transiently O O
elevated O O
by O O
spironolactone B-drug B-drug
, O O
minimally O O
elevated O O
by O O
levodopa B-drug B-drug
, O O
and O O
suppressed O O
by O O
oral O O
contraceptives B-group B-group
and O O
digoxin B-drug B-drug
. O O

Careful O O
observations O O
on O O
hepatotoxicity O O
are O O
suggested O O
when O O
acetaminophen B-drug B-drug
is O O
prescribed O O
with O O
caffeine B-drug B-drug
. O O

Lipids O O
: O O
Pretreatment O O
and O O
follow-up O O
blood O O
lipids O O
should O O
be O O
obtained O O
under O O
fasting O O
conditions O O
. O O

This O O
effect O O
should O O
be O O
kept O O
in O O
mind O O
when O O
bleeding O O
times O O
are O O
determined O O
. O O

Trecator B-brand B-brand
may O O
potentiate O O
the O O
adverse O O
effects O O
of O O
other O O
antituberculous B-group O
drugs I-group O
administered O O
concomitantly O O
. O O

Immunodeficiency-associated O O
lymphocyte O O
disorders O O
( O O
plasmacytic O O
hyperplasia O O
, O O
polymorphic O O
proliferation O O
, O O
and O O
B-cell O O
lymphomas O O
) O O
occur O O
in O O
patients O O
who O O
have O O
congenital O O
or O O
acquired O O
immunodeficiencies O O
including O O
those O O
resulting O O
from O O
immunosuppressive B-group B-group
therapy O O
. O O

Prescribing O O
. O O

- O O
Hydroxychloroquine B-drug B-drug
( O O
e.g. O O
, O O
Plaquenil B-brand B-brand
) O O
or O O

The O O
risk O O
of O O
myopathy O O
is O O
also O O
increased O O
by O O
the O O
following O O
lipid-lowering O O
drugs O O
that O O
are O O
not O O
potent O O
CYP3A4 O O
inhibitors O O
, O O
but O O
which O O
can O O
cause O O
myopathy O O
when O O
given O O
alone O O
. O O

Codeine B-drug B-drug
in O O
combination O O
with O O
other O O
narcotic B-group B-group
analgesics I-group I-group
, O O
general O O
anesthetics B-group B-group
, O O
phenothiazines B-group B-group
, O O
tranquilizers B-group B-group
, O O
sedative-hypnotics B-group B-group
, O O
or O O
other O O
CNS B-group B-group
depressants I-group I-group
( O O
including O O
alcohol B-drug B-drug
) O O
has O O
additive O O
depressant O O
effects O O
. O O

Potential O O
for O O
serious O O
reactions O O
such O O
as O O
risk O O
of O O
myopathy O O
including O O
rhabdomyolysis O O
. O O

Heparin B-drug B-drug
: O O
Since O O
heparin B-drug B-drug
is O O
contraindicated O O
in O O
patients O O
with O O
heparin-induced B-drug O
thrombocytopenia O O
, O O
the O O
co-administration O O
of O O
Argatroban B-drug B-drug
and O O
heparin B-drug B-drug
is O O
unlikely O O
for O O
this O O
indication O O
. O O

If O O
these O O
products O O
are O O
needed O O
, O O
they O O
should O O
be O O
given O O
at O O
least O O
2 O O
hours O O
before O O
cimetidine B-drug B-drug
administration O O
. O O

Terfenadine B-drug B-drug
: O O
Administration O O
of O O
terfenadine B-drug B-drug
with O O
VIRACEPT B-brand B-brand
resulted O O
in O O
the O O
appearance O O
of O O
unchanged O O
terfenadine B-drug B-drug
in O O
plasma O O
; O O

increased O O
levels O O
of O O
fibrinogen O O
and O O
fibrinogen O O
activity O O
; O O

Probenecid B-drug B-drug
: O O
Probenecid B-drug B-drug
is O O
known O O
to O O
interact O O
with O O
the O O
metabolism O O
or O O
renal O O
tubular O O
excretion O O
of O O
many O O
drugs O O
( O O
e.g. O O
, O O
acetaminophen B-drug B-drug
, O O
acyclovir B-drug B-drug
, O O
angiotensin-converting B-group B-group
enzyme I-group I-group
inhibitors I-group I-group
, O O
aminosalicylic B-drug B-drug
acid I-drug I-drug
, O O
barbiturates B-group B-group
, O O
benzodiazepines B-group B-group
, O O
bumetanide B-drug B-drug
, O O
clofibrate B-drug B-drug
, O O
methotrexate B-drug B-drug
, O O
famotidine B-drug B-drug
, O O
furosemide B-drug B-drug
, O O
nonsteroidal B-group B-group
anti-inflammatory I-group I-group
agents O I-group
, O O
theophylline B-drug B-drug
, O O
and O O
zidovudine B-drug B-drug
) O O
. O O

The O O
data O O
suggest O O
that O O
18-MC B-drug_n B-drug_n
has O O
a O O
narrower O O
spectrum O O
of O O
actions O O
and O O
will O O
have O O
a O O
substantially O O
greater O O
therapeutic O O
index O O
than O O
ibogaine B-drug_n B-drug_n
. O O

Cyclopentolate B-drug B-drug
may O O
interfere O O
with O O
the O O
anti-glaucoma O O
action O O
of O O
carbachol B-drug B-drug
or O O
pilocarpine B-drug B-drug
; O O

Anticonvulsants B-group B-group
( O O
carbamazepine B-drug B-drug
, O O
felbamate B-drug B-drug
, O O
phenobarbital B-drug B-drug
, O O
phenytoin B-drug B-drug
, O O
topiramate B-drug B-drug
) O O
: O O
Increase O O
the O O
metabolism O O
of O O
ethinyl B-drug B-drug
estradiol I-drug I-drug
and/or O O
some O O
progestins B-group B-group
, O O
leading O O
to O O
possible O O
decrease O O
in O O
contraceptive O O
effectiveness O O
. O O

Anticoagulants B-group B-group
: O O
While O O
studies O O
have O O
not O O
shown O O
diclofenac B-drug B-drug
to O O
interact O O
with O O
anticoagulants B-group B-group
of I-group O
the I-group O
warfarin I-group B-drug
type I-group O
, O O
caution O O
should O O
be O O
exercised O O
, O O
nonetheless O O
, O O
since O O
interactions O O
have O O
been O O
seen O O
with O O
other O O
NSAIDs B-group B-group
. O O

Methenamine B-drug B-drug
therapy O O
Urinary O O
excretion O O
of O O
amphetamines B-group B-group
is O O
increased O O
, O O
and O O
efficacy O O
is O O
reduced O O
by O O
acidifying O B-group
agents O I-group
used O O
in O O
methenamine B-drug B-drug
therapy O O
. O O

Dose O O
adjustment O O
of O O
lapatinib B-drug B-drug
should O O
be O O
considered O O
for O O
patients O O
who O O
must O O
receive O O
concomitant O O
strong O O
inhibitors O O
or O O
concomitant O O
strong O O
inducers O O
of O O
CYP3A4 O O
enzymes O O
. O O

Short-term O O
controlled O O
studies O O
failed O O
to O O
show O O
that O O
taking O O
the O O
drug O O
significantly O O
affects O O
prothrombin O O
times O O
when O O
administered O O
to O O
individuals O O
on O O
coumarin-type B-group B-group
anticoagulants I-group I-group
. O O

Monitoring O O
of O O
plasma O O
phenytoin B-drug B-drug
concentrations O O
may O O
be O O
helpful O O
when O O
possible O O
drug O O
interactions O O
are O O
suspected O O
. O O

SUSTIVAhas O O
the O O
potential O O
to O O
decrease O O
serum O O
concentrations O O
of O O
amprenavir B-drug B-drug
. O O

Interaction O O
of O O
gentamycin B-drug B-drug
and O O
atracurium B-drug B-drug
in O O
anaesthetised O O
horses O O
. O O

This O O
response O O
has O O
been O O
attributed O O
to O O
inhibition O O
of O O
renal O O
prostaglandin O O
synthesis O O
. O O

Although O O
not O O
observed O O
in O O
this O O
study O O
, O O
adverse O O
effects O O
could O O
potentially O O
arise O O
from O O
co-administration O O
of O O
cephalexin B-drug B-drug
and O O
metformin B-drug B-drug
by O O
inhibition O O
of O O
tubular O O
secretion O O
via O O
organic O O
cationic O O
transporter O O
systems O O
. O O

In O O
bioavailability O O
studies O O
with O O
normal O O
subjects O O
, O O
the O O
concurrent O O
administration O O
of O O
antacids B-group B-group
at O O
therapeutic O O
levels O O
did O O
not O O
significantly O O
influence O O
the O O
bioavailability O O
of O O
TRANXENE B-brand B-brand
tablets O O
. O O

Nitroglycerin B-drug B-drug
: O O
DynaCirc B-brand B-drug
( O O
isradipine B-drug B-drug
) O O
has O O
been O O
safely O O
coadministered O O
with O O
nitroglycerin B-drug B-drug
. O O

Even O O
though O O
such O O
interactions O O
were O O
not O O
seen O O
during O O
clinical O O
studies O O
with O O
nicardipine B-drug B-drug
HCl I-drug I-drug
, O O
an O O
increased O O
volume O O
of O O
circulating O O
fluids O O
might O O
be O O
required O O
if O O
such O O
an O O
interaction O O
were O O
to O O
occur O O
. O O

Patients O O
receiving O O
concurrent O O
administration O O
of O O
substrates O O
of O O
C.P.A O O
. O O
were O O
not O O
excluded O O
from O O
clinical O O
trials O O
of O O
grepafloxacin B-drug B-drug
. O O

Warfarin B-drug B-drug
Keppra B-brand B-brand
( O O
1000 O O
mg O O
twice O O
daily O O
) O O
did O O
not O O
influence O O
the O O
pharmacokinetics O O
of O O
R O O
and O O
S B-drug B-drug
warfarin I-drug I-drug
. O O

Hepatotoxic O O
Drugs O O
Increased O O
side O O
effects O O
may O O
occur O O
when O O
leflunomide B-drug B-drug
is O O
given O O
concomitantly O O
with O O
hepatotoxic O O
substances O O
. O O

Physicians O O
needing O O
to O O
treatpatients O O
co-infected O O
with O O
tuberculosis O O
andusing O O
a O O
nevirapine B-drug B-drug
containing O O
regimen O O
mayuse O O
rifabutin B-drug B-drug
instead O O
. O O

In O O
a O O
pharmacokinetic O O
study O O
, O O
38 O O
healthy O O
female O O
subjects O O
received O O
ketoconazole B-drug B-drug
200 O O
mg O O
twice O O
daily O O
for O O
7 O O
days O O
, O O
with O O
coadministration O O
of O O
alosetron B-drug B-drug
1 O O
mg O O
on O O
the O O
last O O
day O O
. O O

ketoconazole B-drug B-drug
) O O
, O O
macrolide B-group B-group
antibiotics I-group I-group
( O O
e.g O O
. O O
erythromycin B-drug B-drug
) O O
, O O
and O O
HIV B-group B-group
protease I-group I-group
inhibitors I-group I-group
( O O
e.g O O
. O O
ritonavir B-drug B-drug
, O O
indinavir B-drug B-drug
and O O
saquinavir B-drug B-drug
) O O
should O O
have O O
their O O
dose O O
of O O
SUBUTEX B-brand B-brand
or O O
SUBOXONE B-brand B-brand
adjusted O O
. O O

It O O
may O O
be O O
necessary O O
to O O
adjust O O
the O O
dosage O O
of O O
oral O O
anticoagulants B-group B-group
upon O O
beginning O O
or O O
stopping O O
disulfiram B-drug B-drug
. O O
since O O
disulfiram B-drug B-drug
may O O
prolong O O
prothrombin O O
time O O
. O O

Caution O O
is O O
advised O O
nonetheless O O
, O O
since O O
interactions O O
have O O
been O O
seen O O
with O O
other O O
nonsteroidal O B-group
agents O I-group
of O O
this O O
class O O
. O O

The O O
simplest O O
inference O O
is O O
that O O
the O O
toxicity O O
and O O
effectiveness O O
of O O
polyenes O B-group
are O O
determined O O
by O O
their O O
relative O O
avidities O O
for O O
the O O
predominant O O
sterol O O
in O O
cell O O
membranes O O
. O O

In O O
Study O O
1 O O
, O O
patients O O
receiving O O
bolus-IFL O O
plus O O
AVASTIN B-brand B-brand
had O O
a O O
higher O O
incidence O O
of O O
Grade O O
3-4 O O
diarrhea O O
and O O
neutropenia O O
. O O

Plasma O O
TCA B-group B-group
concentrations O O
may O O
need O O
to O O
be O O
monitored O O
and O O
the O O
dose O O
of O O
the O O
TCA B-group B-group
may O O
need O O
to O O
be O O
reduced O O
if O O
a O O
TCA B-group B-group
is O O
co-administered O O
with O O
Duloxetine B-drug B-drug
. O O

Although O O
there O O
is O O
little O O
risk O O
for O O
loss O O
of O O
contraceptive O O
efficacy O O
, O O
the O O
clinical O O
significance O O
of O O
these O O
increased O O
exposures O O
in O O
terms O O
of O O
safety O O
is O O
not O O
known O O
. O O

Additional O O
clinical O O
experience O O
may O O
reveal O O
other O O
drugs O O
affected O O
by O O
the O O
concomitant O O
administration O O
of O O
Tagamet B-brand B-brand
. O O

Tricyclic B-group B-group
Antidepressants I-group I-group
: O O
Use O O
of O O
thyroid B-group O
products I-group O
with O O
imipramine B-drug B-drug
and O O
other O O
tricyclic B-group B-group
antidepressants I-group I-group
may O O
increase O O
receptor O O
sensitivity O O
and O O
enhance O O
antidepressant O O
activity O O
transient O O
cardiac O O
arrhythmias O O
have O O
been O O
observed O O
. O O

Effects O O
of O O
Felbatol B-brand B-brand
on O O
Low-Dose O O
Combination B-group O
Oral I-group O
Contraceptives I-group B-group
A O O
group O O
of O O
24 O O
nonsmoking O O
, O O
healthy O O
white O O
female O O
volunteers O O
established O O
on O O
an O O
oral O O
contraceptive B-group B-group
regimen O O
containing O O
30 O O
mg O O
ethinyl B-drug B-drug
estradiol I-drug I-drug
and O O
75 O O
mg O O
gestodene B-drug B-drug
for O O
at O O
least O O
3 O O
months O O
received O O
2400 O O
mg/day O O
of O O
felbamate B-drug B-drug
from O O
midcycle O O
( O O
day O O
15 O O
) O O
to O O
midcycle O O
( O O
day O O
14 O O
) O O
of O O
two O O
consecutive O O
oral O O
contraceptive B-group B-group
cycles O O
. O O

The O O
median O O
survival O O
for O O
CHOP-HAART O O
patients O O
was O O
not O O
reached O O
, O O
whereas O O
the O O
medial O O
survival O O
of O O
CHOP O O
patients O O
was O O
7 O O
months O O
( O O
P O O
= O O
0.03 O O
) O O
. O O

increased O O
platelet O O
count O O
; O O

Tadalafil B-drug B-drug

Cisapride B-drug B-drug
was O O
well O O
tolerated O O
when O O
administered O O
alone O O
or O O
with O O
fluoxetine B-drug B-drug
. O O

H2 B-group B-group
Blockers I-group I-group
and O O
Proton B-group B-group
Pump I-group I-group
Inhibitors I-group I-group
( O O
PPIs B-group B-group
) O O

Antihistamines B-group B-group
may O O
partially O O
counteract O O
the O O
anticoagulation O O
effects O O
of O O
heparin B-drug B-drug
or O O
warfarin B-drug B-drug
. O O

Since O O
FOSCAVIR B-brand B-brand
decreases O O
serum O O
concentrations O O
of O O
ionized O O
calcium O O
, O O
concurrent O O
treatment O O
with O O
other O O
drugs O O
known O O
to O O
influence O O
serum O O
calcium O O
concentrations O O
should O O
be O O
used O O
with O O
particular O O
caution O O
. O O

Beta-adrenergic B-group B-group
blocking I-group I-group
drugs I-group I-group
add O O
some O O
further O O
antihypertensive O O
effect O O
to O O
captopril B-drug B-drug
, O O
but O O
the O O
overall O O
response O O
is O O
less O O
than O O
additive O O
. O O

chymotrypsin B-drug O
; O O

In O O
vitro O O
studies O O
in O O
human O O
liver O O
microsomes O O
indicate O O
that O O
ertapenem B-drug B-drug
does O O
not O O
inhibit O O
metabolism O O
mediated O O
by O O
any O O
of O O
the O O
following O O
six O O
cytochrome O O
p450 O O
( O O
CYP O O
) O O
isoforms O O
: O O
1A2 O O
, O O
2C9 O O
, O O
2C19 O O
, O O
2D6 O O
, O O
2E1 O O
and O O
3A4 O O
. O O

These O O
events O O
required O O
medical O O
intervention O O
in O O
some O O
patients O O
. O O

- O O
Digoxin B-drug B-drug
: O O
Interaction O O
studies O O
in O O
humans O O
have O O
shown O O
no O O
effect O O
on O O
digoxin B-drug B-drug
blood O O
levels O O
. O O

Potassium-depleting B-group B-group
diuretics I-group I-group
are O O
a O O
major O O
contributing O O
factor O O
to O O
digitalis B-group B-group
toxicity O O
. O O

Rhabdomyolysis O O
has O O
been O O
observed O O
in O O
patients O O
receiving O O
HMG-CoA B-group B-group
reductase I-group I-group
inhibitors I-group I-group
administered O O
alone O O
( O O
at O O
recommended O O
dosages O O
) O O
or O O
concomitantly O O
with O O
immunosuppressive B-group B-group
drugs I-group I-group
including O O
cyclosporine B-drug B-drug
. O O

Magnesium B-drug B-drug
and O O
therapeutics O O
. O O

Interactions O O
with O O
lipid-lowering O O
drugs O O
that O O
can O O
cause O O
myopathy O O
when O O
given O O
alone O O
. O O

Geriatric O O
Use O O

Quetiapine B-drug B-drug
fumarate I-drug I-drug
( O O
'Seroquel B-brand B-brand
' O O
) O O
is O O
a O O
newly O O
introduced O O
atypical B-group B-group
antipsychotic I-group I-group
with O O
demonstrated O O
efficacy O O
in O O
the O O
treatment O O
of O O
positive O O
and O O
negative O O
symptoms O O
of O O
schizophrenia O O
. O O

glucagon B-drug O
; O O

In O O
the O O
case O O
of O O
severe O O
neutropenia O O
( O O
500 O O
cells/mm3 O O
for O O
seven O O
days O O
or O O
more O O
) O O
during O O
a O O
course O O
of O O
TAXOL B-brand B-brand
therapy O O
, O O
a O O
20 O O
% O O
reduction O O
in O O
dose O O
for O O
subsequent O O
courses O O
of O O
therapy O O
is O O
recommended O O
. O O

Based O O
on O O
adult O O
data O O
, O O
lower O O
doses O O
of O O
caffeine B-drug B-drug
may O O
be O O
needed O O
following O O
coadministration O O
of O O
drugs O O
which O O
are O O
reported O O
to O O
decrease O O
caffeine B-drug B-drug
elimination O O
( O O
e.g. O O
, O O
cimetidine B-drug B-drug
and O O
ketoconazole B-drug B-drug
) O O
and O O
higher O O
caffeine B-drug B-drug
doses O O
may O O
be O O
needed O O
following O O
coadministration O O
of O O
drugs O O
that O O
increase O O
caffeine B-drug B-drug
elimination O O
( O O
e.g. O O
, O O
phenobarbital B-drug B-drug
and O O
phenytoin B-drug B-drug
) O O
. O O

- O O
Disulfiram B-drug B-drug
( O O
e.g. O O
, O O
Antabuse B-brand B-brand
) O O
or O O

Rifampin B-drug B-drug
: O O
Coadministration O O
of O O
rifampin B-drug B-drug
and O O
MEPRON B-brand B-brand
Suspension O O
results O O
in O O
a O O
significant O O
decrease O O
in O O
average O O
steady- O O
state O O
plasma O O
atovaquone B-drug B-drug
concentrations O O
. O O

When O O
digoxin B-drug B-drug
and O O
BREVIBLOC B-brand B-brand
were O O
concomitantly O O
administered O O
intravenously O O
to O O
normal O O
volunteers O O
, O O
there O O
was O O
a O O
10-20 O O
% O O
increase O O
in O O
digoxin B-drug B-drug
blood O O
levels O O
at O O
some O O
time O O
points O O
. O O

Grapefruit O O
juice O O
increases O O
ethinyl B-drug B-drug
estradiol I-drug I-drug
concentrations O O
and O O
would O O
be O O
expected O O
to O O
increase O O
progesterone B-drug B-drug
serum O O
levels O O
as O O
well O O
; O O

Rifabutin B-drug B-drug

Acetazolamide B-drug B-drug
and O O
sodium B-drug B-drug
bicarbonate I-drug I-drug
used O O
concurrently O O
increases O O
the O O
risk O O
of O O
renal O O
calculus O O
formation O O
. O O

Efavirenz I-drug B-drug

Moreover O O
, O O
the O O
basal O O
and O O
dmPGE2-induced B-drug_n B-drug_n
jejunal O I-drug_n
net O O
fluid O O
transfers O O
were O O
the O O
same O O
in O O
cecectomized O O
and O O
in O O
control O O
rats O O
. O O

Antacids B-group B-group
: O O
In O O
a O O
clinical O O
pharmacology O O
study O O
, O O
coadministration O O
of O O
an O O
antacid B-group B-group
( O O
aluminum B-drug B-drug
hydroxide I-drug I-drug
, O O
magnesium B-drug B-drug
hydroxide I-drug I-drug
, O O
and O O
simethicone B-drug B-drug
) O O
with O O
fosinopril B-drug B-drug
reduced O O
serum O O
levels O O
and O O
urinary O O
excretion O O
of O O
fosinoprilat B-drug_n B-drug
as O O
compared O O
with O O
fosinopril B-drug B-drug
administered O O
alone O O
, O O
suggesting O O
that O O
antacids B-group B-group
may O O
impair O O
absorption O O
of O O
fosinopril B-drug B-drug
. O O

The O O
renal O O
effects O O
of O O
nephrotoxic O O
compounds O O
may O O
be O O
potentiated O O
by O O
Carboplatin B-drug B-drug
. O O

Further O O
, O O
in O O
clinical O O
studies O O
with O O
PROSCAR B-brand B-brand
( O O
finasteride B-drug B-drug
, O O
5 O O
mg O O
) O O
when O O
used O O
in O O
older O O
men O O
who O O
have O O
benign O O
prostatic O O
hyperplasia O O
( O O
BPH O O
) O O
, O O
PSA O O
levels O O
are O O
decreased O O
by O O
approximately O O
50 O O
% O O
. O O

Amiodarone B-drug B-drug
may O O
suppress O O
certain O O
CYP450 O O
enzymes O O
, O O
including O O
CYP1A2 B-drug O
, O O
CYP2C9 B-drug O
, O O
CYP2D6 B-drug O
, O O
and O O
CYP3A4 B-drug O
. O O

Influence O O
of O O
estradiol B-drug B-drug
and O O
progesterone B-drug B-drug
on O O
the O O
sensitivity O O
of O O
rat O O
thoracic O O
aorta O O
to O O
noradrenaline B-drug B-drug
. O O

Use O O
of O O
Cerubidine B-brand B-drug
in O O
a O O
patient O O
who O O
has O O
previously O O
received O O
doxorubicin B-drug B-drug
increases O O
the O O
risk O O
of O O
cardiotoxicity O O
. O O

Because O O
Anafranil B-brand B-brand
is O O
highly O O
bound O O
to O O
serum O O
protein O O
, O O
the O O
administration O O
of O O
Anafranil B-brand B-brand
to O O
patients O O
taking O O
other O O
drugs O O
that O O
are O O
highly O O
bound O O
to O O
protein O O
( O O
e.g. O O
, O O
warfarin B-drug B-drug
, O O
digoxin B-drug B-drug
) O O
may O O
cause O O
an O O
increase O O
in O O
plasma O O
concentrations O O
of O O
these O O
drugs O O
, O O
potentially O O
resulting O O
in O O
adverse O O
effects O O
. O O

Olanzapine B-drug B-drug
: O O
Coadministration O O
of O O
eszopiclone B-drug B-drug
3 O O
mg O O
and O O
olanzapine B-drug B-drug
10 O O
mg O O
produced O O
a O O
decrease O O
in O O
DSST O O
scores O O
. O O

METHOD O O
: O O
This O O
study O O
was O O
a O O
multicenter O O
randomized O O
double-blind O O
study O O
of O O
101 O O
patients O O
who O O
were O O
randomly O O
assigned O O
1:1:1 O O
to O O
receive O O
everolimus B-drug B-drug
tablets O O
at O O
doses O O
of O O
0.5 O O
mg O O
, O O
1 O O
mg O O
, O O
or O O
2 O O
mg O O
twice O O
daily O O
with O O
cyclosporine B-drug B-drug
and O O
prednisone B-drug B-drug
. O O

The O O
onset O O
of O O
symptoms O O
usually O O
occurred O O
within O O
hours O O
( O O
most O O
commonly O O
1 O O
to O O
4 O O
hours O O
) O O
following O O
the O O
administration O O
of O O
contrast O O
media O O
. O O

The O O
coadministration O O
of O O
aspirin B-brand B-brand
decreases O O
the O O
biologic O O
half-life O O
of O O
fenoprofen B-drug B-drug
because O O
of O O
an O O
increase O O
in O O
metabolic O O
clearance O O
that O O
results O O
in O O
a O O
greater O O
amount O O
of O O
hydroxylated B-drug_n O
fenoprofen I-drug_n B-drug
in O O
the O O
urine O O
. O O

If O O
NovoLog B-brand B-brand
is O O
mixed O O
with O O
NPH B-drug B-drug
human I-drug I-drug
insulin I-drug I-drug
, O O
NovoLog B-brand B-brand
should O O
be O O
drawn O O
into O O
the O O
syringe O O
first O O
. O O

The O O
fraction O O
of O O
STADOL B-brand B-brand
NS I-brand I-brand
absorbed O O
is O O
unaffected O O
by O O
the O O
concomitant O O
administration O O
of O O
a O O
nasal B-group B-group
vasoconstrictor I-group I-group
( O O
oxymetazoline B-drug B-drug
) O O
, O O
but O O
the O O
rate O O
of O O
absorption O O
is O O
decreased O O
. O O

Minor O O
symptoms O O
such O O
as O O
flushing O O
, O O
skin O O
reactions O O
, O O
dyspnea O O
, O O
hypotension O O
, O O
or O O
tachycardia O O
do O O
not O O
require O O
interruption O O
of O O
therapy O O
. O O

Spermine B-drug B-drug
, O O
and O O
to O O
a O O
lesser O O
extent O O
, O O
spermidine B-drug_n B-drug
, O O
enhanced O O
the O O
translocating O O
action O O
of O O
oleate O O
and O O
increased O O
its O O
effectiveness O O
in O O
transferring O O
the O O
phosphohydrolase O O
from O O
the O O
soluble O O
to O O
the O O
microsomal O O
fraction O O
. O O

Carcinogenesis O O
, O O
Mutagenesis O O
and O O
Impairment O O
of O O
Fertility O O
A O O
two-year O O
carcinogenesis O O
study O O
was O O
conducted O O
in O O
female O O
and O O
male O O
rats O O
, O O
at O O
intramuscular O O
doses O O
of O O
15 O O
mg/kg/30 O O
days O O
, O O
10 O O
mg/rat/30 O O
days O O
and O O
10 O O
mg/rat/15 O O
days O O
. O O

Although O O
in O O
vivo O O
studies O O
have O O
not O O
been O O
done O O
to O O
see O O
if O O
etodolac B-drug B-drug
clearance O O
is O O
changed O O
by O O
coadministration O O
of O O
phenylbutazone B-drug B-drug
, O O
it O O
is O O
not O O
recommended O O
that O O
they O O
be O O
coadministered O O
. O O

Products O O
containing O O
calcium B-drug B-drug
and O O
other O O
multivalent B-drug O
cations I-drug O
likely O O
will O O
interfere O O
with O O
absorption O O
of O O
alendronate B-drug B-drug
. O O

Enoxaparin B-drug B-drug
dosed O O
as O O
a O O
1.0 O O
mg/kg O O
subcutaneous O O
injection O O
q12h O O
for O O
four O O
doses O O
did O O
not O O
alter O O
the O O
pharmacokinetics O O
of O O
eptifibatide B-drug B-drug
or O O
the O O
level O O
of O O
platelet O O
aggregation O O
in O O
healthy O O
adults O O
. O O

These O O
results O O
indicate O O
that O O
the O O
pancreatic O O
alpha O O
cell O O
of O O
the O O
diabetic O O
Chinese O O
hamster O O
responds O O
excessively O O
to O O
arginine B-drug B-drug
, O O
as O O
is O O
seen O O
in O O
the O O
human O O
diabetic O O
. O O

The O O
mean O O
AUC O O
values O O
of O O
LNG O O
were O O
decreased O O
by O O
32 O O
% O O
[ O O
90 O O
% O O
CI O O
: O O
20-45 O O
] O O
in O O
one O O
study O O
and O O
52 O O
% O O
[ O O
90 O O
% O O
CI O O
: O O
42-52 O O
] O O
in O O
another O O
study O O
. O O

Cohort O O
1 O O
then O O
received O O
amprenavir B-drug B-drug
plus O O
rifabutin B-drug B-drug
for O O
10 O O
days O O
, O O
and O O
cohort O O
2 O O
received O O
amprenavir B-drug B-drug
plus O O
rifampin B-drug B-drug
for O O
4 O O
days O O
. O O

Protease B-group B-group
Inhibitors I-group I-group
: O O
In O O
vitro O O
data O O
indicate O O
that O O
indinavir B-drug B-drug
and O O
ritonavir B-drug B-drug
markedly O O
inhibit O O
the O O
metabolism O O
of O O
cisapride B-drug B-drug
which O O
can O O
result O O
in O O
an O O
increase O O
in O O
plasma O O
cisapride B-drug B-drug
levels O O
and O O
prolongation O O
of O O
the O O
QT O O
interval O O
on O O
the O O
ECG O O
. O O

Death O O
due O O
to O O
fulminant O B-drug
pancreatitis O O
possibly O O
related O O
to O O
intravenous O O
pentamidine B-drug B-drug
and O O
HIVID B-drug B-drug
has O O
been O O
reported O O
. O O

These O O
findings O O
should O O
be O O
taken O O
into O O
account O O
for O O
proper O O
interpretation O O
of O O
serum O O
PSA O O
when O O
evaluating O O
men O O
treated O O
with O O
finasteride B-drug B-drug
. O O

The O O
dosage O O
of O O
these O O
medications O O
should O O
not O O
be O O
changed O O
and O O
they O O
should O O
not O O
be O O
stopped O O
without O O
consulting O O
the O O
physician O O
, O O
even O O
if O O
the O O
patient O O
feels O O
better O O
after O O
initiating O O
treatment O O
with O O
FORADIL B-brand B-brand
. O O

Diuretic B-group B-group
agents I-group I-group
reduce O O
the O O
renal O O
clearance O O
of O O
lithium B-drug B-drug
and O O
add O O
a O O
high O O
risk O O
of O O
lithium B-drug B-drug
toxicity O O
. O O

The O O
action O O
of O O
the O O
benzodiazepines B-group B-group
may O O
be O O
potentiated O O
by O O
anticonvulsants B-group B-group
, O O
antihistamines B-group B-group
, O O
alcohol B-drug B-drug
, O O
barbiturates B-group B-group
, O O
monoamine B-group B-group
oxidase I-group I-group
inhibitors I-group I-group
, O O
narcotics B-group B-group
, O O
phenothiazines B-group B-group
, O O
psychotropic B-group B-group
medications I-group I-group
, O O
or O O
other O O
drugs O O
that O O
produce O O
CNS O O
depression O O
. O O

Although O O
there O O
is O O
no O O
documentation O O
of O O
such O O
, O O
a O O
similar O O
interaction O O
between O O
ethotoin B-drug B-drug
and O O
the O O
coumarin B-group B-group
anticoagulants I-group I-group
may O O
occur O O
. O O

if O O
necessary O O
, O O
amiodarone B-drug B-drug
can O O
continue O O
to O O
be O O
used O O
after O O
insertion O O
of O O
a O O
pacemaker O O
in O O
patients O O
with O O
severe O O
bradycardia O O
or O O
sinus O O
arrest O O
. O O

Although O O
neither O O
dexamethasone B-drug B-drug
nor O O
retinyl B-drug B-drug
acetate I-drug I-drug
affected O O
the O O
proliferation O O
of O O
prostatic O O
epithelium O O
in O O
RPMI1640 O O
containing O O
transferrin B-drug_n B-drug
alone O O
, O O
they O O
modify O O
the O O
mitogenic O O
effect O O
of O O
EGF B-drug_n B-drug_n
and O O
insulin B-drug B-drug
. O O

Barbiturates B-group B-group
and O O
glutethimide B-drug B-drug
should O O
not O O
be O O
administered O O
to O O
patients O O
receiving O O
coumarin B-group B-group
drugs I-group I-group
. O O

If O O
pregnancy O O
occurs O O
while O O
taking O O
AMEVIVE B-brand B-brand
, O O
continued O O
use O O
of O O
the O O
drug O O
should O O
be O O
assessed O O
. O O

drugs O O
affecting O O
blood O O
elements O O
; O O

Electrolyte O O
Disturbances O O
Patients O O
with O O
hypokalemia O O
or O O
hypomagnesemia O O
should O O
have O O
the O O
condition O O
corrected O O
whenever O O
possible O O
before O O
being O O
treated O O
with O O
Cordarone B-drug B-brand
I.V. I-drug O
, O O
as O O
these O O
disorders O O
can O O
exaggerate O O
the O O
degree O O
of O O
QTc O O
prolongation O O
and O O
increase O O
the O O
potential O O
for O O
TdP O O
. O O

Potentially O O
fatal O O
drug O O
interactions O O
may O O
occur O O
when O O
coadministered O O
with O O
digoxin B-drug B-drug
, O O
as O O
this O O
may O O
enhance O O
cardiovascular O O
depression O O
and O O
bradyarrhythmias O O
may O O
occur O O
. O O

Interacts O O
with O O
valproic B-drug B-drug
acid I-drug I-drug

Furthermore O O
, O O
arsenate B-drug_n B-drug
and O O
phosphate B-drug B-drug
do O O
not O O
appear O O
to O O
share O O
a O O
common O O
transport O O
pathway O O
in O O
the O O
duodenum O O
and O O
no O O
evidence O O
was O O
obtained O O
for O O
any O O
interaction O O
between O O
the O O
two O O
at O O
this O O
level O O
. O O

Ingestion O O
of O O
diclofenac B-drug B-drug
may O O
increase O O
serum O O
concentrations O O
of O O
digoxin B-drug B-drug
and O O
methotrexate B-drug B-drug
and O O
increase O O
cyclosporine B-drug B-drug
s O O
nephrotoxicity O O
. O O

No O O
dose O O
adjustment O O
is O O
necessary O O
when O O
Simulect B-brand B-brand
is O O
added O O
to O O
triple-immunosuppression O O
regimens O O
including O O
cyclosporine B-drug B-drug
, O O
corticosteroids B-group B-group
, O O
and O O
either O O
azathioprine B-drug B-drug
or O O
mycophenolate B-drug B-drug
mofetil I-drug I-drug
. O O

Inhibition O O
of O O
the O O
other O O
isozymes O O
evaluated O O
( O O
CYPs O O
2A1 O O
, O O
2C9 O O
, O O
2C19 O O
, O O
2D6 O O
, O O
3A4 O O
, O O
and O O
3E1 O O
) O O
was O O
0-16 O O
% O O
. O O

Taken O O
together O O
, O O
these O O
results O O
suggest O O
that O O
the O O
site O O
of O O
the O O
inhibitory O O
action O O
of O O
RR B-drug_n B-drug_n
is O O
at O O
the O O
InsP O B-drug_n
( O O
3 O O
) O O
receptor O O
, O O
or O O
its O O
closely O O
associated O O
proteins O O
. O O

Iodometric O O
titration O O
of O O
the O O
polymer O O
conjugates O O
was O O
used O O
to O O
determine O O
the O O
extent O O
of O O
immobilised O O
cysteine B-drug B-drug
. O O

The O O
duration O O
of O O
the O O
period O O
following O O
treatment O O
with O O
AMEVIVE B-brand B-brand
before O O
one O O
should O O
consider O O
starting O O
other O O
immunosuppressive B-group B-group
therapy O O
has O O
not O O
been O O
evaluated O O
. O O

Plasma O O
membrane O O
and O O
intracellular O O
mobilization O O
of O O
calcium O B-drug
ions O O
are O O
intimately O O
related O O
to O O
platelet O O
activation O O
and O O
release O O
of O O
platelet O O
contents O O
. O O

Prior O O
administration O O
of O O
succinylcholine B-drug B-drug
had O O
no O O
effect O O
on O O
the O O
duration O O
of O O
neuromuscular O O
block O O
following O O
initial O O
or O O
maintenance O O
bolus O O
doses O O
of O O
NIMBEX B-brand B-brand
. O O

- O O
Increased O O
serum O O
triglyceride O O
and O O
phospholipid O O
concentration O O
. O O

Patients O O
receiving O O
flurbiprofen B-drug B-drug
and O O
furosemide B-drug B-drug
or O O
other O O
diuretics B-group B-group
should O O
be O O
observed O O
closely O O
to O O
determine O O
if O O
the O O
desired O O
effect O O
is O O
obtained O O
. O O

Quinolones B-group B-group
, O O
including O O
nalidixic B-drug B-drug
acid I-drug I-drug
, O O
may O O
enhance O O
the O O
effects O O
of O O
the O O
oral O O
anticoagulant B-group B-group
warfarin B-drug B-drug
or O O
its O O
derivatives O O
. O O

Coadministration O O
of O O
Itraconazole B-drug B-drug
and O O
cyclosporine B-drug B-drug
, O O
tacrolimus B-drug B-drug
or O O
digoxin B-drug B-drug
has O O
led O O
to O O
increased O O
plasma O O
concentrations O O
of O O
the O O
latter O O
three O O
drugs O O
. O O

The O O
administration O O
of O O
other O O
potassium-sparing B-group O
antihypertensives I-group B-group
with O O
NSAIDs B-group B-group
has O O
been O O
shown O O
to O O
reduce O O
the O O
antihypertensive O O
effect O O
in O O
some O O
patients O O
and O O
result O O
in O O
severe O O
hyperkalemia O O
in O O
patients O O
with O O
impaired O O
renal O O
function O O
. O O

Anastrozole B-drug B-drug
inhibited O O
in O O
vitro O O
metabolic O O
reactions O O
catalyzed O O
by O O
cytochromes O O
P450 O O
1A2 O O
, O O
2C8/9 O O
, O O
and O O
3A4 O O
but O O
only O O
at O O
relatively O O
high O O
concentrations O O
. O O

( O O
Effects O O
may O O
be O O
decreased O O
when O O
used O O
concurrently O O
with O O
thiazide B-group B-group
diuretics I-group I-group
; O O

Chloral B-drug B-drug
hydrate I-drug I-drug
and O O
methaqualone B-drug B-drug
interact O O
pharmacologically O O
with O O
orally O O
administered O O
anticoagulant B-group B-group
agents I-group I-group
, O O
but O O
the O O
effect O O
is O O
not O O
clinically O O
significant O O
. O O

Standard O O
therapy O O
includes O O
antibiotics B-group B-group
, O O
such O O
as O O
penicillin B-drug B-drug
and O O
gentamicin B-drug B-drug
; O O

This O O
effect O O
has O O
been O O
attributed O O
to O O
inhibition O O
of O O
prostaglandin O O
synthesis O O
. O O

Leucovorin B-drug B-drug
: O O
The O O
concentration O O
of O O
5-fluorouracil B-drug B-drug
is O O
increased O O
and O O
its O O
toxicity O O
may O O
be O O
enhanced O O
by O O
leucovorin B-drug B-drug
. O O

Caution O O
is O O
warranted O O
and O O
therapeutic O O
concentration O O
monitoring O O
is O O
recommended O O
for O O
antiarrhythmics B-group B-group
when O O
coadministered O O
with O O
CRIXIVAN B-brand B-brand
. O O

This O O
slowing O O
potentiates O O
amphetamines B-group B-group
, O O
increasing O O
their O O
effect O O
on O O
the O O
release O O
of O O
norepinephrine O B-drug
and O O
other O O
monoamines O O
from O O
adrenergic O O
nerve O O
endings O O
; O O

The O O
majority O O
of O O
these O O
reports O O
concerned O O
variable O O
elevations O O
in O O
prothrombin O O
times O O
without O O
clinically O O
significant O O
sequelae O O
. O O

Effects O O
of O O
Antacids B-group B-group
on O O
Felbatol B-brand B-brand
The O O
rate O O
and O O
extent O O
of O O
absorption O O
of O O
a O O
2400 O O
mg O O
dose O O
of O O
Felbatol B-brand B-brand
as O O
monotherapy O O
given O O
as O O
tablets O O
was O O
not O O
affected O O
when O O
coadministered O O
with O O
antacids B-group B-group
. O O

There O O
has O O
been O O
too O O
little O O
experience O O
with O O
the O O
coadministration O O
of O O
TAMBOCOR B-brand B-brand
with O O
nifedipine B-drug B-drug
or O O
diltiazem B-drug B-drug
to O O
recommend O O
concomitant O O
use O O
. O O

Because O O
of O O
the O O
risk O O
of O O
increased O O
exposure O O
tonevirapine B-drug B-drug
, O O
caution O O
should O O
be O O
used O O
inconcomitant O O
administration O O
, O O
and O O
patients O O
should O O
be O O
monitored O O
closely O O
for O O
nevirapine-associated O B-drug
adverse O O
events O O
. O O

Cardiac B-group B-group
Glycosides I-group I-group
: O O
In O O
a O O
study O O
of O O
young O O
healthy O O
male O O
subjects O O
no O O
evidence O O
of O O
a O O
direct O O
pharmacokinetic O O
captopril-digoxin B-drug O
interaction O O
could O O
be O O
found O O
. O O

Monitor O O
cardiovascular O O
status O O
. O O

This O O
response O O
has O O
been O O
attributed O O
to O O
inhibition O O
of O O
renal O O
prostaglandin O O
synthesis O O
. O O

methadone I-drug B-drug
concentration O O

There O O
is O O
no O O
information O O
regarding O O
the O O
effect O O
on O O
lamivudine B-drug B-drug
pharmacokinetics O O
of O O
higher O O
doses O O
of O O
TMP/SMX B-drug B-drug
such O O
as O O
those O O
used O O
to O O
treat O O
Pneumocystis O O
carinii O O
pneumonia O O
. O O

Based O O
on O O
known O O
metabolic O O
profiles O O
, O O
clinically O O
significant O O
drug O O
interactions O O
are O O
not O O
expected O O
between O O
VIRACEPT B-brand B-brand
and O O
dapsone B-drug B-drug
, O O
trimethoprim/sulfamethoxazole B-drug B-drug
, O O
clarithromycin B-drug B-drug
, O O
erythromycin B-drug B-drug
, O O
itraconazole B-drug B-drug
or O O
fluconazole B-drug B-drug
. O O

Therefore O O
, O O
close O O
monitoring O O
of O O
serum O O
cyclosporin B-drug B-drug
level O O
is O O
recommended O O
and O O
, O O
if O O
necessary O O
, O O
chloroquine B-drug B-drug
should O O
be O O
discontinued O O
. O O

Lapatinib B-drug B-drug
inhibits O O
human O O
P-glycoprotein O O
. O O

Oral O O
anticoagulants B-group B-group
may O O
potentiate O O
the O O
hypoglycemic O O
action O O
of O O
hypoglycemic B-group B-group
agents I-group I-group
, O O
eg O O
, O O
tolbutamide B-drug B-drug
and O O
chlorpropamide B-drug B-drug
, O O
by O O
inhibiting O O
their O O
metabolism O O
in O O
the O O
liver O O
. O O

The O O
drugs O O
that O O
inhibit O O
cytochrome O O
P450 O O
2D6 O O
include O O
some O O
that O O
are O O
not O O
metabolized O O
by O O
the O O
enzyme O O
( O O
quinidine B-drug B-drug
; O O

No O O
formal O O
drug/drug O O
interaction O O
studies O O
with O O
Plenaxis B-brand B-brand
were O O
performed O O
. O O

Coadministration O O
of O O
warfarin B-drug B-drug
did O O
not O O
affect O O
the O O
pharmacokinetics O O
of O O
levetiracetam B-drug B-drug
. O O

All O O
antagonists O B-group
decreased O O
the O O
time O O
spent O O
in O O
the O O
light O O
zone O O
in O O
this O O
test O O
, O O
which O O
suggested O O
that O O
these O O
compounds O O
have O O
anxiogenic O O
effects O O
. O O

iv O O
. O O

Nucleoside O B-group
Analogues O O
Didanosine B-drug O
Co-administration O O
of O O
COPEGUS B-brand B-brand
and O O
didanosine B-drug B-drug
is O O
not O O
recommended O O
. O O

Glutathione-S-transferase O O
( O O
GST O O
) O O
activity O O
, O O
however O O
, O O
did O O
not O O
differ O O
from O O
control O O
values O O
for O O
any O O
dose O O
or O O
at O O
any O O
time O O
point O O
in O O
cerebral O O
and O O
hepatic O O
tissues O O
. O O

Thus O O
, O O
if O O
a O O
patient O O
has O O
been O O
titrated O O
to O O
a O O
stable O O
dosage O O
of O O
EQUETROTM B-brand B-brand
, O O
and O O
then O O
begins O O
a O O
course O O
of O O
treatment O O
with O O
one O O
of O O
these O O
CYP3A4 O O
or O O
epoxide O O
hydrolase O O
inhibitors O O
, O O
it O O
is O O
reasonable O O
to O O
expect O O
that O O
a O O
dose O O
reduction O O
for O O
EQUETROTM B-brand B-brand
may O O
be O O
necessary O O
. O O

In O O
a O O
ten-subject O O
study O O
, O O
coadministration O O
of O O
diltiazem B-drug B-drug
( O O
120 O O
mg O O
bid O O
) O O
with O O
lovastatin B-drug B-drug
resulted O O
in O O
a O O
3-4 O O
times O O
increase O O
in O O
mean O O
lovastatin B-drug B-drug
AUC O O
and O O
Cmax O O
vs. O O
lovastatin B-drug B-drug
alone O O
; O O

. O O

In O O
clinical O O
trials O O
in O O
patients O O
undergoing O O
PTCA/PCI O O
, O O
co-administration O O
of O O
Angiomax B-brand B-brand
with O O
heparin B-drug B-drug
, O O
warfarin B-drug B-drug
, O O
thrombolytics B-group B-group
or O O
glycoprotein O B-group
IIb/IIIa O I-group
inhibitors O I-group
was O O
associated O O
with O O
increased O O
risks O O
of O O
major O O
bleeding O O
events O O
compared O O
to O O
patients O O
not O O
receiving O O
these O O
concomitant O O
medications O O
. O O

Drug/Laboratory O O
Test O O
Interactions O O
The O O
urine O O
of O O
patients O O
who O O
take O O
Lodine B-brand B-brand
can O O
give O O
a O O
false-positive O O
reaction O O
for O O
urinary O O
bilirubin O O
( O O
urobilin O O
) O O
due O O
to O O
the O O
presence O O
of O O
phenolic O O
metabolites O O
of O O
etodolac B-drug B-drug
. O O

Hormonal B-group B-group
Contraceptives I-group I-group
: O O
It O O
has O O
not O O
been O O
established O O
if O O
there O O
is O O
a O O
pharmacokinetic O O
interaction O O
between O O
acitretin B-drug B-drug
and O O
combined B-group O
oral I-group O
contraceptives I-group B-group
. O O

Beta-blockers B-group B-group
not O O
only O O
block O O
the O O
therapeutic O O
effects O O
of O O
beta-agonists B-group B-group
, O O
but O O
may O O
produce O O
severe O O
bronchospasm O O
in O O
COPD O O
patients O O
. O O

A O O
smaller O O
24-week O O
study O O
has O O
suggested O O
nevirapine B-drug B-drug
may O O
be O O
superior O O
to O O
the O O
PI B-group O
nelfinavir B-drug B-drug
. O O

Therefore O O
, O O
monitoring O O
of O O
theophylline B-drug B-drug
plasma O O
levels O O
should O O
be O O
considered O O
and O O
dosage O O
of O O
theophylline B-drug B-drug
adjusted O O
as O O
required O O
. O O

